adenine has been researched along with pci 32765 in 1676 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1062 (63.37) | 24.3611 |
| 2020's | 614 (36.63) | 2.80 |
| Authors | Studies |
|---|---|
| Buggy, JJ; Chang, B; Honigberg, LA; Li, S; Loury, D; Miller, RA; Pan, Z; Sirisawad, M; Smith, AM; Thamm, DH; Verner, E | 1 |
| Buggy, J; Honigberg, LA; MacGlashan, D; Schroeder, JT; Smith, A | 1 |
| Blum, KA; Buggy, JJ; Byrd, JC; Flynn, J; Gordon, AL; Hamdy, A; Herman, SE; Hertlein, E; Jaglowski, S; Johnson, AJ; Jones, J; Ramanunni, A; Zhang, X | 1 |
| Buggy, JJ; Chang, BY; Chen, J; Francesco, M; Huang, MM; Magadala, P; Robinson, WH; Sokolove, J | 1 |
| Pope, RM; Ruderman, EM | 1 |
| Burger, JA | 3 |
| Adimoolam, S; Allende, MT; Buggy, JJ; Evan, GI; Kortlever, R; Monclús, HA; Soucek, L; Swigart, LB | 1 |
| Balakrishnan, K; Buggy, JJ; Burger, JA; Chen, SS; Chiorazzi, N; Gandhi, V; Keating, MJ; O'Brien, S; Ponader, S; Wierda, WG | 1 |
| Flinn, IW | 1 |
| Harrison, C | 1 |
| Buggy, JJ; Chang, BY; de Rooij, MF; Eldering, E; Geest, CR; Kuil, A; Pals, ST; Spaargaren, M | 1 |
| Castillo, JJ; Ingham, RR; Winer, ES | 1 |
| Alinari, L; Baiocchi, RA; Christian, B | 1 |
| Corneth, OB; de Bruijn, MJ; Delsing, D; Dingjan, GM; Elewaut, D; Hendriks, RW; Kil, LP; Rimmelzwaan, GF; Thaiss, F; van Hamburg, JP; van Loo, PF; van Nimwegen, M | 1 |
| Acharya, C; Anderson, KC; Buggy, JJ; Cagnetta, A; Calle, Y; Carrasco, DR; Cea, M; Chang, BY; Elias, L; Fulciniti, M; Hu, Y; Kong, SY; Lin, J; Matsui, W; Munshi, NC; Richardson, P; Sellitto, MA; Tai, YT; Treon, SP; Wang, Q; Yang, G; Zhao, JJ; Zhong, MY | 1 |
| Balasubramanian, S; Buggy, JJ; Ceribelli, M; Emre, NC; Ferrer, M; Guha, R; Kohlhammer, H; Mathews, LA; Platig, J; Powell, J; Shaffer, AL; Shinn, P; Staudt, LM; Thomas, C; Waldmann, TA; Wright, G; Xiao, W; Xu, W; Yang, Y; Young, RM; Zhang, M; Zhao, H | 1 |
| Wiestner, A | 5 |
| Edwards, CM | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Anderson, KC; Tai, YT | 1 |
| Advani, RH; Boyd, TE; Buggy, JJ; Chang, BY; Fowler, NH; Furman, RR; Grant, B; Hamdy, A; Hedrick, E; Izumi, R; Kolibaba, KS; Rodriguez, S; Sharman, JP; Smith, SM; Sukbuntherng, J | 1 |
| Leonard, JP | 2 |
| Bashmakov, A; Buggy, JJ; Chang, BY; Du, Y; Grewal, S; Hutcheson, J; Mohan, C; Sajitharan, D; Satterthwaite, AB; Vanarsa, K; Zhou, XJ | 1 |
| Brown, JR | 7 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H | 1 |
| Buggy, JJ; Burger, JA | 1 |
| Barrientos, J; Rai, K | 1 |
| Aue, G; Buggy, JJ; Chapman, CM; Chen, J; Herman, SE; Hsieh, MM; Keyvanfar, K; Liu, D; McAuley, EM; Pérez-Galán, P; Pittaluga, S; Raffeld, M; Sun, X; Tisdale, JF; Wiestner, A | 1 |
| Hamasy, A; Nore, BF; Smith, CI; Vargas, L | 1 |
| Newberry, KJ; Wang, M; Zhang, L | 1 |
| Dolgin, E | 2 |
| Gustafsson, MO; Hussain, A; Mohamed, AJ; Mohammad, DK; Nore, BF; Smith, CI | 1 |
| Doubek, M; Mayer, J; Mráz, M | 1 |
| Advani, RH; Auer, R; Barrientos, JC; Beaupre, DM; Blum, KA; Buggy, JJ; Chang, BY; Cheng, N; Chmielowska, E; Clow, F; Dreyling, M; Fang, B; Goy, A; Jedrzejczak, WW; Johnson, P; Jurczak, W; Kahl, BS; Kunkel, LA; Li, L; Martin, P; McGreivy, J; Newberry, K; Ou, Z; Radford, J; Romaguera, JE; Rule, S; Spurgeon, SE; Stilgenbauer, S; Wang, ML; Williams, ME; Zhang, L | 1 |
| Blum, KA; Buggy, JJ; Burger, JA; Byrd, JC; Chang, BY; Clow, F; Coleman, M; Coutre, SE; Flinn, IW; Furman, RR; Grant, B; Hedrick, E; Heerema, NA; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Sharman, JP; Sukbuntherng, J; Wierda, WG; Zhao, W | 1 |
| Foà, R; Guarini, A | 1 |
| Andritsos, LA; Beckwith, KA; Buggy, JJ; Byrd, JC; Caligiuri, MA; Chang, BY; Chappell, DL; Dubovsky, JA; Flynn, JM; Frissora, FW; Furman, R; Hessler, JD; Jaglowski, S; Johnson, AJ; Jones, JA; Larkin, KM; Lehman, AM; Liu, TM; Maddocks, K; Mishra, A; Muthusamy, N; Natarajan, G; Satoskar, AR; Sharman, J; Smith, LL; Smucker, KA; Stefanovski, MR; Woyach, JA; Zhong, Y | 1 |
| Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
| Jain, N; O'Brien, S | 1 |
| Bertoni, F; Zucca, E | 1 |
| Buggy, JJ; Chang, BY; Chang, S; De Rooij, MF; Elias, L; Francesco, M; Herman, SE; Huang, MM; Kuil, A; Magadala, P; Pals, ST; Spaargaren, M; Steggerda, SM; Wiestner, A; Wilson, W | 1 |
| Akinleye, A; Chen, Y; Liu, D; Mukhi, N; Song, Y | 1 |
| Alkan, S; Amin, HM; Cinar, B; Cinar, M; Hamedani, F; Mo, Z | 1 |
| Danilov, AV | 1 |
| Sharma, SP | 1 |
| Aalipour, A; Advani, RH | 1 |
| Ansell, SM | 1 |
| Chen, Y; Deng, Y; Deng, ZK; He, ZM; Li, YY; Tao, SD; Yu, L; Zhang, X | 1 |
| Buggy, JJ; Cheng, S; Coleman, M; Furman, RR; Guo, A; Leonard, JP; Liu, M; Lu, P; Ma, J; Wang, YL | 1 |
| Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Bojnik, E; Buggy, JJ; Byrd, JC; Chang, BY; Davis, ME; Dubovsky, JA; Efremov, DG; Gobessi, S; Goettl, VM; Harrington, BK; Johnson, AJ; Laurenti, L; MacMurray, J; Ruppert, AS; Smith, LL; Smucker, KA; Stefanovski, MR; Towns, WH; Woyach, JA | 1 |
| Asahara, H; Buggy, JJ; Chang, BY; Kodama, T; Nagai, Y; Shinohara, M; Takayanagi, H | 1 |
| Blum, KA; Buggy, JJ; Burger, JA; Byrd, JC; Chang, BY; Clow, F; Coleman, M; Coutre, SE; Furman, RR; Graef, T; Grant, B; Hamdy, A; Heerema, NA; Izumi, R; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Richards, DA; Sharman, JP; Wierda, WG; Zhao, W | 1 |
| Alejandro, L; Bhatt, V; Ganetsky, A; Michael, A | 1 |
| Bhang, HE; Chan, FC; Cooke, VG; Derti, A; Dietze, K; Dörken, B; Farsidjani, A; Frick, M; Fritsch, C; Gascoyne, RD; Hummel, M; Kauffmann, A; Kim, S; Korn, JM; Kovats, S; Kridel, R; Lenz, G; Meissner, B; Monahan, J; Morrissey, MP; Naylor, T; Pfister, E; Rahal, R; Rakiec, D; Romero, R; Ruddy, D; Sellers, WR; Stegmeier, F; Steidl, C; Tzankov, A | 1 |
| Byrd, JC; Clow, F; Flynn, J; Furman, RR; Ghia, E; James, DF; Johnson, AJ; Jones, J; Kipps, TJ; Lozanski, A; Lozanski, G; Lucas, D; Maddocks, K; Mantel, R; O'Brien, S; Rassenti, L; Ruppert, AS; Smith, LL; Smucker, K; Williams, K; Woyach, JA; Zhao, W; Zhong, Y | 1 |
| Dias, AL; Jain, D | 1 |
| Adekunle, O; Akinleye, A; Furqan, M | 1 |
| Cameron, F; Sanford, M | 1 |
| Austin, CP; Boxer, MB; Duveau, DY; Ferrer, M; Goldlust, IS; Guha, R; Huang, W; Jadhav, A; Jiang, JK; Keller, JM; Leclair, CA; Leister, W; Liu, D; Maloney, DJ; Martin, SE; Mathews Griner, LA; McKnight, C; Michael, S; Mierzwa, T; Mott, BT; Patel, P; Peyser, BD; Rai, G; Shinn, P; Simeonov, A; Staudt, LM; Thomas, CJ; Walsh, MJ; Yasgar, A; Young, RM | 1 |
| Blum, KA; Maddocks, K | 1 |
| Guha, M | 1 |
| Davids, MS | 2 |
| Aoki, S | 1 |
| Li, JY; Wang, M; Xu, W | 1 |
| Gaidano, G; Rossi, D | 1 |
| Buggy, JJ; Butchar, JP; Byrd, JC; Cheney, C; Herman, SE; Johnson, AJ; Kohrt, HE; Levy, R; Muthusamy, N; Rafiq, S; Sagiv-Barfi, I; Zhang, X | 1 |
| Chang, B; Chang, S; Farooqui, M; Gyamfi, JA; Herman, SE; Mustafa, RZ; Pittaluga, S; Wiestner, A | 1 |
| Arons, E; Burger, JA; Kreitman, RJ; Ravandi, F; Sivina, M | 1 |
| Aue, G; Calvo, KR; Farooqui, M; Geisler, CH; Gyamfi, JA; Herman, SE; Jones, J; Lipsky, A; Liu, D; Maric, I; Marti, GE; Martyr, S; Mustafa, RZ; Niemann, CU; Pedersen, LB; Saba, N; Soto, S; Valdez, J; Wiestner, A | 1 |
| Schwarzbich, MA; Witzens-Harig, M | 1 |
| Kim, E; Kohler, RH; Miller, MA; Turetsky, A; Weissleder, R | 1 |
| Berkova, Z; Braun, FK; Kwak, LW; Mathur, R; Neelapu, S; Samaniego, F; Sehgal, L; Wise, JF | 1 |
| Cubitt, CL; Del Valle, JR; Hu, CC; Kriss, CL; Pinilla-Ibarz, JA; Ranatunga, S; Tang, CH; Tao, J | 1 |
| Benjamini, O; Burger, JA; Garg, N; James, D; Kantarjian, H; Keating, MJ; Komarova, NL; O'Brien, S; Wierda, WG; Wodarz, D | 1 |
| Awan, FT | 2 |
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Aschenbrenner, DS | 2 |
| Cheng, S; Coleman, M; Furman, RR; Guo, A; Leslie, C; Lu, P; Ma, J; Perez, AR; Racchumi, J; Setty, M; Steggerda, SM; Wang, YL; Wu, H; Xu, G | 1 |
| Barrientos, JC; Blum, KA; Buggy, JJ; Byrd, JC; Chang, BY; Dave, SS; Furman, RR; Jaglowski, SM; James, DF; Johnson, AJ; Li, DH; Lichter, P; Liu, TM; Lozanski, A; Lozanski, G; Ozer, HG; Ruppert, AS; Steggerda, SM; Stilgenbauer, S; Versele, M; Woyach, JA; Xue, L; Yilmaz, AS; Zapatka, M; Zhang, J | 1 |
| Barr, PM; Barrientos, JC; Bloor, A; Brown, JR; Byrd, JC; Caligaris-Cappio, F; Chu, AD; Clow, F; Coutre, S; Cymbalista, F; de Vos, S; Dearden, C; Delgado, J; Devereux, S; Fardis, M; Furman, RR; Gill, D; Hillmen, P; Jaeger, U; James, DF; Jones, JJ; Kay, NE; Kipps, TJ; McGreivy, J; Montillo, M; Moreno, C; Mulligan, SP; O'Brien, S; Pocock, C; Reddy, NM; Robak, T; Schuh, A; Schuster, SJ; Tam, CS; Thornton, P | 1 |
| Dea, T; Hsu, G; Mannis, G; Mauro, T; Wu, D | 1 |
| Huang, A; Xing, L | 1 |
| O'Brien, SM | 2 |
| Chanan-Khan, AA; Hallek, M; Howes, A; Kay, NE; Mahler, M; Osterborg, A; Salman, M; Sun, S; Wan, Y; Zhuang, SH | 1 |
| Cao, Y; Castillo, JJ; Chen, J; Hunter, ZR; Kanan, S; Liu, X; Patterson, CJ; Rodig, S; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Jimeno, A; McDermott, J | 1 |
| Brown, JR; Davids, MS | 1 |
| de Rooij, MF; Eldering, E; Kater, AP; Spaargaren, M | 1 |
| Cheng, S; Coleman, M; Guo, A; Lu, P; Ma, J; Martin, P; Wang, YL; Zong, H | 1 |
| Bihani, T; Byth, KF; Collins, M; Ezell, SA; Grosskurth, SE; Mayo, M; Parmentier, J; Passino, M; Reimer, C; Tepsuporn, S; Wang, S | 1 |
| Foà, R | 1 |
| Small, S | 1 |
| Staudt, LM; Young, RM | 1 |
| Cravatt, BF; Dix, MM; Douhan, J; Gilbert, AM; Hayward, MM; Hett, EC; Hulce, JJ; Johnson, TO; Joslyn, C; Kath, JC; Lanning, BR; Niessen, S; Roberts, LR; Schnute, ME; Wang, C; Wei, B; Whitby, LR; Whiteley, LO | 1 |
| Zinzani, PL | 1 |
| Amorim, S; Balasubramanian, S; Bandyopadhyay, N; de Vries, R; Flinn, I; Fourneau, N; Friedberg, JW; Hellemans, P; Hivert, B; Morschhauser, F; Oki, Y; Smit, JW; Thieblemont, C; Vermeulen, J; Westin, J; Younes, A | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Ceribelli, M; Ferrer, M; Guha, R; Joshi, S; Keller, JM; Kelly, PN; Liu, D; Mathews Griner, LA; Nerle, S; Normant, E; Patel, PR; Sandy, P; Shaffer, AL; Shinn, P; Staudt, LM; Thomas, CJ; Wright, GW; Xiao, W; Yang, Y | 1 |
| Bruhn, C | 1 |
| Ewald, F; Grabinski, N | 1 |
| Ali, S; Blecua, P; Chang, B; Chen-Kiang, S; Chiron, D; Di Liberto, M; Elemento, O; Ely, S; Eng, K; Huang, X; Johnson, A; Leonard, JP; Martin, P; Mason, CE; Mathew, S; Sharman, J; Vijay, P | 1 |
| Bagcchi, S | 2 |
| Burbury, K; Cole-Sinclair, M; Filshie, R; Horton, L; Kamel, S; Keating, MJ; Khot, A; Levade, M; Nandurkar, H; Reynolds, J; Sandhu, S; Schischka, S; Tam, CS; Tan, S; Ysebaert, L | 1 |
| Burger, JA; Cardenas-Turanzas, M; de Weerdt, I; Ferrajoli, A; Garg, N; Hartmann, E; Hoellenriegel, J; Huang, X; Jeyakumar, G; Jorgensen, JL; Kantarjian, H; Keating, MJ; Lerner, S; Nogueras-González, GM; O'Brien, S; Rosenwald, A; Rosin, NY; Wierda, WG; Zacharian, G | 1 |
| Ghia, P | 2 |
| Hutchinson, C; Rule, S; Shah, N | 1 |
| Anreddy, N; Chen, ZS; Fu, LW; Kathawala, RJ; Li, XJ; Ma, SL; Patel, A; Wang, YJ; Yang, PQ; Zhang, H; Zhang, YK | 1 |
| Buggy, JJ; Cheng, M; Clow, F; Fardis, M; Goldstein, L; Hamdy, A; Izumi, R; James, DF; Kunkel, LA; Smith, DD | 1 |
| Cheng, S; Coleman, M; Guo, A; Lu, P; Ma, J; Wang, YL | 1 |
| Burger, JA; Komarova, NL; Wodarz, D | 1 |
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Haura, EB; Rix, U | 1 |
| Byrd, JC; Dong, S; Dubovsky, JA; Guinn, D; Johnson, AJ; Kutok, J; Lehman, A; Woyach, JA; Zhong, Y | 1 |
| Antin, JH; Blazar, BR; Byrd, JC; Cutler, C; Devine, SM; Du, J; Dubovsky, JA; Elias, L; Flynn, R; Harrington, BK; Hill, GR; Jaglowski, S; Johnson, AJ; Kaffenberger, B; Koreth, J; Lehman, A; Luznik, L; MacDonald, KK; Maillard, I; Munn, DH; Murphy, WJ; Muthusamy, N; Panoskaltsis-Mortari, A; Ritz, J; Serody, JS; Soiffer, RJ; Towns, WH; Wong, HK; Yang, C; Zhong, Y | 1 |
| Bodo, J; Durkin, L; Hsi, ED; Lin, J; Smith, MR; Sun, D; Zhao, X | 1 |
| Bowles, KM; Lawes, MJ; MacEwan, DJ; Murray, MY; Rushworth, SA; Shafat, MS; Zaitseva, L | 1 |
| Yamamoto, K | 1 |
| Bordet, JC; Cadot, S; David, E; Garcia, C; Laurent, PA; Levade, M; Michallet, AS; Payrastre, B; Sié, P; Tam, C; Ysebaert, L | 1 |
| Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W | 1 |
| Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP | 1 |
| Liu, H; Pan, Z; Zhang, Q | 1 |
| Buggins, AG; Devereux, S; Fegan, C; Forconi, F; Jones, CH; Pepper, C; Pratt, G; Stevenson, FK; Walsby, EJ | 1 |
| Niemann, CU | 2 |
| Chung, C; Lee, R | 1 |
| Blum, KA; Byrd, JC; Christian, B; Flynn, J; Jaglowski, S; Jenkins, C; Jones, JA; Lozanski, G; Maddocks, K; Porcu, P; Wei, L | 1 |
| Herrera, AF; Jacobsen, ED | 1 |
| Cao, Y; Castillo, JJ; Chen, J; Hunter, ZR; Kanan, S; Liu, X; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A | 1 |
| Badar, T; Burger, JA; O'Brien, S; Wierda, WG | 1 |
| Baran-Marszak, F; Bernard, S; Cymbalista, F; Danglade, D; Gardano, L; Gribben, J; Laguillier, C; Lazarian, G; Ledoux, D; Marzec, J; Roger, C; Thieblemont, C; Varin-Blank, N | 1 |
| Sinha, G | 1 |
| Kim, SS; Lee, CS; Rattu, MA | 1 |
| Govindarajan, R; Johnsurd, J; Kaur, V; Mehta, P | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J | 1 |
| Bockx, M; Bode, N; Cuyckens, F; de Jong, J; Laenen, A; Leclercq, L; Mannens, G; Murphy, J; Scheers, E; Skee, D; Sukbuntherng, J | 1 |
| Boey, EJ; Keating, MJ; McMullen, JR; Ooi, JY; Seymour, JF; Tam, CS | 1 |
| Bomben, R; Ciardullo, C; D'Agaro, T; Dal Bo, M; Famà, R; Gaidano, G; Gattei, V; Monti, S; Rasi, S; Rossi, D; Rossi, F; Zucchetto, A | 1 |
| Intlekofer, AM; Mancebo, SE; Myskowski, PL; Smith, JR; Zelenetz, AD | 1 |
| Chiba, M; Shibata, Y | 1 |
| Burger, JA; Ferrajoli, A; Keating, MJ; O'Brien, S; Thompson, PA; Wierda, WG | 1 |
| Arthur, DC; Aue, G; Calvo, KR; Childs, R; Farooqui, MZ; Geisler, CH; Herman, SE; Hughes, TE; Jones, J; Lee, YS; Lipsky, A; Maric, I; Marti, G; Martyr, S; Niemann, CU; Pedersen, LB; Pittaluga, S; Saba, N; Soto, S; Stetler-Stevenson, M; Tian, X; Valdez, J; Wiestner, A; Young, NS; Yuan, C | 1 |
| Beaupre, DM; Furtado, M; McGreivy, J; Munneke, B; Rule, S; Wang, ML | 1 |
| Auger, MJ; Bowles, KM; Craig, JI; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Kharfan-Dabaja, MA | 1 |
| Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Lamothe, B; Sivina, M; Wierda, WG | 1 |
| Burger, J; Estrov, Z; Ferrajoli, A; George, B; Jain, N; Jain, P; James, D; Kantarjian, H; Keating, M; O'Brien, S; Wierda, W | 1 |
| Cao, Y; Castillo, JJ; Chen, J; Davids, MS; Hatjiharissi, E; Hunter, ZR; Kanan, S; Liu, X; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Das, S; Franqui, R; Gu, Z; Hao, M; Huang, J; Janz, S; Levasseur, D; Salama, ME; Shi, J; Tao, Y; Tricot, G; Wendlandt, E; Xu, H; Yang, Y; Zhan, F | 1 |
| Govindarajulu, B; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
| Dangi-Garimella, S | 1 |
| Pettitt, AR; Slupsky, JR; Till, KJ | 1 |
| Giri, S; Hahn, A; Martin, MG; Yaghmour, G | 1 |
| Fegan, C; Pepper, C | 1 |
| Dagger, SA; Duyvestyn, JM; Forfang, L; Langdon, WY; Myklebust, JH; Oksvold, MP; Smeland, EB; Taylor, SJ | 1 |
| Castillo, JJ; Ghobrial, IM; Treon, SP | 2 |
| Burckhardt, L; Czerwinski, DK; Kohrt, HE; Levy, R; Sagiv-Barfi, I | 1 |
| Champlin, RE; Wang, ML; Wang, Y; Zhang, LL | 1 |
| Alinari, L; Blum, KA; Quinion, C | 1 |
| Calvert, V; Guendel, I; Iordanskiy, S; Kashanchi, F; Kehn-Hall, K; Petricoin, E; Saifuddin, M; Sampey, GC; Van Duyne, R | 1 |
| Bilotti, E; Blum, KA; Burger, JA; Byrd, JC; Coleman, M; Coutre, SE; Furman, RR; Heerema, NA; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Shaw, Y; Wierda, WG; Zhao, W; Zhou, C | 1 |
| Champlin, RE; Cheah, CY; Chihara, D; Fowler, NH; Hagemeister, FB; Romaguera, JE; Seymour, JF; Wang, ML | 1 |
| Danilov, AV; Dunbar, N; Manda, S; Marx-Wood, CR | 1 |
| Byrd, JC; Chauhan, V; de Jong, J; Hellemans, P; James, D; Jiao, J; Loury, DJ; Mannaert, E; Murphy, J; O'Brien, S; Skee, D; Sukbuntherng, J | 1 |
| Chang, BY; Czerwinski, DK; Kohrt, HE; Levy, R; Ng, PP; Sagiv-Barfi, I | 1 |
| Bowen, D; Call, TG; Chanan-Khan, A; Conte, M; Ding, W; Hanson, CA; Kay, NE; Leis, JF; Nowakowski, GS; Parikh, SA; Schwager, SM; Shanafelt, TD; Slager, SL; Tsang, M | 1 |
| Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Clow, F; Flinn, IW; Friedberg, JW; Graef, T; James, DF; O'Brien, S; Rai, K; Tran, A | 1 |
| Badolia, R; Dangelmaier, C; Eble, JA; Ellmeier, W; Kahn, M; Kunapuli, SP; Manne, BK | 1 |
| Amiot, M; Brosseau, C; Chiron, D; Dousset, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Touzeau, C | 1 |
| Dhillon, S; Kim, ES | 1 |
| Herishanu, Y; Katz, BZ | 1 |
| Molica, S | 4 |
| Borah, BJ; Call, TG; Chaffee, KG; Chanan-Khan, AA; Ding, W; Finnes, HD; Kay, NE; Leis, JF; Parikh, SA; Shanafelt, TD; Slager, SL | 1 |
| Chavez, JC; Pinilla-Ibarz, J | 1 |
| Burger, JA; Keating, MJ; O'Brien, SM; Sanford, DS; Wierda, WG | 1 |
| Bergmann, M; Wendtner, CM | 1 |
| Balakrishnan, K; Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Lamothe, B; Wierda, WG; Woyach, JA | 1 |
| Hagiwara, K; Iida, H; Kunishima, S; Miyata, Y; Nagai, H; Naoe, T | 1 |
| de Rooij, MF; Kater, AP; Kersten, MJ; Kuil, A; Pals, ST; Spaargaren, M | 1 |
| Beckwith, KA; Byrd, JC; Guinn, D; Hing, ZA; Johnson, AJ; Lapalombella, R; Lehman, AM; Mantel, R; Smith, LL; Williams, E; Williams, K; Woyach, JA | 1 |
| Benjamini, O; Burger, JA; Champlin, R; Estrov, Z; Faderl, S; Ferrajoli, A; Hosing, C; Jain, P; Keating, MJ; Khouri, IF; O'Brien, S; Rozovski, U; Shpall, E; Thompson, PA; Wierda, WG | 1 |
| Barf, T; Driessen, C; Filippov, DV; Hoogendoorn, S; Kaptein, A; Liu, N; Overkleeft, HS; van de Kar, B; van der Marel, GA; van der Stelt, M | 1 |
| Advani, RH; Argyropoulos, KV; Aster, JC; Cao, Y; Castillo, JJ; Cheng, M; Clow, F; Ghobrial, I; Graef, T; Green, R; Harris, NL; Hunter, ZR; Kanan, S; Laubach, JP; Li, J; Meid, K; Palomba, ML; Patterson, CJ; Rodig, S; Salman, Z; Treon, SP; Tripsas, CK; Varma, G; Warren, D; Xu, L; Yang, G; Zehnder, JL | 1 |
| Lynn Wang, Y; Smith, SM; Zhang, SQ; Zhang, SY | 1 |
| Müschen, M | 1 |
| Affara, NI; Arribas, J; Beaulieu, ME; Elias, L; Evan, GI; Jauset, T; Massó-Vallés, D; Pedersen, K; Serrano, E; Sodir, NM; Soucek, L; Whitfield, JR | 1 |
| Al-Ali, HK; Ebert, T; Jaekel, N; Niederwieser, D; Schubert, S; Wang, SY | 1 |
| Bodo, J; Chen-Kiang, S; Di Liberto, M; Durkin, L; Elemento, O; Eng, K; Hsi, ED; Shetty, S; Smith, MR; Zhao, X | 1 |
| Balakrishnan, K; Burger, JA; Faia, K; Fu, M; Gandhi, V; Keating, MJ; Kutok, JL; O'Brien, S; Peluso, M; Rosin, NY; Wierda, WG | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Ding, N; Feng, L; Fu, K; Li, X; Pan, Z; Ping, L; Shi, Y; Song, Y; Wu, L; Zheng, X; Zhu, J | 1 |
| Andritsos, LA; Blum, KA; Byrd, JC; Dong, S; Dubovsky, JA; Flynn, J; Jaglowski, SM; Johnson, AJ; Jones, JA; Lehman, A; Liu, TM; Lozanski, A; Lozanski, G; Maddocks, K; Strattan, E; Woyach, JA; Zhang, X; Zhong, Y | 1 |
| Kronabel, D | 1 |
| Schneider, SM; Smithson, CR | 1 |
| Treon, SP | 1 |
| Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L | 1 |
| Spoelstra, SL | 1 |
| Lee, WH; Lin, WW; Wang, LS; Wu, AT; Yeh, CT; Yuan, CC; Zucha, MA | 1 |
| Gong, J; Mita, M; Rimel, B; Sachdev, E | 1 |
| Gentile, M; Morabito, F; Polliack, A; Seymour, JF | 1 |
| Aymerich, M; Campo, E; Colomer, D; Lagisetti, C; López-Guerra, M; López-Otín, C; Montraveta, A; Rodríguez, V; Roldán, J; Rosich, L; Villamor, N; Webb, TR; Xargay-Torrent, S | 1 |
| Farooqui, M; Herman, SE; Jones, J; Mustafa, RZ; Wiestner, A; Wong, DH | 1 |
| Lamanna, N | 1 |
| Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H | 1 |
| Berglöf, A; Hamasy, A; Kimby, E; Krstic, A; Månsson, R; Meinke, S; Österborg, A; Palma, M; Smith, CI | 1 |
| Andritsos, LA; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Hall, N; Heerema, NA; Jaglowski, SM; James, DF; Johnson, AJ; Jones, JA; Lozanski, G; Maddocks, KJ; Munneke, B; Nagar, V; Neuenburg, JK; Ruppert, AS; Smucker, K; Stefanos, M; West, JS; Woyach, JA | 1 |
| Thieblemont, C | 2 |
| Ansell, SM; Chakraborty, R; Gertz, MA; Kapoor, P | 1 |
| Chen, C; Griffin, JD; Hu, C; Liu, J; Liu, Q; Liu, S; Nonami, A; Stone, RM; Wang, A; Wang, B; Wang, L; Wang, W; Weisberg, EL; Wu, H; Wu, J; Yu, K; Zhao, Z | 1 |
| Feugier, P; Michallet, AS; Ysebaert, L | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Fischer, K; Hallek, M; Kreuzer, KA; Langerbeins, P; Pflug, N; Rhein, C; Stilgenbauer, S; Wendtner, CM | 1 |
| Smith, MR | 1 |
| Byrd, JC; Long, M | 1 |
| Dubovsky, JA; Fabbro, SK; Gru, AA; Jones, JA; Smith, SM | 1 |
| Abruzzo, L; Andritsos, LA; Awan, F; Blum, KA; Byrd, JC; Davis, M; Flynn, JM; Gordon, A; Grever, MR; Heerema, NA; Jaglowski, SM; Johnson, AJ; Jones, JA; Lozanski, A; Lozanski, G; Maddocks, KJ; Mantel, R; Ruppert, AS; Smith, LL; Woyach, JA; Zhao, W | 1 |
| Advani, R; Barr, PM; Barrientos, JC; Beaupre, DM; Blum, KA; Chang, BY; Clow, F; de Vos, S; Elstrom, RL; Fardis, M; Fowler, NH; Gerecitano, J; Goy, A; Habermann, TM; Kenkre, VP; Lih, CJ; McGreivy, J; Moussa, D; Munneke, B; Pittaluga, S; Schmitz, R; Shaffer, AL; Shustov, A; Staudt, LM; Vose, JM; Williams, PM; Wilson, WH; Wright, G; Yang, Y; Young, RM | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Kantarjian, HM; Keating, MJ; O'Brien, SM; Smith, SC; Stingo, F; Thompson, PA; Wierda, WG | 1 |
| Brower, V | 2 |
| Dearden, C; Iyengar, S; Rogers, M; Wotherspoon, A | 1 |
| Fiore, W; Gatti, M; Generali, D; Gianardi, V; Grisafi, D; Grumi, C; Lanza, F; Maestro, A; Piazzoni, L; Ravelli, A; Scaglione, F; Tasca, F; Tessari, R; Tirone, G | 1 |
| Bayerl, S; Dreyling, M; Hiddemann, W; Hutter, G; Zimmermann, Y; Zoellner, AK | 1 |
| Amorim, S; Bernard, S; Brice, P; Brière, J; de Kerviler, E; Goldwirt, L; Mourah, S; Sauvageon, H; Thieblemont, C | 1 |
| Hunter, Z; Treon, SP; Xu, L | 1 |
| Bhalla, KN; Bradner, JE; Coarfa, C; Devaraj, SG; Fiskus, W; Krieger, S; Li, L; Qi, J; Rajapakshe, K; Saenz, DT; Shah, B; Sharma, S; Sun, B; Wang, ML; Zhang, L | 1 |
| Al-Hakim, A; Brower, ME; Bullock, J; Chang, CJ; Chen, XH; Chiu, HJ; de Claro, RA; Farrell, AT; Habtemariam, B; Justice, R; Kaminskas, E; Kane, RC; Lee, SL; Lu, DR; McGinn, KM; Nie, L; Pazdur, R; Pfuma, E; Saber, H; Verdun, N; Wang, Y | 1 |
| Calvo, KR; Farooqui, MZ; Herman, SE; Lee, YS; Maric, I; Marti, GE; Martyr, S; Niemann, CU; Salem, D; Skarzynski, M; Soto, S; Stetler-Stevenson, M; Valdez, J; Wiestner, A; Yuan, C | 1 |
| Abdul-Aziz, A; Bowles, KM; Lawes, M; MacEwan, DJ; Pillinger, G; Rushworth, SA; Zaitseva, L | 1 |
| Banaei, N; Deresinski, S; Forrester, JA; Forrester, JD; Gomez, CA; Gregg, D; Nguyen, M; Weiser, TG | 1 |
| Aue, G; Farooqui, MZ; Gunti, S; Herman, SE; Kardava, L; Lee, YS; Lipsky, A; Maric, I; Marti, GE; Moir, S; Notkins, AL; Salem, D; Soto, S; Stetler-Stevenson, M; Sun, C; Tian, X; Valdez, J; Wiestner, A; Yuan, C | 1 |
| Levato, L; Mirabelli, R; Molica, S | 1 |
| Bastian, D; Fu, J; Heinrichs, J; Liu, C; McDonald, DG; Nguyen, H; Pidala, J; Schutt, SD; Wu, Y; Yu, XZ | 1 |
| Bari, S; Clow, F; Doyle, M; Faust, E; Fung, M; Gayko, U; James, D; Price, S; Sun, S; Zhuang, SH | 1 |
| Burger, JA; Chan, WC; Davis, RE; Fanale, MA; Fayad, L; Fowler, N; Fu, K; Hagemeister, FB; Hoellenriegel, J; Huang, X; Kantarjian, H; Keating, MJ; Kwak, LW; Neelapu, S; O'Brien, S; Oki, Y; Romaguera, JE; Samaniego, F; Sivina, M; Takahashi, K; Vose, JM; Wierda, W; Xiao, L | 1 |
| Bye, AP; Fry, MJ; Gibbins, JM; Stainer, AR; Unsworth, AJ; Vaiyapuri, S | 1 |
| Robak, T; Smolewski, P; Witkowska, M | 1 |
| Hojjat-Farsangi, M; Jadidi-Niaragh, F; Kokhaei, P; Mellstedt, H; Osterborg, A; Sotoodeh Jahromi, A | 1 |
| Chen, C; Chen, L; Gray, NS; Hu, C; Li, X; Liu, J; Liu, Q; Wang, A; Wang, B; Wang, C; Wang, J; Wang, L; Wang, W; Weisberg, EL; Wu, H; Wu, J; Yan, XE; Ye, Z; Yu, K; Yun, CH; Zhang, W; Zhao, P; Zhao, Z | 1 |
| de Jong, J; de Vries, R; de Zwart, L; Hellemans, P; Jiao, J; Mannaert, E; Murphy, J; Skee, D; Smit, JW; Snoeys, J; Sukbuntherng, J; Vliegen, M | 1 |
| Cheu, L; Chittur, SV; Conklin, DS; Karimipoor, M; Kokabee, L; Sevinsky, CJ; Tenniswood, M; Wang, WL; Wang, X | 1 |
| Balasubramanian, S; Hamadani, M; Hari, PN | 1 |
| Collins, RH; Dietrich, MF; Gerber, DE | 1 |
| Cullinane, AM; Farooqui, MZ; Herman, SE; Holland, SM; Lipsky, AH; Lozier, JN; Marti, G; Martyr, S; Nghiem, K; Niemann, CU; Saba, N; Soto, S; Sun, C; Tian, X; Uzel, G; Valdez, J; Wiestner, A | 1 |
| Boissard, F; Fournié, JJ; Poupot, M; Quillet-Mary, A; Ysebaert, L | 1 |
| Almarzouqi, SJ; Chevez-Barrios, P; Khan, K; Lee, AG; Malik, AI; Morgan, ML; Yalamanchili, S | 1 |
| Gandhi, V; Keating, MJ; Patel, V; Wierda, WG | 1 |
| Andritsos, LA; Awan, FT; Bingman, A; Blum, KA; Byrd, JC; Flynn, JM; Jaglowski, SM; Jones, JA; Lozanski, G; Maddocks, KJ; Rogers, KA; Ruppert, AS; Woyach, JA | 1 |
| Goede, V; Hallek, M | 1 |
| Ballard, TE; Bessire, AJ; Dahal, UP; Geoghegan, KF; Schneider, RP; Vaz, AD | 1 |
| Coldwell, MJ; Forconi, F; Hidalgo, MS; Ishfaq, M; Krysov, S; Leonard, E; Linley, A; Packham, G; Steele, AJ; Stevenson, FK; Thirdborough, SM; Valle-Argos, B; Wagner, SD; Willis, AE; Yeomans, A | 1 |
| Bode, N; de Vries, R; Huang, M; Jejurkar, P; Jong, Jd; Sips, L; Sukbuntherng, J; Timmerman, P; Verhaeghe, T; Weng, N | 1 |
| Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R | 1 |
| Cerchietti, L; Chang, B; Chiosis, G; Elenitoba-Johnson, K; Gerecitano, J; Goldstein, RL; Leonard, JP; Melnick, A; Shaknovich, R; Taldone, T; Tam, W; Yang, SN | 1 |
| Bognar, M; Eitelhuber, AC; Krappmann, D; Kutzner, K; Nagel, D; Vincendeau, M | 1 |
| Beijnen, JH; Rood, JJM; Schellens, JHM; Schinkel, AH; Sparidans, RW; van Hoppe, S | 1 |
| Hawkes, N | 2 |
| Angelucci, E; Cabras, MG | 1 |
| Iida, S | 1 |
| Agathanggelou, A; Brown, J; Davies, N; Hillmen, P; Kwok, M; Lau, A; Moss, P; Oldreive, C; Parry, H; Petermann, E; Pratt, G; Smith, E; Stankovic, T; Stewart, G; Taylor, M | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Aoki, T; Ishizawa, K; Morishita, T; Munakata, W; Ogura, M; Suzuki, T; Takahara, S; Tobinai, K; Uchida, T; Ushijima, Y | 1 |
| Burger, JA; Sivina, M | 1 |
| Barber, DL; Datti, A; Gronda, M; Hurren, R; Lin, FH; MacLean, N; Minden, MD; Rotin, LE; Schimmer, AD; Slassi, M; Wang, X; Wrana, J | 1 |
| Butchar, JP; Byrd, JC; Campbell, A; Carson, WE; Elavazhagan, S; Fang, H; Fatehchand, K; Gautam, S; Mehta, P; Mo, X; Reader, BF; Ren, L; Stiff, A; Tridandapani, S | 1 |
| de Rooij, MF; Kersten, MJ; Kraan, W; Kuil, A; Pals, ST; Spaargaren, M; Treon, SP | 1 |
| Woyach, JA | 8 |
| Dearden, C | 1 |
| Hagiwara, K; Iida, H; Nagai, H; Tokunaga, T | 1 |
| Bairey, O; Barr, PM; Bartlett, NL; Burger, JA; Cheng, M; Clow, F; Coutre, S; Devereux, S; Gaidano, G; Ghia, P; Grosicki, S; Hellmann, A; Hillmen, P; James, DF; Janssens, A; Kipps, TJ; Li, J; Maslyak, Z; Mayer, J; McCarthy, H; O'Dwyer, M; Offner, F; Owen, C; Polliack, A; Quach, H; Robak, T; Schuh, A; Siddiqi, T; Simpson, D; Stevens, DA; Styles, L; Suri, D; Tam, CS; Tedeschi, A | 1 |
| Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Biancotto, A; Braylan, RC; Calvo, KR; Chang, BY; Farooqui, MZ; Gomez-Rodriguez, J; Herman, SE; Jones, J; Lee, YS; Maric, I; Marti, GE; Martyr, S; Niemann, CU; Stetler-Stevenson, M; Sun, C; Valdez, J; Wiestner, A; Wong, DH; Yuan, CM | 1 |
| Balasubramanian, S; Bandyopadhyay, N; Bence-Bruckler, I; Bothos, J; Caballero, D; Cho, SG; Dreyling, M; Enny, C; Goldberg, JD; Hess, G; Jerkeman, M; Joao, C; Jurczak, W; Offner, F; Rizo, A; Rule, S; Rusconi, C; Silva, RS; Sun, S; Traina, S; Trneny, M; Vermeulen, J; Witzens-Harig, M | 1 |
| Martin, P | 1 |
| Humphreys, WG; Shu, YZ; Yang, Y | 1 |
| Abdul-Aziz, A; Bowles, KM; Lawes, MJ; MacEwan, DJ; Murray, MY; Piddock, R; Pillinger, G; Rushworth, SA; Shafat, MS; Zaitseva, L | 1 |
| Amorim, S; Bay, JO; Beldjord, K; Berger, J; Brice, P; Cabannes-Hamy, A; De Kerviler, E; Goldwirt, L; Lemal, R; Mourah, S; Pérignon, R; Poulain, S; Sauvageon, H; Thieblemont, C; Tournilhac, O | 1 |
| Kim, JH; Kim, SJ; Kim, WS; Park, C; Ryu, K | 1 |
| Arimany-Nardí, C; Aymerich, M; Cabezas, S; Campo, E; Clot, G; Colomer, D; Jiménez, L; Lee-Vergés, E; López-Guerra, M; López-Guillermo, A; Montraveta, A; Pastor-Anglada, M; Pérez-Galán, P; Pinyol, M; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
| Brooks, S; Daniel, C; Ganetsky, A; Islam, P; Kaye, AH; Mato, AR; Nabhan, C; Nasta, S; Porter, DL; Schuster, SJ; Strelec, L; Svoboda, J | 1 |
| Dahlqvist, G; de Jésus Ngoma, P; Horsmans, Y; Kabamba, B; Lanthier, N; Sempoux, C; Shindano, T; Van Den Neste, E | 1 |
| Coleman, M; Galanina, N; Guo, A; Lu, P; Nabhan, C; Smith, SM; Wang, YL | 1 |
| Gronda, M; Hurren, R; Minden, MD; Rotin, LE; Schimmer, AD; Slassi, M; Wang, X | 1 |
| Bornhäuser, M; Heidenreich, F; Link, CS; Middeke, JM; Muetherig, A; Oelschlägel, U; Platzbecker, U; Reinhardt, J; Rücker-Braun, E; Schetelig, J; Schmiedgen, M; Teipel, R; Trautmann-Grill, K; von Bonin, M | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Rule, SA; Tucker, DL | 1 |
| Advani, R; Auer, R; Barr, PM; Bloehdorn, J; Blum, KA; Chen, Z; Chen-Kiang, S; Chmielowska, E; DiLiberto, M; Dreyling, M; Furman, RR; Goy, A; Iberri, D; Jurczak, W; Kozin, E; Leonard, JP; Maddocks, K; Martin, P; Noto, K; Phillips, T; Portell, C; Ruan, J; Rule, S; Spurgeon, S; Stilgenbauer, S; Wagner-Johnston, N; Williams, ME | 1 |
| Foluso, O; Glick, A; Jaiyesimi, I; Stender, M | 1 |
| Barrett, DM; Beckwith, KA; Byrd, JC; Cogdill, AP; Cook, DR; Do, P; Fraietta, JA; Gill, S; Hulitt, J; Johnson, AJ; June, CH; Kudchodkar, SB; Lacey, SF; Levine, BL; Long, M; Maddocks, K; Maus, MV; McGettigan, SE; Melenhorst, JJ; Muthusamy, N; Patel, PR; Porter, DL; Ruella, M; Woyach, JA; Xu, J; Zhang, C; Zheng, Z | 1 |
| Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B | 1 |
| Fraietta, JA; Gill, S; June, CH; Kalos, M; Kawalekar, OU; Kenderian, SS; Klichinsky, M; Lacey, SF; Liu, X; Mato, A; Maus, MV; Milone, M; Nunez-Cruz, S; Qayyum, S; Ruella, M; Schuster, SJ; Shestova, O; Wasik, MA; Zhang, Q | 1 |
| Bay, JO; Dougé, A; Guièze, R; Lemal, R; Ravinet, A; Tournilhac, O | 1 |
| Byrd, JC; Caligiuri, MA; Campbell, A; Carson, WE; Dubovsky, J; Duggan, M; Harrington, B; Howard, JH; Hsu, V; Keller, K; Kendra, K; Landi, I; Mace, T; McMichael, E; Muthusamy, N; Old, M; Reiff, S; Stiff, A; Tridandapani, S; Trikha, P; Uppati, S; Wesolowski, R; Yu, L; Zhong, Y | 1 |
| Ott, G; Rauert-Wunderlich, H; Rosenwald, A; Rudelius, M | 1 |
| Kimber, T; Seymour, JF; Tam, CS | 1 |
| Bacher, U; Binder, M; Bleckmann, A; Braulke, F; Haase, D; Hasenkamp, J; Hellige, N; Jung, W; Schanz, J; Shumilov, E; Ströbel, P; Trümper, L; Wulf, G | 1 |
| Gaidano, G; Ghia, P; Malcikova, J; Montserrat, E; Moreno, C; Pospisilova, S; Rosenquist, R; Rossi, D; Stamatopoulos, K; Sutton, LA; Tausch, E | 1 |
| Andritsos, LA; Jaglowski, SM; McBride, A; Vela, CM | 1 |
| Barassi, C; Bernasconi, E; Bertoni, F; Cascione, L; Gaudio, E; Goodstal, S; Kwee, I; Ponzoni, M; Rinaldi, A; Stathis, A; Tarantelli, C; Targa, A; Zucca, E | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Kaur, V; Swami, A | 2 |
| Bitar, C; Bray, A; Cowen, EW; Farooqui, MZ; Marti, G; Saba, NS; Soto, S; Valdez, J; Wiestner, A | 1 |
| Delmer, A; Durot, E; Michonneau, D; Pannetier, M; Peffault De Latour, R; Quinquenel, A; Sicre de Fontbrune, F; Socié, G | 1 |
| Aurran-Schleinitz, T; Birsen, R; Hunault, M; Leblond, V; Lemal, R; Wanquet, A | 1 |
| Castillo, JJ; Dubeau, TE; Gustine, JN; Meid, K; Treon, SP | 1 |
| Cavallari, M; Cavazzini, F; Cuneo, A; Foà, R; Formigaro, L; Lista, E; Martinelli, S; Quaglia, FM; Rigolin, GM | 1 |
| Chowdhury, SK; Ma, S | 1 |
| Ahn, IE; Burger, JA; Estrov, Z; Farooqui, M; Ferrajoli, A; Jain, N; Keating, MJ; Konoplev, SN; O'Brien, S; Sivina, M; Vitale, C; Wierda, WG; Wiestner, A | 1 |
| Ezzeldin, E; Iqbal, M; Shakeel, F | 1 |
| Arnason, J; Avigan, D; Bhan, A; Cen, O; Chen, SS; Chiorazzi, N; Engel, P; Gattei, V; Halibozek, PJ; Longnecker, R; O'Keeffe, MS; Terhorst, C; Wang, N; Yigit, B | 1 |
| Dagher, R; Donnelly, ET; Kalanovic, D; Koehler, M; Rothenberg, ML | 1 |
| Magro, CM; Mulvey, JJ; Nuovo, GJ | 1 |
| Damon, LE | 1 |
| Geng, LY; Li, PP; Li, XY; Lu, K; Wang, X; Zhou, XX | 1 |
| Chihara, D; Kim, P; Lee, HJ; Mouhayar, E; Wang, M | 1 |
| Bojarczuk, K; Efremov, DG; Gobessi, S; Innocenti, I; Laurenti, L; Pozzato, G; Sasi, BK | 1 |
| Beà, S; Behrend, D; Dunleavy, K; Fontan, L; Grant, C; Gyamfi, J; Herman, SE; Liu, D; Melnick, A; Navarro, A; Pittaluga, S; Roschewski, M; Saba, NS; Skarzynski, M; Tian, X; Underbayev, C; Weniger, MA; Wiestner, A; Wilson, WH | 1 |
| Brown, JR; Buhrlage, SJ; Castillo, JJ; Chen, J; Chen, JG; Cohen, P; Gray, N; Hunter, ZR; Liu, S; Liu, X; Patterson, CJ; Tan, L; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G; Zhang, W; Zhang, X | 1 |
| Norman, P | 1 |
| Delgado, J; Montserrat, E | 1 |
| Steingart, R; Tripathi, A | 1 |
| Mihailescu, L; Riordan, R; Rule, S; Tucker, DL | 1 |
| Follows, G; Hamilton, MS; Kruger, A; Naylor, G; Rule, SA; Tucker, DL | 1 |
| Bose, P; Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Kumar Patel, V | 1 |
| Andersson, PO; Asklid, A; Hansson, L; Karlsson, C; Karlsson, K; Lauri, B; Lundin, J; Mattsson, M; Norin, S; Österborg, A; Sandstedt, A; Winqvist, M | 1 |
| Abruzzo, LV; Bozic, I; Brown, JR; Burger, JA; Carter, SL; Cibulskis, K; Dal Cin, P; Davids, MS; Dubuc, AM; Fan, J; Fraser, C; Gabriel, S; Getz, G; Han, Y; Hoellenriegel, J; Kantarjian, H; Keating, MJ; Kharchencko, P; Konoplev, S; Landau, DA; Lander, E; Letai, A; Li, S; Livak, KJ; Neuberg, D; Nowak, MA; O'Brien, S; Sarosiek, K; Sivina, M; Sougnez, C; Stewart, C; Taylor-Weiner, A; Wan, Y; Wang, L; Weitz, DA; Werner, L; Wierda, WG; Wu, CJ; Zenz, T; Zhang, H; Zou, L | 1 |
| Ding, K; Lai, Y; Luo, M; Tu, Z; Xiao, J; Yao, K; Zhang, Y; Zou, Y | 1 |
| Akyüz, N; Binder, M; Bokemeyer, C; Ford, CT; Knop, S; Krohn-Grimberghe, A; Mährle, T; Schliffke, S; Thenhausen, T | 1 |
| Cheson, BD | 3 |
| Chen, L; de Miranda, NF; Dlugosz-Danecka, M; Galazka, K; Jurczak, W; Machaczka, M; Mansouri, L; Morin, RD; Pan-Hammarström, Q; Peng, R; Rosenquist, R; Sander, B; Wasik, AM; Wu, C; Zhang, H | 1 |
| Baseggio, L; Catallo, R; Chebel, A; Ffrench, M; Magaud, JP; Manzoni, D; Michallet, AS; Roualdes, O; Salles, G | 1 |
| Bernasconi, E; Bertoni, F; Gaudio, E; Kwee, I | 1 |
| Caron, F; Duan, A; Fraser, G; Healey, JS; Hillis, C; Leong, DP; Siegal, D | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J | 1 |
| de Jong, J; de Vries, R; Hellemans, P; Jiao, J; Lawitz, E; Mannaert, E; Marbury, T; Skee, D; Smith, W; Sukbuntherng, J; Swerts, D | 1 |
| Berglöf, A; Blomberg, KE; Hamasy, A; Mohammad, DK; Smith, CI; Vihinen, M; Wang, Q; Yu, L | 1 |
| Gallardo, M; Hornbaker, MJ; Larsson, CA; Lee, HJ; Ma, H; Mejia, A; Pageon, LR; Post, SM; Qi, Y; Quintas-Cardama, A; Su, X; Zhang, X | 1 |
| Acharya, C; Acharya, P; Anderson, KC; Ballestrero, A; Cagnetta, A; Cea, M; Chauhan, D; Fraternali-Orcioni, G; Gobbi, M; Hideshima, T; Lemoli, RM; Lovera, D; Mastracci, L; Miglino, M; Monacelli, F; Montecucco, F; Munshi, N; Nencioni, A; Soncini, D; Tai, YT; Treon, SP; Yang, C | 1 |
| Andrews, DW; Brauer, PM; Hariharan, S; Leber, B; Oakes, CC; Oppermann, S; Shi, Y; Spaner, DE; Ylanko, J; Zúñiga-Pflücker, JC | 1 |
| Chan, KL; Lew, TE; Lokan, J; Prince, HM; Tam, CS | 1 |
| Marini, BL; Perissinotti, AJ; Samanas, L | 1 |
| De Jong, J; de Zwart, L; Mannaert, E; Monshouwer, M; Snoeys, J; Sukbuntherng, J | 1 |
| Chigaev, A; Colombatti, A; Del Poeta, G; Gattei, V; Hartmann, TN; Tissino, E; Zucchetto, A | 1 |
| Herman, SE; Wiestner, A | 1 |
| Wendtner, CM | 3 |
| Danilov, AV; Gordon, MJ; Raess, PW; Spurgeon, SEF; Young, K | 1 |
| Allen, SL; Castillo, JJ; Hunter, ZR; Mason, C; Rini, JN; Savona, S; Treon, SP; Xu, L | 1 |
| Abdelghaffar, HA; Abousamra, NK; Anastas, V; Barber, E; Calvo, KR; Corrigan-Cummins, M; Elbaz, O; Farooqui, M; Herman, SE; Saba, NS; Saleh, LM; Sarasua, SM; Sun, C; Wang, W; Wiestner, A; Zhao, Z | 1 |
| Khashab, T; Konoplev, SN; Loghavi, S; Samaniego, F | 1 |
| Berdel, WE; Grauer, OM; Kerkhoff, A; Keßler, T; Lenz, G; Lutz, M; Rebber, E; Schulze, AB; Wiebe, S; Zoubi, T | 1 |
| Borsky, M; Brown, JR; Calogero, R; Cerna, K; Davids, MS; Doubek, M; Kipps, TJ; Mayer, J; Mraz, M; Osickova, J; Pavlasova, G; Pospisilova, S; Seda, V; Trbusek, M | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E | 1 |
| Ahn, IE; Farooqui, M; Gea-Banacloche, J; Jerussi, T; Tian, X; Wiestner, A | 1 |
| Couzens, L; Eichelberger, MC; Farooqui, MZ; Gao, J; Sun, C; Tian, X; Wiestner, A | 1 |
| Advani, RH; Coutre, SE; Iberri, DJ; Kim, J; Kwong, BY; Sabile, JM; Stevens, LA | 1 |
| Deinzer, J; Désiré, L; Gierschik, P; Hermkes, E; Mertens, D; Schade, A; Stilgenbauer, S; Walliser, C; Wiese, S; Zapatka, M | 1 |
| Chao, TY; Chiou, JF; Hsiao, M; Huang, SP; Huynh, TT; Jan, HJ; Lin, CM; Su, YK; Wei, L; Whang-Peng, J; Wu, AT | 1 |
| Belmont, LD; Bergeron, P; Bowman, K; Burton, L; Choy, R; Crawford, JJ; Eigenbrot, C; Estevez, A; Franke, Y; Gogol, E; Johnson, AR; Katewa, A; Kohli, PB; Li, H; Lin, M; Mortara, K; Ortwine, DF; Penuel, E; Tam, C; Wu, J; Young, WB; Yu, C | 1 |
| Liu, C; Liu, D; Tsui, ST; Wu, J | 1 |
| Bachow, SH; Barr, PM; Cheson, BD; Claxton, DF; Evens, AM; Feldman, T; Fitzpatrick, DM; Goy, A; Hill, BT; Howlett, C; Kaur, G; Kiselev, P; Lamanna, N; Landsburg, DJ; Mato, AR; Nabhan, C; Nasta, SD; Porter, D; Pu, JJ; Schuster, SJ; Sehgal, AR; Skarbnik, AP; Strelec, LE; Svoboda, J; Ujjani, CS; Vandegrift, A; Zent, CS | 1 |
| Audrito, V; Burger, JA; Deaglio, S; Fiorcari, S; Grisendi, G; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L; Ten Hacken, E; Zucchini, P | 1 |
| Hilmer, SN; Mulligan, SP; Ward, CM; Whalley, D | 1 |
| Al Nawakil, C; Cymbalista, F; Dilhuydy, MS; Dupuis, J; Goudot, FX; Keating, MJ; Lévy, V; Meune, C; Michallet, AS; Quinquenel, A; Tam, CS; Thompson, PA; Van Den Neste, E; Ysebaert, L | 1 |
| Choi, I; Fukuhara, N; Hatake, K; Ishikawa, T; Kinoshita, T; Kitano, T; Maruyama, D; Matsuno, Y; Nagai, H; Nishikawa, T; Nishikori, M; Shibayama, H; Takahara, S; Tobinai, K; Uchida, T | 1 |
| Chen, C; Chen, L; Gray, NS; Hu, C; Li, X; Liu, J; Liu, Q; Wang, A; Wang, B; Wang, C; Wang, J; Wang, L; Wang, W; Weisberg, EL; Wu, H; Yan, XE; Ye, Z; Yun, CH; Zhang, W; Zhao, P; Zhao, Z | 1 |
| Furtado, LV; Galanina, N; Guo, A; Kadri, S; Lee, J; Long, B; Lu, P; Ming, M; Segal, JP; Sharma, S; Stock, W; Tang, WJ; Van Slambrouck, C; Venkataraman, G; Wang, W; Wang, YL | 1 |
| Kalpadakis, C; Karouzakis, P; Koulieris, E; Moschogiannis, M; Pangalis, GA; Rontogianni, D; Sachanas, S; Yiakoumis, X | 1 |
| Brown, JR; Call, TG; Chu, AD; Clow, F; Coutre, SE; Furman, RR; Hallek, M; Hillmen, P; Ilhan, O; James, DF; Jones, JA; Keating, MJ; Li, Y; Mato, AR; O'Brien, S; Österborg, A; Siddiqi, T; Stevens-Brogan, M; Stilgenbauer, S; Tam, C; Thirman, MJ | 1 |
| Roskoski, R | 1 |
| Armitage, JO; Bennett, CL; Berger, JR; Carson, KR; Georgantopoulos, P; Hrushesky, WJ; Norris, LB; Raisch, DW; Sartor, O | 1 |
| Molica, S; Polliack, A | 1 |
| Arcidiacono, MV; Casciano, F; Celeghini, C; Cuneo, A; Melloni, E; Rigolin, GM; Rimondi, E; Secchiero, P; Voltan, R; Zauli, G | 1 |
| Gill, S; June, CH; Kenderian, SS; Klichinsky, M; Lacey, SF; Melenhorst, JJ; Ruella, M; Shestova, O; Wasik, MA | 1 |
| Bocchia, M; Brambilla, CZ; Candi, V; Fabbri, A; Gozzetti, A; Papini, G | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS | 1 |
| Barańska-Rybak, W; Mital, A; Nowicki, R; Sobjanek, M; Sławińska, M; Wilkowska, A | 1 |
| Amin, HM; Chen, L; Chen, RW; Das, M; Marcucci, G; Mohanty, A; Ngo, VN; Pham, LV; Pillai, R; Rosen, ST; Sandoval, N; Wang, M; Weisenburger, DD | 1 |
| Bohn, JP; Steurer, M; Wanner, D | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Reinhardt, HC | 1 |
| Koffman, B; Schorr, A | 1 |
| Jeyakumar, D; O'Brien, S | 1 |
| Awan, FT; Ayala, E; El-Asmar, J; Hamadani, M; Kharfan-Dabaja, MA | 1 |
| Bararia, D; Bird, L; Christie, AL; Christodoulou, A; Haebe, S; Jacobson, C; Kopp, N; Layer, JV; Redd, RA; Rodig, SJ; Saur, A; Tivey, T; Tschuri, S; van Bodegom, D; Weigert, O; Weinstock, DM; Zapf, S; Zimber-Strobl, U | 1 |
| Clayton, F; Girard, N; Poole, A; Tantravahi, SK | 1 |
| Goldschmidt, N; Rund, D | 1 |
| Blachly, JS; Bottoni, A; Byrd, JC; El-Gamal, D; Johnson, AJ; Lai, TH; Lapalombella, R; Larkin, K; Lehman, A; Liu, C; Mantel, R; Plunkett, W; Reiff, S; Rizzotto, L; Sampath, D; Smith, LL; Woyach, JA | 1 |
| Abraham, I; Acharya, U; Vincelette, ND; Yun, S | 1 |
| Bailey, NG; Beyersdorf, N; Chowdhury, P; Fujiwara, H; Hristov, AC; Lim, MS; Lu, Y; Murga-Zamalloa, C; Polk, A; Suemori, K; Wang, T; Wilcox, RA | 1 |
| Caraivan, I; Issara, K; Yossi, S | 1 |
| Brown, JR; Byrd, JC; Clow, F; Coutre, SE; Dyer, MJ; Hillmen, P; Jaglowski, S; Keating, MJ; Logan, AC; Mato, AR; Miklos, DB; O'Brien, S; Rezvani, AR; Ryan, CE; Sahaf, B; Styles, L | 1 |
| Ailawadhi, S; Akhtar, S; Ansell, SM; Bashir, Y; Caulfield, TR; Chanan-Khan, A; Chitta, K; Cogen, D; Coleman, M; Edenfield, B; Hudec, R; Jiang, J; Linder, S; Martin, P; Novak, A; Paulus, A; Paulus, SM; Roy, V; Samuel, K; Tran, D; Witzig, T; Yousaf, H | 1 |
| Bartoo, GT; Bowen, DA; Call, TG; Chaffee, KG; Chanan-Khan, A; Conte, M; Ding, W; Finnes, HD; Kay, NE; Kenderian, SS; Leis, J; McCullough, KB; Merten, JA; Parikh, SA; Schwager, SM; Shanafelt, TD; Slager, SL; Smith, MD | 1 |
| Palomba, ML | 1 |
| Ailawadhi, S; Chanan-Khan, A; Paulus, A | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Argyropoulos, K; Castillo, JJ; Hunter, ZR; Palomba, ML; Treon, SP; Yang, G | 1 |
| Carey, J; Gilreath, JA; Halwani, A; Stephens, DM; Sweetenham, JW; Vrontikis, A | 1 |
| Chavez, JC; Horna, P; Hussaini, MO; Pinilla-Ibarz, J; Rehman, A | 1 |
| Aurran-Schleinitz, T; Birsen, R; Bonnet, C; Boubaya, M; Choquet, S; Cymbalista, F; Delarue, R; Dietrich, PY; Dupuis, J; Fahri, J; Lamy, T; Leblond, V; Lemal, R; Lepretre, S; Levy, V; Michallet, AS; Re, D; Troussard, X; Wanquet, A; Ysebaert, L | 1 |
| Al Jijakli, A; Boyle, E; Chamoun, K; Choquet, S; Delrieu, V; Delwail, V; Hoang-Xuan, K; Houillier, C; Larrieu-Ciron, D; Morschhauser, F; Soussain, C | 1 |
| Bahlo, J; Call, TG; Chaffee, KG; Chanan-Khan, AA; Ding, W; Eichhorst, B; Fischer, K; Goede, V; Hallek, M; Kay, NE; Leis, JF; Noseworthy, PA; Parikh, SA; Schwager, SM; Shanafelt, TD; Slager, SL | 1 |
| Cuneo, A; Ghia, P | 1 |
| Chen, L; Chen, Y; Choi, MY; Cui, B; Kipps, TJ; Rassenti, LZ; Widhopf Ii, GF; Wu, C; Yu, J; Zhang, L | 1 |
| Bergmann, M; Drucker, C; Egle, A; Einberger, C; Follows, G; Hauswirth, A; Heinz, M; Hoermann, G; Jaeger, U; Jilma, B; Kazianka, L; Melchardt, T; Pabinger, I; Porpaczy, E; Quehenberger, P; Raderer, M; Skrabs, C; Staber, PB; Struve, S; Thalhammer, R; Thomas, W; Wendtner, CM | 1 |
| Ruella, M; Soubeyran, P | 1 |
| Bilotti, E; Buske, C; Castillo, JJ; Cornell, RF; de Larrea, CF; Dimopoulos, MA; García-Sanz, R; Graef, T; Granell, M; Heffner, LT; Kastritis, E; Kyrtsonis, MC; Leblond, V; Li, J; Ma, S; Macdonald, D; Matous, JV; Oriol, A; Shustik, C; Singh, P; Symeonidis, A; Tam, C; Tedeschi, A; Tournilhac, O; Treon, S; Trotman, J | 1 |
| Baseggio, L; Callet-Bauchu, E; Quintela, A; Salles, G; Sujobert, P | 1 |
| Cravatt, BF; Lum, KM; Whitby, LR; Zaro, BW | 1 |
| Bergmeier, W; Conley, PB; Lee, RH; Piatt, R | 1 |
| Brooks, HD; Burke, JM; Fanning, S; Farber, CM; Greenwald, DR; Klein, L; Kolibaba, KS; Mahadevan, D; Miskin, HP; Schreeder, MT; Sharman, JP; Sportelli, P; Weiss, MS | 1 |
| Beyer, A; Ganti, B; Majkrzak, A; Theyyunni, N | 1 |
| Smith, LL | 1 |
| Ailawadhi, S; Ansell, SM; Bergsagel, PL; Braggio, E; Buadi, FK; Chanan-Khan, A; Colgan, JP; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Greipp, PT; Grogan, M; Habermann, TM; Hayman, SR; Hwa, YL; Inwards, DJ; Jevremovic, D; Johnston, PB; Kapoor, P; Ketterling, RP; King, RL; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Markovic, SN; Mauermann, M; Micallef, IN; Mikhael, JR; Morice, WG; Novak, A; Nowakowski, GS; Porrata, LF; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK; Thompson, CA; Witzig, TE; Zeldenrust, SR | 1 |
| Herishanu, Y; Katchman, H; Polliack, A | 1 |
| Huang, J; Huang, S; Jin, J; Li, C; Li, X; Ma, Z; Wang, H; Yan, X; Yin, X; Yu, M; Zhou, Y | 1 |
| Diels, J; Dorman, E; Sengupta, N; Sorensen, S; Trambitas, C; van Sanden, S; Wildgust, M; Xu, Y | 1 |
| Gaona-Morales, J; García-Boyero, R; González-Bonet, LG | 1 |
| Ahn, KW; Calzada, O; Cashen, AF; Cohen, JB; Costa, LJ; Epperla, N; Farmer, L; Fenske, TS; Ghosh, N; Hamadani, M; Hari, PN; Kanate, AS; Kenkre, VP; Nabhan, C; Oak, E; Tallarico, M | 1 |
| Augustson, B; Brown, R; Gibson, J; Grigoriadis, G; Harrison, S; Ho, JP; Horvath, N; Jaksic, W; Johnston, A; Joshua, D; Kalff, A; Kalro, A; Lee, C; Mollee, P; Prince, HM; Quach, H; Roberts, AW; Spencer, A; Szer, J; Talaulikar, D; Tam, CS; Trotman, J; Ward, C; Zannettino, A | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, S; Robins, H; Sivina, M; Vignali, M; Wierda, WG; Yin, Q; Yusko, E | 1 |
| Robak, T; Stilgenbauer, S; Tedeschi, A | 1 |
| Coffey, G; Conley, P; Guo, A; Lu, P; Pandey, A; Wang, YL | 1 |
| Deeks, ED | 1 |
| Brown, JR; Davids, MS; Deng, J; Fernandes, SM; Isik, E; Letai, A | 1 |
| Kim, AH; Paley, MA; Strand, V | 1 |
| Desuki, A; Hasibeder, A; Heβ, G; Kriege, O; Lopez, PA; Michel, C; Radsak, MP; Schulz, C; Stadler, N; Teschner, D; Weber, ANR | 1 |
| Adler, AI; Goodall, M; Mikudina, B | 1 |
| Amer, AM; Burger, JA; Chen, SS; Chiorazzi, N; Emson, CL; Ferrajoli, A; Garg, N; Hellerstein, MK; Huang, X; Kantarjian, H; Keating, MJ; Li, KW; O'Brien, S; Sivina, M; Turner, SM; Wierda, WG; Wodarz, D; Yan, XJ | 1 |
| Bejar, J; Kreiniz, N; Polliack, A; Tadmor, T | 1 |
| Barrientos, JC; Brown, JR; Byrd, JC; Chang, S; Cymbalista, F; Dearden, C; Furman, RR; Gill, D; Hillmen, P; Hsu, E; James, DF; Montillo, M; Mulligan, SP; O'Brien, S; Plascencia, C; Tedeschi, A | 1 |
| Coluccio, V; Luppi, M; Marietta, M; Paolini, A | 1 |
| Barrientos, JC; Beaupre, DM; Chen, R; Coleman, M; Collins, GP; de Vos, S; Dimery, I; Flowers, CR; Ma, S; Martin, P; Morschhauser, F; Munneke, B; Noy, A; Peles, S; Smith, A; Smith, S; Thieblemont, C | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kantarjian, H; Keating, M; O'Brien, S; Thompson, PA; Wierda, WG | 1 |
| Danilov, AV; DeLoughery, TG; McCarty, OJT; Olson, SR; Shatzel, JJ; Tao, DL | 1 |
| Au-Yeung, R; Chan, TS; Chim, CS; Kwong, YL; Wong, SC | 1 |
| Alexander, WM; Browne, CM; Buhrlage, SJ; Card, JD; Dhe-Paganon, S; Eck, MJ; Ficarro, SB; Gray, NS; Lamberto, I; Marto, JA; McNally, R; Park, E; Seo, HS; Zhang, T | 1 |
| Alt, FW; Ambrogio, C; Blasco, RB; Brown, JR; Cheong, TC; Chiarle, R; Compagno, M; Gostissa, M; Karaca, E; Kasar, SN; Langellotto, F; Meng, FL; Pighi, C; Poggio, T; Sun, J; Voena, C; Wang, Q; Wiestner, A; Wu, CJ; Yeap, LS | 1 |
| Barry, ST; Berdel, WE; Cruzalegui, F; Dai, B; Davies, BR; Erdmann, K; Erdmann, T; Grau, M; Grondine, M; Hudson, K; Klener, P; Lenz, G; Lenz, P; Lynch, JT; Mayo, M; Molinsky, J; Ott, G; Pfeifer, M; Polanska, UM; Schwammbach, D; Staiger, AM; Trneny, M; Tuskova, D; Vočková, P; Zapukhlyak, M | 1 |
| Ahn, I; Albitar, A; Albitar, M; DeDios, I; Estella, J; Farooqui, M; Ma, W; Wiestner, A | 1 |
| Banerjee, R; Howlett, C; Mato, AR; Nabhan, C; Schuster, SJ; Skarbnik, A; Timlin, C; Ujjani, C | 1 |
| Banerji, V; Barrientos, JC; Brown, JR; Glynn, RJ; Jacobsen, ED; Jones, JA; Lampson, BL; Michaud, GF; Moslehi, JJ; Savage, KJ; Walewska, R; Yu, L | 1 |
| Advani, R; Castillo, JJ; Chen, JG; Demos, M; Dubeau, T; Furman, RR; Gustine, J; Hunter, ZR; Kofides, A; Liu, X; Meid, K; Palomba, ML; Patterson, CJ; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Abrisqueta, P; Bosch, F; Delgado, J; García-Marco, JA; Giraldo, P; González, M; Hernández-Rivas, JA; Jarque, I; Loscertales Pueyo, J; Martínez, R; Ramírez Payer, Á; Terol, MJ; Yáñez, L | 1 |
| Daikos, G; Diamantopoulos, PT; Giannakopoulou, N; Pantazatou, A; Psichogiou, M; Rougala, N; Viniou, NA; Zervakis, K | 1 |
| Ambudkar, SV; Chen, ZS; Fu, LW; Huang, LH; Kathawala, RJ; Patel, A; Patel, BA; Qiu, LH; Shukla, S; Wang, YJ; Yang, DH; Zhang, H; Zhang, YK | 1 |
| Bayly, E; Piggin, A; Tam, CS | 1 |
| Drozd-Sokołowska, J; Dudziński, M; Giannopoulos, K; Hałka, J; Hołojda, J; Hus, M; Iskierka-Jażdżewska, E; Jamroziak, K; Knopińska-Posłuszny, W; Kumiega, B; Kyrcz-Krzemień, S; Mądro, E; Osowiecki, M; Piotrowska, M; Piszczek, W; Robak, T; Steckiewicz, P; Szeremet, A; Warzocha, K; Wieszczy, P; Wojciechowska, M; Zaucha, JM | 1 |
| Abrahamse-Testroote, MCJ; Alemayehu, WG; Doorduijn, JK; Farooqui, MZ; Geisler, CH; Herman, SEM; Itälä-Remes, MA; Kimby, E; Kirkby, N; Kozak, T; Niemann, CU; Polliack, A; Tjønnfjord, GE; van Oers, MHJ; van T' Veer, MB; Vojdeman, FJ; Walewski, J; Wiestner, A; Wittebol, S; Wu, KL | 1 |
| Castillo, JJ; Hunter, ZR; Liu, X; Treon, SP; Xu, L; Yang, G | 1 |
| Imlay-Gillespie, L; Lee, A; Mulligan, S; Sandhu, S; Shumack, S | 1 |
| Campidelli, A; Cymbalista, F; De Guibert, S; Delmer, A; Dilhuydy, MS; Dupuis, J; Feugier, P; Fornecker, LM; Ghez, D; Leblond, V; Lequeu, H; Michallet, AS; Subtil, F; Tournilhac, O; Vilque, JP; Ysebaert, L | 1 |
| Dreyling, M; Hallek, M; Jerkeman, M; Kimby, E; Staudt, L; Thieblemont, C | 1 |
| Acuña, C; Alfaro, J; Almirez, RG; Avila, P; Barde, A; Belmar, S; Bernales, S; Chakravarty, S; Chauhan, S; Delgado, L; Flores, C; Fuentealba, G; Gaete, D; Hung, DT; Kanno, S; McCullagh, E; Nayak, AK; Patel, D; Pérez de Arce, F; Pham, SM; Pujala, B; Quinn, KP; Rai, R; Sharma, VK; Upendra, TVR; Ureta, G | 1 |
| Andritsos, LA; Byrd, JC; Fabian, C; Flynn, JM; Guinn, D; Jaglowski, SM; Johnson, AJ; Jones, JA; Lehman, A; Maddocks, K; Woyach, JA; Yu, L | 1 |
| Mertens, D; Stilgenbauer, S | 1 |
| Agarwal, R; Arnau, GM; Blombery, P; Chan, YC; Dawson, MA; Dawson, SJ; Doig, K; Ftouni, S; Hunter, T; Jiang, D; Jones, K; Lam, E; Papenfuss, AT; Petrone, P; Semple, T; Seymour, JF; Silva, MJ; Sinha, D; Tam, CS; Vedururu, R; Wall, M; Wallach, E; Westerman, D; Wong, SQ; Yeh, P; Zivanovic, A | 1 |
| Hutchinson, L | 1 |
| Deng, AL; Deng, C; Kim, YR; Lichtenstein, EA; O'Connor, OA | 1 |
| Hill, BT; Waldron, M; Winter, A | 1 |
| Ahmed, M; Badillo, M; Bell, T; Chen, W; Chen, Z; Fang, B; Guo, H; Huang, S; Huang, SY; Kadri, S; Lam, L; Li, C; Li, L; Li, S; Liu, Y; Nomie, K; Oriabure, O; Pham, L; Richard, S; Santos, D; Segal, J; Shao, Y; Sharma, S; Tao, W; Thirumurthi, S; Wang, J; Wang, M; Wang, YL; Yi, Q; Zhang, H; Zhang, L; Zhou, S | 1 |
| Baselga, J; Brea, EJ; Chang, AY; De Stanchina, E; Fennell, M; Garippa, R; Mondello, P; Scheinberg, DA; Seshan, V; Toska, E; Wendel, HG; Younes, A | 1 |
| Byrd, JC; Caruthers, S; Coleman, J; Johnson, AJ; Jones, D; Lozanski, G; Tu, H; Woyach, JA; Zhao, W | 1 |
| Eischen, CM; Moore, DJ; Moyo, TK; Wilson, CS | 1 |
| Chen, W; Lee, HJ; Nomie, K; Oriabure, O; Romaguera, J; Srour, SA; Wang, ML; Ye, H | 1 |
| Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Byrd, JC; Cole, G; Coutre, S; Cymbalista, F; Dearden, C; Furman, RR; Hillmen, P; Jaeger, U; James, DF; Montillo, M; Moreno, C; Mulligan, SP; O'Brien, S; Pagel, JM; Reddy, NM; Robak, T; Sukbuntherng, J; Suzuki, S | 1 |
| Bochner, BS; Cao, Y; Dispenza, MC; Gordon, LI; Ma, S; Petrich, AM; Regan, JA | 1 |
| Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL | 1 |
| Andrasiak, I; Knopinska-Posluszny, W; Rybka, J; Wrobel, T | 1 |
| Barr, PM; Burger, JA; Byrd, JC; Cheng, M; Coutre, S; Flinn, IW; Furman, RR; Hillmen, P; Jaeger, U; James, DF; Jones, JA; Kipps, TJ; Ninomoto, J; O'Brien, SM; Schuster, SJ; Tam, C | 1 |
| Chocholska, S; Drab-Urbanek, E; Goracy, A; Hus, M; Ibanez, B; Jankowska-Lecka, O; Jawniak, D; Kowal, M; Macheta, A; Nowaczynska, A; Podhorecka, M; Szymczyk, A | 1 |
| Bi, C; Dalton, WS; Darville, L; Di Liberto, M; Distler, A; Fang, B; Fu, K; Han, Y; Jacobson, T; Jiang, H; Koomen, JM; Li, J; Lwin, T; Meads, MB; Moscinski, LC; Rebatchouk, D; Shah, B; Shain, KH; Silva, A; Silva, M; Sotomayor, E; Tao, J; Wang, M; Zhang, L; Zhao, X | 1 |
| Abruzzo, L; Andritsos, LA; Awan, FT; Blachly, JS; Blum, KA; Byrd, JC; Chase, W; Coleman, J; Davis, M; Doong, TJ; Flynn, JM; Gordon, A; Grever, MR; Guinn, D; Heerema, NA; Jaglowski, S; Johnson, AJ; Jones, D; Jones, JA; Lehman, A; Lozanski, A; Lozanski, G; Lucas, M; Maddocks, K; Mantel, R; McWhorter, S; Ny, F; Rogers, K; Ruppert, AS; Smith, LL; Woyach, JA; Zhao, W | 1 |
| Brunati, AM; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Guzzardo, V; Martinello, L; Martini, V; Piazza, F; Pizzi, M; Raggi, F; Saraggi, D; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Aitken, CN; Ansell, SM; Asmus, E; Bowen, DA; Braggio, E; Call, TG; Chanan-Khan, AA; Conte, MJ; Ding, W; Dong, H; Feldman, AL; Greipp, PT; Habermann, TM; He, R; Kay, NE; LaPlant, BR; Le-Rademacher, J; Leis, JF; Lin, Y; Liu, X; Micallef, I; Nowakowski, GS; Parikh, SA; Secreto, CR; Shanafelt, TD; Sinha, S; Tian, S; Van Dyke, DL; Viswanatha, DS; Wellik, LE; Wiseman, GA; Witzig, TE; Wu, X; Yan, H; Zhang, H | 1 |
| Ding, N; Feng, L; Li, J; Lin, Y; Liu, Y; Pan, Z; Ping, L; Shi, C; Shi, Y; Song, Y; Wang, X; Zhu, J | 1 |
| Barr, PM | 1 |
| Apatira, M; Beaupre, DM; Chang, BY; Chen, CT; Cheung, LWK; Eckert, K; Ezell, SA; Hsieh, S; Hsu, SJ; Kuo, HP; Schweighofer, KJ; Sirisawad, M; Versele, M | 1 |
| Albrecht, C; Aurran-Schleinitz, T; Cymbalista, F; Dartigeas, C; Dilhuydy, MS; Dupuis, J; Feugier, P; Michallet, AS; Sinet, P; Tournilhac, O; Ysebaert, L | 1 |
| Barr, PM; Brander, DM; Cheson, BD; Claxton, DF; Cruz, AL; Daniel, C; Fanning, M; Foon, K; Gashonia, L; Goy, A; Henick Bachow, S; Hill, BT; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Lenhart, J; Mato, AR; Nabhan, C; Pu, JJ; Schuster, SJ; Skarbnik, AP; Svoboda, J; Timlin, C; Ujjani, CS; Winter, AM; Yacur, M; Zent, CS | 1 |
| Casellato, A; Macaccaro, P; Mandato, E; Nunes, SC; Piazza, F; Semenzato, G; Trentin, L; Tubi, LQ; Visentin, A; Zaffino, F | 1 |
| Iakobishvili, Z; Kornowski, R; Raanani, P; Wasserstrum, Y | 1 |
| Aw, A; Brown, JR | 2 |
| Agathanggelou, A; Da Costa, D; Davies, NJ; Delansorne, R; Hillmen, P; Kearns, P; Kwok, M; Mao, J; Moss, P; Oldreive, CE; Paneesha, S; Parry, H; Perry, T; Pratt, G; Reverdy, C; Skowronska, A; Smith, E; Stankovic, T; Stewart, GS; Taylor, AMR; Yadollahi, S; Yates, E; Zlatanou, A | 1 |
| Burbury, K; Carney, D; Chai, KL; Rowan, G; Seymour, JF; Tam, CS | 1 |
| Aw, A; Birner, A; Davids, MS; Hellman, JM | 1 |
| Awoonor-Williams, E; Rowley, CN; Walsh, AG | 1 |
| Cairoli, R; Frustaci, AM; Mazzucchelli, M; Montillo, M; Tedeschi, A | 1 |
| Murthy, V; Paneesha, S; Weaving, S | 1 |
| Helber, MJ; Meacham, PJ; Moore, JE; Rothberg, PG; Williams, AM; Zent, CS | 1 |
| Kharfan-Dabaja, MA; Rafei, H | 1 |
| Kalpadakis, C; Koulieris, E; Moschogiannis, M; Pangalis, GA; Rontogianni, D; Sachanas, S; Tsirkinidis, P; Yiakoumis, X | 1 |
| Bhaumik, S; Butman, JA; Ceribelli, M; Chen, L; Cole, DE; Desai, JV; Dunleavy, K; Gea-Banacloche, J; Heiss, J; Higham, CS; Jaffe, ES; Lionakis, MS; Little, RF; Lucas, N; Melani, C; Pittaluga, S; Roschewski, M; Schmitz, R; Staudt, LM; Steinberg, SM; Stetler-Stevenson, M; Thomas, CJ; Widemann, BC; Wilson, WH; Yang, Y | 1 |
| Alanio, A; Baron, M; Challan Belval, T; Denis, B; Malphettes, M; Vignon, M; Zini, JM | 1 |
| Bence-Bruckler, I; Caballero, D; Chiou, CF; Cho, SG; Diels, J; Dreyling, M; Enny, C; Goldberg, JD; Hess, G; Jerkeman, M; Joao, C; Jurczak, W; Rule, S; Rusconi, C; Santucci Silva, R; Traina, S; Trambitas, C; Vermeulen, J; Witzens-Harig, M; Zhou, W | 1 |
| Catherwood, M; Glavey, S; Leader, M; Marafioti, T; McCartney, Y; McCloy, M; Murphy, P; Quinn, J; Sargent, J; Thornton, P | 1 |
| Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
| Göckeritz, E; Guastafierro, A; Hallek, M; Hassenrück, F; Krause, G; Neumann, L; Pizevska, M; Vondey, V | 1 |
| Chen, J; Dong, J; Fan, T; Li, H; Li, J; Nie, X; Rong, Z; Wang, A; Wang, F; Wang, J; Wang, K; Wang, X | 1 |
| Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Byrd, JC; Caligaris-Cappio, F; Chang, B; Chung, D; Cole, G; Coutre, SE; Cymbalista, F; Delgado, J; DeVos, S; Furman, RR; Gau, L; Hillmen, P; Hsu, E; Jaeger, U; James, DF; Kipps, TJ; Lin, J; Montillo, M; Moreno, C; Mulligan, SP; Munir, T; O'Brien, S; Pagel, JM; Reddy, NM; Tam, CS; Thornton, P | 1 |
| Edelmann, J; Gribben, JG | 1 |
| Albericio, F; Cosialls, AM; de la Banda, E; Gil, J; González-Barca, EM; González-Gironès, DM; Iglesias-Serret, D; Lavilla, R; Núñez-Vázquez, S; Pomares, H; Pons, G; Preciado, S; Saura-Esteller, J | 1 |
| O'Brien, S; Tran, PN | 1 |
| Badoux, X; Thorp, BC | 1 |
| Alonso-Gordoa, T; Gajate, P; Grande, E; Molina-Cerrillo, J | 1 |
| Chen, Y; Hu, YY; Ma, JJ; Tao, SD; Yu, L; Zhou, LT | 1 |
| Mátrai, Z; Tomcsányi, J; Tomcsányi, K | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Chung, E; Gaudio, E; Haendler, B; Kwee, I; Lejeune, P; Mensah, AA; Ocker, M; Rinaldi, A; Schmees, N; Siegel, S; Spriano, F; Stathis, A; Tarantelli, C; Zucca, E | 1 |
| Barr, I; Douglas, AP; Leung, V; Slavin, MA; Tam, CS; Trubiano, JA | 1 |
| Heimersson, K; Lundin, J; Mellstedt, H; Österborg, A; Palma, M; Winqvist, M | 1 |
| Bastian, S; Cogliatti, S; Fischer, A; Hohloch, K; Mey, U; Padberg, B; Saub, J; Schanz, U | 1 |
| Carey, EJ; Douglas, DD; Horsley-Silva, JL; Kahn, A; Lam-Himlin, DM; Reeder, CB | 1 |
| Al Balwi, M; Al Mugairi, AM; Damlaj, M | 1 |
| Baran, AM; Barr, PM; Feldman, MM; Gupta, N; Janelsins, MC; Meacham, PJ; Newsom-Stewart, C; Valencia, HE; Williams, AM; Zent, CS | 1 |
| Allan, JN; Lee, EH; Minkis, K; Newsom, E; Parra, CE | 1 |
| Albi, E; Ascani, S; Aureli, P; Baldoni, S; Del Papa, B; Di Ianni, M; Dorillo, E; Falzetti, F; Sportoletti, P | 1 |
| Danilov, AV; Hamilton, BJ; Jones, JD; Rigby, WFC; Skopelja-Gardner, S | 1 |
| Brown, JN; Hammond, JM; Titus-Rains, KS | 1 |
| Andritsos, LA; Awan, F; Beckwith, K; Byrd, JC; Caligiuri, MA; Cheney, C; Do, P; Flynn, JM; Fraietta, JA; Gordon, A; Johnson, AJ; Jones, JA; June, CH; Lehman, AM; Long, M; Maddocks, KJ; Maus, MV; Mundy, BL; Muthusamy, N; Woyach, JA | 1 |
| Chen, P; Gu, A; Guo, X; Hong, Y; Liu, X; Wang, J; Wang, S; Zhao, P | 1 |
| Bittenbring, J; Böttcher, S; Dietrich, S; Döhner, H; Dreger, P; Hallek, M; Hegenbart, U; Ho, A; Kneba, M; Krämer, I; Scheid, C; Schmitz, N; Stadler, M; Stilgenbauer, S; Uharek, L; Zeis, M | 1 |
| Baculea, S; Cote, S; Mealing, S; Singh, M; Whelan, J | 1 |
| England, JT; Leitch, HA | 1 |
| Conaway, MR; Petroni, GR; Portell, CA; Wages, NA; Williams, ME | 1 |
| Dutton, D; Lowry, L; Roach, H | 1 |
| Alwhaibi, A; Andrick, B; Bryan, LJ; DeRemer, DL; Khan, R; Pantin, J; Quershi, S; Somanath, PR | 1 |
| Aquino, R; Balasubramanian, S; Chaturvedi, S; Davis, C; Liu, Y; Lu, R; Schaffer, M; Stepanchick, E; Versele, M; Yang, J | 1 |
| Gessl, A; Jäger, U; Perkmann, T; Pickl, WF; Skrabs, C | 1 |
| Ali, N; Jafri, SIM; Malik, F; Naglak, M; Pickens, PV; Sundermeyer, M | 1 |
| Buchanan, J; Clifford, R; Knight, SJL; Robbe, P; Schuh, A; Taylor, JC; Wordsworth, S | 1 |
| Asklid, A; Diels, J; Eketorp-Sylvan, S; Hansson, L; Jäger, U; Österborg, A; Repits, J; Søltoft, F | 1 |
| Besson, H; Diels, J; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lestelle, D; MacDougall, F | 1 |
| Apollonio, B; Chiu, H; Chopra, R; Couto, S; Flynt, E; Gandhi, AK; Hagner, PR; Ortiz, M; Ramsay, AG; Thakurta, A; Trotter, M; Waldman, MF; Wang, M | 1 |
| Fayad, L; Fowler, N; Jain, P; Kanagal-Shamanna, R; Medeiros, LJ; Nastoupil, L; Oki, Y; Romaguera, J; San Lucas, FA; Wang, M; Westin, JR | 1 |
| de Weerdt, I; Kater, AP; Koopmans, SM; van Gelder, M | 1 |
| Hallek, M | 1 |
| Brodsky, P; Castillo, JJ; Ganz, T; Hunter, ZR; Kersten, MJ; Meid, K; Pals, ST; Patterson, CJ; Treon, SP; Tsakmaklis, N; Vos, JM; Xu, L; Yang, G | 1 |
| Jones, SC; Lee, R; Nayernama, A; Waldron, PE; Wroblewski, T | 1 |
| Allsup, D; Bloor, A; Collett, L; Dimbleby, C; Hillmen, P; Hockaday, A; Howard, DR; Hulme, C; McMahon, K; McParland, L; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC | 1 |
| Auer, R; Beaupre, D; Cavazos, N; Clow, F; Dreyling, M; Goldberg, JD; Goy, A; Hess, G; Kahl, B; Liu, B; Rule, S; Vermeulen, J; Wang, M; Wildgust, M; Yang, S | 1 |
| Doorduijn, JK; Hiemcke-Jiwa, LS; Huibers, MMH; Leguit, RJ; Minnema, MC; Radersma-van Loon, JH; Rood, JJM; Westerweel, PE | 1 |
| Layer, F; Saluzzo, S; Stary, G; Stingl, G | 1 |
| Allan, JN; Arruga, F; Deaglio, S; Furman, RR; Gaudino, F; Liou, HC; Moscvin, M; Ouk, S; Serra, S; Vaisitti, T; Vitale, N; Zakrzewski, JL | 1 |
| Byrd, JC; Lakshmanan, A | 1 |
| Bantscheff, M; Dittus, L; Muelbaier, M; Werner, T | 1 |
| Balachandran, DD; Bashoura, L; Faiz, SA; Stewart, J; Sudhakaran, S | 1 |
| McMullen, J; Tam, C; Tang, CPS | 1 |
| Law, YXT; Lee, LS | 1 |
| Bahlo, J; Becker, N; Claus, R; Döhner, H; Eichhorst, B; Filarsky, K; Fischer, K; Garding, A; Hallek, M; Kuchenbauer, F; Lichter, P; Mertens, D; Plass, C; Robrecht, S; Rouhi, A; Stilgenbauer, S; Weichenhan, D; Weigel, A; Wolf, C; Zucknick, M | 1 |
| Arora, M; Blazar, BR; Chang, S; Cutler, CS; Dubovsky, J; Flowers, ME; Jagasia, M; Jaglowski, S; James, DF; Lal, I; Li, Y; Logan, AC; Miklos, D; Nakamura, R; Pusic, I; Styles, L; Waller, EK | 1 |
| Hua, L; Liu, X; Niu, M; Shan, QQ; Tu, Y; Xie, P; Yu, R; Yue, C; Zhou, T | 1 |
| Barrette, AM; Birtwistle, MR; Bouhaddou, M | 1 |
| Chai, NN; Jordan, S; Kim, I; Klein, AS; Wu, G | 1 |
| Bayers, S; Stewart, J; Vandergriff, T | 1 |
| Alsuliman, A; Basar, R; Burger, JA; Daher, M; Estrov, Z; Ferrajoli, A; Gokdemir, E; Harris, D; Imahashi, N; Jain, N; Keating, M; Kim, E; Kondo, K; Liu, E; Muftuoglu, M; Rezvani, K; Shaim, H; Shpall, EJ; Sobieski, C; Thompson, PA; Wierda, W | 1 |
| Dalal, B; Dogra, S; Meka, SG; Otoupalova, E | 1 |
| Dadashian, EL; Flemington, EK; Fontan, L; Herman, SEM; Iyer, JR; Liu, D; Lobelle-Rich, P; Melnick, A; Nichols, CM; Saba, NS; Safah, H; Tanios, G; Underbayev, C; Wiestner, A; Wong, DH | 1 |
| Cacace, F; De Renzo, A; Leone, S; Mainolfi, CG; Memoli, M; Notarangelo, M; Pane, F; Scalia, G; Trastulli, F; Vitagliano, O | 1 |
| Chamilos, G; Kontoyiannis, DP; Lionakis, MS | 2 |
| Anderson, DM; Ansell, SM; Bartlett, NL; Costello, BA; Fehniger, TA; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Kuruvilla, JG; LaPlant, BR; Qi, J; Ramirez, C; Reeder, CB; Siegel, BA; Thye, LS | 1 |
| Beilhack, A; Leich, E; Ott, G; Rauert-Wunderlich, H; Rosenfeldt, MT; Rosenwald, A; Rudelius, M; Solimando, AG | 1 |
| de Jong, J; Hellemans, P; Huang, Y; Jiao, JJ; Mesens, S; Ouellet, D; Sukbuntherng, J | 1 |
| Gaballa, S; Jacob, J; Sato, R | 1 |
| Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M | 1 |
| Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG | 1 |
| Bao, S; Bian, XW; Chen, C; Fang, X; Feng, H; Gimple, RC; Huang, Z; Ke, SQ; Ping, YF; Rich, JN; Shi, Y; Wu, Q; Yu, JS; Zhai, K; Zhou, W | 1 |
| Ayed, AO; Parikh, SA | 1 |
| Cai, JP; Hu, GX; Tang, P; Wang, C; Wen, J; Xie, S; Xu, RA; Zhang, BW; Zhou, Q | 1 |
| Burger, JA; Thompson, PA | 1 |
| Bigenzahn, JW; Choi, HS; Felberbauer, F; Gisslinger, H; Gültekin, S; Hoermann, G; Jäger, U; Jeryczynski, G; Kazianka, L; Kenner, L; Korkmaz, B; Kornauth, C; Krall, N; Kralovics, R; Kubicek, S; Lopez de la Fuente, O; Mayerhoefer, ME; Merkel, O; Miura, K; Müllauer, L; Ocko, K; Prager, GW; Prutsch, N; Ringler, A; Sabler, M; Schmolke, AS; Simonitsch-Klupp, I; Snijder, B; Sperr, WR; Staber, PB; Superti-Furga, G; Valent, P; van der Kouwe, E; Vladimer, GI | 1 |
| Bastie, JN; Brion, A; Dartigeas, C; de Guibert, S; Delmer, A; Dupuis, J; Ghez, D; Godet, S; Herbaux, C; Leblond, V; Protin, C; Quinquenel, A; Ysebaert, L | 1 |
| Best, OG; Christopherson, RI; Mulligan, SP; Shen, Y | 1 |
| Huang, S; Huang, W; Kahl, BS; Li, Y; Lu, L; Nomie, K; Rui, L; Safe, S; Wang, F; Wang, M; Yang, DT; Zhang, L; Zhu, F | 1 |
| Bairey, O; Barr, PM; Burger, J; Coutre, S; James, DF; Kipps, TJ; Owen, C; Robak, T; Styles, L; Tedeschi, A; Zhou, C | 1 |
| Jiang, F; Verma, P | 1 |
| Flodrova, P; Hegenbart, U; Kimmich, C; Maier, B; Pika, T; Schönland, SO | 1 |
| Mehta, AK; Phadke, VK; Serota, DP | 1 |
| Baculea, S; Côté, S; Diels, J; Dorman, E; Fahrbach, K; Sanden, SV; Xu, Y | 1 |
| Coulter, EM; Cuthill, K; Devereux, S; Folarin, N; Mele, S; Patten, PEM; Pepper, A; Phillips, EH; Townsend, W | 1 |
| Alberelli, MA; Autore, F; De Candia, E; Innocenti, I; Laurenti, L | 1 |
| Hałaburda, K; Hołojda, J; Hus, M; Iskierka-Jażdżewska, E; Jamroziak, K; Knopinska-Posłuszny, W; Szymczyk, A; Warzocha, K; Wojciechowska, M | 1 |
| Cairoli, R; Deodato, M; Frustaci, AM; Mazzucchelli, M; Montillo, M; Tedeschi, A | 1 |
| Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L | 1 |
| Foà, R; Mauro, FR | 1 |
| Beham-Schmid, C; Neubauer, M; Robier, C | 1 |
| Bozic, I; Burger, JA; Cibulskis, C; Farooqui, MZH; Fein, J; Getz, G; Herman, SEM; Hoellenriegel, J; Landau, DA; Leshchiner, I; Liu, D; Livitz, D; Neuberg, DS; Ravichandran, S; Rosebrock, D; Sivina, M; Sun, C; Underbayev, C; Wiestner, A; Wu, CJ; Zhang, W; Zviran, A | 1 |
| Castillo, JJ; Dubeau, T; Guang, Y; Gustine, JN; Hunter, ZR; Meid, K; Severns, P; Treon, SP; Xu, L | 1 |
| Ali, N; Carver, J; Clasen, S; Gashonia, L; Hughes, M; Mato, AR; Nabhan, C; Pickens, P; Rhodes, J; Schuster, S; Svoboda, J | 1 |
| Pauff, JM; Satyanarayana, G; Talbott, M; Tillman, BF; Warner, JL | 1 |
| Chan, EKH; Chanan-Khan, A; Cramer, P; Diels, J; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Howes, A; Janssens, A; Loscertales, J; Mahler, M; Rule, S; Salman, M; Santucci-Silva, R; Sengupta, N; Traina, S | 1 |
| Ahn, IE; Ayed, A; Bayer, E; Benedetti, D; Bomben, R; Bulian, P; Burger, JA; Chaffee, KG; Chiarenza, A; Chigaev, A; Dal Bo, M; Del Poeta, G; Ferrajoli, A; Gattei, V; Gutjahr, JC; Hartmann, TN; Härzschel, A; Herman, SEM; Postorino, M; Pozzato, G; Rossi, FM; Santinelli, E; Shanafelt, TD; Sklar, LA; Ten Hacken, E; Tissino, E; Wiestner, A; Zaja, F; Zucchetto, A | 1 |
| Bryja, V; Bryjova, L; Dzimkova, M; Egle, A; Gregorova, M; Hoferova, Z; Janovska, P; Kohoutek, J; Nemcova, T; Ovesna, P; Pavlova, S; Plevova, K; Poppova, L; Pospisilova, S; Radaszkiewicz, T; Skabrahova, H; Smyckova, L; Vasickova, K; Verner, J; Vondalova Blanarova, O | 1 |
| Bosch, F; Cymbalista, F; Geisler, CH; Ghia, P; Gribben, JG; Hillmen, P; Moreno, C; Stilgenbauer, S | 1 |
| Chen, N; Gong, W; Guo, M; Li, Q; Liu, Q; Liu, S; Ma, J; Wang, J; Wang, S; Wang, Y; Zhao, H | 1 |
| Baldari, CT; Capitani, N; Cattaneo, F; D'Elios, MM; Frezzato, F; Gamberucci, A; Manganaro, N; Martini, V; Patrussi, L; Pelicci, PG; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Banaszynski, M; Crawford, R; Stankowicz, M | 1 |
| Liu, L; Shi, B; Wang, X; Xiang, H | 1 |
| Hershkovitz-Rokah, O; Lenz, G; Pulver, D; Shpilberg, O | 1 |
| Bochner, BS; Dispenza, MC; Pongracic, JA; Singh, AM | 1 |
| Bazaz, R; Denning, DW | 1 |
| Brown, JR; Lampson, BL | 1 |
| Jiang, H; Li, G; Lwin, T; Moscinski, L; Ren, Y; Shah, B; Tao, J; Zhao, X | 1 |
| Courtien, AI; Devlin, SM; Drullinsky, P; Gerecitano, J; Kumar, A; Matasar, MJ; McCall, SJ; Miller, ST; Moskowitz, CH; Noy, A; Palomba, ML; Portlock, CS; Sauter, CS; Schoder, H; Straus, DJ; Younes, A; Zelenetz, AD | 1 |
| Bezirgiannidou, Z; Christoforidou, A; Kapsas, G; Kotsianidis, Ι; Papamichos, S | 1 |
| Huang, J; Huang, S; Jin, J; Li, C; Li, F; Li, X; Ma, Z; Pan, J; Wang, J; Yan, X; Yu, M; Zhou, Y | 1 |
| Dahl, C; Eskelund, CW; Geisler, CH; Grønbæk, K; Hutchings, M; Jerkeman, M; Kolstad, A; Kuitunen, H; Laurell, A; Niemann, CU; Pedersen, LB; Räty, R; Toldbod, H; Wader, KF | 1 |
| Rule, S | 1 |
| Redekop, WK; Sinha, R | 1 |
| Betanzos, CM; Eaton, S; Festa, F; Gonzalez-Malerva, L; LaBaer, J; Magee, M; Park, JG; Rauf, F; Rinaldi, C | 1 |
| Belaz, S; Dupont, M; Gaye, E; Le Bot, A; Le Calloch, R; Talarmin, JP; Tattevin, P | 1 |
| Aschan, J; Diels, J; Healy, N; Hillmen, P; Iraqi, W; Wildgust, M | 1 |
| Bachow, SH; Barr, P; Brander, DM; Cheson, BD; Claxton, D; Dorsey, C; Goy, A; Hill, B; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Landsburg, D; Mato, AR; Nabhan, C; Nasta, SD; Pu, J; Schuster, SJ; Skarbnik, A; Svoboda, J; Thompson, MC; Timlin, C; Ujjani, CS; Winter, A; Zent, C | 1 |
| Hay, KA; Turtle, CJ | 1 |
| Du, X; Shang, J; Sun, FD; Wang, PC; Zou, SH | 1 |
| Bandera, A; Bisi, L; Borella, C; Cappelletti, A; Colella, E; Foresti, S; Gori, A; Migliorino, GM; Peri, AM; Verga, L | 1 |
| Anderson, LD; Bensinger, WI; Berdeja, JG; Bilotti, E; Clow, F; Costello, CL; Elias, L; Graef, T; Huff, CA; Jagannath, S; Kwei, L; Laubach, JP; Lebovic, D; Lendvai, N; Richardson, PG; Salman, Z; Siegel, DS; Stockerl-Goldstein, KE; Vij, R | 1 |
| Baron, M; Calleja, A; Damaj, G; Dartigeas, C; Delavigne, K; Dreyfus, B; Dupont, M; Ferrant, E; Ghez, D; Herbaux, C; Laribi, K; Le Calloch, R; Ledoux, MP; Malphettes, M; Paul, F; Protin, C; Souchet, L; Truchan-Graczyk, M; Ysebaert, L | 1 |
| Blum, K; Burger, JA; Byrd, JC; Chu, AD; Coutre, S; Flinn, IW; Furman, RR; Heerema, NA; James, DF; Johnson, AJ; Jones, J; Luan, Y; O'Brien, S; Sharman, J; Wierda, W; Zhao, W | 1 |
| Bertoni, F; Carrassa, L; Chilà, R; Damia, G; Lupi, M; Restelli, V; Vagni, M | 1 |
| Arora, PC; Portell, CA | 1 |
| Allan, JN; Furman, RR | 1 |
| Burger, J; Estrov, Z; Ferrajoli, A; Harris, DM; Jain, N; Jain, P; Keating, MJ; Li, P; Liu, Z; Rozovski, U; Thompson, P; Wierda, W | 1 |
| Lentini, M; Levato, L; Mirabelli, R; Molica, S; Tedeschi, A | 1 |
| Bannerji, R; Blum, KA; Byrd, JC; Chu, AD; Coutre, SE; Fox, CP; Furman, RR; Hillmen, P; Jaglowski, S; James, DF; Kipps, TJ; Montillo, M; O'Brien, SM; Sharman, J; Suzuki, S | 1 |
| Castillo, JJ; Dubeau, T; Gustine, JN; Meid, K; Severns, P; Treon, SP | 1 |
| Cherif-Rebai, K; El Halabi, L; Ghez, D; Michot, JM | 1 |
| Jones, DL; Tuomi, JM; Xenocostas, A | 1 |
| Beccaria, K; Goldwirt, L; Mourah, S; Ple, A; Sauvageon, H | 1 |
| Eichhorst, B; Hallek, M; Shanafelt, TD | 1 |
| Augustin, D; Jaeger, U; Porpaczy, E; Schwarzinger, I; Skrabs, C; Thalhammer, R | 1 |
| Boddy, CS; Ma, S | 1 |
| Wang, YL | 1 |
| Abdel Sater, A; Bérard, C; Bobée, V; Bohers, E; Drieux, F; Dubois, S; Figeac, M; Haioun, C; Jais, JP; Jardin, F; Leroy, K; Marchand, V; Mareschal, S; Molina, TJ; Picquenot, JM; Ruminy, P; Salles, G; Tilly, H; Veresezan, L; Viailly, PJ | 1 |
| Guan, J; Huang, D; Okret, S; Yakimchuk, K | 1 |
| Chen, K; Davids, MS; Hammond, SP; Issa, NC; Marty, FM; Pandit, A | 1 |
| Shah, B; Shain, KH; Silva, AS; Tao, J; Zhao, X | 1 |
| Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T | 1 |
| Boriani, G; Corradini, P; Cuneo, A; Falanga, A; Foà, R; Gaidano, G; Ghia, PP; Marasca, R; Martelli, M; Massaia, M; Mauro, FR; Minotti, G; Molica, S; Montillo, M; Pinto, A; Tedeschi, A; Vitolo, U; Zinzani, PL | 1 |
| Booshehri, LM; Davis, SA; Florence, JM; Krupa, A; Kurdowska, AK; Matthay, MA | 1 |
| Fukuhara, S; Hatta, S; Ito, Y; Izutsu, K; Maeshima, AM; Makita, S; Maruyama, D; Munakata, W; Suzuki, T; Yuda, S | 1 |
| Gu, Y; Huang, B; Li, H; Lu, G; Qi, M; Xia, D; Yang, Y | 1 |
| Appleton, S; Burton, C; Howell, D; Johnson, R; Patmore, R; Roman, E; Smith, A | 1 |
| Chen, X; Hou, M; Howes, A; Hu, J; Hu, Y; Huang, X; Jin, J; Ke, X; Li, J; Liang, Y; Liu, T; Lv, Y; Qiu, L; Ren, H; Salman, M; Sun, A; Sun, S; Wang, J; Wu, P; Zhao, C; Zhou, D | 1 |
| Ahmed, S; Ailawadhi, M; Ailawadhi, S; Alegria, V; Aulakh, S; Chanan-Khan, A; Jani, P; Sluzevich, JC; Vissing, MB | 1 |
| Brandl, R; Busygina, K; Deckmyn, H; Jamasbi, J; Lorenz, R; Seiler, T; Siess, W; Weber, C | 1 |
| Battistello, E; Bonsignore, L; Christie, AL; Ciriello, G; Dheilly, E; Donaldson, MC; Katanayeva, N; Michielin, O; Murakami, MA; Oricchio, E; Tavernari, D; Thome, M; Zoete, V | 1 |
| Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E | 1 |
| Bence-Bruckler, I; Caballero, D; Cho, SG; Dreyling, M; Goldberg, J; Henninger, T; Hess, G; Jerkeman, M; Joao, C; Jurczak, W; Offner, F; Rule, S; Rusconi, C; Thieblemont, C; Trneny, M; Vermeulen, J; Witzens-Harig, M; Zhou, W | 1 |
| Curtis, A; Rajan, S; Rueter, J; Shopland, L; Zhang, R | 1 |
| Brander, DM; Gauthier, G; Mato, AR; Samp, JC; Terasawa, E | 1 |
| Fan, Z; Wang, Y; Wu, Y; Xu, X | 1 |
| Agarwal, R; Anderson, MA; Bressel, M; Burbury, K; Dawson, MA; Dawson, SJ; Di Iulio, J; Dreyling, M; Handunnetti, S; Hicks, RJ; Lade, S; Pott, C; Roberts, AW; Seymour, JF; Tam, CS; Turner, G; Westerman, D | 1 |
| Cheson, BD; Khan, N; Ramzi, P; Skarbnik, A; Trivedi, N; Ujjani, C; Wang, H | 1 |
| Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J | 1 |
| Gertz, MA | 2 |
| Campbell, PJ; Maddy, LE; O'Brien, DP | 1 |
| Mato, A; Rhodes, J; Sharman, JP | 1 |
| Killock, D | 4 |
| Dogan, A; Dubovsky, JA; Horwitz, SM; Kumar, A; Matasar, MJ; Moskowitz, AJ; Porcu, P; Vardhana, S; Younes, A; Zhang, Z | 1 |
| Assouline, S | 1 |
| Amendola, A; Billio, A; Bowles, KM; Chiarenza, A; Ciolli, S; Cortelezzi, A; Coscia, M; Cuneo, A; de la Serna, J; Delgado, AR; Eyre, TA; Farina, L; Foà, R; Follows, G; Forconi, F; Gaidano, G; Galieni, P; Ghia, P; Gonzalez, M; Ilariucci, F; Kennedy, B; Laurenti, L; Marasca, R; Marchetti, M; Mauro, FR; Meneghini, V; Molica, S; Montillo, M; Moreno, C; Musuraca, G; Orlandi, EM; Perez, AM; Piciocchi, A; Re, F; Rigolin, GM; Schuh, A; Smolej, L; Tedeschi, A; Trentin, L; Vignetti, M; Visco, C | 1 |
| Rogers, K | 1 |
| Budziszewska, BK; Czyż, J; Długosz-Danecka, M; Gil, L; Iskierka-Jażdżewska, E; Jamroziak, K; Kopacz, A; Lech-Marańda, E; Puła, B; Rybka, J; Subocz, E; Szymczyk, A; Warzocha, K; Waszczuk-Gajda, A; Zawirska, D | 1 |
| Dasanu, CA | 1 |
| Li, Z; Sheng, L; Wu, J | 1 |
| Andersen, NS; Berg, T; Bethge, W; Bosman, P; Boumendil, A; Bunjes, D; Canepari, ME; Cornelissen, J; Dietrich, S; Dreger, P; Durakovic, N; Finke, J; Fox, CP; Kröger, N; Labussiere-Wallet, H; Ljungman, P; Michallet, M; Montoto, S; Müller, L; Nagler, A; Niederwieser, D; Passweg, J; Russo, D; Schaap, M; Scheid, C; Schetelig, J; Schoemans, H; Scortechini, I; Sobh, M; Stilgenbauer, S; van Gelder, M; Vandenberghe, E; Wulf, G | 1 |
| Awan, FT; Jurczak, W | 1 |
| Allen, J; Badillo, M; Lee, HJ; Ok, CY; Prabhu, V; Romaguera, JE; Sadimin, ET; Schalop, L; Schenkel, J; Tarapore, R; Wang, M; Zloza, A | 1 |
| Liu, Y; Ran, F; Wang, ML; Yang, D; Zhang, D; Zhang, Z; Zhao, G | 1 |
| Göckeritz, E; Hallek, M; Hassenrück, F; Herter, S; Klein, C; Knödgen, E; Krause, G; Midda, SH; Neumann, L; Vondey, V | 1 |
| Andersen, BL; Byrd, JC; Goyal, NG; Johnson, AJ; Maddocks, KJ; Weiss, DM; Westbrook, TD | 1 |
| Bózsik, B; Mátrai, Z; Nényei, Z; Tomcsányi, J | 1 |
| Azevedo, PO; Birbrair, A; Guerra, DAP; Mintz, A; Paiva, AE; Sena, IFG; Silva, WN | 1 |
| Pleyer, C; Sun, C; Wiestner, A | 1 |
| Advani, R; Castillo, JJ; Dubeau, TE; Gustine, JN; Hunter, ZR; Meid, K; Palomba, L; Treon, SP; Xu, L; Yang, G | 1 |
| He, J; Li, H; Tang, B; Tang, P; Yang, H | 1 |
| Beijnen, JH; Dormans, PJA; Rood, JJM; Schellens, JHM; Sparidans, RW; van Haren, MJ | 1 |
| Reagan, PM; Rodgers, TD | 1 |
| Badillo, M; Fayad, L; Fowler, N; Hagemeister, F; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Nastoupil, L; Romaguera, J; Samaniego, F; Srour, SA; Wang, ML; Westin, J; Zhang, L | 1 |
| Ball, S; Maiti, A; Short, NJ; Vutthikraivit, W | 1 |
| Cheng, C; Jones, SC; Nayernama, A; Woronow, D; Wroblewski, T | 1 |
| Forconi, F | 1 |
| Alqahtani, H; Amrock, SM; Choi, M; Churnetski, M; Cohen, JB; Danilov, AV; Gordon, MJ; Hoff, S; James, S; Kittai, A; Manda, S; Persky, D; Rivera, X; Spurgeon, SE | 1 |
| Bohn, JP; Rudzki, J; Steurer, M; Stockhammer, G; Wanner, D | 1 |
| Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J | 1 |
| Bao, S; Bian, XW; Chen, C; Chen, Y; Fang, X; Feng, H; Gimple, RC; Guryanova, OA; He, Z; Huang, Z; Jiang, T; Kim, L; Kung, HF; Liu, C; Liu, Q; Ping, YF; Rich, JN; Shi, Y; Wang, W; Wang, X; Wu, J; Wu, Q; Yu, JS; Zhang, W; Zhou, W | 1 |
| Armstrong, HA; Buhimschi, AD; Byrd, JC; Chen, TL; Crews, CM; Jaime-Figueroa, S; Johnson, AJ; Lehman, AM; Toure, M; Woyach, JA | 1 |
| Balasubramanian, S; Caballero, D; Cheson, BD; Damle, RN; Deshpande, S; Fowler, NH; Gartenberg, GJ; Gopal, AK; Hess, G; Hou, JZ; Jurczak, W; Lill, M; Martin, P; Morton, J; Radford, J; Salles, G; Schaffer, M; Schuster, SJ; Spencer, A; Trotman, J; Vermeulen, J; Vitolo, U; Wang, SS; Yacoub, A | 1 |
| Buske, C; Dimopoulos, MA; García-Sanz, R; Graef, T; Herbaux, C; Kastritis, E; Leblond, V; Li, J; Macdonald, D; Mahe, B; Matous, JV; Orsucci, L; Palomba, ML; Salman, Z; Shustik, C; Tam, C; Tedeschi, A; Treon, SP; Trotman, J | 1 |
| Byström, S; Daneshmanesh, AH; Ghaderi, A; Hansson, L; Hojjat-Farsangi, M; Mellstedt, H; Moshfegh, A; Olin, T; Olsson, E; Österborg, A; Schultz, J; Vågberg, J | 1 |
| Atwal, S; Buske, C; Cohen, A; Huang, J; LeBlond, V; Novotny, W; Owen, RG; Tam, CS; Tedeschi, A | 1 |
| Byrd, JC; Chu, AD; Clow, F; Coutre, S; Eckert, K; Furman, RR; Heerema, NA; Hillmen, P; James, DF; Jones, J; Mato, A; O'Brien, SM; Osterborg, A; Stilgenbauer, S; Tam, C; Wierda, WG; Zhou, C | 1 |
| Ding, N; Gao, H; Hwang, J; Liu, W; Rao, Y; Song, Y; Sun, Y; Wu, Y; Yang, Y; Zhao, M; Zhao, X | 1 |
| de Jong, J; Haddish-Berhane, N; Hellemans, P; Jiao, J; Ouellet, D; Sukbuntherng, J | 1 |
| Cassin, R; Cortelezzi, A; Fattizzo, B; Giannarelli, D; Massari, F; Mattiello, V; Reda, G; Tonella, T | 1 |
| Campbell, BA; Dickinson, M; Fox, LC; Lade, S; Prince, HM; Ryland, G; Yannakou, CK | 1 |
| Flowers, CR; Nastoupil, LJ; Prasad, V | 1 |
| Logan, AC; Rahmat, LT | 1 |
| Agarwal, R; Dawson, MA; Dreyling, M; Tam, CS | 1 |
| Bachy, E; Campo, E; Ceribelli, M; Chan, WC; Chen, L; Davies-Hill, T; Delabie, J; Estephan, F; Gascoyne, RD; Hewitt, SM; Holdhoff, M; Huang, DW; Jaffe, ES; Ji, Y; Kasbekar, M; Kruhlak, MJ; Nakagawa, M; Oellerich, T; Ott, G; Palisoc, MM; Phelan, JD; Pittaluga, S; Rimsza, LM; Rodriguez, FJ; Rosenwald, A; Roulland, S; Schmitz, R; Shaffer, AL; Staudt, LM; Thomas, CJ; Valadez, RR; Wang, JQ; Webster, DE; Wilson, WH; Wright, GW; Xu, W; Yang, Y; Young, RM; Yu, X; Zhao, H | 1 |
| Auer, R; Carroll, C; Simpson, E; Stevens, J; Tappenden, P; Thokala, P; Wong, R; Wright, J | 1 |
| Bonaldi, L; Burei, M; Facco, M; Frezzato, F; Gregianin, M; Imbergamo, S; Piazza, F; Pizzi, M; Pravato, S; Scomazzon, E; Semenzato, G; Trentin, L; Vio, S; Visentin, A | 1 |
| Azam, M; Dwivedi, P; Greis, KD; Grimes, HL; Muench, DE; Wagner, M | 1 |
| Illerhaus, G; Kasenda, B; Schorb, E | 1 |
| Aguilar, C | 1 |
| Nambudiri, VE; Touloukian, EZ; Yosef, A | 1 |
| Brooks, JP; Harada, K; Lobo, FM | 1 |
| Angelopoulou, MK; Barbetseas, J; Bonou, MS; Diamantopoulos, P; Kapelios, CJ; Masoura, C; Viniou, NA | 1 |
| Balk, SP; Cai, C; Chen, S; Gray, NS; Ma, F; Simon, NI; Sowalsky, AG; Ye, H; Yuan, X | 1 |
| Aoki, S; Kawamoto, K; Miyakoshi, S; Nanba, A; Suzuki, T; Uchiyama, T | 1 |
| Chan, SO; Chan, WY; Chen, Y; Deng, Y; Feng, B; Kazi, JU; Li, T; Rönnstrand, L; Shi, Y; Sun, J; Tian, R; Zhao, H; Zou, L | 1 |
| Byrd, JC; Cheney, C; Fabian, CA; Guinn, D; Johnson, AJ; Johnson, AR; Lehman, A; Liu, L; Mantel, R; Muhowski, EM; Reiff, SD; Smith, L; Woyach, JA; Young, WB | 1 |
| Gottlieb, T; Swan, CD | 1 |
| Armstrong-James, D; Bercusson, A; Colley, T; Shah, A; Warris, A | 1 |
| Clifford, H; Hardy, AT; Hughes, CE; Huissoon, AP; Malcor, JD; Montague, SJ; Nicolson, PLR; Nock, SH; Pollitt, AY; Pratt, G; Thomas, MR; Tomlinson, MG; Watson, CN; Watson, S; Watson, SP | 1 |
| Allal, B; Beauvais, D; Boyle, E; Chatelut, E; Danel, C; Genay, S; Goossens, JF; Herbaux, C; Lafont, T; Morschhauser, F; Odou, P | 1 |
| Aldana, G; Jimenez, CA; Moran, C | 1 |
| Till, BG | 1 |
| Brown, JR; Tam, CS | 1 |
| Cheng, MP; Cummins, KC; Davids, MS; Issa, NC; Kubiak, DW; Marty, FM | 1 |
| Anderson, L; Arasaratnam, R; Froehlich, T; Hsiehchen, D; Raj, K | 1 |
| Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H | 1 |
| Albrethsen, M; Faisal, MS; Fazal, S; Khattab, A; Shaikh, H | 1 |
| Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J | 1 |
| Al-Kali, A; Lane, CE; Lehman, JS; McCarter, SJ; Nault, AM; Nowakowski, GS; Parikh, SA; Sidana, S; Vijayvargiya, P; Wilson, JW | 1 |
| Addison, D; Awan, FT; Byrd, JC; Derbala, MH; Guha, A; Wiczer, TE; Woyach, JA; Zhao, Q | 1 |
| Gribben, JG | 1 |
| Devitt, M; Horton, B; Kunk, PR; Maitland, H; Mock, J; Palkimas, S; Portell, CA; Sen, JM; Williams, ME | 1 |
| Ailawadhi, S; Akhtar, S; Allan, J; Ansell, SM; Aulakh, S; Chanan-Khan, AA; Coignet, MV; Furman, R; Jiang, L; Manna, A; Manochakian, R; Paulus, A; Paulus, SM; Roy, V; Sharma, M; Sher, T; Witzig, TE | 1 |
| Barnes, JI; Begaye, A; Coutre, S; Divi, V; Goldhaber-Fiebert, JD; Owens, DK; Wong, R | 1 |
| Blazar, BR; Jaglowski, SM | 1 |
| Campello, E; Imbergamo, S; Piazza, F; Pravato, S; Scomazzon, E; Semenzato, G; Simioni, P; Spiezia, L; Trentin, L; Visentin, A | 1 |
| Awan, FT; Byrd, JC; Heerema, NA; Hoffman, C; Huang, Y; Jones, JA; Lozanski, G; Lucas, M; Maddocks, KJ; Moran, ME; Reid, MA; Rogers, KA; Ruppert, AS; Whitlow, WT; Woyach, JA | 1 |
| Alikhan, M; Andrade, J; Galanina, N; Guo, A; Guo, H; Huang, S; Lee, J; Li, Y; Lu, P; Sukhanova, M; Venkataraman, G; Wang, ML; Wang, YL; Wu, W; Zhang, H; Zhang, LL | 1 |
| Bowen, D; Boysen, J; Call, TG; Chaffee, KG; Chanan-Khan, AA; Ding, W; Hampel, PJ; Hanson, CA; Kabat, B; Kay, NE; Kenderian, SS; Larson, MC; Leis, JF; Muchtar, E; Parikh, SA; Schwager, SM; Shanafelt, TD; Slager, SL | 1 |
| Berglöf, A; Blomberg, KEM; De Paepe, A; Höglund, P; Jaremko, G; Kamali-Moghaddam, M; Kimby, E; Krstic, A; Lundin, J; Månsson, R; Meinke, S; Österborg, A; Palma, M; Peña Perez, L; Shen, Q; Smith, CIE; Wang, Q | 1 |
| Bairey, O; Barr, PM; Burger, JA; Cheng, M; Coutre, SE; Devereux, S; Flinn, IW; Gaidano, G; Ghia, P; Gill, DS; Gribben, JG; Grosicki, S; Hillmen, P; James, DF; Kipps, TJ; Maslyak, Z; McCarthy, H; Mokatrin, A; Moreno, C; Owen, C; Quach, H; Robak, T; Simpson, D; Stevens, DA; Styles, L; Tedeschi, A | 1 |
| Allan, JN; Barr, PM; Beach, DF; Bhavsar, E; Brander, DM; Cheson, BD; Furman, RR; Goy, A; Handunnetti, S; Hill, BT; Jacobs, R; Lamanna, N; Lansigan, F; Mato, AR; Nabhan, C; Pagel, JM; Pickens, PV; Pu, JJ; Rhodes, J; Roeker, LE; Schuster, SJ; Sehgal, AR; Shadman, M; Shah, NN; Skarbnik, AP; Svoboda, J; Tam, CS; Tuncer, HH; Ujjani, CS; Zent, CS | 1 |
| Biro, M; Bourne, K; Brink, R; Butt, D; Croucher, PI; Gracie, G; Hermes, JR; Kelleher, AD; Khoo, WH; Luciani, F; Ma, CS; Moran, I; Munier, CML; Nguyen, A; Parker, A; Phan, TG; Read, MN; Tangye, SG; Young, C; Zaunders, J | 1 |
| Abid, MB; Gundacker, ND; Stromich, J | 1 |
| Gabcova, G; Gajdos, P; Kriegova, E; Manukyan, G; Mikulkova, Z; Papajik, T; Smotkova Kraiczova, V; Turcsanyi, P; Urbanova, R; Zehnalova, S | 1 |
| Estrov, Z; Jain, P; Kanagal-Shamanna, R; Konoplev, S; Zuo, Z | 1 |
| Angerani, S; Anzola, M; Lindberg, E; Winssinger, N | 1 |
| Anwer, F; Durer, C; Durer, S; Faridi, W; Fraz, MA; Ijaz, A; Khan, AY; Kumar, A; Malik, SU; Nasar, A; Qureshi, A; Tariq, MJ; Usman, M | 1 |
| Huang, J; Lazarus, A; Norris, P; Shi, Y; Spaner, DE; Venema, R; Wang, G | 1 |
| Ahmed, M; Badillo, M; Champlin, R; Chen, W; Fayad, L; Fowler, N; Ghorab, A; Gong, T; Hagemeister, F; Jain, P; Kanagal-Shamanna, R; Li, S; Medeiros, LJ; Neelapu, S; Nomie, K; Ok, CY; Romaguera, J; Wang, L; Wang, ML; Zeng, D; Zhang, L; Zhang, S | 1 |
| Castillo, JJ; Chan, GG; Chen, JG; Demos, MG; Dubeau, T; Guerrera, ML; Gustine, JN; Hunter, ZR; Kofides, A; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Cudrnak, T; Saenz-de-Viteri, M | 1 |
| Leleu, X; Magierowicz, M; Poulain, S; Tomowiak, C | 1 |
| Argyropoulos, KV; Palomba, ML | 1 |
| Deng, Y; Hu, L; Lai, C; Li, C; Liu, M; Liu, X; Lu, M; Luo, X; Qiu, Q; Song, Y; Zhang, H; Zheng, H | 1 |
| de Bruin, RCG; de Gruijl, TD; de Weerdt, I; Eldering, E; Endstra, S; Faber, LM; Hofland, T; Jongejan, A; Kater, AP; Lameris, R; Levin, MD; Liu, N; Moerland, PD; Remmerswaal, EBM; Ten Berge, IJM; Tonino, SH; van der Stelt, M; van der Vliet, HJ | 1 |
| Cho, HJ; Hoe, HS; Kang, HJ; Kim, J; Lee, JY; Nam, HY; Nam, JH; Nam, Y; Yoon, G | 1 |
| Carrasco, YR; de Bruijn, MJW; Gardeta, SR; Hendriks, RW; Merino-Cortes, SV; Roman-Garcia, S | 1 |
| Halsey, G; Hamza, OM; Oghumu, S; Papenfuss, TL; Ryan, NM; Saljoughian, N; Satoskar, AR; Sedmak, BE; Seidler, GR; Varikuti, S; Volpedo, G | 1 |
| Caldwell, RD; Gardberg, A; Goutopoulos, A; Grenningloh, R; Head, J; Johnson, T; Jones, CCV; Jones, R; Liu-Bujalski, L; Mochalkin, I; Morandi, F; Neagu, C; Potnick, J; Qiu, H; Sherer, B; Viacava Follis, A | 1 |
| Clowes, M; Hamilton, J; Kaltenthaler, E; Meiklejohn, D; Morley, N; Pollard, D; Simpson, E; Tappenden, P | 1 |
| Bose, P; Chen, LS; Cruz, ND; Feng, S; Gandhi, V; Huang, X; Jain, N; Jiang, Y; Keating, MJ; Kroll, MH; Qiao, W; Thompson, PA; Wierda, WG; Wu, Q | 1 |
| Aczél, D; Alpár, D; Bödör, C; Csomor, J; Eyupoglu, E; Gángó, A; Kiss, R; Matolcsy, A; Mátrai, Z; Nagy, N | 1 |
| Barrientos, JC; Burger, JA; Byrd, JC; Hillmen, P; James, DF; Kipps, TJ; Ninomoto, J; Zhou, C | 1 |
| Roswarski, J; Selig, D; Tallant, A; Wanko, SO | 1 |
| Du, Y; Li, R; Shen, J | 1 |
| Długosz-Danecka, M; Jurczak, W; Rivas Navarro, F | 1 |
| Caldwell, R; Follis, AV; Gardberg, A; Goutopoulos, A; Grenningloh, R; Head, J; Johnson, T; Jones, R; Liu-Bujalski, L; Mochalkin, I; Morandi, F; Neagu, C; Qiu, H; Sherer, B | 1 |
| Gasparrini, M; Hasilo, CP; Negi, S; Paraskevas, S; Rutman, AK; Tchervenkov, J | 1 |
| Davids, MS; Lampson, BL | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Bonina, S; Cafforio, L; Del Giudice, I; Foà, R; Gaidano, G; Guarini, A; Ilari, C; Mariglia, P; Marinelli, M; Mauro, FR; Messina, M; Peragine, N; Raponi, S | 1 |
| Iványi, J; Plander, M; Szendrei, T; Vadvári, Á | 1 |
| Ahmed, M; Bell, T; Gong, T; Guo, H; Huang, S; Jiang, C; Li, CJ; Liu, Y; Lorence, E; Nomie, KJ; Wang, M; Yao, J; Yao, Y; Zeng, D; Zhang, H; Zhang, L; Zhou, S | 1 |
| Chiodin, G; D'Avola, A; Drennan, S; Forconi, F; Johnson, PW; Packham, G; Steele, AJ; Stevenson, FK; Tracy, I; Trentin, L | 1 |
| Almaddah, N; Alsafwah, S; Delgado Ramos, GM | 1 |
| da Cunha-Bang, C; Niemann, CU | 1 |
| Almejún, MB; Balboa, L; Bezares, FR; Borge, M; Cabrejo, M; Colado, A; Cougoule, C; Elías, EE; Fernandez Grecco, H; Fuentes, F; Gamberale, R; Genoula, M; Giordano, M; Jancic, C; Kviatcovsky, D; Maridonneau-Parini, I; Marín Franco, JL; Podaza, E; Risnik, D; Sasiain, MDC | 1 |
| Beylot-Barry, M; Jegou, MH; Oberic, L; Sibaud, V; Vigarios, E; Ysebaert, L | 1 |
| Baloga, E; Baran, AM; Barr, PM; Casulo, C; Friedberg, JW; Helber, M; Moore, J; Reagan, P; Williams, AM; Zent, CS | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Achille, A; Deng, S; Fonseca, R; Jones, SS; Maharaj, K; Pabon-Saldana, M; Pinilla-Ibarz, J; Powers, JJ; Quayle, SN; Sahakian, E; Sotomayor, EM; Villagra, A | 1 |
| Buske, C; Dimopoulos, MA; Salman, Z | 1 |
| Arney, K | 1 |
| Castillo, JJ; Olszewski, AJ | 1 |
| Cavazzini, F; Cuneo, A; Rigolin, GM | 1 |
| Hwang, CK; Kim, BJ; Kolomeyer, AM | 1 |
| Auer, R; Deshpande, S; Dreyling, M; Goy, A; Hernández-Rivas, JÁ; Hess, G; Kahl, B; Parisi, L; Qi, K; Rule, S; Wang, M | 1 |
| Fournié, P; Oberic, L; Sales De Gauzy, T; Soler, V | 1 |
| Agarwal, R; Anderson, MA; Bell, CC; Blombery, P; Chan, YC; Dawson, MA; Dawson, SJ; Ftouni, S; Gilan, O; Gray, DHD; Huang, DCS; Hunter, T; Knezevic, K; Lam, EYN; Li, J; Pott, C; Rayeroux, K; Roberts, AW; Seymour, JF; Tam, CS; Teh, CE; Thijssen, R; Vassiliadis, D; Wall, M; Wong, SQ; Yeh, P; Zordan, A | 1 |
| Baden, LR; Castillo, JJ; Cheng, MP; Dryden-Peterson, SL; Dubeau, TE; Gustine, JN; Hammond, SP; Issa, NC; Kusztos, AE; Treon, SP; Woolley, AE | 1 |
| Rogers, KA | 1 |
| Long, M | 1 |
| Doll, D; Letendre, P | 1 |
| Crawford, C; Furman, RR; Namn, Y | 1 |
| Dadashian, EL; Herman, SEM; Iyer, JR; Kruhlak, MJ; Liu, D; McAuley, EM; Shaffer, AL; Staudt, LM; Wiestner, A; Young, RM | 1 |
| Abramson, JS; Barr, PM; Bartlett, NL; Blachly, JS; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Fruth, B; Heerema, NA; Hurria, A; Kuzma, C; Larson, RA; Little, RF; Litzow, M; Lozanski, G; Major-Elechi, B; Mandrekar, SJ; Nattam, S; Owen, C; Ozer, HG; Parikh, SA; Rogers, KA; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA; Zhao, W | 1 |
| Alentorn, A; Assayag, F; Daniau, M; Davi, F; Guegan, J; Hoang-Xuan, K; Labiod, D; Le Garff-Tavernier, M; Menet, E; Mokhtari, K; Peyre, M; Pouzoulet, F; Royer-Perron, L; Schnitzler, A; Soussain, C | 1 |
| Jain, N | 1 |
| Bista, A; Boornazian, L; Brown, JR; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Cramer, P; Cymbalista, F; Dilhuydy, MS; Dreyling, M; Ewer, MS; Fraser, G; Ghia, P; Graef, T; Jaeger, U; Liu, EY; Mahler, M; Moslehi, J; O'Brien, SM; Reddy, V; Rule, S; Shanafelt, TD; Treon, S; Valentino, R; Vempati, R; Yang, H | 1 |
| Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W | 1 |
| Kadri, S; Landesman, Y; Lee, J; Lu, P; Maltsev, N; Ming, M; Shacham, S; Sharma, S; Sukhanova, M; Wang, W; Wang, YL; Wu, W; Xie, B | 1 |
| Andersson, PO; Asklid, A; Hansson, L; Karlsson, C; Karlsson, K; Lauri, B; Lundin, J; Mattsson, M; Norin, S; Österborg, A; Rosenquist, R; Sandstedt, A; Späth, F; Winqvist, M | 1 |
| Hermansen, JU; Munthe, LA; Skånland, SS; Taskén, K; Tjønnfjord, GE | 1 |
| Brown, JR; Kater, AP | 1 |
| Anz, B; Ben-Yehuda, D; Clow, F; Demirkan, F; Flinn, IW; Gill, D; Greil, R; Gribben, JG; Hsu, E; James, DF; Larratt, L; Lih, CJ; Moreno, C; Novak, J; Samoilova, O; Simkovic, M; Strugov, V; Styles, L; Tedeschi, A; Zhou, C | 1 |
| Ansell, SM; Buske, C; Castillo, JJ; Chavez, JC; Eyre, TA; Issa, S; Itchaki, G; Nayak, L; Palomba, ML; Paludo, J; Pasvolsky, O; Shain, KH; Simpson, D; Talaulikar, D; Tam, CS; Tedeschi, A; Treon, SP; Varettoni, M | 1 |
| Andreeff, M; Burger, JA; Cheng, M; Clow, F; Estrov, Z; Ferrajoli, A; Huang, X; Jain, N; Jorgensen, J; Kadia, T; Kantarjian, H; Keating, MJ; Kim, E; Li, J; Mathew, T; Nogueras-Gonzalez, GM; O'Brien, S; Ohanian, M; Sivina, M; Thompson, P; Wierda, WG | 1 |
| Gill, MK; Knezevic, A; Leskov, I | 1 |
| Dobrovolsky, D; Donovan, KA; Faust, T; Fischer, ES; Gray, NS; Leahy, C; Li, Z; Morrow, S; Nowak, RP; Treon, SP; Wang, ES; Weinstock, DM; Yang, G | 1 |
| Arnason, JE; Bazemore, J; Boruchov, AM; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Jacobson, CA; Kim, HT; Maegawa, R; Miskin, HP; Nicotra, A; Rueter, J; Savell, A; Sportelli, P; Stampleman, L | 1 |
| Robak, T | 1 |
| Ahmad, S; Altoos, R; Goldstein, SC; Mori, S; Patel, RD; Persky, DO; Shen, Q; Smith, T; Varela, J | 1 |
| Berger, MF; Campos, C; Codega, P; Daras, M; DeAngelis, LM; Grommes, C; Hatzoglou, V; Kaley, TJ; Lin, A; Manne, M; Mellinghoff, IK; Nolan, CP; Panageas, KS; Pentsova, EI; Piotrowski, AF; Reiner, AS; Stone, J; Tang, SS; Thomas, AA; Viale, A; Wolfe, J | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, BF; Estenfelder, S; Fink, AM; Fischer, K; Hallek, M; Illmer, T; Klaproth, H; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Bertoni, F; Cascione, L; Gaudio, E; Stathis, A; Tarantelli, C; Zucca, E | 1 |
| Barac, A; Chaudhry, GM; Dani, S; Ganatra, S; Groarke, JD; Hayek, SS; Mahmood, SS; Martin, DT; Neilan, TG; Nohria, A; Patten, R; Shah, S; Sharma, A; Venesy, D | 1 |
| Chang, Y; Ding, K; Guo, C; Hao, P; Li, Z; Wang, X; Zhang, C | 1 |
| Braggio, E; Call, TG; Chanan-Khan, AA; Ding, W; Fang, H; Hanson, CA; Kay, NE; Kenderian, SS; Leis, JF; Muchtar, E; Parikh, SA; Rabe, KG; Reichard, KK; Schwager, SM; Shanafelt, TD; Slager, SL; Smoley, SA; Van Dyke, DL | 1 |
| Romero, D | 3 |
| Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E; Tsitsi Nding Tsogou, P | 1 |
| Akhtar, OS; Attwood, K; Hare, R; Hernandez-Ilizaliturri, FJ; Lund, I; Torka, P | 1 |
| Agathangelidis, A; Coscia, M; Fonte, E; Gerousi, M; Ghia, P; Gounari, M; Kotta, K; Moysiadis, T; Muzio, M; Nenou, A; Ntoufa, S; Papakonstantinou, N; Ranghetti, P; Scarfò, L; Stamatopoulos, K; Stavroyianni, N; Tedeschi, A; Vilia, MG; Xochelli, A | 1 |
| Alijanazreh, H; Gentile, M; Hamamreh, Y; Hindiyeh, M; Kashkeesh, A; Morabito, F; Morabito, L; Recchia, AG; Sabatleen, A; Skafi, M | 1 |
| Li, P; Lin, Q; Ning, Z; Qian, X; Qiu, X; Xie, S; Ye, L | 1 |
| Fukuhara, N; Nishikawa, T; Tobinai, K; Uchida, T | 1 |
| Ho, AKH; Koh, XQ; Liau, MMQ; Tan, CL; Tan, KB | 1 |
| Chui, W; Handunnetti, S; Slavin, MA; Tam, C; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Długosz-Danecka, M; Jurczak, W; Wang, M | 1 |
| Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A | 1 |
| Byrd, JC; Stephens, DM | 1 |
| de Beer, R; de Boer, OJ; de Porto, AP; de Vos, AF; Florquin, S; Hendriks, RW; Liu, Z; van der Poll, T | 1 |
| Bogusz, AM; Bond, D; Guo, L; Hill, BT; Hsi, ED; Hughes, ME; Koike, A; Landsburg, DJ; Maddocks, KJ; Nasta, SD; Ondrejka, SL; Schuster, SJ; Svoboda, J; Winter, AM | 1 |
| Feng, J; Hu, R; Jiang, H; Lin, N; Liu, X; Wang, L; Yan, Y; Zhang, B; Zhang, Q; Zhou, X | 1 |
| Arribas, AJ; Bertoni, F; Cascione, L; Curti, E; Gaudio, E; Priebe, V; Rossi, D; Spriano, F; Stathis, A; Tarantelli, C; Zhang, L; Zucca, E | 1 |
| Bretonnière, C; Delaunay, J; Grossi, O; Hay, B; Jeddi, F; Lavergne, RA; Le Pape, P; Miailhe, AF; Pineau, S; Sadot-Lebouvier, S | 1 |
| Bartlett, NL; Blum, KA; Chen, Z; Chen-Kiang, S; DiLiberto, M; Dittus, C; Huang, X; Inghirami, G; Leonard, JP; Maddocks, K; Martin, P; Park, S; Ridling, L; Ruan, J | 1 |
| Araghi, M; Bock, C; de la Fuente, OL; Demirtas, D; Gruber, M; Hilgarth, M; Hoermann, G; Hubmann, R; Jäger, U; Krall, N; Krausgruber, T; Kubicek, S; Pemovska, T; Porpaczy, E; Rendeiro, AF; Ringler, A; Runggatscher, K; Schmidl, C; Schnabl, S; Shehata, M; Skrabs, C; Snijder, B; Staber, PB; Superti-Furga, G; Taubert, C; Vladimer, GI | 1 |
| Kim, GW; Kwon, SH; Lee, DH | 1 |
| Bjarnason, G; McCaw, L; Muhowski, EM; Shi, Y; Spaner, DE; Wang, C; Wang, G; Woyach, JA | 1 |
| Hallek, M; Nguyen, PH; Niesen, E | 1 |
| Bougnoux, ME; Delarue, R; Duréault, A; Galliot, R; Guery, R; Lanternier, F; Lortholary, O; Molina, TJ; Montillet, M; Pouvaret, A | 1 |
| Burger, JA; Cohen, JB; Flowers, CR; Fowler, NH; Lunning, MA; Miskin, HP; Nastoupil, LJ; O'Brien, S; Purdom, MA; Schreeder, MT; Siddiqi, T; Sportelli, P; Vose, JM; Weiss, MS; Wierda, WG | 1 |
| Brooks, AN; Campagna, DR; Carrasco, RD; Cartun, ZJ; Cibulskis, CL; DeCaprio, JA; Ebert, BL; Fan, J; Fleming, MD; Gambe, RG; Getz, G; Ghia, EM; Herman, SEM; Kipps, TJ; Leshchiner, I; Martinez, AZ; Neuberg, D; Obeng, EA; Rassenti, LZ; Reed, R; Regis, FFD; Sun, J; Taylor-Weiner, A; Ten Hacken, E; Wan, Y; Wang, L; Wiestner, A; Wu, CJ; Yin, S | 1 |
| Ahmed, M; Jung, D; Lorence, E; Nomie, K; Wang, J; Wang, M; Zhang, L | 1 |
| Bose, P; Chen, LS; Gandhi, V | 1 |
| Autore, F; Corbingi, A; Innocenti, I; Laurenti, L; Morelli, F; Pasquale, R; Pompili, M; Sorà, F | 1 |
| Akhter, N; Feinglass, J; Lentz, R; Ma, S | 1 |
| Andritsos, LA; Awan, FT; Butchar, J; Byrd, JC; Campbell, A; Carson, WE; Castro, CE; Chen, T; Cheney, CM; Harrington, BK; Hertlein, E; Lucas, CR; McWilliams, EM; Mo, X; Muthusamy, N; Rogers, KA; Tridandapani, S; Wasmuth, R; Woyach, J | 1 |
| Barr, PM; Burger, JA; Byrd, JC; Chang, S; Cramer, P; Dilhuydy, MS; Graef, T; Lin, T; Mato, A; Tedeschi, A | 1 |
| Barr, PM; Burger, JA; Byrd, JC; Coutre, S; Flinn, IW; Furman, RR; Ghia, P; James, DF; Kipps, TJ; Ninomoto, J; O'Brien, S; Sharman, J; Stevens, DA; Tam, CS; Wierda, WG; Zhou, C | 1 |
| Liu, H; Liu, J; Zeng, Q | 1 |
| Gasser, J; Gillet, G; Kadiu, I; Keaney, J; Scholz, D | 1 |
| Arnall, JR; Hartsell, L; Janes, A; Larck, C; Park, S | 1 |
| Ayyappan, S; Christian, BA; Epperla, N; Jones, D; Maddocks, K; Shana'ah, AY; Woyach, JA | 1 |
| Fang, J; Han, X; Liu, R; Liu, T; Shi, D; Wu, Y; Xu, J; Yao, X; Zhang, J | 1 |
| Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Byrd, JC; Chang, S; Coutre, S; Cymbalista, F; Devereux, S; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Ninomoto, J; O'Brien, SM; Reddy, NM; Robak, T; Tedeschi, A | 1 |
| Deng, L; Ding, N; He, Y; Li, J; Liu, W; Ping, L; Song, Y; Wang, X; Xie, Y; Ying, Z; Zhang, C; Zhu, J | 1 |
| Alves, D; Caldeira, D; Costa, J; Ferreira, JJ; Pinto, FJ | 1 |
| Faiz, SA; Hagemeister, FB; Jimenez, CA; Lopez-Mattei, J; Stewart, J; Styskel, BA | 1 |
| Bantscheff, M; Bassi, ZI; Burley, GA; Dai, H; Dittus, L; Harling, JD; Hughes, SE; Kerr, WJ; Lithgow, H; Muelbaier, M; Smith, IED; Tinworth, CP | 1 |
| Berca, C; Burger, JA; Di Noia, JM; Fresia, P; Landoni, AI; Morande, PE; Oppezzo, P; Seija, N; Sivina, M; Uriepero, A | 1 |
| Chiron, D | 1 |
| Garcia, C; Levade, M; Payrastre, B; Series, J; Sié, P; Viaud, J; Ysebaert, L | 1 |
| Bittolo, T; Bo, MD; Bomben, R; Bulian, P; D'Agaro, T; Degan, M; Ferrero, S; Gattei, V; Ladetto, M; Rossi, FM; Tissino, E; Vit, F; Zaja, F; Zamò, A; Zucchetto, A | 1 |
| Brunasso, AMG; Giovanni, B; Ibatici, A; Massone, C; Sola, S | 1 |
| Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Byrd, JC; Coutre, S; Dai, S; Furman, RR; Hillmen, P; Jaeger, U; James, DF; Kipps, TJ; Montillo, M; Moreno, C; Mulligan, SP; O'Brien, S; Pagel, JM; Reddy, NM; Tam, CS; Thornton, P; Vezan, R; Woyach, JA | 1 |
| Naydenov, AV; Taylor, LP | 1 |
| McCaw, L; Shi, Y; Spaner, DE; Tsui, H; Wang, G | 1 |
| Byrd, JC | 1 |
| Bhanot, N; Goel, K; Min, Z; Patibandla, SK; Shah, A; Uchin, J | 1 |
| Ding, N; Liu, W; Rao, Y; Song, Y; Sun, Y; Yang, Z; Zhu, J | 1 |
| Blair, IA; Glickson, JD; Guo, L; Hofbauer, S; Lee, SC; Liu, X; Lu, P; Mesaros, C; Nath, K; Nelson, DS; Pickup, S; Roman, JC; Schuster, SJ; Shestov, AA; Wang, HY; Wang, YL; Wasik, MA; Zhang, Q | 1 |
| Bennis, Y; Chouaki, T; Delette, C; Joseph, C; Maizel, J; Marolleau, JP; Nyga, R; Simon, L; Slama, M; Zogheib, E | 1 |
| Ayuk, F; Ditschkowski, M; Gerbitz, A; Greinix, H; Halter, J; Hilgendorf, I; Holler, E; Jedlickova, Z; Klein, S; Kobbe, G; Lawitschka, A; Middeke, JM; Schäfer-Eckart, K; Stadler, M; Stelljes, M; Wagner-Drouet, E; Winkler, J; Wolff, D; Zeiser, R | 1 |
| Paydas, S | 1 |
| Balasubramanian, S; Belada, D; Carey, J; Cheung, MC; Chiattone, CS; Dührsen, U; Gurion, R; Hong, X; Johnson, P; Jurczak, W; Leppä, S; Liu, G; Lopez-Hernandez, A; Patti, C; Rai, S; Samoilova, O; Sehn, LH; Shreeve, SM; Staudt, LM; Suh, C; Sun, S; Thieblemont, C; Turgut, M; Vermeulen, J; Wilson, W; Yeh, SP; Younes, A; Zhu, J; Zhuang, SH; Zinzani, PL | 1 |
| Chen, H; Chen, X; Fan, Y; Mao, R; Ming, Y; Wu, Y; Xu, Y; Yang, R; Yao, M | 1 |
| Cairoli, R; Deodato, M; Frustaci, AM; Montillo, M; Tedeschi, A; Zamprogna, G | 2 |
| Ahn, IE; Basumallik, N; Soto, S; Tian, X; Wiestner, A | 1 |
| Gourd, E | 1 |
| Bernal, Y; Brentjens, RJ; Devlin, SM; Geyer, MB; Halton, E; Hsu, M; Palomba, ML; Park, JH; Purdon, TJ; Rivière, I; Sadelain, M; Sénéchal, B; van Leeuwen, DG; Wang, X; Wang, Y | 1 |
| Ahmed, S; Ailawadhi, S; Akhtar, S; Alegria, V; Aulakh, S; Bhatia, K; Chanan-Khan, A; Chini, EN; Coignet, M; Heckman, M; Jani, P; Malavasi, F; Manna, A; Meghji, Z; Paulus, A; Sharma, A; Sher, T | 1 |
| Amiot, M; Bellanger, C; Chiron, D; Le Bris, Y; Le Gouill, S; Maisonneuve, H; Moreau, A; Moreau, P; Papin, A; Pellat-Deceunynck, C; Tessoulin, B; Touzeau, C | 1 |
| Patil, N; Went, RG | 1 |
| Lishner, M; Schamroth Pravda, M; Schamroth Pravda, N | 1 |
| Henley, P; Man, S | 1 |
| Aurran, T; Béné, MC; Collignon, A; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Dmytruk, N; Dupuis, J; Durot, E; Ghez, D; Gilardin, L; Godet, S; Lepretre, S; Lévy, V; Merabet, F; Ohanyan, H; Quinquenel, A; Roos Weil, D; Toussaint, E; Vignon, M; Ysebaert, L | 1 |
| Della Peruta, M; El-Kholy, M; Evans, R; Gohil, SH; Harasser, M; Nathwani, AC; Paredes-Moscosso, SR | 1 |
| Bai, R; Du, X; Jiang, L; Li, L; Liu, N; Ma, CS; Ruan, Y; Wu, X; Xia, S; Xing, Y; Zhao, Q; Zhao, X; Zuo, S | 1 |
| Levy, I; Polliack, A; Tadmor, T | 1 |
| Bennett, CL; Georgantopoulos, P; Norris, LB; Yang, H | 1 |
| De Simone, C; Laurenti, L; Mannino, M; Peris, K; Sollena, P | 1 |
| Bommuluri, V; Doddipalla, R; Kaliyaperumal, M; Korupolu, RB; Mohan P, KVK; Rumalla, CS; Vajjha, S | 1 |
| Ahearne, MJ; Allchin, RL; Doran, AG; Keane, T; Kelly, ME; Mamand, S; Wagner, SD | 1 |
| Autore, F; Corbingi, A; Criscuolo, M; Fianchi, L; Innocenti, I; Laurenti, L; Morelli, F; Pagano, L; Sica, S; Sorà, F | 1 |
| Diker, O | 1 |
| Gogtay, N; Jain, H; Sengar, M | 1 |
| Janssens, A; Maertens, J; Mercier, T | 1 |
| Mandrekar, SJ; Ruppert, AS; Woyach, JA | 1 |
| Bond, DA; Woyach, JA | 1 |
| Brunham, L; Christidi, E; Garcia, A; Huang, H; Keller, G; Laksman, Z; Lee, J; Lin, E; Nartiss, Y; Protze, S; Shafaattalab, S; Tibbits, GF | 1 |
| Lucijanic, M; Skelin, M | 1 |
| Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O | 1 |
| Accordi, B; Basso, G; Bresolin, S; Facco, M; Frezzato, F; Martini, V; Piazza, F; Raggi, F; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Castro, JE; Choi, MY; Heinen, A; Jacobs, C; Kipps, TJ; Lengerke-Diaz, PA; Lujan, JV; McCarthy, C; Moreno-Cortes, EF; Ramirez-Segura, CA | 1 |
| Ding, W; Koehler, AB; Vijayvargiya, P | 1 |
| Barosi, G; Gaidano, G; Girmenia, C; Marchetti, M; Pane, F; Rambaldi, A; Tura, S; Zinzani, PL | 1 |
| Ding, Z; Fan, B; Huang, W; Shi, X; Song, S; Xu, T | 1 |
| Ahmed, M; Badillo, M; Bell, T; Di Francesco, ME; Draetta, G; Feng, N; Futreal, A; Guo, H; Han, G; Haun, R; Heffernan, T; Jones, P; Lan, R; Liu, Y; Lorence, E; Lorenzi, PL; Mackintosh, SG; Mao, X; Marszalek, J; Nomie, K; Pham, LV; Song, X; Sun, Y; Wang, L; Wang, M; Yao, Y; Zhang, H; Zhang, J; Zhang, L; Zhang, S; Zhou, S | 1 |
| Slupsky, JR | 1 |
| Choi, CM; Choi, YJ; Hong, JY; Kim, DH; Lee, JC; Rho, JK; Suh, C; Yoon, DH | 1 |
| Awan, FT; Bhat, SA; Byrd, JC; El Boghdadly, Z; Guerrero, T; Levine, LB; Lucas, F; Mousa, L; Rogers, KA; Shindiapina, P; Sigmund, AM; Sullivan, M; Wiczer, TE; Woyach, JA; Zhao, Q | 1 |
| Bernlochner, I; Busygina, K; Denzinger, V; Lorenz, R; Siess, W; Weber, C | 1 |
| Awan, FT; Bibikova, E; Brown, JR; Byrd, JC; Charuworn, P; Frigault, MM; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Linghu, B; Pagel, JM; Patel, P; Schuh, A; Stephens, DM; Wang, MH; Woyach, J | 1 |
| Tam, C; Tang, PSC | 1 |
| Chen, G; Deng, Y; Hu, L; Li, C; Liu, M; Liu, X; Luo, X; Qiu, Q; Shi, T; Song, Y; Yan, X; Yang, S; Zhang, H; Zheng, H | 1 |
| Bhargava, P; Byrd, JC; Chanan-Khan, AA; Darif, M; Dreiling, LK; Ferrante, L; Furman, RR; Hillmen, P; Howes, A; James, DF; Jones, J; Kay, NE; Londhe, A; Mobasher, M; Mun, Y; Ni, A; Rabe, KG; Reddy, V; Seymour, JF; Shanafelt, TD; Sharman, JP; Soumerai, JD; Stark, T; Xing, G; Zelenetz, AD | 1 |
| Berger, A; Best, S; Bruss, N; Danilov, AV; Kittai, A; Liu, T | 1 |
| Alvarado, Y; Ayala, A; Borthakur, G; Bose, P; Burger, J; Cruz, N; DiNardo, C; Estrov, Z; Ferrajoli, A; Fowler, N; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Ohanian, M; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Sondermann, K; Takahashi, K; Thompson, P; Wang, X; Wei, C; Wierda, W; Yilmaz, M | 1 |
| Baş, V; Baysal, M; Demir, AM; Demirci, U; Gülsaran, SK; Kirkizlar, HO; Umit, E | 1 |
| Bansal, A; Jhaveri, KD; Lucia, S; Manohar, S; Sakhiya, V; Wanchoo, R | 1 |
| Advani, P; Ailawadhi, S; Paulus, A | 1 |
| Blaize, M; Blez, D; Boissonnas, A; Combadière, C; Fekkar, A; Ghez, D; Leblond, V; Meghraoui-Kheddar, A; Menezes, N; Portalier, A; Soussain, C | 1 |
| Aw Yeang, HX; Flinsenberg, TWH; Guo, Y; Handunnetti, S; Hu, N; Koldej, R; Liu, Y; Neeson, PJ; Noori, T; Ritchie, D; Roberts, AW; Seymour, JF; Song, X; Tam, CS; Tantalo, DG; Thia, KYT; Trapani, JA; Tromedjo, CC; Voskoboinik, I; Wang, L | 1 |
| Aczél, D; Ádám, E; Alpár, D; Bödör, C; Eyüpoglu, E; Farkas, P; Fésüs, V; Galik, B; Gángó, A; Gyenesei, A; Kiss, R; Kozma, A; Krizsán, S; Marosvári, D; Matolcsy, A; Mátrai, Z; Nagy, Á; Nagy, N; Reiniger, L; Réti, M; Tasnády, S | 1 |
| Angelopoulou, M; Bitsani, C; Dimou, M; Iliakis, T; Kalyva, S; Koudouna, A; Kyrtsonis, MC; Panayiotidis, P; Papaioannou, P; Pardalis, V; Tsaftaridis, P; Vassilakopoulos, TP | 1 |
| Buske, C; Grunenberg, A | 1 |
| Wierda, WG | 1 |
| Alinari, L; Bond, DA; Maddocks, K | 1 |
| Hanna, KS | 1 |
| Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R | 1 |
| Jiang, XN; Lee, J; Li, XQ; Sheng, D; Sun, CB; Wang, WG; Zhou, XY | 1 |
| Gołos, A; Hołojda, J; Hus, M; Iskierka-Jażdżewska, E; Jamroziak, K; Piszczek, W; Puła, B; Steckiewicz, P; Szeremet, A; Warzocha, K; Wojciechowska, M; Zaucha, JM | 1 |
| Levêque, D | 1 |
| Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A | 1 |
| Albattah, A; Alhijji, I; Alokka, R; Elazzazy, S; Ghasoub, R; Nemir, A; Taha, R | 1 |
| Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS | 1 |
| Akritidou, MA; Anagnostopoulos, A; Belloni, D; Chartomatsidou, E; Ferrero, E; Ghia, P; Kotta, K; Ntoufa, S; Papakonstantinou, N; Rosenquist, R; Rovida, A; Stamatopoulos, K; Stavroyianni, N; Trangas, T | 1 |
| Balmanoukian, A; Berlin, JD; Borazanci, E; Chandler, J; Dimery, I; George, TJ; Graef, T; Guan, S; Gutierrez, M; Hong, D; Luke, JJ; Mita, A; Munster, P; Rasco, D; Samakoglu, S; Veeder, M; Wakelee, H | 1 |
| Castelli, R; Deliliers, GL; Preti, C; Schiavon, R | 1 |
| Dhanoa, JS; Emmons, R; Hashmi, H | 1 |
| Abrão, MS; Batteux, F; Chapron, C; Chouzenoux, S; Doridot, L; Jeljeli, M; Nicco, C; Reis, FM; Riccio, LGC; Santulli, P | 1 |
| Ashraf, A; Cheema, H; Collins, NJ; Ezad, S; Khan, AA; Ngo, DTM; Sverdlov, AL | 1 |
| Arora, M; Chang, S; Clow, F; Cutler, C; Flowers, MED; Jagasia, MH; Jaglowski, S; Lal, ID; Logan, AC; Miklos, D; Nakamura, R; Pusic, I; Styles, L; Waller, EK | 1 |
| Castillo, JJ; Chan, GG; Chen, JG; Demos, MG; Dubeau, TE; Guerrera, ML; Gustine, JN; Hunter, ZR; Keezer, A; Kofides, A; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Barrie, M; Bijou, F; Blonski, M; Boyle, E; Cassoux, N; Choquet, S; Clavert, A; Coisy, S; Daniau, M; El Yamani, A; Ertault de la Bretonnière, M; Ghesquières, H; Gressin, R; Hoang-Xuan, K; Houillier, C; Houot, R; Leclercq, D; Lelez, ML; Leruez, S; Moluçon-Chabrot, C; Nicolas-Virelizier, E; Rezai, K; Soussain, C; Touitou, V | 1 |
| Bauer, K; Gamperl, S; Hadzijusufovic, E; Peter, B; Smiljkovic, D; Stefanzl, G; Valent, P; Willmann, M | 1 |
| Bernardeschi, P; Del Rosso, A; Fontanelli, G; Milandri, C; Pirrotta, MT | 1 |
| Bishop, R; Bloor, A; Boucher, R; Brock, K; Devereux, S; Fegan, C; Forconi, F; Fox, CP; Gribben, JG; Hillmen, P; MacDonald, D; McCaig, A; Munir, T; Muñoz-Vicente, S; Patten, PEM; Pettitt, A; Rawstron, AC; Schuh, A; Yates, FJ | 1 |
| Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L | 1 |
| Fink, AM | 1 |
| Beaupre, DM; Dang, NH; Delioukina, M; Ghosh, N; Goy, A; Kingsley, E; Knapp, M; Morgan, DS; Munoz, J; Neuenburg, JK; Ping, J; Ramchandren, R; Ruan, J | 1 |
| Badros, A; Bukhari, A; Dahiya, S; El Chaer, F; Hardy, N; Hutnick, E; Kocoglu, MH; Koka, R; Lee, ST; Rapoport, AP; Ruehle, K; Shanholtz, C; Singh, Z; Yared, J | 1 |
| Arbelaez, MI; Castillo, JJ; Hunter, ZR; Moreno, DF; Treon, SP | 1 |
| Al-Toubah, T; Cives, M; Schell, MJ; Soares, HP; Strosberg, JR; Zhou, JM | 1 |
| Aloyz, R; Doyon, D; Paliouras, M; Sharif-Askari, B | 1 |
| Autore, F; Ciolli, S; Coscia, M; Cuneo, A; D'Arena, G; Del Poeta, G; Efremov, DG; Foà, R; Frustaci, A; Gentile, M; Ibatici, A; Innocenti, I; Laurenti, L; Levato, L; Mauro, FR; Morelli, F; Murru, R; Piciocchi, A; Reda, G; Rigolin, GM; Scarfò, L; Schiattone, L; Sportoletti, P; Tedeschi, A; Trentin, L | 1 |
| Chen, G; Deng, X; Deng, Z; Gui, F; He, Z; Huang, X; Jiang, J; Li, L; Li, Y; Lu, Y; Song, S; Su, J; Weisberg, E; Wu, X; Yun, CH; Zhang, J; Zhang, YM | 1 |
| Dong, J; Li, S; Liu, G | 1 |
| Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC | 1 |
| Chang, HC; Chen, CL; Chiang, YR; Chuang, TH; Hsieh, CC; Huang, CM; Keshari, S; Sipayung, AD; Su, LJ; Yang, WC | 1 |
| Lemal, R; Tournilhac, O | 1 |
| Chidambaram, D; Napper, S; Prabaharan, CB; Rajamanickam, K; Sakharkar, MK; Yang, AB | 1 |
| Basso, K; Bosch, F; Dalla-Favera, R; Grandori, C; Inghirami, G; Mittan, SK; Pasqualucci, L; Persaud, M; Rabadan, R; Scuoppo, C; Wang, J | 1 |
| Staudt, L; Wilson, WH; Younes, A | 1 |
| Lucijanić, M; Miketic, T; Skelin, M | 1 |
| Ambinder, AJ; Hambley, B; Merrill, SA; Shanbhag, S | 1 |
| Stirrups, R | 1 |
| Anz, B; Bairey, O; Barr, PM; Burger, JA; Demirkan, F; Fedorov, V; Flinn, IW; Gaidano, G; Gill, D; Greil, R; Gribben, JG; Kipps, TJ; Lin, J; Moreno, C; Robak, T; Simpson, D; Stevens, D; Styles, L; Tedeschi, A; Webb, T | 1 |
| Heintel, D; Nösslinger, T; Staber, P; Steurer, M; Stühlinger, MC; Weltermann, A | 1 |
| Lu, H; Xu, C; Yang, M; Zhou, Y | 1 |
| Castillo, JJ; Treon, SP | 2 |
| Kater, AP; Levin, MD; Niemann, CU | 1 |
| Gandhi, V; Jain, N; Wierda, W | 1 |
| Chau, N; Korprasertthaworn, P; Miners, JO; Nair, PC; Rowland, A | 1 |
| Au-Yeung, R; Kwong, YL; Leung, RYY; Pang, A | 1 |
| Balasubramanian, S; Barr, PM; Barrientos, JC; Brown, JR; Byrd, JC; Chanan-Khan, AA; Cheng, M; Coutre, SE; Cramer, P; Dilhuydy, MS; Eckert, K; Fraser, G; Hallek, M; Hillmen, P; Howes, A; Jaeger, U; James, DF; Kipps, TJ; Londhe, A; Mahler, M; Moreno, C; Ninomoto, J; O'Brien, SM; Salman, M; Solman, IG; Stilgenbauer, S | 1 |
| Allan, JN; Arruga, F; Bracciamà, V; Coscia, M; D'Arena, G; Deaglio, S; Forconi, F; Furman, RR; Gaidano, G; Gizzi, K; Packham, G; Vaisitti, T; Vitale, N; Yeomans, A | 1 |
| Abeykoon, JP; Ansell, SM; Dingli, D; Dispenzieri, A; Gertz, MA; Go, R; Gonsalves, W; Greipp, P; Habermann, T; Inwards, D; Kapoor, P; King, R; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Manske, M; Muchtar, E; Novak, AJ; Parikh, SA; Rajkumar, V; Thompson, CA; Warsame, R; Witzig, TE; Zanwar, S | 1 |
| Arias-Martínez, A; Carriles, C; Menárguez-Blanc, R; Ordóñez-Fernández, L; Rosado-María, MC | 1 |
| Angerani, S; Chang, D; Feng, S; Lindberg, E; Riezman, H; Winssinger, N | 1 |
| Field, J; George, G; Singavi, A; Voshtina, E; Wright, N | 1 |
| Huang, L; Li, JM; Wu, C; Xu, WB; Yan, H; Ye, CJ; Yu, Q | 1 |
| Aisa, Y; Ito, C; Kamiya, T; Mizuno, K; Mori, T; Nakazato, T; Nishiyama-Fujita, Y; Ogura, S | 1 |
| de Boer, R; de Weerdt, I; Eldering, E; Hofland, T; Kater, AP; Tannheimer, S; Ter Burg, H; Tonino, SH | 1 |
| Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Byrd, JC; Coutre, S; Dai, S; Dean, JP; Hillmen, P; Jaeger, U; Kipps, TJ; Montillo, M; Moreno, C; Mulligan, SP; Munir, T; O'Brien, S; Reddy, NM; Szoke, A; Tam, CS; Woyach, JA | 1 |
| Arthurs, B; Bar-Meir, M; Barzic, N; Ben-Ami, R; Benjamini, O; Bogot, N; Brown, JR; Cohen, R; De Boer, F; Eichhorst, B; Gottesman, B; Herishanu, Y; Hill, B; Jain, P; Kater, AP; Korem, M; Lachish, T; Malphettes, M; Messina, JA; Mous, R; Mulligan, SP; Nijland, M; Okamoto, K; Rowe, JM; Ruchlemer, R; Soussain, C; Tadmor, T; Talha, M; Tonino, SH | 1 |
| Awan, FT; Bhat, SA; Byrd, JC; Hirsch, J; Kander, EM; Ooka, L; Rogers, KA; Wang, TF; Wiczer, T; Woyach, JA; Zhao, Q | 1 |
| Glickson, J; Jillab, M; Liu, X; Melnikov, O; Nath, K; Nunez-Cruz, S; Wang, HY; Wasik, MA; Zhang, Q | 1 |
| Assouline, S; Christofides, A; MacDonald, D; Matthews, BA; Prica, A; Sangha, R; Sehn, LH; Skrabek, P | 1 |
| Al Zoubi, S; Chiazza, F; Coldewey, SM; Collino, M; Collotta, D; Martin, L; O'Riordan, CE; Purvis, GSD; Stiehler, L; Thiemermann, C; Wissuwa, B | 1 |
| Bretagne, M; Brown, JR; Funck-Brentano, C; Groarke, JD; Johnson, DB; Lebrun-Vignes, B; Manouchehri, A; Moslehi, JJ; Reddy, NM; Roden, DM; Salem, JE; Yang, T | 1 |
| Bergler-Klein, J | 1 |
| Westin, J | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Yoon, JH; Yoon, S | 1 |
| Castillo, JJ; Chan, GG; Chen, JG; Demos, MG; Dubeau, T; Guerrera, ML; Gustine, JN; Hunter, ZR; Keezer, A; Kofides, A; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Addison, D; Awan, F; Bhat, S; Byrd, JC; Dickerson, T; Guha, A; Haddad, D; Philippon, J; Porter, K; Rogers, KA; Waller, A; Wiczer, T; Woyach, JA | 1 |
| Bai, XF; Barajas, JM; Elkholy, KH; Ghoshal, K; Hu, P; Jacob, ST; Khan, WN; Li, D; Lin, CH; Noonan, AM; Wani, NA; Yu, L; Zhang, X | 1 |
| Barot, SV; Lee, SS; Patel, BJ; Valent, JN | 1 |
| Burudpakdee, C; Kabadi, SM; Near, A; Wada, K | 2 |
| Gan, N; Li, H; Sun, Q; Suo, Z; Tang, B; Tang, P; Yang, H; Zhang, M; Zhao, L | 1 |
| Bai, LY; Chiu, CF; Liang, SH | 1 |
| Alreefi, M; Caglar, D; Dufresne, P; Lee, TC; Loo, VG; Mascarella, MA; Richardson, K; Sadeghi, N; Schweitzer, L; Silver, J | 1 |
| Goy, A; Guan, S; Herrera, AF; Hill, JS; Kwei, K; Liu, EA; Mehta, A; Pagel, JM; Phillips, T; Ramchandren, R; Svoboda, J | 1 |
| Baran, AM; Barr, PM; Bushart, J; Moore, J; Rich, L; Schaffer, M; Williams, AM; Zent, CS | 1 |
| Merli, M; Passamonti, F | 1 |
| Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dai, S; Dean, JP; Devereux, S; Ghia, P; Grosicki, S; Hillmen, P; Kipps, TJ; Lal, I; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Simpson, D; Tedeschi, A | 1 |
| Cheng, D; Kong, S; Li, T; Li, X; Sun, S; Wang, L; Yu, Q | 1 |
| Thermos, G; Tosios, KI | 1 |
| Cheng, J; Shi, Q; Tang, A; Yu, L; Zi, F | 1 |
| Bilotta, C; Cavaliere, FM; Cesini, L; Foà, R; Iacobini, M; Mauro, FR; Pentimalli, TM; Prezzo, A; Quinti, I | 1 |
| Cao, Z; Li, Z; Wu, P; Yang, X | 1 |
| Backman, JT; Elonen, E; Neuvonen, M; Neuvonen, PJ; Niemi, M; Olkkola, AM; Tapaninen, T; Tornio, A | 1 |
| Emond, B; Lefebvre, P; Mato, A; Romdhani, H; Sundaram, M; Wang, S | 1 |
| Hara, S; Ishikawa, T; Nakamura, M; Yamashita, D; Yoshioka, S | 1 |
| Fujinami, H; Iida, S; Inagaki, H; Ito, A; Komatsu, H; Kusumoto, S; Marumo, Y; Masaki, A; Narita, T; Ohshima, Y; Ri, M; Sasaki, H; Tachita, T; Yoshida, T | 1 |
| Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
| Arletti, L; Benatti, S; Fiorcari, S; Luppi, M; Maccaferri, M; Maffei, R; Marasca, R; Potenza, L | 1 |
| Bethge, W; Boumendil, A; Browne, P; Cornelissen, J; Corradini, P; Dreger, P; Durakovic, N; Fox, CP; Hoek, J; Koster, L; Kroger, N; Krüger, W; Michallet, M; Montoto, S; Muller, L; Passweg, J; Russo, D; Schaap, N; Scheid, C; Schetelig, J; Schoemans, H; Sobh, M; van Gelder, M; Wulf, G | 1 |
| Banerji, V; Brown, K; Bucher, O; Dawe, DE; Dhaliwal, DH; Geirnaert, M; Hibbert, I; Johnston, JB; Uminski, K | 1 |
| Bandyopadhyay, A; Bhunia, D; Chakravarty, D; Das, AA; Ghosh, S; Mandal, PC; Siddiqui, KN | 1 |
| Chatron, E; Hansmann, Y; Karol, A; Martin, A; Petitdemange, A; Ruch, Y | 1 |
| Chen, X; Chen, Y; Liu, J; Liu, Z; Shi, M; Yu, J; Zhang, T | 1 |
| Matutes, E; Molica, S; Polliack, A; Tam, C | 1 |
| Bora, P; Domenici, E; Leonardelli, L; Lorenzini, F; Mione, MC; Misselbeck, K; Morine, MJ; Parolo, S; Priami, C; Savoca, V | 1 |
| Bandera, A; Benzecry, V; Grancini, A; Peri, AM; Peyvandi, F; Reda, G; Rossio, R; Tafuri, F | 1 |
| Dai, L; Gong, Y; Jin, X; Liu, Y; Peng, Y; Pu, W; Pu, X; Wang, X; Wang, Y | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Andreadis, C; Fakhri, B | 1 |
| Aguilar-Company, J; Los-Arcos, I; Ruiz-Camps, I | 1 |
| Ahn, IE | 1 |
| Ball, S; Borthakur, G; Das, A; Edwards, PJ; Hardwicke, F; Maiti, A; Short, NJ; Vutthikraivit, W | 1 |
| Braggio, E; Call, TG; Ding, W; Fonder, AL; Hampel, PJ; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Rabe, KG; Schwager, SM; Slager, SL; Van Dyke, DL; Wang, Y; Witzig, TE | 2 |
| Carver, J; Goodfriend, J; Mato, A; Narkhede, M; Rhodes, J; Roeker, LE; Sarraf Yazdy, M | 1 |
| Eichhorst, B; Fürstenau, M; Hallek, M | 1 |
| Gutierrez, C; Wu, CJ | 1 |
| Printz, C | 1 |
| Gan, N; Li, H; Peng, X; Suo, Z; Tang, P; Wei, X; Zhang, M; Zhao, L | 1 |
| Habib, P; Huber, M; Simonowski, A; Wilhelm, T; Zorn, CN | 1 |
| Mhibik, M; Sun, C; Wiestner, A | 1 |
| Grainger, BT; Issa, S | 1 |
| Choi, I; Hatake, K; Sekiguchi, N; Shibayama, H; Teshima, T; Yoshinari, N | 1 |
| Alanazi, F; Dobie, G; Gazwani, AM; Handunnetti, SM; Jackson, DE; Kuriri, FA; Omar, MMA; Sze, DM; Tam, C; Tang, CPS | 1 |
| Dean, JP; Gururaja, T; Hill, RJ; Hopper, M; Kinoshita, T; Mongan, A | 1 |
| Buhimschi, AD; Crews, CM; Hines, J; Jaime-Figueroa, S; Toure, M | 1 |
| Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A | 1 |
| Burger, JA; Duenas, DE; Estrov, Z; Ferrajoli, A; Jain, N; Kantarjian, H; Keating, MJ; Kim, E; Schlette, EJ; Sivina, M; Solis Soto, LM; Strati, P; Thompson, PA; Wierda, WG; Wistuba, II | 1 |
| Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA | 1 |
| Itani, K; Kohno, K; Kondo, Y; Nakamura, K; Nakayama, T; Otsuka, M; Saburi, M; Soga, Y | 1 |
| Danhof, S; Düll, J; Einsele, H; Grathwohl, D; Kortüm, M; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Rosenwald, A; Steinhardt, MJ; Zhou, X | 1 |
| Cheng, Y; Dang, Q; Huang, J; Shi, W; Yang, L; Zhang, Y; Zhou, H | 1 |
| Hwang, JP; Malek, AE; Nieto, Y; Raad, II; Shafi, MA; Siddiqui, S; Szvalb, AD; Torres, HA | 1 |
| Baran, AM; Barr, PM; Evans, AG; Meacham, PJ; Moore, J; Zent, CS | 1 |
| Baumann, T; Giannarelli, D; Molica, S; Montserrat, E | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Alonso-Pérez, V; Bastida, JM; Benito, R; García, JL; García-Tuñón, I; Gruber, M; Hernández-Rivas, JM; Hernández-Sánchez, JM; Hernández-Sánchez, M; Herrero, AB; Martín-Izquierdo, M; Ordóñez, JL; Quijada-Álamo, M; Rodríguez-Vicente, AE; San Segundo, L; Ten Hacken, E; Wu, CJ; Yin, S | 1 |
| Alqahtani, H; Brander, D; Choi, M; Churnetski, M; Cohen, J; Danilov, AV; Gordon, MJ; Hill, B; Patel, K; Persky, D; Rivera, X; Salous, T; Shadman, M; Sitlinger, A; Stephens, D; Wisniewski, P | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A | 1 |
| An, N; Gao, Y; Guan, M; Jiang, Y; Li, X; Liu, N; Ruan, Y; Shang, H; Wang, L; Xing, Y; Yang, X; Zhang, H; Zhong, C | 1 |
| Koehler, A | 1 |
| Blijlevens, NMA; Cornelissen, JJ; Dinmohamed, AG; Doorduijn, JK; Kater, AP; Levin, MD; van der Straten, L; Visser, O | 1 |
| Hallek, M; Hassenrück, F; Krause, G | 1 |
| Alpár, D; Bock, C; Bödör, C; Farlik, M; Fortelny, N; Krausgruber, T; Mátrai, Z; Nemc, A; Penz, T; Rendeiro, AF; Réti, M; Schmidl, C; Schuster, LC; Tasnády, S; Zhao, F | 1 |
| Benedetti, D; Bittolo, T; Bomben, R; Caldana, C; Cattarossi, I; Chiarenza, A; Chivilò, H; D'Arena, G; Del Poeta, G; Di Raimondo, F; Gaidano, G; Gattei, V; Gentile, M; Hartmann, TN; Innocenti, I; Laurenti, L; Moia, R; Nanni, P; Norris, K; Olivieri, J; Pepper, C; Polesel, J; Pozzato, G; Pozzo, F; Rossi, D; Rossi, FM; Santinelli, E; Tissino, E; Tripepi, G; Zaina, E; Zaja, F; Zucchetto, A | 1 |
| Bai, G; Cai, S; Chen, Y; Ding, J; Duan, W; Ning, Y; Song, P; Xie, H; Zhang, H; Zhang, T; Zhou, J | 1 |
| Bates, OM; Beddoe, ME; Garling, EE; Godwin, CD; Laszlo, GS; Walter, RB | 1 |
| Ahirwar, DK; Ganju, RK; Halsey, G; Hamza, O; Holcomb, EA; Jha, BK; Maryala, RJ; Oghumu, S; Saljoughian, N; Satoskar, AR; Singh, B; Varikuti, S; Verma, C; Viana, AG; Volpedo, G | 1 |
| Albayrak, M; Cömert, P; Öztürk, HB; Reis Aras, M; Şahin, O; Yıldız, A | 1 |
| Al-Sawaf, O; Eichhorst, B; Hallek, M | 1 |
| Anderson, LD; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Girnius, S; Karanes, C; Lee, Y; Liu, E; Lunning, M; Matous, JV; Niesvizky, R; Salman, Z; Shustik, C; Stuart, R; Usmani, SZ; Valent, J | 1 |
| Brener, H; Brener, ZZ; Losev, A | 1 |
| Badillo, M; Cramer, F; Lee, HJ; Romaguera, JE; Schmelz, JL; Wang, M | 1 |
| Bonney, S; Cooksey, L; Coutinho, M; Guinn, BA; Jordaens, S; Mills, KI; Orchard, K; Orchard, L; Van Tendeloo, V | 1 |
| Fausto, R; Nogueira, BA; Pinto, RMA; Simões, MF; Simões, S; Tabanez, AM | 1 |
| Beishuizen, A; Bhojwani, D; Burke, GAA; Burkhardt, B; Cairo, M; Howes, A; Jong, J; Kabickova, E; Liu, G; Minard-Colin, V; Norris, RE; Nottage, K; Pinarli, FG; Salman, M; Tacyildiz, N; Trixhe, XW | 1 |
| Boudny, M; Trbusek, M | 1 |
| Gauthier, J; Hawkins, RM; Hay, KA; Hirayama, AV; Li, DH; Lymp, J; Maloney, DG; Pender, BS; Phi, TD; Purushe, J; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Turtle, CJ; Vakil, A; Yeung, CCS | 1 |
| Bennis, Y; Boone, M; Chouaki, T; Delette, C; Joseph, C; Mabille, C; Maizel, J; Marolleau, JP; Nyga, R | 1 |
| Barnes, M; Buttar, B; Gondal, K; Kaell, A; Kumar, V; Le, TH; Siddique, H | 1 |
| Chen, H; Liu, Z; Luo, Q; Pan, W; Qiu, M; Sun, J; Wang, G; Wang, J; Yan, X; Yang, D; Yi, H; Yuan, L; Zhang, L; Zhou, S | 1 |
| Agarwal, A; Chang, BH; Danilov, AV; Druker, BJ; Eide, CA; Kaempf, A; Kurtz, SE; Long, N; Mori, M; Tognon, CE; Tyner, JW | 1 |
| Bhatnagar, V; De Claro, RA; Farrell, AT; Gwise, T; King-Kallimanis, BL; Kluetz, PG; Kwitkowski, V; Wroblewski, T | 1 |
| Castillo, JJ; Chan, GG; Chen, J; Demos, MG; García-Sanz, R; Hunter, ZR; Jiménez, C; Kofides, A; Liu, X; Munshi, M; Treon, SP; Tsakmaklis, N; Wiestner, A; Xu, L; Yang, G | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Heinz, WJ; Hensel, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Pflug, N; Ritgen, M; Robrecht, S; Sasse, S; Stilgenbauer, S; Tausch, E; Tresckow, JV; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
| Choi, J; Häupl, B; Huang, DW; Oellerich, T; Phelan, JD; Shaffer, AL; Staudt, LM; Wang, Z; Wright, GW; Young, RM; Yu, X; Zhao, H | 1 |
| Barrett, TD; Chang, BY; Crowther, M; James, DF; Kinoshita, T; Marimpietri, C; Mokatrin, A; Ninomoto, J; Sukbuntherng, J | 1 |
| Demerdash, Y; Hanna, BS; Lichter, P; Roessner, PM; Schulz, R; Seiffert, M; Stilgenbauer, S; Yazdanparast, H | 1 |
| B Peters, K; T Low, J | 1 |
| Brand, M; Brunner, C; Doescher, J; Greve, J; Hoffmann, TK; Jackson, EK; Jeske, SS; Laban, S; Schuler, PJ; Ziebart, A | 1 |
| Arnason, J; Aviv, A; Avivi, I; Bairey, O; Ben Baruch, S; Dvid, V; Herishanu, Y; Kirgner, I; Perry, C; Raz, MA; Sarid, N; Shvidel, L | 1 |
| Cai, Y; Chen, X; Guo, J; Hu, Y; Li, D; Lin, D; Liu, S; Wen, Z; Xu, Y; Zhu, J | 1 |
| Advani, RH; Beaupre, DM; Bhatia, S; Chen, R; Co, M; Davis, RE; De Vos, S; Eckert, K; Flinn, IW; Fowler, NH; Knapp, M; Martin, P; Mena, R; Nastoupil, L; Neelapu, SS; Neuenburg, JK; Palomba, ML; Ping, J | 1 |
| Cao, J; Hu, X; Jin, J; Lv, F; Tao, Z; Wang, L; Zhang, J | 1 |
| Achenbach, SJ; Call, TG; Chanan-Khan, AA; Ding, W; Finnes, HD; Fonder, AL; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; McCullough, KB; Muchtar, E; Nedved, AN; Parikh, SA; Rabe, KG; Schwager, SM; Shanafelt, TD; Slager, SL; Smith, MD | 1 |
| Calogero, A; Casale, B; Ciccozzi, M; Martinelli, E; Papa, A; Sagnelli, C; Sagnelli, E; Sica, A | 1 |
| Asbury, K; Bering, J; Hartmann, C; Vikram, HR | 1 |
| Barrientos, JC; Barta, SK; Chong, EA; Gerson, JN; Landsburg, DJ; LoRe, VA; Loren, AW; Mato, AR; Nasta, SD; Rhodes, JM; Schuster, SJ; Svoboda, J | 1 |
| Brown, JR; Cohen, A; Eichhorst, BF; Hilger, J; Hillmen, P; Huang, J; Lamanna, N; O'Brien, SM; Qiu, L; Salmi, T; Tam, CS; Wu, K | 1 |
| Blum, K; Burger, JA; Byrd, JC; Coutre, SE; Dean, JP; Flinn, IW; Furman, RR; Heerema, NA; Liu, EA; Luan, Y; O'Brien, S; Sharman, JP; Wierda, W; Zhao, W | 1 |
| Dąbrowska-Kugacka, A; Daniluk, P; Lasocka, Z; Lewicka, E; Nabiałek-Trojanowska, I; Zarzycka, E; Zaucha, JM | 1 |
| Babal, P; Danihel, L; Drgona, L; Hojsikova, I; Kyselovic, J; Ladicka, M; Mosna, K; Tomasova, R; Vranovska, M | 1 |
| Akarsu, S; Fetil, E; Lebe, B; Nazli, EC; Ozbagcivan, O | 1 |
| Asteriti, E; Duerr-Stoerzer, S; Einhaus, J; Henes, J; Keppeler, H; Klein, R; Pecher, AC; Schmid, H; Schneidawind, C; Schneidawind, D; Secker, KA | 1 |
| Blachly, JS; Byrd, JC; Doong, TJ; Gregory, CT; Larkin, K; Lozanski, A; Lozanski, G; Lucas, F; Misra, S; Ngankeu, A; Orwick, S; Ozer, HG; Rogers, KA; Sampath, D; Thangavadivel, S; Woyach, JA; Yilmaz, SA | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; Alqahtani, F; Alzahrani, KS; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Mahmood, HM; Nadeem, A | 1 |
| Anderson, MA; Blombery, P; Handunnetti, SM; Kuss, BJ; Lew, TE; Lin, VS; Nguyen, T; Roberts, AW; Seymour, JF; Tam, CS; Westerman, DA | 1 |
| Ertek, M; İskender, D; İskender, G | 1 |
| Suzumiya, J; Takizawa, J | 1 |
| Antin, JH; Fantozzi, PJ; Treister, N; Villa, A | 1 |
| Campbell, M; Hanna, KS; Husak, A; Sturm, S | 1 |
| Bertorelle, R; Briani, C; Cacciavillani, M; Campagnolo, M; Candiotto, C; Castellani, F; Salvalaggio, A; Trentin, L; Visentin, A | 1 |
| Angeletti, I; Arrigo, G; Biagi, A; Bomben, R; Botta, C; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Foà, R; Fraticelli, V; Gaidano, G; Gattei, V; Gentile, M; Herishanu, Y; Laurenti, L; Loseto, G; Mauro, FR; Moia, R; Morabito, F; Murru, R; Pietrasanta, D; Polliack, A; Rago, A; Recchia, AG; Reda, G; Rigolin, GM; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Tripepi, G; Varettoni, M; Vigna, E; Zucchetto, A | 1 |
| Castillo, JJ; Ghobrial, IM; Guerrera, ML; Meid, K; Skarbnik, AP; Soumerai, JD; Treon, SP; Yang, G | 1 |
| Bezares, RF; Borge, M; Colado, A; Cordini, G; Elías, EE; Fernández Grecco, H; Gamberale, R; Giordano, M; Jancic, C; Keitelman, I; Podaza, E; Risnik, D; Trevani, A; Vergara Rubio, M | 1 |
| Azam, M; Chutipongtanate, S; Dwivedi, P; Greis, KD; Grimes, HL; Muench, DE | 1 |
| Matsue, K; Miura, D; Narita, K; Takeuchi, M; Terao, T; Tsushima, T | 1 |
| Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L | 1 |
| Choi, YS; Do, YR; Kim, MK; Kim, SJ; Kim, WS; Ko, YH; Koh, Y; Lee, GW; Mun, YC; Suh, C; Yang, DH; Yoon, DH; Yoon, SE | 1 |
| Davis, MR; Patterson, TF; Thompson, GR | 1 |
| Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M | 1 |
| Brown, A; George, P; Weinkove, R | 1 |
| Kater, AP; Melenhorst, JJ | 1 |
| Ashelford, K; Corcoran, DB; Fegan, CD; Giles, PJ; Lewis, T; Miraz Rahman, K; Pepper, AGS; Pepper, C; Thurston, DE; Walsby, EJ | 1 |
| Forghieri, F; Luppi, M; Potenza, L | 1 |
| Lasica, M; Tam, CS | 2 |
| Astle, J; Badar, T; Hamadani, M; Hari, PN; Kakar, IK; Zellner, K | 1 |
| Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L | 1 |
| Baumann, T; Delgado, J; Montserrat, E | 1 |
| Bhalla, S; Gabrilove, J; Sigel, K; Thibaud, S; Tremblay, D; Zimmerman, B | 1 |
| Gonzalez, RM; Pidala, J | 1 |
| Booth, S; MacLean, P; Morley, N; Parisi, L; Rule, S; Tucker, D; Vandenberghe, E | 1 |
| Huang, Y; Lin, N; Tan, B; Zhang, B | 1 |
| Chen, FL; Li, WY; Pang, DW | 1 |
| Bleul, S; Braig, M; Duque-Afonso, J; Duyster, J; Finke, J; Illerhaus, G; Lauer, EM; Marks, R; Mutter, J; Prinz, M; Reinacher, PC; Scherer, F; Schorb, E; Waterhouse, M | 1 |
| Anastasopoulou, A; DiPippo, AJ; Kontoyiannis, DP | 1 |
| Adasme, MF; Haupt, VJ; Heinrich, JC; Herman, J; Jennings, GS; Louat, T; Moreau, Y; Parisi, D; Salentin, S; Schroeder, M; Sprangers, B; Van Belle, K | 1 |
| Ablard, C; Bernard, S; Brice, P; Chevret, S; Harel, S; Kroemer, M; Madelaine, I; Thieblemont, C; Zerbit, J | 1 |
| Archibald, WJ; Call, TG; Chanan-Khan, AA; Ding, W; Fonder, AL; Herrmann, J; Kabat, BF; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Rabe, KG; Schwager, SM; Shanafelt, TD; Slager, SL; Wang, Y | 1 |
| Gianfelici, V; Levato, L; Molica, S | 1 |
| Gabrilove, J; Hardy-Abeloos, C; Pinotti, R | 1 |
| Dmitrieva, EA; Ignatova, AA; Maschan, AA; Nikitin, EA; Novichkova, GA; Panteleev, MA; Poletaev, AV; Polokhov, DM; Ptushkin, VV; Seregina, EA; Vorobyev, VI; Voronin, KA | 1 |
| Bogusz, AM; Brooks, S; June, CH; Lacey, SF; Liu, X; Melenhorst, JJ; Nejati, R; Nunez-Cruz, S; Orlando, EJ; Schuster, SJ; Strauser, HT; Wang, HY; Wasik, MA; Watt, C; Zhang, P; Zhang, Q | 1 |
| Davidoff, AJ; Gross, CP; Huntington, SF; Isufi, I; Kothari, S; Patel, KK | 1 |
| Pailla, SR; Prajapati, S; Rangaraj, N; Sampathi, S; Shah, S | 1 |
| Aitken, SL; DiPippo, AJ; Frei, M; Jain, N; Kontoyiannis, DP; Thompson, P; Wierda, W | 1 |
| Burla, L; Fink, D; Imesch, P; Metzler, JM | 1 |
| Chen, P; Li, BZ; Zhang, H; Zhang, XH | 1 |
| Fang, H; Feng, Y; Hou, K; Huang, L; Jia, Y; Shao, S; Yu, Z | 1 |
| Lentini, M; Levato, L; Molica, S; Zappalà, D | 1 |
| Hochman, MJ; Martin, DB | 1 |
| Bhat, S; Blachly, JS; Byrd, JC; Chiang, CL; Coombes, KR; Doong, TJ; Hu, EY; Jones, D; Lozanski, A; Lozanski, G; Muthusamy, N; Ozer, HG; Rogers, KA; Saygin, C; Workman, SE; Woyach, JA | 1 |
| Allouchery, M; Delaunay, P; Delwail, V; Guidez, S; Lafay-Chebassier, C; Pérault-Pochat, MC; Salvo, F; Tomowiak, C | 1 |
| Baumann, TS; Delgado, J; Lentini, M; Levato, L; Molica, S; Montserrat, E | 1 |
| Bijou, F; Ferrant, E; Michallet, AS; Quinquenel, A; Ysebaert, L | 1 |
| De Silva, N; Droogendijk, J; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Gregor, M; Hallek, M; Hohloch, K; Illmer, T; Kater, AP; Langerbeins, P; Niemann, CU; Robrecht, S; Schöttker, B; Simon, F; Stilgenbauer, S; Tausch, E; van der Klift, M; van der Spek, E; von Tresckow, J; Wendtner, CM | 1 |
| Lim, KJC; Tam, CS | 2 |
| Bax, DJC; Borst, J; Brown, JR; Chiodin, G; Dubois, J; Eldering, E; Fernandes, SM; Forconi, F; Haselager, MV; Kater, AP; Kielbassa, K; Tam, C; Ter Burg, J | 1 |
| Beylot-Barry, M; Protin, C; Recher, C; Sibaud, V; Vigarios, E; Ysebaert, L | 1 |
| Lee, J; Wang, YL | 1 |
| Anagnostopoulos, A; Chatzidimitriou, A; Galigalidou, C; Gemenetzi, K; Ghia, P; Ioannou, N; Iskas, M; Koravou, E; Kotouza, M; Kotta, K; Kouvatsi, A; Papazoglou, D; Pasentsis, K; Psomopoulos, F; Ramsay, AG; Scarfó, L; Stamatopoulos, K; Stavroyianni, N; Vardi, A; Vlachonikola, E | 1 |
| Budziszewska, BK; Dlugosz-Danecka, M; Drozd-Sokolowska, J; Dudzinski, M; Giannopoulos, K; Halka, J; Holojda, J; Hus, M; Iskierka-Jazdzewska, E; Jamroziak, K; Jurczak, W; Knopinska-Posluszny, W; Kumiega, B; Lech-Maranda, E; Osowiecki, M; Piszczek, W; Pluta, A; Pula, B; Robak, T; Steckiewicz, P; Subocz, E; Szeremet, A; Szymczyk, A; Waszczuk-Gajda, A; Wichary, R; Wojciechowska, M; Zaucha, JM; Zawirska, D | 1 |
| Beijnen, JH; Jamalpoor, A; Janssen, MJ; Masereeuw, R; Rood, JJM; Schinkel, AH; Sparidans, RW; van Haren, MJ; van Hoppe, S; Wasmann, RE | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Ntanasis-Stathopoulos, I | 1 |
| Chen, Z; Li, Y; Tian, C | 1 |
| Andres, M; Baile, M; Barna, G; Bron, D; Chatzikonstantinou, T; Chiarenza, A; Coscia, M; Cuéllar-García, C; Cuneo, A; De Paoli, L; De Paolis, MR; Del Poeta, G; Delgado, J; Dimou, M; Dos Santos, G; Doubek, M; Enrico, A; Farina, L; Ferrari, A; Foà, R; Foglietta, M; Garcia-Marco, JA; Gentile, M; Ghia, P; Gimeno, E; Hakobyan, Y; Herishanu, Y; Hernández-Rivas, JÁ; Herold, T; Itchaki, G; Iyengar, S; Jaksic, O; Janssens, A; Kalashnikova, O; Kater, AP; Kersting, S; Laurenti, L; Levin, MD; Lista, E; Malerba, L; Marasca, R; Marchetti, M; Marquet, J; Mauro, FR; Mirás, F; Montserrat, E; Motta, M; Munir, T; Niemann, CU; Nikitin, E; Orsucci, L; Ortiz Pareja, M; Papaioannou, M; Pocali, B; Popov, VM; Quaglia, FM; Quaresmini, G; Rambaldi, A; Reda, G; Rigolin, GM; Rossi, D; Rossi, G; Ruchlemer, R; Scarfò, L; Shah, N; Shrestha, A; Šimkovič, M; Špaček, M; Sportoletti, P; Stamatopoulos, K; Stanca, O; Stavroyianni, N; Strugov, V; Tam, C; Trentin, L; Van Der Spek, E; Vandenberghe, E; Varettoni, M; Vitale, C; Wasik-Szczepanek, E; Yassin, M; Zdrenghea, M | 1 |
| Chi, L; Dabaja, B; Fayad, LE; Furqan, F; Morrison, MW; Nastoupil, LJ; Neelapu, SS; Pinnix, CC; Samaniego, F; Steiner, RE; Strati, P; Thompson, PA; Watson, G | 1 |
| He, YZ; Li, X; Wang, L | 1 |
| Barnes, M; Kaell, A; Kumar, V; LiPera, W; Sharma, P | 1 |
| Budziszewska, BK; Długosz-Danecka, M; Gil, L; Hus, M; Iskierka-Jażdżewska, E; Jamroziak, K; Jurczak, W; Lech-Marańda, E; Osowiecki, M; Piszczek, W; Puła, B; Rybka, J; Salomon-Perzyński, A; Steckiewicz, P; Subocz, E; Szukalski, Ł; Szymczyk, A; Waszczuk-Gajda, A; Zaucha, JM | 1 |
| Forns, TE; Neff, JL; Pabon, CM; Wang, J | 1 |
| Christofides, A; Kuruvilla, P; Sehn, LH; Stakiw, J | 1 |
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Kyung, D; Lama, TG; O'Brien, S | 1 |
| Christophe, B; Julien, S; Marcaillou, M; Marion, B; Stéphanie, D | 1 |
| Barnea Slonim, L; Behdad, A; Chen, Q; Ma, S | 1 |
| Casey, J; Cheah, CY; Chin, CK; Crawford, J; Do, B; Gandhi, MK; Grigg, A; Hamad, N; Hawkes, EA; Ho, SJ; Issa, S; Lewis, KL; Manos, K; Nastoupil, L; Wood, P | 1 |
| Dreger, P; Fan, F; Gern, U; Hückelhoven-Krauss, A; Liu, Y; Müller-Tidow, C; Neuber, B; Schmitt, A; Schmitt, M; Schubert, ML; Sellner, L; Stock, S; Wang, L; Wang, S; Yoo, HJ | 1 |
| Abrisqueta, P; Bobillo, S; Boix, J; Bosch, F; Carabia, J; Castellví, J; Céspedes Torrez, DH; Crespo, M; Escoda, L; Jiménez, I; Martínez-Ricarte, F; Nieto, JC; Pagès, C; Palacio, C; Perla, C; Puigdefàbregas, L; Purroy, N; Seoane, J | 1 |
| Reynolds, G; Slavin, M; Teh, BW | 1 |
| Chanas-Larue, A; Gibson, SB; Henson, ES; Johnston, JB; Villalpando-Rodriguez, GE | 1 |
| Ahn, IE; Tian, X; Wiestner, A | 1 |
| Belada, D; Buske, C; Castillo, JJ; Chan, WY; Cohen, A; Cull, G; Czyz, J; D'Sa, S; Dimopoulos, M; Fernández de Larrea, C; Huang, J; Jurczak, W; Leblond, V; Lee, HP; Libby, E; Marlton, P; Matous, JV; McCarthy, H; Minnema, MC; Motta, M; Mulligan, S; Opat, S; Owen, RG; Ro, S; Sanz, RG; Schneider, J; Siddiqi, T; Tam, CS; Tani, M; Tedeschi, A; Trneny, M; Trotman, J; Wahlin, BE | 1 |
| Biagi, A; Bomben, R; Bruno, A; Cantonetti, M; Chiarenza, A; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Di Raimondo, F; Gattei, V; Innocenti, I; Laurenti, L; Postorino, M; Pozzo, F; Rossi, FM; Zucchetto, A | 1 |
| Aarup, K; Andersen, MA; Bergmann, OJ; Christiansen, I; Enggaard, L; Frederiksen, H; Frederiksen, M; Nielsen, T; Niemann, CU; Pedersen, RS; Rotbain, EC; Thomsen, RH | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Connor, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, GAM; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Loscertales, J; Mato, A; Mayer, J; Nottage, K; Pavlovsky, MA; Rule, S; Salman, M; Samoilova, O; Santucci Silva, R; Schuier, N; Sun, S; Tamegnon, M | 1 |
| Boutoille, D; Brochard, J; Guimard, T; Le Pape, P; Leterrier, M; Mahe, B; Mahe, J; Morio, F; Morrier, M; Raffi, F | 1 |
| Abbadessa, A; Arcaini, L; Benevolo, G; Corbingi, A; Del Fabro, V; Deodato, M; Dogliotti, I; Fabbri, N; Ferrari, A; Ferrero, S; Ferretti, VV; Frustaci, AM; Gentile, M; Greco, C; Klersy, C; Laurenti, L; Luminari, S; Merli, M; Motta, M; Musto, P; Piazza, F; Rizzi, R; Varettoni, M; Visco, C | 1 |
| Bierman, P; Hansen, N; Kallam, A | 1 |
| Agostinelli, C; Alessandrini, A; Bertuzzi, C; Broccoli, A; Bruni, F; Evangelista, V; Guglielmo, A; Massi, A; Patrizi, A; Pileri, A; Piraccini, BM; Starace, M; Zinzani, PL | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; von Tresckow, J | 1 |
| Abruzzo, LV; Andersen, BL; Awan, FT; Banks, C; Bhat, SA; Byrd, JC; Dean, A; Grantier, C; Heerema, NA; Huang, Y; Jones, JA; Lozanski, G; Lucas, M; Maddocks, KJ; Rogers, KA; Ruppert, AS; Valentine, TR; Weiss, DM; Woyach, JA | 1 |
| Brion, A; Charollais, R; Daguindau, E; Deconinck, E; Roussel, X | 1 |
| Ahn, IE; Fleisher, T; Gaglione, E; Lotter, J; Maric, I; Mu, R; Pittaluga, S; Pleyer, C; Rampertaap, S; Rosenzweig, S; Soto, S; Stetler-Stevenson, M; Sun, C; Superata, J; Tian, X; Wiestner, A; Yuan, CM | 1 |
| Burger, JA; Khanlari, M; Liu, W; Medeiros, LJ; Tang, G; Tang, Z; Toruner, G; Xu, J | 1 |
| Cui, Y; Feng, D; Liu, X; Zheng, M; Zhong, D | 1 |
| Cordoba, R | 1 |
| Fan, L; Kong, YL; Li, JY; Liang, JH; Pan, BH; Wang, L; Wu, JZ; Xia, Y; Xu, W; Zhu, HY | 1 |
| Dong, TC; Feng, B; Gao, AH; Hu, XB; Kan, WJ; Li, J; Li, JN; Wang, HL; Wang, ZJ; Wu, WB; Xia, CM; Xiang, YQ; Xu, L; Zhang, XT; Zhou, YB | 1 |
| Cana, D; Hess, G; Higer, M; Podlech, J; Schadmand-Fischer, S; Schwarting, A; Teschner, D; Theobald, M; Wölfel, T | 1 |
| Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H | 1 |
| Dobber, JA; Kater, AP; Kersting, S; Levin, MD; Mattson, M; Mous, R; Nasserinejad, K; Niemann, CU; Ostrowski, SR; Svanberg, R; Tran, HTT | 1 |
| Deng, Q; Jiang, Y; Li, Z; Liu, M; Mu, J; Sun, L; Wang, X; Zhang, R | 1 |
| Borra, S; Huang, Q; Janjan, N; Li, J; Shrestha, S; Sundaram, M; Wang, L | 1 |
| Chen, Z; Fu, X; Hou, Z; Jin, Y; Li, Q; Wang, J; Yuan, X; Zhang, Y; Zhao, X | 1 |
| Barrientos, JC; Blum, LK; Burger, JA; Byrd, JC; Dean, JP; Hillmen, P; Hoh, HY; Kay, NE; Kipps, TJ; Lal, ID; Mongan, A; Mulligan, SP; O'Brien, S; Solman, IG | 1 |
| Ammatuna, E; Blum, S; Boersma, R; Breems, D; Chalandon, Y; Chitu, DA; Cloos, J; Deeren, D; Fehr, M; Griskevicius, L; Hoogendoorn, M; Huls, G; Jongen-Lavrencic, M; Klein, SK; Legdeur, MC; Löwenberg, B; Manz, MG; Ossenkoppele, GJ; Pabst, T; Söhne, M; Stussi, G; Tick, L; Valk, PJM; van de Loosdrecht, AA; van der Poel, MWM; van Lammeren-Venema, D; van Marwijk Kooy, R; van Zeventer, I | 1 |
| Lebas, D; Leguern, A; Modiano, P; Preta, LH; Wiart, T | 1 |
| Advani, R; Branagan, AR; Castillo, JJ; Ghobrial, IM; Gustine, J; Hunter, ZR; Laubach, JP; Liu, X; Meid, K; Palomba, ML; Patterson, CJ; Treon, SP; Xu, L; Yang, G | 1 |
| Fancher, KM; Pappacena, JJ | 1 |
| Cordoba, R; de Jong, J; Dlugosz-Danecka, M; Hellemans, P; Jiao, J; Jurczak, W; Mitselos, A; Ouellet, D; Panizo, C; Sukbuntherng, J; Wrobel, T | 1 |
| Call, TG; Cherng, HJ; Ding, W; Ferrajoli, A; Hampel, PJ; Jain, N; Khanlari, M; Lin, P; McPhail, ED; Miranda, RN; Parikh, SA; Tawbi, HA; Wierda, WG | 1 |
| Despina, F; Efstathios, K; Meletios Athanasios, D | 1 |
| Allan, JN; Barr, PM; Billio, A; Brander, DM; Cavallari, M; Cimino, G; Coscia, M; Cucci, R; Cuneo, A; de la Serna, J; Di Raimondo, F; Doubek, M; Farina, L; Ferrarini, I; Foà, R; Gaidano, G; Gentile, M; Ghia, P; Hill, BT; Ilariucci, F; Jacobs, R; Lamanna, N; Lansigan, F; Laurenti, L; Marchetti, M; Mato, AR; Mauro, FR; Medina Perez, A; Molica, S; Orlandi, EM; Pagel, JM; Piciocchi, A; Pu, JJ; Rigolin, GM; Roeker, L; Schuster, SJ; Sehgal, AR; Shadman, M; Shah, NN; Skarbnik, AP; Spacek, M; Tam, CS; Tedeschi, A; Trentin, L; Ujjani, CS; Vignetti, M; Winter, A | 1 |
| Jiang, Z; Lin, G; Shi, L; Wang, Y; Zhang, Y | 1 |
| Li, X; Liu, Q; Song, T; Wang, C; Wang, Y; Wu, H; Ye, Z | 1 |
| Bertorelle, R; Facco, M; Frezzato, F; Imbergamo, S; Piazza, F; Piva, E; Pravato, S; Romano Gargarella, L; Scapinello, G; Semenzato, G; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Barozzi, P; Fiorcari, S; Ghia, P; Luppi, M; Maccaferri, M; Maffei, R; Marasca, R; Potenza, L; Scarfò, L; Vallerini, D | 1 |
| Breland, UM; Marvyin, K; Tjønnfjord, EB; Tjønnfjord, GE | 1 |
| Brousset, P; Evrard, SM; Kanoun, S; Laurent, C; Meggetto, F; Péricart, S; Syrykh, C; Ysebaert, L | 1 |
| Bergón-Sendín, M; Carretero-López, F; Mateos-Mayo, A; Parra-Blanco, V; Pulido-Pérez, A; Suárez-Fernández, R | 1 |
| Bellido, M; Dobber, JA; Dompeling, EC; Dubois, J; Enggaard, L; Frederiksen, H; Janssens, A; Kater, AP; Kersting, S; Levin, MD; Mattsson, M; Mellink, CHM; Mous, R; Nasserinejad, K; Niemann, CU; Poulsen, CB; Ranti, J; Schjødt, I; Tran, HTT; Veldhuis, GJ | 1 |
| Anderson, MA; Blombery, P; Davis, JE; Handunnetti, SM; Koldej, RM; Ludford-Menting, M; Ritchie, DS; Roberts, AW; Seymour, JF; Sharpe, C; Tam, CS | 1 |
| Baldini, L; Cassin, R; Giannarelli, D; Mauro, FR; Noto, A; Reda, G; Trentin, L; Visentin, A | 1 |
| Emond, B; Gupta, D; Huang, Q; Lafeuille, MH; Lefebvre, P; Mato, A; Sundaram, M | 1 |
| Diz Küçükkaya, R; Hindilerden, F; Yönal Hindilerden, İ | 1 |
| Stilgenbauer, S | 1 |
| Gogia, A; Gupta, R; Kirar, S; Mallick, S | 1 |
| Cuneo, A; De Propris, MS; Del Giudice, I; Foà, R; Guarini, A; Intoppa, S; Mariglia, P; Mauro, FR; Milani, ML; Peragine, N; Raponi, S; Rigolin, GM; Soddu, S | 1 |
| Busca, A; Candoni, A; Cattaneo, C; Dargenio, M; Facchinelli, D; Fanci, R; Farina, F; Laurenti, L; Lessi, F; Marchesi, F; Marchesini, G; Nadali, G; Pagano, L; Picardi, M; Prezioso, L; Spolzino, A; Tisi, MC; Trastulli, F; Verga, L; Visentin, A | 1 |
| Kater, AP; Kersting, S; Levin, MD; Mattsson, M; Nasserinejad, K; Niemann, CU; Ranti, J; Thi Tuyet Tran, H | 1 |
| Khosravi, S; Maleki, N; Mousavi, SA; Mousavi-Fatemi, K | 1 |
| Harari, D; Luo, TY; Shi, Y; Spaner, DE; Tsui, H; Wang, G; Xia, M | 1 |
| Chen, F; Guo, H; Huang, L; Jiang, X; Li, W; Liang, Z; Liu, S; Ou, Q; Pang, D; Wei, X; Wu, X; Zhou, D | 1 |
| Burger, JA; Chen, SS; Chiorazzi, N; Estrov, Z; Ferrajoli, A; Huang, X; Jain, N; Keating, MJ; Kim, E; Sivina, M; Vaca, A; Wierda, WG; Xiao, L | 1 |
| Bapat, A; Cetinbas, M; Clauss, S; Ellinor, PT; Hanley, A; Hulsmans, M; Iwamoto, Y; Lebrun-Vignes, B; Lundby, A; Milan, DJ; Moslehi, J; Nahrendorf, M; Sadreyev, RI; Salem, JE; Schloss, MJ; Tedeschi, J; Wojtkiewicz, G; Xiao, L | 1 |
| Beauchamp, E; Berthiaume, LG; Dong, WF; Gamma, JM; Gray, DW; Iyer, A; Lakshmanan, M; Lim, ST; Mackey, JR; Perinpanayagam, MA; Postovit, LM; Raju, A; Read, KD; Tan, SY; Tergaonkar, V; Vincent, KM; Wyatt, PG; Yap, MC | 1 |
| Andorsky, D; Clark, J; Kabadi, SM; Sharman, J | 1 |
| Arnall, JR; DiSogra, KY; Janes, A; Moore, DC; Park, SI; Tran, T | 1 |
| Chen, RZ; Chen, W; Ding, CY; Li, JY; Wang, L; Xia, Y; Xu, W; Zhu, HY | 1 |
| Inano, T; Komatsu, N; Mori, Y; Ota, Y; Tsukune, Y; Yasuda, H | 1 |
| Ding, GS; Fu, ZR; Guo, M; Li, PL; Liu, F; Liu, H; Song, SH; Sun, KY; Zhao, YY | 1 |
| Autore, F; Bacigalupo, A; Chiusolo, P; Giammarco, S; Innocenti, I; Laurenti, L; Metafuni, E; Sica, S; Sora, F | 1 |
| Luo, QY; Pan, WT; Qiu, MZ; Sun, J; Yang, DJ; Yang, LQ; Zhang, L; Zhou, SN | 1 |
| Kidoguchi, K; Kimura, S; Kizuka-Sano, H; Kubato, Y; Nishimura, Y | 1 |
| Hoshino, E; Okahashi, N; Uchihara, M | 1 |
| Callender, LA; Coldewey, SM; Collino, M; Collotta, D; Ferreira Alves, G; Greaves, DR; Krieg, N; Mohammad, S; O'Riordan, CE; Purvis, GSD; Sheikh, MH; Thiemermann, C; Wissuwa, B | 1 |
| Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; De Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Levy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini Piocelle, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan-Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L | 1 |
| Bartoli, L; Messori, A | 1 |
| Ahmad, SF; Al-Harbi, NO; Alanazi, WA; Alqahtani, F; Alsanea, S; Attia, SM; Ibrahim, KE; Mahmood, HM; Nadeem, A | 1 |
| Borsky, M; Brown, JR; Cerna, KA; Davids, MS; Doubek, M; Fernandes, SM; Filip, D; Jaeger, U; Janikova, A; Kipps, TJ; Kostalova, L; Kren, L; Liskova, K; Mayer, J; Mraz, M; Ondrisova, L; Oppelt, J; Pavlasova, GM; Pospisilova, S; Rassenti, LZ; Sandova, V; Seda, V; Sharma, S; Shehata, M; Vojackova, E; Zeni, PF | 1 |
| Boytchev, I; De Menthon, M; Lambotte, O; Lazure, T; Noël, N; Pacoureau, L; Rocher, L | 1 |
| Ali, T; He, K; Jiang, A; Li, S; Li, W; Liu, Y; Liu, Z; Ren, Q; Shah, FA | 1 |
| Bodet-Milin, C; Bossard, C; Bouabdallah, K; Callanan, MB; Cartron, G; Casasnovas, O; Chiron, D; Gastinne, T; Herbaux, C; Le Gouill, S; McCulloch, R; Morschhauser, F; Nadal, N; Ragot, S; Rossi, C; Rule, S; Tchernonog, E; Tessoulin, B | 1 |
| Aquino, R; Balasubramanian, S; Chaturvedi, S; Davis, C; de Jong, J; Fourneau, N; Oki, Y; Schaffer, M; Younes, A | 1 |
| Bluszcz, A; Górniak, P; Hus, M; Iskierka-Jażdżewska, E; Jamroziak, K; Juszczyński, P; Machnicki, MM; Makuch-Łasica, H; Nowak, G; Pępek, M; Puła, B; Płoski, R; Rydzanicz, M; Steckiewicz, P; Stokłosa, T; Szymczyk, A | 1 |
| Baumann, T; Giannarelli, D; Molica, S | 1 |
| Giannarelli, D; Molica, S; Montserrat, E | 1 |
| Aceves, SS; Allenspach, EJ; Bamshad, MJ; Bauman, BM; Butte, MJ; Camp, ND; Church, JA; Cooper, MA; Dabbah, G; Gray, J; Hagin, D; James, RG; Jordan, MB; Lundgren, I; Luthers, CR; Meitlis, I; Milner, JD; Nickerson, DA; Phan, IQ; Rawlings, DJ; Schmitt, EG; Schuval, S; Schwartz, DM; Skoda-Smith, S; Snow, AL; Starita, LM; Stinson, JR; Torgerson, TR | 1 |
| Novo, M; Santambrogio, E; Vitolo, U | 1 |
| Abeykoon, JP; Advani, RH; Ansell, SM; Castillo, JJ; Demos, MG; Flynn, CA; Gertz, MA; Guerrera, ML; Gustine, JN; Hunter, ZR; Kapoor, P; King, R; Kofides, A; Liu, X; Mein, K; Munshi, M; Palomba, ML; Treon, SP; Tsakmaklis, N; Yang, G; Zanwar, S | 1 |
| Şener, YZ | 1 |
| Andritsos, LA; Awan, FT; Byrd, JC; Khountham, S; Lachowiez, C; Mo, X; Mousa, L; Rogers, KA; Shindiapina, P; Spurgeon, SE; Wiczer, T; Woyach, JA | 1 |
| Aspelund, T; Björkholm, M; Gíslason, GK; Gottfreðsson, M; Kristinsson, SY; Landgren, O; Rögnvaldsson, S; Steingrímsson, V; Turesson, I; Þorsteinsdóttir, S | 1 |
| Smolej, L | 1 |
| Cavallini, C; Chignola, R; Dando, I; Donadelli, M; Galasso, M; Krampera, M; Lovato, O; Pizzolo, G; Pozza, ED; Romanelli, MG; Scupoli, MT | 1 |
| Danilov, AV; Persky, DO | 1 |
| Amatya, N; Andreotti, A; Engen, JR; Fulton, DB; Joseph, RE; Wales, TE | 1 |
| Arango-Hisijara, I; Barrientos, JC; Chen, R; Cheung, LW; Chong, E; Coleman, M; Collins, GP; de Vos, S; Flowers, CR; Hauns, B; Kwei, K; Ma, S; Martin, P; Morschhauser, F; Noy, A; Peles, S; Smith, SD; Thieblemont, C; Wu, S | 1 |
| Lichter, AS; Moslehi, JJ; Ratain, MJ | 1 |
| Barr, PM; Barrientos, JC; Brander, DM; Cheson, BD; Dorsey, C; Flinn, IW; Fonseca, GA; Ghosh, N; Hamadeh, IS; Kambhampati, S; Lamanna, N; Lansigan, F; LaRatta, N; Luning Prak, ET; Mato, AR; Miskin, HP; Pagel, JM; Paskalis, D; Pu, JJ; Rai, KR; Reeves, JA; Roeker, L; Schuster, SJ; Sitlinger, A; Skarbnik, AP; Sportelli, P; Svoboda, J; Tsao, P; Weiss, MS; Weissbrot, H | 1 |
| Falbo, M; Iannaccaro, P; Levato, L; Prejanò, S; Santoro, RC | 1 |
| Lamanna, N; Lipsky, A | 1 |
| Avsec, D; Gobec, M; Jakopin, Ž; Markovič, T; Mlinarič-Raščan, I; Nabergoj, S; Podgornik, H | 1 |
| Bhardwaj, M; Grover, P; Mehta, L; Mukherjee, D; Naved, T | 1 |
| Macip, S; Massip-Salcedo, M; Qusairy, Z; Rada, M | 1 |
| Awan, FT; Tong, D; Zaha, VG | 1 |
| Elsawa, SF; Ghazal, SM; Han, W; Karbalivand, M; Mallat, S; Matissek, SJ; Munshi, M; Reilly, BM; Sayed, M; Treon, SP; Walker, SR; Yang, G | 1 |
| Behnia, S; Cassaday, RD; Chauncey, TR; Gopal, AK; Graf, SA; Kanan, S; Krakow, E; Lynch, RC; Morris, K; Rasmussen, H; Smith, SD; Soma, L; Voutsinas, JM; Wu, QV | 1 |
| Chen, X; Chen, Y; Chen, Z; Dai, S; Duan, Y; Guo, M; Jiang, L; Li, J; Qu, L; Wu, D | 1 |
| Abreu, MM; Gouvea, J; Jewett, A; Ko, MW; Maharaj, D; Srinivasan, G | 1 |
| Al-Janazreh, H; Angeletti, I; Biagi, A; Bomben, R; Bossio, S; Cassin, R; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Cutrona, G; D'Arrigo, G; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Ferrarini, M; Foà, R; Fronza, G; Gaidano, G; Galimberti, S; Gattei, V; Gentile, M; Herishanu, Y; Jaksic, O; Laurenti, L; Loseto, G; Martino, EA; Mauro, FR; Mendicino, F; Menichini, P; Moia, R; Monti, P; Morabito, F; Murru, R; Neri, A; Pietrasanta, D; Polliack, A; Rago, A; Reda, G; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Trentin, L; Tripepi, G; Varettoni, M; Vigna, E; Visentin, A; Zucchetto, A | 1 |
| Kirzhner, M; Shildkrot, Y; Sieburth, RM; Weaver, CD | 1 |
| Gopireddy, RR; Mahapatra, S; Maruthapillai, A | 1 |
| García-Cosío, M; López-Gutiérrez, M; López-Jiménez, FJ; Marquet-Palomanes, J; Martín-Moro, F; Pian-Arias, H | 1 |
| Chandrashekar, N; McKenney, R | 1 |
| Benner, B; Carson, WE | 1 |
| Deng, Y; Gao, X; Li, C; Liu, X; Luo, X; Qiu, Q; Song, Y; Yan, X; Zhang, H | 1 |
| Alsuliman, T; Banet, A; Brissot, E; Corre, E; Dulery, R; Faict, S; Genthon, A; Ikhlef, S; Lapusan, S; Legrand, O; M'hammedi-Bouzina, F; Malard, F; Marjanovic, Z; Mohty, M; Schaeffer, L; Sestili, S; Van de Wyngaert, Z | 1 |
| Feller, F; Saling, C; Vikram, HR | 1 |
| Andres, M; Nagler, M; Novak, U; Pellegrini, L; Suter, T | 1 |
| Byfield, SD; Kabadi, SM; LE, L; Olufade, T | 1 |
| Chang, YY; Chen, W; Chen, Y; Fang, H; Tong, GY; Wang, T; Wang, ZY; Wu, HL; Yu, RQ | 1 |
| Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L | 1 |
| Allal, B; Chatelut, E; De Barros, S; Despas, F; Gallais, F; Obéric, L; White-Koning, M; Ysebaert, L | 1 |
| Farmer, J; Mehraban Far, P; Rullo, J; Urton, T | 1 |
| Gabizon, R; London, N | 1 |
| Chi, S; Kaku, E; Kuzume, A; Minami, Y; Nagata, A; Nakamura, H; Nishizawa, A; Sato, N; Yamauchi, N; Yuda, J | 1 |
| Choudhry, A; Irwin, D; Thompson, S; Wilson, K | 1 |
| Balla, J; Bidiga, L; File, I; Markóth, C; Mátyus, J; Szász, R | 1 |
| Angeletti, I; Biagi, A; Bomben, R; Botta, C; Caracciolo, D; Cassin, R; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Cutrona, G; D'Arrigo, G; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Ferrarini, M; Foà, R; Fronza, G; Gaidano, G; Galimberti, S; Gattei, V; Gentile, M; Herishanu, Y; Laurenti, L; Loseto, G; Martino, EA; Mauro, FR; Mendicino, F; Moia, R; Morabito, F; Murru, R; Neri, A; Pietrasanta, D; Polliack, A; Rago, A; Reda, G; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Trentin, L; Tripepi, G; Varettoni, M; Vigna, E; Visentin, A; Zucchetto, A | 1 |
| Herranz-Pinto, P; Mayor-Ibarguren, A; Quintana-Castanedo, L; Tarín-Vicente, E | 1 |
| Friedrichs, J; Heck, J; Krause, O | 1 |
| Akhter, N; El Hangouche, N; Feinglass, J; Gong, FF; Lentz, R; McGee, K; Singh, A | 1 |
| Allsup, D; Durairaj, S; Holding, S; Khan, S; Phumphukhieo, P | 1 |
| Maddocks, K | 1 |
| Baldwin, DA; Chen, Y; Franzen, CA; Gao, J; Khan, N; Larson, RA; Li, L; Lu, P; Ma, S; McClure, R; Nejati, R; Niu, N; Pei, J; Sukhanova, M; Tu, Y; Venkataraman, G; Wang, S; Wang, YL; Wasik, MA; Wu, W | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Philip, PA | 1 |
| Buti, N; Chaidos, A; Innes, A; Maynard, S; Milojkovic, D; Mirvis, E; Palanicawandar, R; Paleja, K; Ros-Soto, J; Sharp, H | 1 |
| Blum, LK; Burger, JA; Dean, JP; James, DF; Kipps, TJ; Mongan, A; Solman, IG | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Chang, MH; Eom, HS; Han, SH; Hyun, SY; Jo, JC; Kim, DS; Kim, HJ; Kim, SH; Kim, SJ; Kim, WS; Kwak, JY; Kwon, JH; Lee, JH; Lee, JO; Lee, SS; Oh, SY; Ryoo, HM; Suh, C; Yang, DH; Yi, JH; Yoon, DH | 1 |
| Arrillaga-Romany, IC; Bouffard, MA; Chwalisz, BK; Massoth, LR; Romero, JM | 1 |
| Boidol, B; Caron, P; Chong, SJF; Davids, MS; Guillemette, C; Heintel, D; Herbaux, C; Hopfinger, G; Jäger, R; Jäger, U; Kazianka, L; Kornauth, C; Kubicek, S; Mayerhöfer, ME; Pemovska, T; Poulain, S; Raderer, M; Simonitsch-Klupp, I; Sperr, WR; Staber, PB; Tournilhac, O; Van der Kouwe, E | 1 |
| Alinari, L; Baiocchi, RA; Byrd, JC; Chen, TL; Harrington, B; Hertlein, E; Lehman, AM; Orlemans, E; Prouty, A; Sampath, D; Sloan, S; Truxall, J; Wasmuth, R; Woyach, JA | 1 |
| Chen, Y; Hu, J; Huang, Y; Jiang, P; Li, J; Wang, L; Wen, J; Zhang, Y | 1 |
| Brander, DM; Burke, JM; Chandler, JC; Flinn, IW; Ghosh, N; Kambhampati, S; Kolibaba, KS; Lansigan, F; Lunin, SD; Mato, AR; Miskin, HP; Schreeder, MT; Schuster, SJ; Sharman, JP; Shtivelband, M; Sportelli, P; Travis, PM; Weiss, MS; Zweibach, A | 1 |
| Boccadoro, M; Boccellato, E; Cassin, R; Coscia, M; Cuneo, A; De Paoli, L; Foà, R; Gaidano, G; Gentile, M; Griggio, V; Laurenti, L; Marchetti, M; Mauro, FR; Montalbano, MC; Murru, R; Orsucci, L; Pennese, E; Perutelli, F; Porrazzo, M; Reda, G; Rigolin, GM; Rivela, P; Salvetti, C; Scarfò, L; Schiattone, L; Tedeschi, A; Trentin, L; Vassallo, F; Visentin, A; Vitale, C; Zamprogna, G | 1 |
| Bhalla, KN; Birdwell, C; Burger, J; Coarfa, C; Crews, CM; Davis, JA; Deng, Q; Ferrajoli, A; Fiskus, W; Green, MR; Jain, N; Jin, W; Khoury, JD; Lara, BH; Mill, CP; Perera, D; Saenz, DT; Yang, H | 1 |
| Haioun, C; Lemonnier, F; Roulin, L | 1 |
| Abbruzzese, JL; Agrawal, L; Ansstas, G; Arrowood, CC; Carson, CC; Collichio, FA; Conway, KC; Dees, EC; Edmiston, SN; Eroglu, Z; Garrett-Mead, N; Googe, PB; In, GK; Ivanova, A; Ivy, SP; Kendra, KL; Khushalani, NI; Liu, G; McKinnon, K; Moschos, SJ; Nikolaishvilli-Feinberg, N; Ollila, DW; Serody, JS; Thomas, NE; Wang, HH; Wang, P | 1 |
| Atene, CG; Bonfiglio, S; Fiorcari, S; Forghieri, F; Ghia, P; Ljungström, V; Luppi, M; Maccaferri, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L; Scarfò, L; Tagliafico, E; Trenti, T; Zucchini, P | 1 |
| Tazi, I | 1 |
| Arampatzi, P; Dietrich, O; Fuhr, V; Rauert-Wunderlich, H; Riedel, A; Rosenwald, A; Saliba, AE; Vafadarnejad, E | 1 |
| Brown, JR; Danilov, AV; Maier, D; Quinson, AM; Siddiqi, T; Smith, D; Spurgeon, SE | 1 |
| Atene, CG; Debbia, G; Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Potenza, L | 1 |
| Jerkeman, M | 1 |
| Han, KM; Hoe, HS; Jeon, SG; Kang, RJ; Kim, J; Kim, KT; Kim, SM; Koh, YH; Lee, HJ; Nam, HY; Park, H; Song, M; Suk, K; Sung, YM | 1 |
| Burger, JA; Burrows, F; Chen, R; Chen, Y; Keating, MJ; Liu, C; Plunkett, W; Sivina, M; Thompson, PA; Tsai, J; Wierda, WG; Xiong, P | 1 |
| Bohn, M; Bravo-Ljubetic, L; Lee, RWJ; Petrushkin, H | 1 |
| Cleveland, JL; Fahmi, NA; Gao, J; Jiang, H; Li, T; Lwin, T; Meads, MB; Park, PM; Qi, J; Ren, Y; Sehgal, L; Shah, BD; Shain, KH; Silva, AS; Singh, S; Sotomayor, EM; Sun, J; Tao, J; Wang, M; Wang, MY; Wang, X; Zhang, W; Zhao, X | 1 |
| Allan, JN; Cheson, BD; Coleman, M; Frigault, MM; Izumi, R; Jones, D; Kipps, TJ; Patel, P; Quah, C; Raman, RK; Rogers, KA; Sharman, JP; Thompson, PA; Wang, MH | 1 |
| Beckmann, L; Berg, V; Bloehdorn, J; Claasen, J; da Palma Guerreiro, A; Dickhut, C; Eichhorst, B; Fink, AM; Fischer, K; Frenzel, LP; Hallek, M; Hülsemann, MF; Loroch, S; Merkel, O; Oliverio, M; Robrecht, S; Seifert, M; Sickmann, A; Stilgenbauer, S; Sun, C; Tausch, E; Thomalla, D; Underbayev, C; Vaughn, L; Wendtner, CM; Wiestner, A; Zahedi, RP | 1 |
| Al-Ghazawi, M; Najib, N; Najib, O; Saleh, MI; Salem, I | 1 |
| Chaleteix, C; Creuzet, E; Moniot, M; Nourrisson, C; Poirier, P | 1 |
| Andritsos, LA; Anghelina, M; Blachly, JS; Call, T; Carson, WE; Chihara, D; Dauki, A; Grever, MR; Guo, L; Ivy, SP; James, LR; Jones, D; Jones, JA; Kreitman, RJ; Lozanski, G; Lucas, DM; McLaughlin, EM; Ngankeu, A; Phelps, M; Ravandi, F; Rogers, KA; Ruppert, AS; Schiffer, CA; Wei, L | 1 |
| Jung, SH; Kang, SY; Kim, JM; Kim, JS; Lee, YR; Noh, EM; Park, BH; Park, J; Song, HK; Youn, HJ | 1 |
| Fukuhara, N; Hirasawa, T; Kikuchi, M; Maekawa, M; Mano, N; Ogura, J; Onishi, Y; Onodera, K; Sato, T; Sato, Y; Shigeta, K; Takasaki, S | 1 |
| Amruz Cerna, K; Benes, V; Borsky, M; Brychtova, Y; Doubek, M; Kostalova, L; Kren, L; Krivanek, J; Kudlickova Peskova, M; Liskova, K; Loja, T; Mayer, J; Mladonicka Pavlasova, G; Mraz, M; Musilova Litzmanova, K; Ondrisova, L; Oppelt, J; Panovska, A; Pospisilova, S; Seda, V; Sharma, S; Tan, Z; Verner, J; Vojackova, E; Zhang, S; Zicha, D | 1 |
| Adachi, N; Araki, K; Fujita, S; Fukuhara, S; Honma, D; Inaki, K; Kagiyama, Y; Kato, A; Katsumoto, T; Kitabayashi, I; Kobayashi, Y; Nakagawa, M; Ono, Y; Shima, Y; Tobinai, K; Yamagata, K | 1 |
| Banerji, A; Hochberg, EP; Luk, SO; Phadke, NA | 1 |
| Abruzzo, LV; Bhat, S; Byrd, JC; Grever, M; Heerema, NA; Hertlein, EK; Huang, Y; Jaglowski, SM; Kittai, AS; Labanowska, J; Lapalombella, R; Maddocks, KJ; Miller, CR; Rogers, KA; Ruppert, AS; Woyach, JA | 1 |
| Kawano, K; Kawano, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Uchida, H | 1 |
| Carballido, E; Imanirad, I; Kim, DW; Kim, RD; Martinez, M; Mehta, R; Schell, MJ; Strosberg, J; Tan, E; Yu, J; Zhou, JM | 1 |
| Almeida, LEF; Arora, T; Combs, CA; Kamimura, S; Quezado, ZMN; Smith, ML; Thein, SL; Vogel, S | 1 |
| Einwächter, H; Konukiewitz, B; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Verbeek, M; Wiedemann, GM | 1 |
| Beaupre, D; Chhabra, S; de Vos, S; Huang, DW; Kimball, AS; Kwei, K; Neuenburg, JK; Phillips, T; Ping, J; Popplewell, L; Staudt, LM; Wilson, WH; Wright, G | 1 |
| Carras, S; Claves, F; Lefebvre, C; Siest, R; Valmary-Degano, S | 1 |
| Ahn, IE; Baptista, MJ; Baskar, S; Gaglione, EM; Keyvanfar, K; Sun, C; Wiestner, A | 1 |
| Al-Janazreh, H; Angeletti, I; Biagi, A; Bomben, R; Bossio, S; Cassin, R; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Cutrona, G; D Arrigo, G; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Ferrarini, M; Foà, R; Fronza, G; Gaidano, G; Galimberti, S; Gattei, V; Gentile, M; Herishanu, Y; Laurenti, L; Loseto, G; Martino, EA; Mauro, FR; Menichini, P; Moia, R; Monti, P; Morabito, F; Murru, R; Neri, A; Olivieri, J; Pietrasanta, D; Polliack, A; Rago, A; Reda, G; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Trentin, L; Tripepi, G; Varettoni, M; Vigna, E; Visentin, A; Zucchetto, A | 1 |
| Limaye, S; Limaye, V | 1 |
| Kawashima, I; Kirito, K; Kondo, T; Koshiishi, M; Kumagai, T; Nakagawa, Y; Nakajima, K; Odate, T; Oishi, N; Suzuki, J; Tanaka, M; Yamamoto, T | 1 |
| Fu, X; Li, L; Li, X; Li, Z; Sun, Z; Wang, X; Zhang, L; Zhang, M; Zhang, X; Zhou, Z | 1 |
| Ciuculete, DC; Dan, GA; Popescu, RA | 1 |
| Gandhi, V; Timofeeva, N | 1 |
| Deng, H; Deng, Q; Jiang, Y; Li, Q; Liu, M; Mu, J; Pu, Y; Qian, Z | 1 |
| Balasubramanian, S; Carey, J; Gerecitano, J; Hodkinson, B; Johnson, P; Major, C; Schaffer, M; Sehn, LH; Shreeve, SM; Staudt, LM; Sun, S; Vermeulen, J; Wang, S; Wilson, W; Zinzani, PL | 1 |
| Bednarska, K; Blyth, E; Clancy, L; Gandhi, MK; Gunawardana, J; Hapgood, G; Hennig, S; Hoang, T; Keane, C; Law, SC; Loo-Oey, D; Merida de Long, L; O'Rourke, K; Sabdia, MB; Tobin, JWD | 1 |
| Anderson, MA; Juneja, S; Leitinger, EJ; Nelson, N; Wright, RM | 1 |
| Dong, Q; Lu, K; Tang, X; Xu, L; Zhang, N | 1 |
| Al Hashmi, H; Al Shammasi, Z; Alanazi, W; Ayyad, A; Bahaliwah, Z; Blowi, B; Elsoudi, H; Ibrahim, I; Kaloyannidis, P | 1 |
| Francis, JH; Grommes, C; Hatzoglou, V; Krebs, S; Mauguen, A; Mellinghoff, IK; Schaff, LR; Schöder, H; Yildirim, O | 1 |
| Ayala, A; Borthakur, G; Bose, P; Burger, J; Estrov, Z; Ferrajoli, A; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Lopez, W; O'Brien, S; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, S; Wang, W; Wang, X; Wierda, WG | 1 |
| Anz, B; Cheung, LWK; Demirkan, F; Flinn, IW; Gill, D; Greil, R; Gribben, JG; Larratt, L; Moreno, C; Nguyen, AN; Simkovic, M; Styles, L; Tedeschi, A; Wang, Z; Zhou, C | 1 |
| Barbieux, S; Bossard, JB; Boyle, EM; Cambier, N; Carpentier, B; Chanteau, G; Escure, G; Hieulle, J; Morschhauser, F; Renaud, L; Terriou, L; Tilmont, R; Wemeau, M | 1 |
| Attard, N; Basu, TN; Calonje, E; Patten, PEM; Salisbury, J; Wimalachandra, M | 1 |
| Calabria, S; Dondi, L; Esposito, I; Martini, N; Pedrini, A; Piccinni, C; Ronconi, G | 1 |
| Arepalli, S; Baynes, K; Srivastava, SK; Venkat, AG | 1 |
| Cao, J; Fan, X; Jiang, L; Liu, Y; Wang, X; Wang, Z; Xia, Y; Yan, M | 1 |
| Fein, JG; Mathai, M | 1 |
| Ahn, IE; Baptista, MJ; Blackburn, A; Eik, D; Gaglione, EM; Kendall, EK; Keyvanfar, K; Mhibik, M; Qi, J; Rader, C; Sun, C; Wiestner, A | 1 |
| Bera, AK; Gan, H; Gurbani, D; Liu, Y; Park, JM; Potts, MB; Pruett-Miller, SM; Sakurada, SM; von Hoyningen-Huene, SJ; Westover, KD; Yang, SW; Zhuang, W | 1 |
| Al-Sawaf, O; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Langerbeins, P; Pelzer, BW; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Belliere, J; Casemayou, A; Colliou, E; El Hachem, H; Faguer, S; Feuillet, G; Kounde, C; Piedrafita, A; Schanstra, JP | 1 |
| Doki, N; Ishikawa, T; Kawakita, T; Nakahara, S; Okada, M; Osumi, T; Sawa, M; Shiratori, S; Toyosaki, M; Ueda, Y; Yoshinari, N | 1 |
| Zent, CS | 1 |
| Čengić, M; Gverić-Krečak, V; Krečak, I; Nakić, M; Skorić, I | 1 |
| Alvarado, Y; Ayala, A; Borthakur, G; Bose, P; Burger, JA; Cruz, N; DiNardo, C; Estrov, Z; Ferrajoli, A; Fowler, N; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Ohanian, M; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, SA; Wang, W; Wang, X; Wei, C; Wierda, WG; Yilmaz, M | 1 |
| Anderson, KC; Buhrlage, SJ; Cameron, M; Castillo, JJ; Che, J; Chen, JG; Demos, MG; Gray, NS; Guerrera, ML; Hunter, ZR; Kofides, A; Liu, X; Meid, K; Munshi, M; Munshi, NC; Patterson, CJ; Tan, L; Treon, SP; Tsakmaklis, N; Wang, J; Xu, L; Yang, G | 1 |
| Banerji, V; Davidson, L; Gibson, SB; Ishdorj, G; Johnston, JB; Katyal, CS; Kost, S; Marshall, A; Nugent, Z; Squires, M | 1 |
| Kazarin, O; Shulman, K; Sofer, O; Tannous, E | 1 |
| Cairoli, A; Horisberger, A; Ribi, C; Stalder, G; Tsilimidos, G | 1 |
| Branagan, AR; Castillo, JJ; Demos, M; Flynn, CA; Guerrera, ML; Gustine, JN; Hunter, ZR; Kofides, A; Leventoff, C; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Sarosiek, S; Treon, SP; Tsakmaklis, N; White, T; Xu, L; Yang, G | 1 |
| Constantin, G; Ferrarini, I; Fumagalli, L; Laudanna, C; Montresor, A; Rigo, A; Toffali, L; Vinante, F | 1 |
| Kwok, M; Stankovic, T | 1 |
| Thangavadivel, S; Woyach, JA | 1 |
| Mato, AR; Thompson, MC | 1 |
| Kaliamurthi, S; Peslherbe, GH; Selvaraj, C; Selvaraj, G; Singh, SK; Wei, DQ | 1 |
| Armanious, M; Chavez, JC; Emole, J; Fradley, M; Gliksman, M; Hawk, F; Lee, DH; Pinilla-Ibarz, J; Rhea, IB; Schabath, MB; Seok, K; Shah, B; Viganego, F; Welter-Frost, A | 1 |
| Abeykoon, JP; Dasari, S; Hanson, CA; Manske, M; Nowakowski, KE; Stenson, MJ; Timm, MM; Van Dyke, DL; Witzig, TE; Wu, X | 1 |
| Fujita, S; Kataoka, K; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Okamoto, S; Sakurai, M; Shimizu, T; Tanigawa, T | 1 |
| Ahn, IE; Brown, JR | 1 |
| Iizuka, H; Izumi, H; Mitsumori, T; Miyake, K; Noguchi, M; Okubo, M; Osawa, T; Sawada, T; Sekiguchi, Y; Takizawa, H; Tomita, S; Yoshikawa, S | 1 |
| Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA | 1 |
| Li, J; Miao, Y; Xu, W | 1 |
| Mulder, TA; Österborg, A; Palma, M | 1 |
| Bornhauser, B; Bourquin, JP; Butler, M; Dobay, MP; Hagelaar, R; Hoff, FW; Jenni, S; Kornblau, SM; Kuiper, RP; Meijerink, JP; Tee, TM; van der Meer, LT; van Ingen Schenau, DS; van Leeuwen, FN; Vervoort, BMT; Yu, J | 1 |
| Argnani, L; Broccoli, A; Carella, M; Stefoni, V; Zinzani, PL | 1 |
| Branagan, AR; Cao, Y; Castillo, JJ; Demos, MG; Flynn, CA; Ghobrial, IM; Guerrera, ML; Hunter, ZR; Kofides, A; Leventoff, CR; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Roccaro, AM; Sacco, A; Sarosiek, SR; Treon, SP; Tsakmaklis, N; White, TP; Xu, L; Yang, G | 1 |
| Adhinaveni, R; Al Essa, W; Andorno, A; Boldorini, RL; De Paoli, L; Favini, C; Ferri, V; Forestieri, G; Gaidano, G; Margiotta Casaluci, G; Moia, R; Patriarca, A; Rasi, S; Rossi, D; Sagiraju, S; Schipani, M; Talotta, D; Terzi Di Bergamo, L | 1 |
| Berentsen, S; Cassin, R; Castillo, JJ; Cruijsen, M; D'Sa, S; De Haas, M; Fattizzo, B; Fotiou, D; Frederiksen, H; Jalink, M; Kastritis, E; Oosten, LEM; Patriarca, A; Treon, SP; Vos, JMI | 1 |
| Cuesta-Mateos, C; Juárez-Sánchez, R; Loscertales, J; Mateu-Albero, T; Mol, W; Muñoz-Calleja, C; Terrón, F | 1 |
| Brullo, C; Russo, E; Spallarossa, A; Tasso, B; Villa, C | 1 |
| Cronin, JF; Smith, MR; Weiss, RF | 1 |
| Byrd, JC; Chanan-Khan, A; Furman, RR; Garcia-Marco, JA; Ghia, P; Hamdy, A; Higgins, K; Hillmen, P; Illés, A; Izumi, R; Jurczak, W; Kater, AP; Kay, N; Lepretre, S; Mato, A; O'Brien, S; Patel, P; Pinilla-Ibarz, J; Robak, T; Rothbaum, W; Seymour, JF; Sohoni, S; Stilgenbauer, S; Yenerel, MN | 1 |
| Wang, C | 1 |
| Abruzzo, LV; Beckwith, K; Bhat, SA; Bond, DA; Byrd, JC; Goldstein, D; Grever, MR; Heerema, NA; Huang, Y; Kittai, AS; Miller, C; Rogers, KA; Ruppert, AS; Woyach, JA | 1 |
| Cheng, L; Huang, M; Jiang, L; Wei, J; Xu, H; Zhou, M | 1 |
| Côté-Sergent, A; Emond, B; Ghosh, N; Huang, Q; Lafeuille, MH; Lefebvre, P | 1 |
| Alpár, D; Bödör, C; Deák, B; Demeter, J; Farkas, P; Gángó, A; Hanna, E; Kiss, R; Kotmayer, L; Lévai, D; Matolcsy, A; Mátrai, Z; Timár, B | 1 |
| Limaye, V; Wilkinson, M; Yeung, D | 1 |
| Abdel-Samad, N; Booth, AM; Chen, BE; Cheung, MC; Couban, S; Crump, M; Fraser, GAM; Hay, AE; Lam, S; Mandrekar, SJ; McDonald, G; Mittmann, N; Owen, C; Prica, A; Ruppert, AS; Shepherd, LE; Sperlich, C; van der Jagt, R; Woyach, JA; Yen, H | 1 |
| Fraser, G; Hillis, C; Leong, D; Sestier, M | 1 |
| Argnani, L; Bertuzzi, C; Broccoli, A; Casadei, B; Coppola, PE; Sabattini, E; Stefoni, V; Zinzani, PL | 1 |
| Castillo, JJ; Flynn, CA; LaMacchia, J; Pozdnyakova, O; Sarosiek, S; Treon, SP | 1 |
| Alshahrouri, B; Dürig, T; Fassihi, R; Schwing, Q; Yang, F | 1 |
| Baek, DW; Cho, HJ; Kim, J; Lee, JM; Moon, JH; Sohn, SK | 1 |
| Feldman, RC; Hyman, DA; Price, WN; Ratain, MJ | 1 |
| Bayram, E; Özer, T; Paydaş, S; Türker, M | 1 |
| Amaya-Chanaga, CI; Barr, PM; Byrd, JC; Dai, S; Dean, JP; Ghia, P; Hillmen, P; Mulligan, SP; Munir, T; O'Brien, SM; Siddiqi, T; Tedeschi, A; Woyach, J | 1 |
| Azar, MM; Cheung, H; Deng, Y; Gan, G; Holowka, T; Isufi, I; Malinis, M; Perreault, S | 1 |
| Ammad Ud Din, M; Bress, J; Hassan, H; Jamshed, S; Mustafa, SS | 1 |
| Campos, S; Evans, JP; Fournier, JCL; Patel, VK; Thomas, DA; Tomkinson, NCO; White, GV; Zappacosta, F | 1 |
| Albert, E; Amat, P; Andreu, R; Fox, L; García, D; Giménez, E; López-Jiménez, J; Navarro, D; Olea, B; Remigia, MJ; Saus, A; Solano de la Asunción, C; Solano, C; Terol, MJ | 1 |
| Barr, PM; Barrientos, JC; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Kay, NE; Leis, JF; Lesnick, CE; Litzow, MR; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, R; Tallman, MS; Tschumper, RC; Wang, XV; Zhang, CC | 1 |
| Bittner, A; Bogner, C; Bullinger, L; Denker, S; Dürig, J; Frick, M; Hoffmann, J; Hüttmann, A; Janz, M; Kase, J; Keller, U; Krohn, U; Marks, R; Mathas, S; Na, IK; Schmitt, CA; Trenker, C | 1 |
| Aslan, B; Bertilaccio, MTS; Chen, LS; Fowlkes, NW; Gagea, M; Gandhi, V; Iles, LR; Kismali, G; Mahendra, M; Marszalek, JR; Peoples, M; Vellano, CP; Wang, J; Zheng, X | 1 |
| Castillo, JJ; Sarosiek, S; Treon, SP | 1 |
| Te Raa, D; Tournilhac, O; van Gelder, M; Visser, HPJ | 1 |
| Bailly, S; Camboni, A; Hansenne, A; Van Den Neste, E | 1 |
| Akay, OM; Akdeniz, A; Akpınar, S; Aydoğdu, İ; Baştürk, A; Batur, DS; Berber, İ; Çekdemir, D; Çetin, G; Davulcu, EA; Demircioğlu, S; Deveci, B; Dinçyürek, HD; Doğu, MH; Durusoy, SS; Ertop, Ş; Ferhanoğlu, B; Güneş, AK; Gürkan, E; İlhan, G; Kaya, E; Kızıklı, A; Kurtoğlu, E; Mehtap, Ö; Okan, V; Okay, M; Özcan, MA; Özcan, Ö; Özet, G; Özkocamaz, V; Pepedil Tanrıkulu, F; Sahip, B; Saydam, G; Sayınalp, N; Seyhanlı, A; Sönmez, M; Terzi, H; Tombak, A; Turgut, B; Uçar, MA; Ümit, EG; Ünal, A; Yavaşoğlu, İ; Yıldırım, R; Yılmaz, M | 1 |
| Abdel-Qadir, H; Austin, PC; Calvillo-Argüelles, O; Lee, DS; Leong, D; Nanthakumar, K; Pang, A; Prica, A; Sabrie, N; Thavendiranathan, P | 1 |
| Sun, Y; Tian, X; Wu, S; Yan, S; Yuan, J; Zhang, Q; Zhao, R; Zhou, K | 1 |
| Hroch, M; Kriegelstein, M; Marek, A | 1 |
| Antin, J; Chin, KK; Cutler, C; Gooptu, M; Ho, V; Inyang, EA; Jaglowski, S; Kim, HT; Koreth, J; Pidala, J; Romee, R; Shapiro, R; Soiffer, R | 1 |
| Alvarez, JD; Balasubramanian, S; Bonfiglio, F; Bruscaggin, A; Condoluci, A; di Bergamo, LT; Faderl, MR; Forestieri, G; Fourneau, N; Gerber, B; Hodkinson, B; Koch, R; Pirosa, MC; Rossi, D; Schaffer, M; Spina, V; Stussi, G; Wu, W; Zucca, E | 1 |
| Abrisqueta, P; Acha, D; Arguiñano Pérez, JM; Baltasar, P; Bello, JL; Berruezo, MJ; Cuellar-García, C; Delgado, J; Fernández Álvarez, R; Fernández de la Mata, M; Fernández-Zarzoso, M; García Malo, MD; García Martin, P; García Muñoz, R; Godoy, A; Hernández-Rivas, JÁ; Jarque, I; Lancharro Anchel, A; Lario, A; López Rubio, M; Loriente, C; Losada Castillo, MDC; Loscertales, J; Marco, F; Medina, Á; Oliveira, A; Ortiz, M; Osorio, S; Pérez Persona, E; Pérez, I; Ramírez Payer, Á; Ramos, R; Ríos, E; Rodríguez, A; Smucler Simonovich, A; Suarez, A; Terol, MJ; Vidal Manceñido, MJ; Villanueva, M; Yáñez, L | 1 |
| Burger, JA; Ferrajoli, A; Jain, N; Kantarjian, H; Keating, M; Kim, E; Sivina, M; Thompson, P; Wierda, WG | 1 |
| Baratè, C; Biagi, A; Borella, C; Cairoli, R; Cassin, R; Cavalloni, C; Chiarenza, A; Ciolli, S; Coscia, M; Del Poeta, G; Deodato, M; Di Raimondo, F; Fresa, A; Frustaci, AM; Greco, A; Ielo, C; Lapietra, G; Laurenti, L; Mauro, FR; Montillo, M; Morelli, F; Murru, R; Pelle, AC; Postorino, M; Reda, G; Rossi, V; Sportoletti, P; Tedeschi, A; Varettoni, M; Vitale, C; Zamprogna, G | 1 |
| Branagan, AR; Castillo, JJ; Demos, MG; Flynn, CA; Guerrera, ML; Gustine, JN; Hunter, ZR; Kofides, A; Leventoff, C; Liu, X; Meid, K; Munshi, M; O'Donnell, E; Patterson, CJ; Raje, N; Sarosiek, S; Treon, SP; Tsakmaklis, N; White, T; Xu, L; Yang, G; Yee, AJ | 1 |
| Alrifai, T; Larson, ML; Miller, IJ; Yun, NK | 1 |
| Hroch, M; Kriegelstein, M; Mžik, M; Váňová, N | 1 |
| Balasubramanian, S; Cretenet, G; Eldering, E; Kater, AP; Leverson, JD; Martens, AW; Slinger, E | 1 |
| Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P | 1 |
| Albano, F; Arena, V; Bardi, A; Cafforio, L; Cuneo, A; Cura, F; Del Giudice, I; Foà, R; García-Jacobo, RE; Guarini, A; Ilari, C; Marchetti, M; Mariglia, P; Mauro, FR; Melandri, A; Molica, S; Nanni, M; Peragine, N; Piciocchi, A; Raponi, S; Reda, G; Rigolin, GM; Sportoletti, P; Trentin, L; Vignetti, M | 1 |
| Jin, L; Liu, KY; Liu, Y; Mo, Y; Yue, EL | 1 |
| Carda, JP; Gomes da Silva, M; Gonçalves, HM; Mariz, JM; Monteiro, P; Raposo, J; Santos, L | 1 |
| Arango-Hisijara, I; Buske, C; Dimopoulos, MA; García-Sanz, R; Hauns, B; Heffner, LT; Herbaux, C; Kastritis, E; Leblond, V; MacDonald, D; Mahe, B; Matous, JV; Palomba, ML; Ping, J; Shustik, C; Tam, CS; Tedeschi, A; Treon, SP; Trotman, J; Varettoni, M | 2 |
| Gao, S; Liu, X; Xu, B | 1 |
| Steck, AJ | 1 |
| Di Rocco, A; Leccisotti, L; Malfona, F; Martelli, M; Moleti, ML; Petrucci, L; Testi, AM | 1 |
| Batlevi, CL; De Frank, S; Drullinsky, P; Gerecitano, JF; Hamilton, A; Hamlin, PA; Horwitz, SM; Kumar, A; Matasar, MJ; Michaud, L; Moskowitz, A; Moskowitz, CH; Nakajima, R; Nichols, C; Rademaker, J; Salles, G; Schöder, H; Seshan, V; Stewart, CM; Straus, D; Tsui, DWY; Whiting, K; Younes, A; Zelenetz, AD | 1 |
| Allan, JN; Badoux, XC; Dean, JP; Flinn, I; Ghia, P; Jackson, S; Jacobs, R; James, DF; Kipps, TJ; Kuss, BJ; Moreno, C; Ninomoto, J; Opat, S; Pagel, JM; Pak, Y; Siddiqi, T; Szafer-Glusman, E; Tam, CS; Tedeschi, A; Wierda, WG; Zhou, C | 1 |
| Akpinar, S; Altuntas, F; Bagci, M; Bilgir, O; Cagliyan, GA; Celik, S; Dal, MS; Davulcu, EA; Dogu, MH; Ekinci, O; Erkurt, MA; Eser, B; Hacibekiroglu, T; Hindilerden, F; Hindilerden, IY; Korkmaz, G; Korkmaz, S; Namdaroglu, S; Ozatli, D; Ozcan, BG; Ozturk, HBA; Serin, I; Tekinalp, A; Tiryaki, TO; Turgut, B; Ulas, T | 1 |
| Figg, WD; Peer, CJ; Zimmerman, SM | 1 |
| Ghosh, N; Hu, B; Jacobs, R; Levine, J; Moore, DC; Moyo, TK; Park, SI; Smith, ET; Soni, AC | 1 |
| Arena, V; Bardi, A; Cafforio, L; Cappelli, LV; Cuneo, A; De Propris, MS; Del Giudice, I; Foa, R; Guarini, A; Ilari, C; Mariglia, P; Mauro, FR; Peragine, N; Piciocchi, A; Raponi, S; Rigolin, GM; Soscia, R | 1 |
| Jin, G; Ren, S; Song, J; Wang, X | 1 |
| Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME | 1 |
| Farahany, J; Malik, AB; Mittal, M; Mukhopadhyay, A; Nepal, S; Tiruppathi, C; Tsukasaki, Y | 1 |
| Björkholm, M; Dickman, PW; Kristinsson, SY; Landgren, O; Lund, SH; Steingrímsson, V; Weibull, CE | 1 |
| Bishton, M; Chen, R; Chong, G; Collins, GP; Eckert, K; Eliadis, P; Jurczak, W; Karlin, L; Lee, Y; Neuenburg, JK; Peyrade, F; Ramchandren, R; Tam, CS; Wang, M; Wu, KL | 1 |
| Bäumer, N; Bäumer, S; Becht, M; Berdel, WE; Dersch, P; Faust, A; Geyer, C; Greune, L; Lenz, G; Margeta, R; Rüter, C; Schlütermann, A; Wittmann, L | 1 |
| Bohne, LJ; Dorey, TW; Jansen, HJ; Jones, DL; Liu, Y; Rose, RA; Tuomi, JM | 1 |
| Bloomquist, MS; Curry, CV; Curry, JL; Diwan, AH; Krishnan, B; Rivero, G | 1 |
| Chekalin, E; Chen, B; Doseff, AI; Gallo, KA; Misek, SA; Neubig, RR; Newbury, PA; Paithankar, S | 1 |
| Balasubramanian, S; Fan, Y; Hodkinson, B; Huang, DW; Shreeve, M; Staudt, LM; Vermeulen, J; Wilson, WH; Wright, GW | 1 |
| Minotti, G; Zinzani, PL | 1 |
| Adamson, PJ; Badenoch, PR; Brennan, C; Gordon, DL; Marshman, G; Tam, PCK; Teh, JSK | 1 |
| Al-Sawaf, O; Balser, C; Cramer, P; Eckart, MJ; Eichhorst, B; Fink, AM; Fischer, K; Freier, W; Fürstenau, M; Gaska, T; Hallek, M; Kreuzer, KA; Langerbeins, P; Müller, L; Reiser, M; Robrecht, S; Schlag, R; Stauch, M; Stilgenbauer, S; Tausch, E; Vehling-Kaiser, U; von Tresckow, J; Wendtner, CM; Zhang, C | 1 |
| Ailawadhi, S; Alegria, V; Chanan-Khan, AA; Clynes, R; Jiang, L; Johnson, C; Liebowitz, D; Menke, DM; Parrondo, RD; Paulus, A; Roy, V | 1 |
| Gallagher, J; Luo, Y; Shi, Y; Spaner, DE; Tsui, H; Wang, G | 1 |
| Balasubramanian, S; Cheson, BD; Deshpande, S; Fowler, NH; Gopal, AK; Hess, G; Hodkinson, B; Salles, G; Schaffer, M; Schuster, SJ; Sun, S; Trotman, J; Vermeulen, J | 1 |
| Avellaneda, M; Badillo, M; Fayad, L; Feng, L; Flowers, CR; Fowler, N; Hagemeister, FB; Hill, HA; Iliescu, C; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Liu, Y; Medeiros, LJ; Moghrabi, OB; Navsaria, L; Nogueras Gonzalez, GM; Ok, CY; Santos, D; Tang, G; Thirumurthi, S; Vega, F; Wang, L; Wang, ML; Xu, G; Yao, Y; Zhao, S | 1 |
| Blumenschein, W; Braggio, E; Call, TG; Ding, W; He, R; Kay, NE; Kenderian, SS; Leis, JF; Parikh, SA; Secreto, CR; Shi, M; Sinha, S; Slager, SL; Tian, S; Van Dyke, DL; Wang, H; Wang, Y; Yan, H; Yearley, JH; Zhao, Q | 1 |
| Davis, JE; Koldej, RM; Mason, K; Ritchie, DS; Sharpe, C; Tam, CS | 1 |
| Barr, H; Gabizon, R; Gurwicz, N; London, N; Prasad, PK; Reddi, RN; Resnick, E; Rogel, A; Shulman, Z | 1 |
| Ling, Y; Liu, Y; Ran, F; Wang, C; Xu, Z; Zhang, Y; Zhao, G | 1 |
| Akber, M; Aleman, S; Bergman, P; Blennow, O; Blixt, L; Bogdanovic, G; Buggert, M; Chen, MS; Chen, P; Friman, G; Gomez, AC; Hansson, L; Hober, S; Lindgren, G; Ljunggren, HG; Ljungman, P; Loré, K; Mielke, S; Muschiol, S; Nilsson, P; Nordlander, A; Norlin, AC; Nowak, P; Österborg, A; Smith, CIE; Söderdahl, G; Thalme, A; Valentini, D; Vesterbacka, J; Wahren-Borgström, E; Wullimann, D | 1 |
| Ahn, IE; Allan, JN; Dean, JP; Krigsfeld, G; Li, J; Moreno, C; O'Brien, SM; Shanafelt, T; Wiestner, A | 1 |
| Guo, Q; Liu, L; Ma, Z; Sun, X; Zhao, Z | 1 |
| Cerio, R; George, C; O'Toole, EA; Steele, L | 1 |
| Beck, J; Brenig, B; Junghanss, C; Kong, W; Ma, Y; Murua Escobar, H; Nolte, I; Ruetgen, BC; Schuetz, E; Sekora, A; Sender, S; Taher, L; Villa-Perez, S | 1 |
| Shah, HR; Stephens, DM | 1 |
| Benedict, K; Chiller, T; Gold, JAW; Jackson, BR; Tolu, SS | 1 |
| Ghosh, S; Mohammed, Z; Singh, I | 1 |
| Cibien, F; Ciolli, S; Coscia, M; Cuneo, A; Foà, R; Fresa, A; Gentile, M; Laurenti, L; Marchetti, M; Mauro, FR; Molica, S; Murru, R; Piazza, F; Pietrasanta, D; Pravato, S; Quaglia, FM; Reda, G; Rigolin, GM; Scarfò, L; Sportoletti, P; Trentin, L; Visentin, A; Vitale, C | 1 |
| Baďurová, K; Gregorová, J; Krejčí, M; Ševčíková, S; Vlachová, M | 1 |
| Allsup, DJ; Arman, M; Booth, Z; Caserta, S; Chacko, AR; Hart, SP; Jarvis, J; Khan, S; Naylor-Adamson, L; Rivero, F | 1 |
| Bories, P; Ysebaert, L | 1 |
| Andreotti, AH; Engen, JR; Fulton, DB; Joseph, RE; Lowe, J; Wales, TE | 1 |
| Branagan, AR; Castillo, JJ; Flynn, CA; Guerrera, ML; Gustine, JN; Hunter, ZR; Kofides, A; Leventoff, CR; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Sarosiek, SR; Treon, SP; Tsakmaklis, N; White, TP | 1 |
| Altuntaş, F; Aslan Candır, B; Dal, MS; Kızıl Çakar, M; Yiğenoğlu, TN | 1 |
| Duan, R; Goldmann, L; Li, Y; Siess, W; von Hundelshausen, P; Weber, C | 1 |
| Bondada, S; Bondada, V; Geddes, JW; Gensel, JC; Iqbal, H; Moore, KL; Yu, CG | 1 |
| Dai, D; Hazle, JD; Jaffray, D; Jimenez, JE; Li, T; Lin, Y; Lu, Y; Macapinlac, HA; Pan, T; Wang, L; Wang, Z; Wu, J; Xu, G; Zhao, R | 1 |
| Cieri, N; Fan, J; Ghia, P; Gohil, SH; Kay, NE; Kharchenko, PV; Kipps, TJ; Lemvigh, CK; Lesnick, C; Li, S; Livak, KJ; Neuberg, DS; Olsen, LR; Parry, EM; Purroy, N; Rassenti, LZ; Scarfò, L; Shanafelt, TD; Slager, SL; Tong, YE; Wu, CJ; Zhang, W | 1 |
| Anz, B; Dai, S; Dean, JP; Demirkan, F; Flinn, IW; Gill, D; Greil, R; Gribben, JG; Hsu, E; Kwei, K; Larratt, L; Moreno, C; Novak, J; Simkovic, M; Strugov, V; Tedeschi, A | 1 |
| Doi, SAR; Furuya-Kanamori, L; Islam, N; Kumar, S; Onitilo, AA; Piwuna, TO | 1 |
| Haga, H; Hishizawa, M; Hori, T; Iga, Y; Kondo, T; Masuda, K; Morimoto, S; Morita, M; Shindo, T; Takaori-Kondo, A; Yamashita, K; Yurugi, K | 1 |
| Aymerich, M; Beà, S; Campo, E; Casanova, M; Cortés-Romera, M; de la Cruz, F; de la Fuente, A; García Sanz, R; Giné, E; González Barca, E; González-López, TJ; Jiménez Ubieto, A; López Jimenez, J; López-Guillermo, A; Marín-Niebla, A; Martín García-Sancho, A; Medina Herrera, A; Muntañola, A; Nadeu, F; Rodríguez, S; Rotger, A; Setoain, X; Terol, MJ | 1 |
| Reddel, S; Sy, J; Tahir, F; Trotman, J | 1 |
| Amantini, C; Maggi, F; Marinelli, O; Morelli, MB; Santoni, G; Santoni, M | 1 |
| Chen, L; Huang, L; Liu, H; Weng, J; Yang, XP | 1 |
| Badillo, M; Fayad, L; Feng, L; Flowers, CR; Fowler, N; Hagemeister, FB; Hill, HA; Iyer, SP; Jain, P; Jorgensen, J; Kanagal-Shamanna, R; Lee, HJ; Li, S; Lin, P; Medeiros, LJ; Nair, R; Nastoupil, L; Navsaria, L; Nogueras Gonzalez, GM; Ok, CY; Patel, KP; Samaniego, F; Santos, D; Steiner, R; Tang, G; Thirumurthi, S; Vega, F; Wagner-Bartak, N; Wang, L; Wang, ML; Wang, SA; Westin, JR; Xu, G; Xuelin, H; Yao, Y; Yin, CC; Zhao, S | 1 |
| Yavorkovsky, LL | 1 |
| Bloehdorn, J; Böttcher, S; Döhner, H; Dreger, P; Dürig, J; Edenhofer, S; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Huber, H; Illert, AL; Illmer, T; Kneba, M; Niemann, CU; Ritgen, M; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Zhang, C | 1 |
| Kumekawa, H; Mizuchi, D; Tamura, K; Watanabe, D | 1 |
| Borbely, J; Egyed, M; Illes, A; Lueff, S | 1 |
| Deng, Q; Jiang, Y; Liu, M; Meng, J; Mu, J; Wang, J; Zhang, R | 1 |
| Chiarenza, A; Ciolli, S; Coscia, M; Cuneo, A; De Paoli, L; Del Poeta, G; Deodato, M; Foa', R; Frustaci, AM; Gaidano, G; Gentile, M; Giannarelli, D; Giordano, A; Guarente, V; Ielo, C; Laurenti, L; Levato, L; Mauro, FR; Moia, R; Molica, S; Murru, R; Noto, A; Reda, G; Rigolin, GM; Sportoletti, P; Stelitano, C; Tedeschi, A; Trentin, L; Visentin, A; Vitale, C | 1 |
| Batlevi, C; Biggar, E; Espeleta, JA; Kumar, A; Lam, HY; Matasar, M; Nichols, C; Owens, C; Qiu, A; Qualls, D; Salles, G; Seshan, V; Subzwari, S; Whiting, K; Younes, A | 1 |
| Chen, Y; Chen, ZS; Li, YD; Ma, XY; Wei, L; Zhao, M | 1 |
| Al Malki, MM; Ali, H; Arslan, S; Forman, S; Marcucci, G; Mei, M; Nakamura, R; Stein, A | 1 |
| Allan, JN; Bannerji, R; Barr, PM; Dean, JP; Ghia, P; Jackson, S; Jacobs, R; Kipps, TJ; Kuss, BJ; Moreno, C; Ninomoto, J; Opat, S; Russell, K; Siddiqi, T; Szafer-Glusman, E; Tam, CS; Tedeschi, A; Trentin, L; Wierda, WG; Zhou, C | 1 |
| Abdel-Wahab, O; Afaghani, J; Aifantis, I; Alencar, A; Bourcier, J; Brandhuber, B; Chaudhry, S; Cho, H; Coombs, CC; Cui, D; Durham, BH; Ebata, K; Erickson, C; Geyer, M; Hogg, SJ; Hyman, DM; Linley, AJ; Lu, SX; Mato, A; Mi, X; Montoya, S; Notti, RQ; Palomba, ML; Park, JH; Penson, A; Roeker, L; Rosendahl, M; Singer, M; Taylor, J; Thompson, MC; Totiger, TM; Tsai, DE; Wang, E; Witkowski, MT; Zelenetz, A | 1 |
| Feng, M; Han, R; He, Y; Hu, C; Li, J; Li, L; Li, Z; Lin, C; Liu, Z; Lu, C; Tang, X; Wang, Y; Zhang, K; Zhang, Y; Zhuang, Y | 1 |
| Albano, F; Arena, V; Autore, F; Cassin, R; Coscia, M; Cuneo, A; Del Poeta, G; Deodato, M; Di Sevo, D; Foà, R; Frustaci, AM; Gentile, M; Ghia, P; Ielo, C; Innocenti, I; Laurenti, L; Mauro, FR; Moia, R; Motta, M; Murru, R; Pennese, E; Piciocchi, A; Pompili, M; Quaglia, FM; Reda, G; Rughini, A; Scarfò, L; Tedeschi, A; Tomasso, A; Trentin, L; Visentin, A | 1 |
| Ferrero, S; Gentile, M; Laurenti, L; Martelli, M; Mauro, FR; Sportoletti, P; Tedeschi, A; Varettoni, M; Visco, C; Zinzani, PL | 1 |
| Arango-Hisijara, I; Barr, PM; Coutre, S; Deshpande, S; McKinney, M; Mokatrin, A; O'Brien, S; Osei-Bonsu, K; Rogers, K; Siddiqi, T; Szoke, A; Valentino, R; Wang, M; Zhu, A | 1 |
| Ambrose, R; Chekaoui, A; Cole, C; Ertl, HCJ; Hasanpourghai, M; Kuranda, K; Mingozzi, F; Newman, D; Novikov, M; Quinn, W; Xiang, Z; Zhou, X | 1 |
| Ferrero, S; Gentile, M; Laurenti, L; Martelli, M; Romana Mauro, F; Sportoletti, P; Tedeschi, A; Varettoni, M; Visco, C; Zinzani, PL | 1 |
| Claushuis, TAM; Cosemans, JMEM; D'Italia, G; Karel, MFA; Kuijpers, MJE; Lemmens, TP; Tullemans, BME | 1 |
| Collins, J; Coombs, CC; Cozad, M; Deal, A; Heiling, H; Mato, A; Muir, M; Muluneh, B; Nguyen, C; Proco, D; Stump, SE | 1 |
| Asawa, P; Chahine, Z; Fazal, S; Samhouri, Y; Vusqa, U | 1 |
| Fadlallah, J; Fieschi, C; Galicier, L; Malphettes, M; Mondesir, J; Oksenhendler, E; Sorin, B; Vigneron, J | 1 |
| Borchmann, P; Bühnen, I; Dietlein, M; Eichenauer, DA; Engert, A; Fuchs, M; Kobe, C; Mauser, M; Plütschow, A; Thorspecken, S; Topp, MS; von Tresckow, B; Wendtner, CM | 1 |
| Matutes, E; Polliack, A | 1 |
| Acou, M; Carrette, S; De Herdt, V; Hemelsoet, D; Madou, K | 1 |
| Chen, Z; Huang, S; Jiang, VC; Liu, Y; Wang, M; Ye, H | 1 |
| Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dearden, C; Ghia, P; Grosicki, S; Hillmen, P; Hsu, E; Kipps, TJ; Li, JY; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Szoke, A; Tedeschi, A; Zhou, C | 1 |
| Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC | 1 |
| Awan, FT; Christensen, BW; Zaha, VG | 1 |
| Aresu, M; Aronson, L; Begum, R; Bryant, A; Bryant, J; Chau, I; Chong, IY; Chua, S; Cunningham, D; Davidson, M; Fribbens, C; Hulkki-Wilson, S; Kalaitzaki, E; Lazaro-Alcausi, R; Rana, I; Rao, S; Starling, N; Turkes, F; Watkins, D | 1 |
| Ferrarini, I; Gandini, F; Rigo, A; Zapparoli, E | 1 |
| Mańdziuk, S; Michalski, A; Piwoński, M; Szklener, K; Żak, K | 1 |
| Black, GS; Byrd, JC; Huang, X; Marth, GT; Misra, S; Qiao, Y; Rogers, KA; Stephens, DM; Tarapcsak, S; Woyach, JA | 1 |
| Wang, W; Zhang, W; Zhang, Y; Zhao, D; Zhou, D | 1 |
| Alfayez, M; AlHaj Issa, Z; Altwijri, A | 1 |
| Huang, Y; Li, J; Li, L; Mao, X; Wang, B; Wang, Y; Yu, F | 1 |
| Andriano, TM; Bose, A; Chilov, M; Dranitsaris, G; Godwin, K; Lacouture, ME; Markova, A; Mato, AR; Nocco, S; Roeker, LE; Wu, S | 1 |
| Arranz, R; Barrenetxea, C; Cañigral, C; Capote, FJ; Conde-Royo, D; Donato, E; Fernández, S; González-Barca, E; Grande, C; Hernández-Rivas, JÁ; Jiménez, A; Marín-Niebla, A; Martín García-Sancho, A; Pastoriza, C; Pérez-Ceballos, E; Puerta, JM; Ramírez, MJ; Rivas, A; Rubio-Azpeitia, E; Salar, A; Sánchez-García, J; Sancho, JM; Teruel, A; Vale, A; Zeberio, I | 1 |
| Deering, KL; Harshaw, Q; Huang, Q; Leslie, LA | 1 |
| Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA | 1 |
| Chakraborty, A; Cheung, LW; DeAnda, F; Dhami, K; Gururaja, TL; Huang, X; Sun, C | 1 |
| Bonfiglio, S; Brake, O; Chiodin, G; D'Avola, A; Del Rio, L; Drennan, S; Forconi, F; Forster, J; Ghia, P; Henderson, I; Lanham, S; Martino, EA; Mraz, M; Ondrisova, L; Parker, H; Potter, KN; Sale, B; Scarfò, L; Stevenson, FK; Strefford, JC; Sutton, LA; Tracy, I | 1 |
| Rogers, KA; Woyach, JA | 1 |
| Bellido, M; Brieghel, C; Dobber, JA; Dompeling, EC; Dubois, J; Enggaard, L; Frederiksen, H; Janssens, A; Kater, AP; Kersting, S; Levin, MD; Mattsson, M; Mellink, CHM; Mous, R; Nasserinejad, K; Niemann, CU; Poulsen, CB; Ranti, J; Schjødt, I; Tran, HTT; van der Kevie-Kersemaekers, AF; Veldhuis, GJ | 1 |
| Belada, D; Boccomini, C; Deshpande, S; Dreyling, M; Flinn, IW; Giri, P; Goy, A; Hamlin, PA; Henninger, T; Hermine, O; Hernández-Rivas, JÁ; Hong, X; Howes, A; Jerkeman, M; Jurczak, W; Kim, SJ; Le Gouill, S; Lewis, D; Mishima, Y; Özcan, M; Perini, GF; Pocock, C; Qin, R; Song, Y; Spurgeon, SE; Storring, JM; Trotman, J; Walewski, J; Wang, ML; Zhu, J; Zinzani, PL | 1 |
| Gerungan, P; Kuss, B; Marlton, P; McGeachie, M; Mulligan, SP; Opat, S; Puig, A; Tam, CS | 1 |
| Allsup, DJ; Molica, S; Polliack, A | 1 |
| Cuker, A; Dhopeshwarkar, N; Hennessy, S; Leonard, CE; Rhodes, JM; Yang, W | 1 |
| Al-Sawaf, O; Böttcher, S; Cramer, P; Eichhorst, BF; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Illmer, T; Klaproth, H; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Fan, L; Gu, D; Jin, H; Li, J; Li, Y; Lu, X; Qin, S; Tang, H; Wang, L; Wu, J; Wu, Z; Xia, Y; Xu, W; Zhu, H; Zuo, X | 1 |
| Lichter, AS; Ratain, MJ; Tannock, IF | 1 |
| Wang, Z; Yong Chan, EC | 1 |
| Écsiová, D; Hroch, M; Šimkovič, M; Uher, M | 1 |
| Akizuki, R; Fujino, A; Nomura, F; Omi, A; Tsujioka, S | 1 |
| Eichhorst, B | 1 |
| Braggio, E; Call, TG; Ding, W; Hampel, PJ; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Parrondo, R; Rabe, KG; Schwager, SM; Shi, M; Slager, SL; Wang, Y | 1 |
| Bhat, SA; Byrd, JC; Grever, MR; Huang, Y; Jaglowski, S; Kittai, AS; Maddocks, K; Rogers, KA; Ruppert, AS; Sigmund, AM; Woyach, JA | 1 |
| Alderuccio, JP; Awan, FT; Ayyappan, S; Barta, SK; Bartlett, NL; Bello, C; Bruno, XJ; Caimi, PF; Chowdhury, SM; Christian, B; Churnetski, MC; Cohen, JB; David, KA; Epperla, N; Geethakumari, PR; Ghosh, N; Greenwell, IB; Grover, NS; Herrera, AF; Hsu, A; Janakiram, M; Kandarpa, M; Karmali, R; Kenkre, VP; Kim, SH; Kothari, S; Kress, A; Lindsey, K; Maakaron, J; Moyo, TK; Olszewski, AJ; Palmisiano, N; Reddy, N; Sawalha, Y; Shea, L; Sheets, J; Shouse, G; Tan, C; Thomas, C; Torka, P; Umyarova, E; Weiner, DM; Wilcox, RA; Zhao, Q; Zurbriggen, L | 1 |
| Battiato, K; Dorsey, C; Falchi, L; Falco, V; Feldman, TA; Fox, Y; Kdiry, S; Laudati, C; Lebowitz, S; Leslie, LA; Martignetti, R; Mato, AR; McCarthy, E; Miskin, HP; Panton, G; Park, JH; Paskalis, D; Pena Velasquez, C; Purdom, M; Roeker, LE; Soumerai, JD; Sportelli, P; Straus, DJ; Thompson, MC; Turpuseema, T; Zelenetz, AD | 1 |
| Ambruso, SL; Barry, M; Edelstein, CL; Li, A; Oto, OA | 1 |
| Balogh, A; Bödör, C; Karvaly, GB; Köllő, Z; Vásárhelyi, B; Vincze, I | 1 |
| Cuneo, A; De Propris, MS; Del Giudice, I; Foà, R; Guarini, A; Intoppa, S; Mauro, FR; Milani, ML; Peragine, N; Rigolin, GM | 1 |
| Cassin, R; Frustaci, AM; Gentile, M; Giannarelli, D; Innocenti, I; Laurenti, L; Mattiello, V; Mauro, FR; Neri, A; Noto, A; Reda, G; Tedeschi, A; Visentin, A | 1 |
| Allan, JN; Barr, PM; Ghia, P; Grigg, AP; Jacobs, R; Krigsfeld, G; Ninomoto, J; O'Brien, S; Tam, CS; Tedeschi, A; Vallisa, D; Walker, P; Wierda, WG; Zhou, C | 1 |
| Araz, M; Artaç, M; Çeneli, Ö; Karaağaç, M; Karakurt Eryilmaz, M; Korkmaz, M | 1 |
| Balasubramanian, S; Boyle, M; Deshpande, S; Enny, C; Freeman, CL; Grau, M; Hodkinson, B; Jiang, A; Jin, L; Lenz, G; Morin, RD; Pararajalingam, P; Schaffer, M; Scott, DW; Sun, S; Vermeulen, J; Xu, W; Zapukhlyak, M | 1 |
| Cai, Z; Huang, YJ; Rai, S; Taipale, K; Tajimi, M; Tanizawa, Y | 1 |
| Boccellato, E; Coscia, M; Montalbano, MC; Perutelli, F; Vitale, C | 1 |
| Colaci, E; Giusti, D; Leonardi, G; Luppi, M; Maccaferri, M; Marasca, R; Pioli, V; Potenza, L; Pozzi, S | 1 |
| Egger, M; Gornicec, M; Lembeck, AL; Maderdonner, M; Prattes, J; Tinchon, C; Wölfler, A | 1 |
| Ailawadhi, S; Braggio, E; Call, TG; Chanan-Khan, AA; Ding, W; Hampel, PJ; Hanson, CA; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Parrondo, R; Rabe, KG; Schwager, SM; Sher, T; Shi, M; Slager, SL; Van Dyke, DL; Wang, Y | 1 |
| Liu, Y; Song, Y; Yin, Q | 1 |
| Cheng, S; Fang, H; Huang, HY; Jiang, L; Li, JF; Ouyang, BS; Qian, Y; Shi, ZY; Wang, L; Xu, PP; Yi, HM; Zhao, WL; Zhu, Y | 1 |
| Fisch, SC; Jonas, BA; Qi, L; Tuscano, JM | 1 |
| Cliff, ERS; Dickinson, M | 1 |
| Birtas Atesoglu, E; Ferhanoglu, B; Ozbalak, M | 1 |
| Eşkazan, AE | 1 |
| Dreyling, M; Le Gouill, S; Wang, ML | 1 |
| Bradley, J; Dempsey, OJ; Melville, P; Mohammed, F; Preston, G; RuiWen Kuo, C | 1 |
| Dobson, R; Gent, DG; Lip, GYH; Rivera-Caravaca, JM; Wright, DJ | 1 |
| Dong, R; Lin, N; Tan, B; Yan, Y; Zeng, X | 1 |
| Barrientos, JC; Deering, KL; Harshaw, Q; Sundaram, M; Trudeau, J | 1 |
| Barna, G; Borbényi, Z; Czeti, Á; Deák, BM; Demeter, J; Farkas, P; Fekete, S; Kotmayer, L; László, T; Márk, Á; Masszi, A; Mikala, G; Plander, M; Sulák, A; Szaleczky, E; Szalóki, G; Szerafin, L; Takács, F; Weisinger, J | 1 |
| Bulieva, NB; Butaev, LS; Chumakova, EP; Fedorova, LV; Gemdzhian, EG; Ilyasov, RK; Kaleikina, LP; Kaplanov, KD; Li, OY; Margolin, OV; Martynova, EV; Melnichenko, EV; Mikhailova, NB; Nesterova, ES; Ptushkin, VV; Tarasenko, EV; Trubyakova, OS; Vorobyev, VI; Yakovleva, EP; Zherebtsova, VA | 1 |
| Aqil, B; Chen, Q; Chen, YH; Gao, J; Kaur, A; Lu, X; Ma, S; Ramos, J; Sukhanova, M | 1 |
| Keam, SJ | 1 |
| Gong, Y; Salter, R | 1 |
| Gracia-Darder, I; Hernando, JDP; Izquierdo-Herce, N; Llull-Ramos, A | 1 |
| Atluri, H; Iwaki, Y; Mita, S; Ogawa, T | 1 |
| Choi, JH; Hur, JY; Won, YW | 1 |
| Kawata, T; Koba, Y; Tamekane, A; Watanabe, M | 1 |
| Bittolo, T; Bomben, R; Bulian, P; Chiarenza, A; Cuneo, A; Degan, M; Del Poeta, G; Del Principe, MI; Di Raimondo, F; Foà, R; Fronza, G; Gattei, V; Gentile, M; Laureana, R; Laurenti, L; Marasca, R; Morabito, F; Olivieri, J; Papotti, R; Polesel, J; Postorino, M; Pozzo, F; Reda, G; Rossi, FM; Tafuri, A; Tissino, E; Vit, F; Zaja, F; Zucchetto, A | 1 |
| Bombardier, N; Esfandiari, N; Pierson, JC | 1 |
| Giannarelli, D; Molica, S | 1 |
| Nasser, R; Saadi, T; Sayed Ahmad, N; Veitsman, E | 1 |
| Araujo-Ayala, F; Bernes-Lasserre, P; Bezombes, C; Campo, E; Colomer, D; Dobaño-López, C; Faria, C; Gava, F; Giménez, R; Gine, E; Lagarde, JM; López-Guillermo, A; Morin, R; Nadeu, F; Norlund, M; Pérez-Galán, P; Playa-Albinyana, H; Serrat, N; Valero, JG | 1 |
| Bose, P; Ferrajoli, A; Garg, N; Jain, N; Jorgensen, JL; Kadia, TM; Keating, MJ; Pemmaraju, N; Peterson, CB; Short, NJ; Thompson, PA; Wang, SA; Wierda, WG | 1 |
| Chen, Y; DerSarkissian, M; Duh, MS; Guo, H; Hakre, S; Mato, AR; Roeker, LE; Ryan, K; Wahlstrom, SK; Yu, L | 1 |
| Büyükkurt, N; Soydaş, B | 1 |
| Chen, SS; Chiorazzi, N | 1 |
| Dunn-Pirio, A; Goodman, AM; Koura, D; Trando, A | 1 |
| Feng, Y; Gale, RP; Huang, X; Li, N; Yang, S; Zhu, R; Zhuo, J | 1 |
| Backx, M; Booth, E; Elmusharaf, N; Joshi, A; Nizami, H | 1 |
| Aroza-Espinar, M; Merlán-Hermida, A; Pérez-Arellano, JL; Suárez-Hormiga, L | 1 |
| Arkenau, HT; Berlin, J; Castellano, D; Chau, I; Chong, E; Dean, JP; Duran, I; Hilger-Rolfe, J; Kim, SY; Lee, KW; Maqueda, MA; Marti, F; Mathew, P; Mellado, B; O'Dwyer, PJ; Oh, DY; Quinn, DI; Saif, MW; Wang, D; Williamson, SK | 1 |
| Karsten, IE; Schmitz, N | 1 |
263 review(s) available for adenine and pci 32765
| Article | Year |
|---|---|
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Risk Factors; Signal Transduction | 2012 |
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Drug Delivery Systems; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2012 |
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2012 |
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Medical Oncology; Morpholines; Mutation; NF-kappa B; Oxazines; Phosphatidylinositol 3-Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases | 2012 |
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmune Diseases; B-Lymphocytes; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2013 |
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome | 2013 |
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Waldenstrom Macroglobulinemia | 2014 |
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Antineoplastic Agents; Autoimmunity; B-Lymphocytes; Epstein-Barr Virus Infections; Gene Expression Regulation, Neoplastic; Genetic Diseases, X-Linked; Humans; Inflammation; Lymphoma; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Small Molecule Libraries; T-Lymphocytes | 2013 |
[Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
Topics: Adenine; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases | 2013 |
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome | 2013 |
Ibrutinib and novel BTK inhibitors in clinical development.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Clinical Trials, Phase III as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2013 |
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; B-Lymphocytes; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction | 2013 |
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Topics: Adenine; Animals; Disease Management; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2013 |
Ibrutinib and indolent B-cell lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2014 |
Ibrutinib: first global approval.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
Topics: Adenine; Animals; Clinical Trials as Topic; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib.
Topics: Adenine; Animals; Antineoplastic Agents; B-Lymphocytes; Humans; Lymphoproliferative Disorders; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2014 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmune Diseases; Clinical Trials as Topic; Crystallography, X-Ray; Drug Discovery; Humans; Models, Molecular; Neoplasms; Piperidines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Small Molecule Libraries | 2014 |
Update on ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Humans; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome | 2014 |
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2015 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine | 2014 |
[Targeted treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sulfonamides | 2014 |
Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Ibrutinib for the treatment of mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lymphoma, Mantle-Cell; Multicenter Studies as Topic; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic | 2014 |
Ibrutinib: a paradigm shift in management of CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2014 |
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations.
Topics: Adenine; Allografts; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Survival Rate | 2015 |
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2015 |
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2015 |
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2015 |
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic | 2015 |
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2015 |
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
Topics: Adenine; DNA-Binding Proteins; Humans; Molecular Targeted Therapy; Piperidines; Pre-B Cell Receptors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Proto-Oncogene Proteins c-bcl-6; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; STAT5 Transcription Factor | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Ibrutinib: a new targeted therapy for hematologic cancers.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; Hematologic Neoplasms; Humans; Piperidines; Proto-Oncogene Mas; Pyrazoles; Pyrimidines | 2015 |
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Topics: Adenine; Antineoplastic Agents; Humans; Killer Cells, Natural; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Signal Transduction; Tumor Microenvironment | 2015 |
Why patients prescribed oral agents for cancer need training: a case study.
Topics: Adenine; Administration, Oral; Antineoplastic Agents; Caregivers; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Needs Assessment; Oncology Nursing; Patient Education as Topic; Patient Safety; Piperidines; Pyrazoles; Pyrimidines; Risk Assessment | 2015 |
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Class Ia Phosphatidylinositol 3-Kinase; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Treatment Outcome | 2015 |
Targets for Ibrutinib Beyond B Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Mice; Multiple Myeloma; Osteoclasts; Phosphorylation; Piperidines; Protein Binding; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2015 |
[Ibrutinib: A new drug of B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence | 2015 |
Ibrutinib for the treatment of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Approval; Drug Costs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2015 |
Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Cost-Benefit Analysis; Creatinine; Decision Making; Geriatric Assessment; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Life Expectancy; Molecular Targeted Therapy; Patient Selection; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Ibrutinib in B lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2015 |
Ibrutinib: from bench side to clinical implications.
Topics: Adenine; Antineoplastic Agents; Biomedical Research; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Piperidines; Pyrazoles; Pyrimidines | 2015 |
First case of mesh infection due to Coccidioides spp. and literature review of fungal mesh infections after hernia repair.
Topics: Adenine; Aged; Antifungal Agents; Coccidioides; Coccidioidomycosis; Female; Fluconazole; Herniorrhaphy; Humans; Hyphae; Male; Middle Aged; Piperidines; Postoperative Complications; Pyrazoles; Pyrimidines; Surgical Mesh | 2015 |
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunophenotyping; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Positron-Emission Tomography; Prevalence; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2015 |
The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic | 2015 |
Treatment options for mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Thalidomide | 2015 |
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
Topics: Adenine; Animals; Autoimmune Diseases; Humans; Immunologic Factors; Neoplasms; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2016 |
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
Topics: Adenine; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
Topics: Adenine; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Genome, Human; Genomics; High-Throughput Nucleotide Sequencing; Humans; Indoles; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Molecular Targeted Therapy; Mutation; Piperidines; Precision Medicine; Pyrazoles; Pyrimidines; Sulfonamides; Vemurafenib | 2015 |
The importance of the tissue microenvironment in hairy cell leukemia.
Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Bone Marrow; CD40 Antigens; Gene Expression Regulation, Leukemic; Humans; Intercellular Adhesion Molecule-1; Leukemia, Hairy Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, CXCR4; Signal Transduction; Spleen; Tumor Microenvironment; Vascular Cell Adhesion Molecule-1 | 2015 |
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Rituximab; Syk Kinase; Tumor Microenvironment | 2015 |
Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Remission Induction; Risk Factors; Signal Transduction | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
Ibrutinib for mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Recurrence; Treatment Outcome | 2016 |
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell | 2016 |
Ibrutinib for treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Design; Drug Resistance; Drugs, Investigational; Humans; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2016 |
Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
Topics: Adenine; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2016 |
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Incidence; Leukemia; Lymphoma; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2016 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2017 |
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Standard of Care; Treatment Outcome | 2016 |
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Standard of Care; Treatment Outcome | 2016 |
Second-generation inhibitors of Bruton tyrosine kinase.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2016 |
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2016 |
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2017 |
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Risk Factors; Sulfonamides | 2016 |
The 21st century revolution in CLL: Why this matters to patients.
Topics: Adenine; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; History, 21st Century; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2016 |
B cell receptor inhibition as a target for CLL therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Age Factors; Atrial Fibrillation; Diarrhea; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pneumonia; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell | 2016 |
Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
Topics: Adenine; Allografts; Antibodies, Monoclonal; Antibodies, Neoplasm; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome; Sulfonamides | 2016 |
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Atrial Fibrillation; Disease Susceptibility; Female; Hemorrhage; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Risk | 2017 |
[Primary lymphoma of the skull: Case report and literature review].
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Craniotomy; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasms, Second Primary; Osteolysis; Parietal Bone; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Radiotherapy, Intensity-Modulated; Remission Induction; Skull Neoplasms | 2016 |
Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Topics: Adenine; Animals; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Neoplasms, Experimental; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2016 |
Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Humans; Immunotherapy; Mutation; Myeloid Differentiation Factor 88; Piperidines; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2016 |
Future therapeutic options for patients with Waldenström macroglobulinemia.
Topics: Adenine; ADP-ribosyl Cyclase 1; Agammaglobulinaemia Tyrosine Kinase; Clinical Trials as Topic; Humans; Membrane Glycoproteins; Myeloid Differentiation Factor 88; Piperidines; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Receptors, CXCR4; Waldenstrom Macroglobulinemia | 2016 |
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Topics: Adenine; Aged; Aspirin; Diarrhea; Hemorrhage; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Staging; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Everolimus; Humans; Myeloid Differentiation Factor 88; Piperidines; Plasma Exchange; Pyrazoles; Pyrimidines; Retreatment; Risk Assessment; Rituximab; Waldenstrom Macroglobulinemia | 2017 |
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2017 |
Front-line treatment of CLL in the era of novel agents.
Topics: Adenine; Aged; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Physical Fitness; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines | 2017 |
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2017 |
From mechanism to therapies in systemic lupus erythematosus.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Activating Factor; Cyclic S-Oxides; Cytokines; Drug Approval; Drug Discovery; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Interleukin-17; Interleukin-6; Isoquinolines; Janus Kinases; Lupus Erythematosus, Systemic; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recombinant Fusion Proteins; Rituximab; Signal Transduction; STAT Transcription Factors | 2017 |
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Topics: Adenine; Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Blood Platelets; Drug Interactions; Drug Substitution; Hemorrhage; Humans; Piperidines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Assessment; Risk Factors; Signal Transduction | 2017 |
Novel agents versus chemotherapy as frontline treatment of CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Clinical Trials as Topic; Comorbidity; Female; Humans; Immunoglobulin Heavy Chains; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Genomics; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Signal Transduction; Waldenstrom Macroglobulinemia | 2017 |
Targeting of B-cell receptor signalling in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Waldenstrom Macroglobulinemia | 2017 |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2017 |
Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Interactions; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides | 2017 |
Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides | 2017 |
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Therapy; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Sulfonamides; Transplantation, Homologous | 2017 |
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Disease Management; Drug Interactions; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Assessment; Stroke | 2017 |
Modeling covalent-modifier drugs.
Topics: Adenine; Drug Discovery; Models, Molecular; Penicillins; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug Discovery; Graft vs Host Disease; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2017 |
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Topics: Adenine; Allografts; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome; Sulfonamides; Tumor Suppressor Protein p53 | 2018 |
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Sulfonamides; Tumor Suppressor Protein p53 | 2017 |
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient Selection; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence | 2017 |
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Clinical Trials as Topic; Disease Management; Drug Interactions; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Severity of Illness Index | 2018 |
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Humans; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2017 |
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tumor Lysis Syndrome | 2018 |
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Management; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Severity of Illness Index | 2017 |
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Risk Assessment; Rituximab; Smith-Magenis Syndrome; Tumor Suppressor Protein p53 | 2017 |
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Topics: Adenine; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Cardiotoxicity; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2018 |
Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Humans; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Count; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Patient Selection; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Assessment; Risk Factors; Treatment Outcome | 2018 |
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Vidarabine | 2018 |
How should we sequence and combine novel therapies in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Smith-Magenis Syndrome; Sulfonamides | 2017 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
How I treat CLL patients with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Autoimmunity; Communicable Diseases; Disease Management; Drug Interactions; Exanthema; Female; Hemorrhage; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Infections; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2018 |
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus, Type 1; Diarrhea; Drug Eruptions; Drug Interactions; Exanthema; Fatigue; Hemorrhage; Humans; Hypertension; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Medication Adherence; Myalgia; Piperidines; Platelet Aggregation Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Molecular Structure; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
Topics: Adenine; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction | 2018 |
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Proteins; Phospholipase C gamma; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Novel therapies for relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Recurrence | 2018 |
Optimal management of the young patient CLL patient.
Topics: Adenine; Age Factors; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome | 2018 |
Chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Diagnosis, Differential; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Risk Factors; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Frontline Therapy of CLL: Evolving Treatment Paradigm.
Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunoglobulin Heavy Chains; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2018 |
Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.
Topics: Adenine; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tumor Microenvironment | 2018 |
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Topics: Adenine; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Hematologic Neoplasms; Hemorrhage; Humans; Piperidines; Platelet Aggregation Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors | 2018 |
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Topics: Adenine; Antineoplastic Agents; Atrial Fibrillation; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Humans; Lymphoma, Non-Hodgkin; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Sulfonamides | 2018 |
Use of acalabrutinib in patients with mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Drug Design; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.
Topics: Adenine; Animals; Blood-Brain Barrier; Brain Neoplasms; Drug Delivery Systems; Glioblastoma; Mice; Pericytes; Piperidines; Pyrazoles; Pyrimidines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Cell Communication; Humans; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2018 |
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Design; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell | 2018 |
Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
Topics: Adenine; Animals; Chronic Disease; Drug Interactions; Graft vs Host Disease; Humans; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Patient Selection; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adenine; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Technology Assessment, Biomedical; United Kingdom; Waldenstrom Macroglobulinemia | 2019 |
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nivolumab; Piperidines; Pyrazoles; Pyrimidines; Recurrence | 2018 |
Ibrutinib in the management of Waldenstrom macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2019 |
Topics: Adenine; Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cyclophosphamide; Doxorubicin; Empyema, Pleural; Fluconazole; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2018 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult | 2018 |
Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
Topics: Adenine; Aged; Antineoplastic Agents; Disease Progression; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Waldenstrom Macroglobulinemia | 2019 |
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Topics: Adenine; Animals; B-Lymphocytes; Chronic Disease; Drug Approval; Drug Resistance; Graft vs Host Disease; Humans; Neoplasms, Plasma Cell; Piperidines; Pyrazoles; Pyrimidines; Steroids; United States; United States Food and Drug Administration | 2018 |
Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Topics: Adenine; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Female; Frail Elderly; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2018 |
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Topics: Adenine; Drug Resistance, Neoplasm; Humans; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Signal Transduction; Waldenstrom Macroglobulinemia | 2018 |
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2018 |
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adenine; Adult; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rituximab; Technology Assessment, Biomedical | 2019 |
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2019 |
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug Therapy, Combination; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Adenine; Administration, Topical; Aged; Anterior Chamber; Antihypertensive Agents; Antineoplastic Agents; Brimonidine Tartrate; Cataract Extraction; Humans; Intraocular Pressure; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Phacoemulsification; Piperidines; Prednisolone; Pyrazoles; Pyrimidines; Sulfonamides; Syndrome; Thiophenes; Timolol; Treatment Outcome; Visual Acuity | 2018 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
Relapsed CLL: sequencing, combinations, and novel agents.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides | 2018 |
Ibrutinib-Associated Atrial Fibrillation.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrial Fibrillation; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Young Adult | 2018 |
Lenalidomide for the treatment of mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Acalabrutinib for adults with mantle cell lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Survival Rate | 2019 |
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Anti-Infective Agents; Anticoagulants; Arthralgia; Atrial Fibrillation; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines | 2019 |
New roles for B cell receptor associated kinases: when the B cell is not the target.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Microenvironment | 2019 |
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; B-Lymphocytes; Humans; Lymphoma, Mantle-Cell; Models, Biological; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction | 2019 |
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Topics: Adenine; Atrial Fibrillation; Databases, Factual; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Risk | 2019 |
Management of adverse effects/toxicity of ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Incidence; Leukemia; Lymphoma; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib for the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction | 2019 |
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
Topics: Adenine; B-Lymphocytes; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; T-Lymphocyte Subsets | 2019 |
Targeting BTK in CLL: Beyond Ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Hematology; Humans; Infection Control; Infections; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Quality of Life; Quinazolinones | 2019 |
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Animals; Arteries; B-Lymphocytes; Benzamides; Blood Platelets; Cell Differentiation; Genetic Diseases, X-Linked; Hemorrhage; Humans; Imidazoles; Mice; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis | 2019 |
Ibrutinib induced acute tubular injury: A case series and review of the literature.
Topics: Acute Kidney Injury; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Topics: Adenine; Bone Marrow; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2019 |
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy | 2019 |
Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Management; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2020 |
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cellulitis; Ecthyma; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Skin | 2020 |
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Blood Viscosity; Gene Expression; Humans; Immunoglobulin M; Mutation; Myeloid Differentiation Factor 88; Piperidines; Progression-Free Survival; Proteasome Inhibitors; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2019 |
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019.
Topics: Adenine; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Receptors, Chimeric Antigen; Treatment Outcome | 2019 |
Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Salvage Therapy; Waldenstrom Macroglobulinemia | 2019 |
Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Topics: Abdominal Pain; Adenine; Constipation; Diarrhea; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Vomiting | 2019 |
How we manage Bing-Neel syndrome.
Topics: Adenine; Amino Acid Substitution; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Mutation, Missense; Myeloid Differentiation Factor 88; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2019 |
[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides | 2019 |
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Brentuximab Vedotin; Canada; Clinical Trials as Topic; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines | 2019 |
What is new in the treatment of Waldenstrom macroglobulinemia?
Topics: Adenine; Antibodies, Monoclonal; Antigens, CD20; Benzamides; Bone Marrow; Disease-Free Survival; Hematology; Humans; Immunoglobulin M; Mutation; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Waldenstrom Macroglobulinemia | 2019 |
Ibrutinib in CLL/SLL: From bench to bedside (Review).
Topics: Adenine; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction | 2019 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors | 2020 |
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2020 |
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Communicable Disease Control; Humans; Immune Checkpoint Inhibitors; Infections; Lymphoproliferative Disorders; Piperidines; Purines; Pyrazines; Quinazolinones; Risk; Rituximab; Sulfonamides; Syndrome | 2020 |
Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adenine; Humans; Lymphoma, B-Cell; Piperidines; Randomized Controlled Trials as Topic; Risk | 2020 |
Clonal dynamics in chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Genome-Wide Association Study; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides; Transcriptome; Whole Genome Sequencing | 2019 |
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; T-Lymphocytes; Tumor Microenvironment | 2019 |
Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.
Topics: Adenine; Female; Humans; Lymphoma; Meningeal Carcinomatosis; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Syndrome | 2020 |
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
An oral drug for chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Antineoplastic Agents; Atrial Fibrillation; Hemorrhage; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Lymphocytosis; Piperidines; Warfarin | 2020 |
The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; STAT3 Transcription Factor | 2020 |
Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
Topics: Adenine; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prognosis | 2020 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2020 |
Fungal Infections Potentiated by Biologics.
Topics: Adenine; Antigens, CD; Biological Products; Clinical Trials as Topic; Humans; Mycoses; Piperidines; Tumor Necrosis Factor-alpha | 2020 |
Management of Ibrutinib Toxicities: a Practical Guide.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Piperidines; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Treatment Outcome | 2020 |
Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Topics: Adenine; Adrenal Cortex Hormones; Chronic Disease; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Piperidines | 2020 |
Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
Topics: Adenine; Aged; Anticarcinogenic Agents; Antifungal Agents; Aspergillosis; Aspergillus; Female; Fungi; Fusariosis; Fusarium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucorales; Mycoses; Piperidines | 2020 |
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome | 2020 |
Ibrutinib dose modifications in the management of CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biotransformation; Clinical Studies as Topic; Clinical Trials as Topic; Cohort Studies; Cytochrome P-450 CYP3A; Disease Susceptibility; Dose-Response Relationship, Drug; Early Termination of Clinical Trials; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Pilot Projects; Piperidines; Practice Patterns, Physicians'; Protein Kinase Inhibitors | 2020 |
Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Genital Neoplasms, Female; Humans; Piperidines; Xenograft Model Antitumor Assays | 2020 |
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2020 |
An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Humans; Piperidines; Pyrazoles; Pyrimidines; Salvage Therapy; Survival Rate; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Eruptions; Ecchymosis; Emollients; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Patient Education as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Severity of Illness Index; Signal Transduction; Skin; Skin Care | 2020 |
Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Molecular Targeted Therapy; Mutation; Piperidines; Prognosis; Treatment Outcome | 2020 |
The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Development; Drug Resistance, Neoplasm; Humans; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Waldenstrom Macroglobulinemia | 2020 |
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Decision-Making; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Disease Susceptibility; Drug Development; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2020 |
[Current diagnosis and treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Comorbidity; Drug Approval; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Piperidines; Prognosis; Purines; Quinazolinones; Rituximab; Smith-Magenis Syndrome; Sulfonamides | 2020 |
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides | 2020 |
Emerging drugs for the treatment of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Design; Drug Resistance; Humans; Mutation; Myeloid Differentiation Factor 88; Orphan Drug Production; Piperidines; Protein Kinase Inhibitors; Rare Diseases; Waldenstrom Macroglobulinemia | 2020 |
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
Topics: Adenine; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Female; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Hairy Cell; Middle Aged; Piperidines; Protein Kinase Inhibitors; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
[Clonal-related transformation from Waldenström macroglobulinemia to diffuse large B cell lymphoma during the treatment of ibrutinib: a case report and literature review].
Topics: Adenine; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2020 |
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides | 2021 |
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration | 2021 |
Managing toxicities of Bruton tyrosine kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Arrhythmias, Cardiac; Arthralgia; Benzamides; Diarrhea; Hemorrhage; Humans; Hypertension; Infection Control; Infections; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2020 |
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antiviral Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Molecular Targeted Therapy; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazines; Thrombosis | 2021 |
Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis.
Topics: Adenine; Atrial Fibrillation; Humans; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2021 |
The rise of covalent proteolysis targeting chimeras.
Topics: Acrylamide; Adenine; Animals; Chimera; Drug Discovery; Humans; Ligands; Molecular Docking Simulation; Piperidines; Proteasome Endopeptidase Complex; Protein Binding; Protein Conformation; Proteolysis; Signal Transduction; Structure-Activity Relationship; Ubiquitin-Protein Ligases; Ubiquitination | 2021 |
Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease.
Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myositis; Piperidines; Pyrimidines; Rituximab | 2021 |
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Genomics of Resistance to Targeted Therapies.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Genomics; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Sulfonamides | 2021 |
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Targeting Bruton's Tyrosine Kinase in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2021 |
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2021 |
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2021 |
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chemistry, Pharmaceutical; COVID-19 Drug Treatment; Drug Delivery Systems; Hematologic Neoplasms; Humans; Inflammation; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; SARS-CoV-2 | 2021 |
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Cardiotoxicity; Heart Failure; Hemorrhage; Humans; Hypertension; Piperidines; Protein Kinase Inhibitors; Tachycardia, Ventricular | 2021 |
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Topics: Adenine; Aged; COVID-19; Disease Management; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors | 2021 |
How to Sequence Therapies in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2021 |
Anti-MAG neuropathy: From biology to clinical management.
Topics: Adenine; Animals; Autoantibodies; Autoantigens; B-Lymphocyte Subsets; CD57 Antigens; Demyelinating Autoimmune Diseases, CNS; Epitopes; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Mammals; Mice; Molecular Mimicry; Myelin Sheath; Myelin-Associated Glycoprotein; Nerve Fibers, Myelinated; Nervous System Autoimmune Disease, Experimental; Paraproteinemias; Paraproteins; Piperidines; Plasma Exchange; Polyradiculoneuropathy; Ranvier's Nodes; Rats; Rituximab | 2021 |
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Topics: Adenine; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Benzodiazepines; Drug Evaluation, Preclinical; Humans; Immunoglobulin Fab Fragments; Immunoglobulin Fc Fragments; Lymphoma, Large B-Cell, Diffuse; Piperidines | 2022 |
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Immunotherapy; Neoplasms; Piperidines; Protein Kinase Inhibitors | 2022 |
Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Waldenstrom Macroglobulinemia | 2021 |
[Chimeric antigen receptor T cells].
Topics: Adenine; Antibodies, Bispecific; Antigens, CD19; Antigens, Neoplasm; Cell Engineering; Clinical Trials, Phase II as Topic; Genetic Engineering; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Receptors, Chimeric Antigen; T-Lymphocytes | 2021 |
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines | 2022 |
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cardiotoxicity; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Breast Neoplasms; Female; Humans; Piperidines | 2022 |
Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
Topics: Adenine; CD79 Antigens; Central Nervous System; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Mutation; Piperidines | 2022 |
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.
Topics: Adenine; Exanthema; Humans; Mucositis; Piperidines | 2022 |
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; T-Lymphocytes; Tumor Microenvironment | 2022 |
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cardiotoxicity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Ibrutinib: Pediatric First Approval.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Bronchiolitis Obliterans Syndrome; Child; Humans; Piperidines; Protein Kinase Inhibitors | 2023 |
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Topics: Adenine; Humans; Quality of Life; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis | 2023 |
227 trial(s) available for adenine and pci 32765
| Article | Year |
|---|---|
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperidines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Salvage Therapy | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Humans; Lymphocyte Count; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence; Survival Analysis | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jurkat Cells; Leishmaniasis, Cutaneous; Leukemia; Listeriosis; Lymphocyte Activation; Mice; Piperidines; Primary Cell Culture; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Th1 Cells; Th2 Cells | 2013 |
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell Adhesion; Chemotaxis, Leukocyte; Flow Cytometry; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2013 |
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2014 |
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Topics: Adenine; Aged; Bone Marrow; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2014 |
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.
Topics: Adenine; Aged; Blood Viscosity; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytosis; Male; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Burden | 2014 |
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Neoplastic Cells, Circulating; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cough; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence; Survival Rate | 2014 |
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2015 |
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Non-Randomized Controlled Trials as Topic; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Severity of Illness Index; Survival Rate; Treatment Outcome; Vincristine; Young Adult | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Treatment Outcome | 2014 |
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Topics: Adenine; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphocyte Count; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Piperidines; Pyrazoles; Pyrimidines | 2015 |
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; B-Lymphocytes; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Class Ib Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Isoquinolines; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation, Missense; Neoplasm Proteins; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Signal Transduction; T-Lymphocytes; Tumor Cells, Cultured | 2014 |
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Young Adult | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Half-Life; Humans; Intestinal Absorption; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2015 |
Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biotransformation; Carbon Radioisotopes; Feces; Half-Life; Humans; Hydrolysis; Hydroxylation; Intestinal Absorption; Intestinal Elimination; Male; Metabolic Clearance Rate; Middle Aged; Oxidation-Reduction; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Renal Elimination | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Single-Blind Method; Survival Rate; Tumor Suppressor Protein p53 | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Studies; Fasting; Female; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2015 |
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Cohort Studies; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Survival Rate | 2015 |
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; Female; Hemoglobins; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Myeloid Differentiation Factor 88; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, CXCR4; Survival Rate; Waldenstrom Macroglobulinemia | 2015 |
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Treatment Outcome | 2015 |
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyrazoles; Pyrimidines; Risk | 2015 |
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Topics: Adenine; Adult; Aged; Base Sequence; CD79 Antigens; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Sequence Data; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2015 |
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; B-Lymphocytes; Bone Marrow; Female; Follow-Up Studies; Humans; Immunity, Humoral; Immunoglobulins; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recovery of Function; Time Factors | 2015 |
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbon Isotopes; Citrus paradisi; Cross-Over Studies; Dose-Response Relationship, Drug; Fasting; Female; Food-Drug Interactions; Fruit and Vegetable Juices; Healthy Volunteers; Humans; Injections, Intravenous; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Time Factors; Young Adult | 2016 |
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Factor VIII; Female; Follow-Up Studies; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Aggregation; Platelet Function Tests; Pyrazoles; Pyrimidines; Risk Factors; von Willebrand Factor | 2015 |
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Asian People; Enzyme Inhibitors; Female; Humans; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome | 2016 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis | 2015 |
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Diarrhea; Epistaxis; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Treatment Outcome | 2016 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Thrombocytopenia | 2016 |
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Topics: Adenine; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bone Marrow; Cell Communication; Cell Differentiation; Cell Movement; Cytokines; Disease Models, Animal; Female; Humans; Immunophenotyping; Inflammation Mediators; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Male; Mice; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; T-Lymphocyte Subsets; Th17 Cells; Tumor Microenvironment | 2016 |
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Sirolimus; Treatment Outcome | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Demography; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Transfer Techniques; Humans; Immunosuppression Therapy; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell; T-Lymphocytes; Time Factors; Treatment Outcome | 2016 |
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hair Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nail Diseases; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Severity of Illness Index; Time Factors | 2016 |
Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Risk Factors; Time Factors; Waldenstrom Macroglobulinemia | 2016 |
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Anemia; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Topics: Adenine; Amino Acid Substitution; Apoptosis; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Mutation, Missense; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Survival Rate; Transcription Factor RelA | 2016 |
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment.
Topics: Adenine; Adult; Aged; Area Under Curve; Biomarkers; Drug Monitoring; Female; Humans; Incidence; Liver Diseases; Liver Function Tests; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Severity of Illness Index | 2017 |
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adenine; Alkynes; Azithromycin; Benzoxazines; Carbamazepine; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Dosage Calculations; Drug Interactions; Fluvoxamine; Humans; Ketoconazole; Male; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Rifampin | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazoles; Pyrimidines | 2016 |
Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Topics: Adenine; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Influenza Vaccines; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Risk Factors; Treatment Outcome | 2016 |
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Treatment Outcome | 2016 |
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Thalidomide | 2016 |
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Ireland; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Treatment Outcome; United Kingdom | 2016 |
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Topics: Adenine; Adult; Aged; B-Lymphocytes; Chimerism; Cohort Studies; Female; Germinal Center; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunomodulation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphocyte Depletion; Male; Middle Aged; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Th2 Cells; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Withholding Treatment | 2016 |
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Survival Rate; Waldenstrom Macroglobulinemia | 2017 |
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Engineering; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome | 2017 |
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; B-Lymphocytes; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Immunotherapy; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Piperidines; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence | 2017 |
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
Topics: Adenine; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Rate | 2018 |
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Topics: Adenine; Aged; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Waldenstrom Macroglobulinemia | 2017 |
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Patient Compliance; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2017 |
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Topics: Adenine; Aged; Anticoagulants; Antineoplastic Agents; Female; Guideline Adherence; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Platelet Aggregation Inhibitors; Platelet Count; Practice Guidelines as Topic; Pyrazoles; Pyrimidines | 2017 |
BTK
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phospholipase C gamma; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2017 |
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cell Transformation, Neoplastic; Disease-Free Survival; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Pyrimidines; Recurrence; Survival Analysis | 2017 |
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2018 |
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; CD52 Antigen; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib treatment improves T cell number and function in CLL patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; CTLA-4 Antigen; Female; Humans; Immunosuppressive Agents; Immunotherapy; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Immunologic; T-Lymphocytes | 2017 |
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
Topics: Adenine; Adult; Aged; Alemtuzumab; Allografts; Antineoplastic Agents, Immunological; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome | 2017 |
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; Models, Theoretical; Molecular Targeted Therapy; Piperidines; Pyrazoles; Pyrimidines; Research Design; Sulfonamides; Treatment Outcome | 2017 |
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Risk Factors; Sex Factors; Survival Rate | 2017 |
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
Topics: Adenine; Comparative Effectiveness Research; Data Collection; Databases, Factual; Hematologic Neoplasms; Humans; Longitudinal Studies; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Treatment Outcome | 2018 |
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Count; Lymphoma, Mantle-Cell; Mutation; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2017 |
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quality of Life; Rituximab; Surveys and Questionnaires; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2017 |
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chronic Disease; Demography; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Severity of Illness Index; Treatment Failure; Young Adult | 2017 |
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CARD Signaling Adaptor Proteins; Disease Progression; Female; Guanylate Cyclase; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Microscopy, Fluorescence; Middle Aged; Odds Ratio; Pilot Projects; Piperidines; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyrimidines; Remission Induction; ROC Curve; Young Adult | 2017 |
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides; Time Factors; Treatment Outcome; United States | 2018 |
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phospholipase C gamma; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Signal Transduction; Treatment Outcome | 2017 |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Physical Fitness; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Rituximab; Surveys and Questionnaires | 2018 |
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
Topics: Adenine; Adult; Animals; beta-Arrestins; Case-Control Studies; Cells, Cultured; Endosomes; Germ-Line Mutation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Knockout; Phosphorylation; Piperidines; Proteolysis; Pyrazoles; Pyrimidines; Receptors, CCR7; Receptors, CXCR4; Src Homology 2 Domain-Containing, Transforming Protein 1 | 2018 |
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Rituximab | 2018 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; International Agencies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2018 |
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Survival Rate | 2018 |
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Topics: Adenine; Aspergillosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Time Factors | 2018 |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Survival Rate | 2018 |
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Odds Ratio; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Virus Activation | 2018 |
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Treatment Outcome | 2018 |
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; International Agencies; Lymphoma, Mantle-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Survival Rate | 2018 |
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Historically Controlled Study; Humans; Intention to Treat Analysis; Lymph Nodes; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperidines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Rituximab; Salvage Therapy | 2018 |
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Outcome Assessment, Health Care; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome | 2018 |
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Topics: Adenine; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Survival Rate | 2019 |
Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; B-Cell Activating Factor; Biomarkers, Tumor; Cell Proliferation; Female; Humans; Immunity, Innate; Inflammation; Interleukin-6; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Stress, Psychological; Tumor Necrosis Factor Ligand Superfamily Member 13; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.
Topics: Adenine; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Survival Rate; Waldenstrom Macroglobulinemia | 2018 |
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis | 2018 |
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erythromycin; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Piperidines; Polymorphism, Single Nucleotide; Pyrazoles; Pyrimidines; Voriconazole | 2018 |
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; T-Lymphocyte Subsets; Treatment Outcome | 2018 |
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Disease-Free Survival; Female; Hemoglobins; Humans; Immunoglobulin M; Infusions, Intravenous; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia | 2018 |
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Topics: Adenine; Adult; Aftercare; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Smith-Magenis Syndrome; Survival Rate | 2018 |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Patient Safety; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Survival Rate | 2018 |
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2018 |
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Blind Method; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Young Adult | 2019 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Survival Analysis | 2018 |
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Treatment Outcome | 2019 |
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Circulating Tumor DNA; Female; Humans; Lymphoma; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Young Adult | 2019 |
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Topics: Adenine; Asian People; Female; Follow-Up Studies; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nivolumab; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Safety | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Piperidines; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Survival Rate | 2019 |
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Topics: Adenine; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Safety | 2019 |
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Topics: Adenine; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Survival Rate | 2019 |
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Cell Proliferation; Cytidine Deaminase; Down-Regulation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Time | 2019 |
Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cytokines; Female; Humans; Janus Kinase Inhibitors; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2019 |
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Placebos; Prednisone; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vincristine; Young Adult | 2019 |
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
Topics: Adenine; Aged; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytokine Release Syndrome; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Receptors, Chimeric Antigen; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Topics: Adenine; Autoimmune Diseases; Disease-Free Survival; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Survival Rate | 2019 |
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.
Topics: Adenine; Adolescent; Adult; Child; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prevalence; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Risk Factors | 2019 |
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2019 |
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Salvage Therapy | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Induction Chemotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mutation; Neoplasm, Residual; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Sulfonamides | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fatigue; Female; Follow-Up Studies; Hemorrhage; Humans; Hypertension; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Piperidines; Pneumonia; Prevalence; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Safety | 2019 |
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Survival Rate | 2019 |
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasms; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib-related atrial fibrillation: A single center Australian experience.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Australia; Female; Hematologic Neoplasms; Hospitalization; Humans; Incidence; Male; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Survival Rate | 2019 |
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrimidines; Time Factors | 2019 |
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) net
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prognosis; Prospective Studies; Pyrazoles; Pyrimidines; Retinal Neoplasms; Salvage Therapy; Survival Rate | 2019 |
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Sulfonamides | 2019 |
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Survival Rate; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Protein p53 | 2019 |
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2019 |
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Treatment Failure | 2020 |
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
A cross-trial comparison of single-agent ibrutinib
Topics: Adenine; Antibodies, Monoclonal, Humanized; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2020 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cardiovascular Diseases; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 2019 |
Hypertension and incident cardiovascular events following ibrutinib initiation.
Topics: Adenine; Aged; Antihypertensive Agents; Female; Heart Diseases; Hematologic Neoplasms; Humans; Hypertension; Incidence; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Stroke | 2019 |
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Topics: Adenine; Aged; Aged, 80 and over; Chlorambucil; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Patient Safety; Piperidines; Prognosis; Progression-Free Survival; Pyrazoles; Pyrimidines; Risk; Treatment Outcome | 2020 |
Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Area Under Curve; Biological Availability; Biological Variation, Population; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Male; Piperidines; Young Adult | 2020 |
Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Aged; Asian People; Female; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2019 |
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Piperidines; Prognosis; Recurrence; Retreatment; Treatment Outcome | 2020 |
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Male; Middle Aged; Phenotype; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome | 2020 |
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Salvage Therapy; Survival Rate | 2020 |
A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Recurrence, Local; Oligopeptides; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Apoptosis; Chromosome Deletion; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 8; Drug Resistance, Neoplasm; Exome Sequencing; Humans; Male; Middle Aged; Myeloid Differentiation Factor 88; NF-kappa B; Phospholipase C gamma; Piperidines; Signal Transduction; Waldenstrom Macroglobulinemia | 2020 |
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Treatment Outcome | 2021 |
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chronic Disease; Clinical Trials, Phase III as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Outcome Assessment, Health Care; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Safety | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Piperidines; Pneumonia; Progression-Free Survival; Remission Induction; Survival Rate | 2020 |
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the fina
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Prednisone; Prospective Studies; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2020 |
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bridged Bicyclo Compounds, Heterocyclic; Coronavirus Infections; COVID-19; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prognosis; Pyrazoles; Pyrimidines; Rituximab; SARS-CoV-2; Sulfonamides | 2020 |
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2020 |
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Piperidines; Survival Rate | 2021 |
Ibrutinib for Chronic Lymphocytic Leukemia with
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Survival Analysis; Tumor Suppressor Protein p53 | 2020 |
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Survival Rate; Waldenstrom Macroglobulinemia | 2020 |
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2020 |
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
Topics: Adenine; Adult; Age Factors; Autografts; Disease-Free Survival; Female; Humans; Immunotherapy; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Risk Factors; Stem Cell Transplantation; Survival Rate; Waldenstrom Macroglobulinemia | 2020 |
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; CD4 Lymphocyte Count; Cognition; Female; Follow-Up Studies; Humans; Hypertension; Hyponatremia; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Piperidines; Progression-Free Survival; Quality of Life; Remission Induction; Retreatment; Sulfonamides; Survival Rate; Thrombocytopenia; Young Adult | 2020 |
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Survival Rate; Vidarabine | 2020 |
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chlorambucil; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Salvage Therapy; T-Lymphocytes, Regulatory | 2020 |
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Topics: Adenine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Netherlands; Piperidines | 2020 |
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contraceptives, Oral; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Interactions; Ethinyl Estradiol; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Levonorgestrel; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Metabolic Clearance Rate; Midazolam; Middle Aged; Piperidines; Waldenstrom Macroglobulinemia | 2020 |
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome | 2021 |
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL)
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Creatinine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prospective Studies; Receptor Tyrosine Kinase-like Orphan Receptors; Recurrence; Sulfonamides; Tumor Suppressor Protein p53 | 2020 |
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Female; Follow-Up Studies; Genes, p53; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm, Residual; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Prednisone; Prognosis; Rituximab; Vincristine | 2020 |
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Topics: Adenine; Female; Humans; Male; Middle Aged; Piperidines; Prognosis; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome; Waldenstrom Macroglobulinemia | 2021 |
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Topics: Adenine; Biomarkers; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Piperidines | 2020 |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Class I Phosphatidylinositol 3-Kinases; Drug Eruptions; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors | 2021 |
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Piperidines | 2021 |
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Topics: Adenine; Administration, Intravenous; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Safety; Treatment Outcome; United States | 2021 |
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Sulfonamides | 2021 |
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Interleukin-2; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Piperidines; Skin Neoplasms | 2021 |
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Tetraspanins | 2021 |
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2021 |
Population Pharmacokinetics of Ibrutinib in Healthy Adults.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Computer Simulation; Humans; Male; Middle Aged; Models, Biological; Piperidines; Smoking; Young Adult | 2021 |
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Piperidines; Survival Rate | 2021 |
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mismatch Repair; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Progression-Free Survival; Treatment Outcome; Young Adult | 2021 |
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Treatment Outcome; Vincristine | 2021 |
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Gene Expression Profiling; Germinal Center; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplastic Stem Cells; Piperidines; Prednisone; Prognosis; Progression-Free Survival; Rituximab; Treatment Outcome; Vincristine | 2021 |
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2021 |
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cytokines; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Premedication; Prospective Studies | 2021 |
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Benzamides; CD3 Complex; Female; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles; United States | 2021 |
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Sulfonamides | 2021 |
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Hypertension; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Rituximab; Survival Rate | 2021 |
BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acids; Animals; Antineoplastic Agents; Apoptosis; Asparaginase; Cell Line, Tumor; Humans; Mice; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction | 2021 |
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Receptors, CXCR4; Waldenstrom Macroglobulinemia | 2021 |
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Prospective Studies; Pyrazines; Survival Rate | 2021 |
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prospective Studies; Rituximab; Survival Analysis; Treatment Outcome | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Rituximab; Treatment Outcome; Vidarabine | 2021 |
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Remission Induction; Rituximab; Tumor Suppressor Protein p53 | 2021 |
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Humans; Karyotype; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Rituximab; Treatment Outcome | 2021 |
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; Female; Humans; Male; Middle Aged; Mutation; Myeloid Differentiation Factor 88; Piperidines; Progression-Free Survival; Receptors, CXCR4; Rituximab; Time Factors; Waldenstrom Macroglobulinemia | 2022 |
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Topics: Adenine; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Piperidines; Pyrazoles; Pyrimidines | 2022 |
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Sulfonamides; Survival Analysis | 2021 |
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Sulfonamides | 2022 |
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Sulfonamides; Treatment Outcome | 2021 |
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Placebo Effect; Protein Kinase Inhibitors | 2022 |
Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
Topics: Adenine; Aged; Female; Humans; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines | 2021 |
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Topics: Adenine; Antineoplastic Agents; CARD Signaling Adaptor Proteins; DNA-Binding Proteins; Exome Sequencing; Genetic Markers; Guanylate Cyclase; Humans; Lymphoma, Follicular; Mutation; Piperidines; Recurrence | 2022 |
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Exome Sequencing; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Progression-Free Survival; Rituximab; Sequence Analysis, RNA; Time Factors | 2022 |
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Topics: Adenine; Antibodies, Viral; BNT162 Vaccine; COVID-19; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunogenicity, Vaccine; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycophenolic Acid; Organ Transplantation; Piperidines; Primary Immunodeficiency Diseases; Prospective Studies; SARS-CoV-2; Seroconversion; Spike Glycoprotein, Coronavirus; Vaccination; Vaccine Efficacy | 2021 |
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Tumor Suppressor Protein p53 | 2022 |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2022 |
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm, Residual; Piperidines; Rituximab | 2022 |
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphopenia; Methotrexate; Middle Aged; Piperidines; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine | 2022 |
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Sulfonamides; Survival Rate | 2022 |
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinazolines | 2022 |
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Topics: Adenine; Adult; Arthralgia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Musculoskeletal Pain; Myalgia; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Topics: Adenine; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Recurrence, Local; Piperidines | 2022 |
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2022 |
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Humans; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab; Treatment Outcome | 2022 |
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Topics: Adenine; Adult; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Triazoles | 2022 |
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2022 |
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Survival Analysis | 2022 |
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines | 2022 |
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Topics: 3' Untranslated Regions; Adenine; Adult; Biological Factors; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Sirolimus | 2022 |
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Frail Elderly; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Piperidines; Rituximab | 2022 |
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy.
Topics: Adenine; Chromosome Deletion; Humans; Lenalidomide; Piperidines | 2022 |
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Piperidines | 2023 |
1186 other study(ies) available for adenine and pci 32765
| Article | Year |
|---|---|
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental; Autoantibodies; Autoimmune Diseases; B-Lymphocytes; Benzofurans; Disease Models, Animal; Dogs; Humans; Lymphocyte Activation; Lymphoma, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Treatment Outcome | 2010 |
Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD; Basophils; Blotting, Western; Calcium; Cell Culture Techniques; Cells, Cultured; Flow Cytometry; Histamine Release; Humans; Immunoglobulin E; Interleukin-13; Interleukin-4; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lymphocytes; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Interleukin-4; Interleukin-6; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; NF-kappa B; Phosphatidylinositol 3-Kinases; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2011 |
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; B-Lymphocytes; Cell Proliferation; Female; Humans; Immune Complex Diseases; Macrophages; Mast Cells; Mice; Mice, Inbred BALB C; Monocytes; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2011 |
More than just B-cell inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Female; Humans; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2011 |
Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Degranulation; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Down-Regulation; Genes, myc; Insulinoma; Mast Cells; Mice; Mice, Transgenic; Models, Theoretical; Pancreatic Neoplasms; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2011 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Chemotaxis, Leukocyte; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2012 |
B-cell receptor inhibitors in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Standard of Care | 2011 |
Trial watch: BTK inhibitor shows positive results in B cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2012 |
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Chemokines; Fibronectins; Flow Cytometry; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Vascular Cell Adhesion Molecule-1 | 2012 |
Novel targeted therapies for mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Cell Cycle; Clinical Trials as Topic; Cyclin D1; DNA Repair; Female; Histocompatibility Antigens Class II; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; NF-kappa B; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; TOR Serine-Threonine Kinases; Translocation, Genetic | 2012 |
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmunity; B-Lymphocytes; Cell Lineage; Gene Expression; Germinal Center; Lupus Erythematosus, Systemic; Lymphocyte Activation; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Piperidines; Plasma Cells; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2012 |
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokines; Coculture Techniques; Cytokines; Down-Regulation; Gene Expression; Humans; Immunoblotting; Mice; Mice, SCID; Multiple Myeloma; Osteoclasts; Osteolysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stromal Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Interferon-beta; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Transcription Factors; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2012 |
BTK inhibition in myeloma: targeting the seed and the soil.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Bone Marrow; Humans; Multiple Myeloma; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
Bruton's tyrosine kinase: oncotarget in myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Growth Processes; Disease Models, Animal; Humans; Mice; Molecular Targeted Therapy; Multiple Myeloma; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2012 |
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Chronic Disease; Disease Management; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Standard of Care | 2012 |
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoantibodies; Autoimmunity; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Kidney; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphocytes; Male; Mice, Congenic; Mice, Inbred C57BL; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Splenomegaly; Treatment Outcome | 2012 |
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured | 2013 |
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.
Topics: Adenine; Aged; Animals; Female; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Two drugs deemed breakthrough therapies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; United States; United States Food and Drug Administration | 2013 |
Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Piperidines; Portraits as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
Cancer's true breakthroughs.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Crizotinib; Drug and Narcotic Control; Drug Discovery; Humans; Piperidines; Pyrazoles; Pyridines; Pyrimidines; United States; United States Food and Drug Administration | 2013 |
Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ζ, regulates shuttling, and attenuates both tonic and induced signaling in B cells.
Topics: 14-3-3 Proteins; Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Motifs; Amino Acid Substitution; Animals; B-Lymphocytes; Cell Line; Cells, Cultured; Chlorocebus aethiops; COS Cells; Humans; Mice; NF-kappa B; Phospholipase C gamma; Phosphorylation; Piperidines; Protein Interaction Maps; Protein Transport; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Ubiquitination | 2013 |
A mechanism-driven treatment for chronic lymphocytic leukemia?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
Toward new treatments for mantle-cell lymphoma?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2013 |
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Cell Line; Cell Survival; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines | 2013 |
Targeting the B-cell signalling pathway in CLL and MCL.
Topics: Adenine; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction | 2013 |
Two targets for the price of one.
Topics: Adenine; Animals; Humans; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Th1 Cells | 2013 |
[Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2013 |
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Apoptosis; Cell Adhesion; Cell Proliferation; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; NF-kappa B; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2014 |
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Survival; Disease Models, Animal; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2014 |
The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Animals; Bone Resorption; Cell Differentiation; Disease Models, Animal; Female; Gene Expression Regulation; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteoporosis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RANK Ligand | 2014 |
A new era of treatment for chronic lymphocytic leukaemia?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Topics: Adenine; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence; Blotting, Western; CARD Signaling Adaptor Proteins; Cell Line; Cell Survival; DNA Primers; Guanylate Cyclase; Humans; Inhibitor of Apoptosis Proteins; Luminescent Measurements; Lymphoma, Mantle-Cell; Microarray Analysis; Molecular Sequence Data; NF-kappa B; NF-kappaB-Inducing Kinase; Piperidines; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; RNA Interference; Sequence Analysis, RNA; Signal Transduction; TNF Receptor-Associated Factor 2; TNF Receptor-Associated Factor 3; Trypan Blue; Ubiquitin-Protein Ligases | 2014 |
Ibrutinib approved for mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Approval; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; United States; United States Food and Drug Administration | 2014 |
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CD40 Ligand; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphocytosis; Male; Middle Aged; Phospholipase C gamma; Phosphorylation; Piperidines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; ZAP-70 Protein-Tyrosine Kinase | 2014 |
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; High-Throughput Screening Assays; Humans; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Imbruvica--next big drug in B-cell cancer--approved by FDA.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Boldly Targeting Kinases without mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Lymphocytosis and ibrutinib treatment of CLL.
Topics: Adenine; Female; Humans; Lymphocytosis; Male; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Drug Interactions; Humans; Killer Cells, Natural; Lymphoma, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab | 2014 |
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Cell Proliferation; Cell Survival; Chemokine CCL3; Chemokine CCL4; Chemokine CXCL12; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Mutation; Neoplasm Proteins; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Cells, Cultured | 2014 |
Idelalisib, ibrutinib show benefits in CLL.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Binding Sites; Cell Line, Tumor; Gene Expression; Genes, Reporter; Heterografts; Humans; Lymphoma; Mice; Models, Molecular; Molecular Conformation; Molecular Imaging; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Single-Cell Analysis | 2014 |
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.
Topics: Adenine; Alternative Splicing; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fas Ligand Protein; fas Receptor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Humans; Introns; Lymphoma, B-Cell; Models, Biological; Piperidines; Polycomb Repressive Complex 2; Protein Binding; Pyrazoles; Pyrimidines; RNA-Binding Proteins; RNA, Antisense; RNA, Long Noncoding; Tumor Suppressor Proteins | 2014 |
Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
Topics: Adenine; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Knockout; Piperidines; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Regulatory Factor X Transcription Factors; Signal Transduction; Transcription Factors; X-Box Binding Protein 1 | 2014 |
Ibrutinib: targeting the hidden CLL.
Topics: Adenine; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2014 |
New approved indication for ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib resistance in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phosphorylation; Piperidines; Point Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Recurrence; Sequence Analysis, DNA | 2014 |
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Binding Sites; Drug Resistance, Neoplasm; Exome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phospholipase C gamma; Piperidines; Point Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Recurrence; Sequence Analysis, DNA | 2014 |
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Topics: Adenine; Aged; Allopurinol; Antimetabolites; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Exanthema; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome | 2015 |
The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Mutation; Piperidines; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Receptors, CXCR4; Waldenstrom Macroglobulinemia | 2015 |
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2014 |
Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; HEK293 Cells; Humans; Interleukin-10; Lymphoma, Large B-Cell, Diffuse; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, SCID; Morpholines; Multiprotein Complexes; NF-kappa B; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Changes in the treatment landscape for chronic lymphoid leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib approved for the treatment of mantle cell lymphoma.
Topics: Adenine; Drug Approval; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; United States; United States Food and Drug Administration | 2013 |
Ibrutinib treatment of CLL: the cancer fights back.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2014 |
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Survival; Cysteine; Genes, erbB-1; Humans; Kinetics; Piperidines; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proteome; Pyrazoles; Pyrimidines; Signal Transduction | 2014 |
A treatment for activated B-cell-like DLBCL?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2014 |
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Topics: Adenine; Animals; Azepines; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; I-kappa B Kinase; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Nuclear Proteins; Piperidines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Pyrazoles; Pyrimidines; Signal Transduction; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2014 |
[Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; ErbB Receptors; Female; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Mice; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinolines; TOR Serine-Threonine Kinases | 2014 |
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Genomics; Humans; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Nitrates; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcr; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome | 2014 |
Ibrutinib monotherapy in chronic lymphoid leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Humans; Leukemia, Lymphoid; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
A breakthrough in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Topics: Adenine; Adenosine Diphosphate; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cells, Cultured; Collagen; Female; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Platelet Aggregation; Pyrazoles; Pyrimidines; Severity of Illness Index | 2015 |
Ibrutinib: better combined with other drugs?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2014 |
Ibrutinib for the treatment of mantle cell lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Clinical Trials as Topic; Half-Life; Hematologic Diseases; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Middle Aged; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Signal Transduction; Treatment Outcome | 2014 |
In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; HL-60 Cells; Humans; In Vitro Techniques; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA, Messenger; Vincristine; Xenograft Model Antitumor Assays | 2014 |
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Cyclohexylamines; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Structure-Activity Relationship; Thiazoles | 2015 |
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Evolution, Molecular; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Mutation; Neoplasm Proteins; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.
Topics: Adenine; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Topics: Adenine; Animals; Disease-Free Survival; Drug Evaluation, Preclinical; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Immunologic Factors; Lymphocyte Activation; Mice, Inbred C57BL; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Female; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Topics: Adenine; Blood Platelets; Collagen; Dimethyl Sulfoxide; Enzyme Inhibitors; Hemostasis; Heparin; Humans; Longitudinal Studies; Phospholipase C gamma; Phosphorylation; Piperidines; Platelet Activation; Platelet Adhesiveness; Pyrazoles; Pyrimidines; Shear Strength; von Willebrand Factor | 2014 |
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Topics: Adenine; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Case-Control Studies; Cell Proliferation; Cells, Cultured; Complement Activation; Flow Cytometry; Fluorescent Antibody Technique; Humans; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Neutrophils; Phagocytosis; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Boron Compounds; Cell Line; Fluorescent Dyes; Humans; Jurkat Cells; K562 Cells; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Class I Phosphatidylinositol 3-Kinases; Cyclams; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Heterocyclic Compounds; Humans; Immunoglobulin Heavy Chains; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Natalizumab; Piperidines; Prognosis; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, CXCR4; Signal Transduction; Survival Analysis | 2015 |
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Topics: Adenine; Amino Acid Substitution; Apoptosis; Cell Survival; Chemokine CXCL12; Codon, Nonsense; Drug Resistance, Neoplasm; Frameshift Mutation; Humans; Myeloid Differentiation Factor 88; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Signal Transduction; Tumor Cells, Cultured; Waldenstrom Macroglobulinemia | 2015 |
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Aminopyridines; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coculture Techniques; Cytokines; Female; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Male; Middle Aged; Morpholines; Oxazines; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Syk Kinase; Tumor Cells, Cultured | 2015 |
Overcoming mantle cell lymphoma's ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinases; Cysteine; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Serine | 2014 |
Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Tumor Lysis Syndrome | 2014 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Animals, Newborn; Atrial Fibrillation; Gene Expression Regulation, Enzymologic; Humans; Infant, Newborn; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Rats; Risk Factors; Signal Transduction | 2014 |
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2014 |
Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.
Topics: Adenine; Aged; Antineoplastic Agents; Fatal Outcome; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Skin Neoplasms | 2015 |
The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib.
Topics: Adenine; Afatinib; Animals; Area Under Curve; Cytosol; Dogs; Glutathione; Hepatocytes; Humans; Kidney; Liver; Macaca fascicularis; Male; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Quinolines; Rats | 2015 |
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 12; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Trisomy | 2015 |
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bone Marrow; Humans; Lymphocytosis; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2015 |
Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; MicroRNAs; Multiple Myeloma; Neoplasm Recurrence, Local; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transcription Factor RelA; Tumor Cells, Cultured | 2015 |
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligopeptides; Piperidines; Proteasome Inhibitors; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2015 |
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Analysis; Withholding Treatment | 2015 |
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Humans; Membrane Proteins; Piperidines; Proto-Oncogene Proteins; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sulfonamides; Waldenstrom Macroglobulinemia | 2015 |
Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; beta Catenin; Bone Marrow Cells; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Humans; Lentivirus; Mice; Multiple Myeloma; Neoplastic Stem Cells; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Side-Population Cells; Signal Transduction | 2015 |
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Adenine; Animals; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Liquid-Liquid Extraction; Male; Piperidines; Plasma; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry; Thalidomide; Tolbutamide | 2015 |
FDA grants accelerated approval for ibrutinib for CLL.
Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Piperidines; Pyrazoles; Pyrimidines; United States; United States Food and Drug Administration | 2014 |
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents; B-Lymphocytes; Case-Control Studies; Cell Movement; Class I Phosphatidylinositol 3-Kinases; Gene Expression Regulation, Leukemic; Germinal Center; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lysophospholipids; Morpholines; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Syk Kinase | 2015 |
Ibrutinib has some activity in Richter's syndrome.
Topics: Adenine; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyrazoles; Pyrimidines | 2015 |
Understanding cancer cell survival is key to patient survival.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2015 |
The targeting of human and mouse B lymphocytes by dasatinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antigens, CD19; Apoptosis; B-Lymphocytes; Bone Marrow Cells; Dasatinib; Flow Cytometry; Humans; Male; Mice, Inbred C57BL; Phospholipase C gamma; Piperidines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Receptors, Antigen, T-Cell; Signal Transduction; Spleen; Thiazoles; Time Factors | 2015 |
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Topics: Adenine; Adjuvants, Immunologic; Animals; Cell Line; Drug Synergism; Female; Injections, Intralesional; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Oligodeoxyribonucleotides; Piperidines; Pyrazoles; Pyrimidines; Rats; Toll-Like Receptor 9 | 2015 |
Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Apoptosis; Cell Line; Cell Survival; Flow Cytometry; Gene Knockdown Techniques; High-Throughput Screening Assays; HIV Infections; HIV-1; Humans; Immunoblotting; Mice; Nitriles; Oligonucleotide Array Sequence Analysis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Hypertension; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Piperidines; Pneumonia; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2015 |
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Retrospective Studies; Risk Factors; Salvage Therapy; Texas; Time Factors; Treatment Failure | 2015 |
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2015 |
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Neoplasm; B7-H1 Antigen; Cell Cycle Checkpoints; Cell Line, Tumor; Immunity, Cellular; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Th1 Cells; Th2 Cells | 2015 |
The efficacy of ibrutinib in the treatment of Richter syndrome.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Prednisone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Syndrome; Vincristine | 2015 |
Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Motifs; Animals; Blood Platelets; Chromones; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Lectins, C-Type; Membrane Glycoproteins; Mice; Morpholines; Phosphatidylinositol 3-Kinases; Piperidines; Platelet Activation; Platelet Membrane Glycoproteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Syk Kinase; Tyrosine | 2015 |
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; CD40 Antigens; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sulfonamides; Tumor Microenvironment | 2015 |
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Blood Platelets; Chemical Precipitation; Cryoglobulins; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Piperidines; Platelet Count; Pyrazoles; Pyrimidines; Rituximab; Thrombocytopenia | 2015 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Drug Discovery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; San Francisco; Societies, Medical | 2015 |
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Topics: Adenine; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Health Expenditures; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medicare Part D; Minnesota; Models, Economic; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Time Factors; Treatment Outcome; United States | 2015 |
Life after ibrutinib? A new unmet need in CLL.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Withholding Treatment | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine | 2015 |
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Cell Activating Factor; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Expression Regulation, Leukemic; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Cells, Circulating; Nitrophenols; Piperazines; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Sulfonamides | 2015 |
The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
Topics: Adenine; Apoptosis; Caspases; Cell Line, Tumor; Cyclin D1; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; NF-kappa B; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Vorinostat | 2015 |
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Proto-Oncogene Proteins c-bcr; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Tumor Cells, Cultured | 2015 |
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Pyrazoles; Pyrimidines; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Chronic Disease; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2015 |
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Hematologic Neoplasms; Humans; Molecular Probes; Netherlands; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2015 |
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Topics: Adenine; Adenocarcinoma; Animals; Antineoplastic Agents; Female; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Piperidines; Pyrazoles; Pyrimidines; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2015 |
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Tuberculosis, Miliary | 2015 |
CCMCL1: a new model of aggressive mantle cell lymphoma.
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Tumor Cells, Cultured | 2015 |
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Topics: Adenine; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cell Proliferation; Cell Survival; Chemokine CCL3; Chemokine CCL4; Chemotaxis; Female; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Prognosis; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Ribosomal Protein S6 Kinases; Signal Transduction; Stromal Cells | 2015 |
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Topics: Acrylamides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; Mice, SCID; Microscopy, Confocal; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chickens; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Phospholipase C gamma; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases; Syk Kinase | 2015 |
Possible influence of some foods on the metabolism of ibrutinib.
Topics: Adenine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Food; Food-Drug Interactions; Humans; Isoenzymes; Liver; Piperidines; Pyrazoles; Pyrimidines | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Combo Therapy Effective for Relapsed CLL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Standard of Care; Treatment Outcome | 2015 |
Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Janus Kinase 2; Middle Aged; Neoplastic Stem Cells; Ovarian Neoplasms; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; STAT3 Transcription Factor; Young Adult | 2015 |
Adnectin-targeted inhibitors: rationale and results.
Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fibronectins; Humans; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclohexylamines; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; RNA Splicing; Spiro Compounds; Spliceosomes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Adhesion; Female; Fibronectins; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Male; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2015 |
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2015 |
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Organ Specificity; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Signal Transduction; STAT5 Transcription Factor | 2016 |
IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cytogenetic Analysis; DNA Mutational Analysis; Female; Genes, Immunoglobulin Heavy Chain; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phenotype; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Treatment Outcome | 2015 |
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antinematodal Agents; Female; Humans; Leukemia, Lymphoid; Male; Middle Aged; Panniculitis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Retrospective Studies; Risk Factors; Treatment Outcome | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Clinical Trials as Topic; Disease Progression; DNA Mutational Analysis; Female; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Ohio; Phospholipase C gamma; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis; Treatment Outcome | 2015 |
Ibrutinib promising in subtype of DLBCL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2015 |
Extramedullary haematopoiesis in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; B-Lymphocytes; Bone Marrow; Clone Cells; Exons; Genes, p53; Hematopoiesis, Extramedullary; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ribs | 2015 |
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sirolimus | 2015 |
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence | 2015 |
MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2015 |
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, Mantle-Cell; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Nuclear Proteins; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Transcription Factor RelA; Transcription Factors; Triazoles | 2015 |
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Clinical Trials as Topic; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; United States | 2015 |
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Topics: Adenine; Antigens, CD20; Antineoplastic Agents; Biopsy; Bone Marrow; CD55 Antigens; Clinical Trials, Phase II as Topic; Complement System Proteins; Cytotoxicity, Immunologic; Drug Interactions; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Rituximab; RNA, Messenger | 2016 |
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blast Crisis; Cell Line, Tumor; Cell Survival; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Piperidines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2015 |
Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Activation; Mice; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
Topics: Adenine; Antineoplastic Agents; B-Cell Activation Factor Receptor; Biomarkers, Tumor; Cell Line, Tumor; Chemokine CCL3; Chemokine CCL4; Enzyme-Linked Immunosorbent Assay; Epidemiologic Methods; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Topics: Adenine; Adenosine Monophosphate; Agammaglobulinaemia Tyrosine Kinase; Blood Platelets; Calcium Signaling; Collagen; Dose-Response Relationship, Drug; Fibrinogen; Hemorrhage; Hemostasis; Humans; Piperidines; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyrimidines; Risk Factors; Time Factors | 2015 |
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
Topics: Adenine; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; Isoenzymes; Male; Molecular Targeted Therapy; Phosphorylation; Piperidines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Up-Regulation | 2015 |
Ibrutinib in Refractory Classic Hodgkin's Lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Female; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Radionuclide Imaging | 2015 |
Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
Topics: Adenine; Antineoplastic Agents; Biomarkers, Tumor; CARD Signaling Adaptor Proteins; DNA Mutational Analysis; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Guanylate Cyclase; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Phenotype; Piperidines; Precision Medicine; Predictive Value of Tests; Pyrazoles; Pyrimidines; Time Factors; Treatment Outcome | 2016 |
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.
Topics: Adenine; Antineoplastic Agents; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Piperidines; Pyrazoles; Pyrimidines; Tumor Microenvironment | 2015 |
Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy.
Topics: Adenine; Antimetabolites, Antineoplastic; Biopsy; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Optic Nerve; Papilledema; Piperidines; Pyrazoles; Pyrimidines; Spinal Puncture | 2016 |
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Caspases; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Hydrazones; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Piperidines; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Tumor Cells, Cultured | 2016 |
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyrimidines | 2016 |
A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry.
Topics: Adenine; Animals; Chromatography, High Pressure Liquid; Humans; Ions; Mass Spectrometry; Models, Chemical; Pharmaceutical Preparations; Piperidines; Proteins; Pyrazoles; Pyrimidines; Rats | 2015 |
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Anti-Idiotypic; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Biosynthesis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; RNA, Messenger; Syk Kinase; Tumor Cells, Cultured | 2016 |
Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bile Acids and Salts; Blood Chemical Analysis; Calibration; Chromatography, High Pressure Liquid; Humans; Liver Diseases; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Quality Control; Tandem Mass Spectrometry; Taurocholic Acid | 2015 |
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Cytokines; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Vidarabine | 2015 |
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cell Line, Tumor; HSP90 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Piperidines; Protein-Tyrosine Kinases; Proteomics; Purines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Syk Kinase | 2015 |
Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blotting, Western; CARD Signaling Adaptor Proteins; Caspases; CD79 Antigens; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Guanylate Cyclase; Humans; Jurkat Cells; Lymphoma, Large B-Cell, Diffuse; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Mutation; Neoplasm Proteins; NF-kappa B; Phenothiazines; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Stereoisomerism | 2015 |
Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Chromatography, Liquid; Humans; Mice; Naphthalenes; Pilot Projects; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tandem Mass Spectrometry | 2016 |
Five cancer drugs back on NHS list after deals with drug companies.
Topics: Adenine; Aniline Compounds; Antineoplastic Agents; Bevacizumab; Brentuximab Vedotin; Cost-Benefit Analysis; Drug Industry; Humans; Immunoconjugates; Neoplasms; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Quinolines; State Medicine; Trastuzumab; United Kingdom | 2015 |
Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
Topics: Adenine; Antineoplastic Agents; Humans; Lymphoproliferative Disorders; Piperidines; Pyrazoles; Pyrimidines | 2015 |
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Topics: Adenine; Animals; Ataxia Telangiectasia Mutated Proteins; DNA Damage; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice, Inbred NOD; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Ethacridine; Glycoside Hydrolases; Humans; Hydrolyzable Tannins; Jurkat Cells; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering | 2016 |
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Calcium Signaling; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Mice; Monocytes; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, IgG | 2016 |
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha4beta1; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Piperidines; Plasma Cells; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, CXCR4; Signal Transduction; Vascular Cell Adhesion Molecule-1; Waldenstrom Macroglobulinemia | 2016 |
Management of prolymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Disease Progression; Humans; Immunophenotyping; Immunotherapy; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Mutation; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Stem Cell Transplantation; T-Lymphocytes; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Topics: Adenine; Bendamustine Hydrochloride; Cell Proliferation; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Oligopeptides; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?
Topics: Adenine; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Sirolimus | 2016 |
Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
Topics: Adenine; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazoles; Pyrimidines; Structure-Activity Relationship; Substrate Specificity | 2016 |
Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; B-Lymphocytes; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidines; Signal Transduction | 2015 |
Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Topics: Adenine; Aged; Central Nervous System Diseases; Female; Humans; Immunoglobulin M; Leukocyte Count; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Syndrome; Treatment Outcome; Waldenstrom Macroglobulinemia | 2016 |
CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
Topics: Adenine; Antineoplastic Agents; Apoptosis; CD79 Antigens; Cell Line, Tumor; Cell Survival; Cluster Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Lymphoma, Large B-Cell, Diffuse; Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction | 2016 |
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Proliferation; Female; Follow-Up Studies; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcriptome; Tumor Cells, Cultured | 2016 |
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Occult HBV reactivation induced by ibrutinib treatment: a case report.
Topics: Adenine; Aged, 80 and over; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Virus Activation | 2015 |
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphorylation; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2016 |
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
Topics: Adenine; Cytarabine; Daunorubicin; Leukemia, Myeloid, Acute; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2016 |
Postibrutinib outcomes in patients with mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Retrospective Studies; Treatment Outcome | 2016 |
Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Topics: Adenine; Aged; Antihypertensive Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dihydropyridines; Drug Interactions; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Verapamil | 2016 |
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Lymphoma, Mantle-Cell; Mice, Inbred NOD; Mice, SCID; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell; T-Lymphocytes; Xenograft Model Antitumor Assays | 2016 |
[Ibrutinib prescription in B-cell lymphoid neoplasms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Clinical Trials as Topic; Drug Resistance, Neoplasm; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Waldenstrom Macroglobulinemia | 2016 |
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Line, Tumor; Cytokines; Gene Expression; Humans; Immunotherapy; Mice; Myeloid-Derived Suppressor Cells; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2016 |
Targeting protein kinase C in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Death; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Molecular Targeted Therapy; Phosphorylation; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Tumor Cells, Cultured | 2016 |
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Central Nervous System Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Osteolysis, Essential; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Class I Phosphatidylinositol 3-Kinases; Gene Expression; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides; Tumor Suppressor Protein p53 | 2016 |
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; MAP Kinase Kinase Kinases; Mice; Molecular Targeted Therapy; Niacinamide; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tumor Lysis Syndrome | 2017 |
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
Topics: Adenine; Amino Acid Substitution; Female; Humans; Immunoglobulin G; Leucine; Mutation, Missense; Myeloid Differentiation Factor 88; Piperidines; Proline; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2016 |
Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
Topics: Adenine; Adult; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous | 2017 |
Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nervous System; Nervous System Diseases; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Retrospective Studies | 2016 |
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome | 2016 |
The use of stable isotope-labeled drug as microtracers with conventional LC-MS/MS to support human absolute bioavailability studies: are we there yet?
Topics: Adenine; Benzodiazepines; Biological Availability; Chromatography, High Pressure Liquid; Humans; Isotope Labeling; Pharmaceutical Preparations; Piperidines; Pyrazoles; Pyrimidines; Tandem Mass Spectrometry | 2016 |
Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system.
Topics: Adenine; Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Drug Compounding; Emulsions; Ethylene Glycols; Female; Nanoparticles; Nanotechnology; Particle Size; Piperidines; Polymers; Polysorbates; Propylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rats, Wistar; Solubility; Surface-Active Agents; Technology, Pharmaceutical; Water | 2016 |
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
Topics: Adenine; Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Piperidines; Pyrazoles; Pyrimidines; Signaling Lymphocytic Activation Molecule Family | 2016 |
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity.
Topics: Adenine; Antineoplastic Agents; Drug Evaluation; Humans; Neoplasms; Patient Selection; Piperazines; Piperidines; Pragmatic Clinical Trials as Topic; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Research Design | 2016 |
Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Biopsy; Drug Administration Schedule; Drug Eruptions; Humans; Iatrogenic Disease; Immunoglobulins, Intravenous; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Phenotype; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Skin; Th1 Cells; Th2 Cells; Time Factors; Treatment Outcome | 2016 |
The use of ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Management; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Research; Treatment Outcome | 2016 |
Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA-Binding Proteins; Wnt Signaling Pathway | 2016 |
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Incidence; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retrospective Studies; Treatment Outcome | 2016 |
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Sulfonamides | 2016 |
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Leukemic; Humans; Interleukin-6; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Mutant Proteins; Myeloid Differentiation Factor 88; Piperidines; Proto-Oncogene Proteins c-hck; Pyrazoles; Pyrimidines; Transcriptional Activation; Waldenstrom Macroglobulinemia | 2016 |
CLL: ibrutinib and transplantation ride together.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome; Waldenstrom Macroglobulinemia | 2016 |
Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Calcification, Physiologic; Combined Modality Therapy; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Osteolysis; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Treatment Outcome; United Kingdom | 2017 |
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2016 |
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Compassionate Use Trials; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Retrospective Studies; Sweden; Treatment Outcome | 2016 |
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Apoptosis; Cell Transdifferentiation; Clonal Evolution; Drug Resistance, Neoplasm; Female; Histiocytic Sarcoma; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Selection, Genetic | 2016 |
Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Catalytic Domain; Hydrogen Bonding; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2016 |
Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
Topics: Adenine; Aged; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; T-Lymphocytes | 2016 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylate Cyclase; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Signal Transduction; Thalidomide; Transfection | 2016 |
The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Proliferation; Dexamethasone; DNA Damage; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Stress, Physiological; Tumor Cells, Cultured | 2016 |
Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines.
Topics: Acetanilides; Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 3-Ring; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Epidermal Growth Factor; Female; Gene Expression; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Neuregulin-1; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Animals; Biocatalysis; Cell Line; Cysteine; Drug Resistance, Neoplasm; Humans; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Threonine; Transfection | 2017 |
p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Topics: Adenine; Angiopoietin-1; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Models, Animal; Disease Progression; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Loss of Heterozygosity; Mice; Mice, Knockout; Mutation; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Topics: Acrylamides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Caspase 3; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Humans; Mice; Mice, SCID; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid Differentiation Factor 88; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Piperidines; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, CXCR4; Signal Transduction; Waldenstrom Macroglobulinemia | 2016 |
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imaging, Three-Dimensional; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Quinazolinones; Reproducibility of Results; Signal Transduction; Stromal Cells; Sulfonamides; Sunitinib; Up-Regulation | 2016 |
Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.
Topics: Adenine; Cell Transformation, Neoplastic; Central Nervous System; Humans; Immune Reconstitution Inflammatory Syndrome; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.
Topics: Adenine; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply.
Topics: Adenine; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Male; Piperidines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Central Nervous System Neoplasms; Humans; Immunophenotyping; Magnetic Resonance Imaging; Male; Middle Aged; Piperidines; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia | 2017 |
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Antigens, CD19; B-Lymphocytes; Biomarkers; Cell Proliferation; Cluster Analysis; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Genes, Tumor Suppressor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; MicroRNAs; Middle Aged; Phenotype; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; RNA Interference; RNA, Messenger | 2017 |
Resolution of lung adenocarcinoma after discontinuation of ibrutinib.
Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Humans; Lung; Lung Neoplasms; Male; Piperidines; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed | 2016 |
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Disease Progression; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Mefloquine; Mianserin; Mirtazapine; Multimodal Imaging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Topics: Adenine; Antigens, CD20; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2016 |
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Topics: Acetanilides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Everolimus; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; TOR Serine-Threonine Kinases; Vorinostat; Xenograft Model Antitumor Assays | 2016 |
Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
Topics: Adenine; Antineoplastic Agents; Biopsy; Disease Management; Exanthema; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Severity of Illness Index; Symptom Assessment | 2018 |
NICE recommends dropping two drugs from Cancer Drugs Fund.
Topics: Adenine; Antineoplastic Agents; Cost-Benefit Analysis; England; Everolimus; Formularies as Topic; Humans; Piperidines; Pyrazoles; Pyrimidines; State Medicine | 2016 |
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Topics: Adenine; Amino Acid Substitution; Animals; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Proteins; Phospholipase C gamma; Piperidines; Pyrazoles; Pyrimidines; Pyrones; Quinolines; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Receptors, Antigen, B-Cell; Signal Transduction | 2016 |
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Humans; Male; Mice; Middle Aged; Neoplastic Stem Cells; Phenotype; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2016 |
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cysteine; Humans; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Threonine | 2016 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2016 |
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Monocytes; Phosphorylation; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; STAT1 Transcription Factor; STAT6 Transcription Factor; Tumor Cells, Cultured | 2016 |
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
Topics: Adenine; Anticoagulants; Atrial Fibrillation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Risk Factors; Stroke; Warfarin | 2016 |
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Atrial Fibrillation; Disease Management; Female; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies | 2016 |
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.
Topics: Acrylamides; Adenine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Conformation; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; src Homology Domains | 2016 |
Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
Topics: Adenine; Agammaglobulinemia; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; Immunosuppression Therapy; Leukemia, Lymphocytic, Chronic, B-Cell; Malacoplakia; Piperidines; Pyrazoles; Pyrimidines; Urinary Bladder | 2016 |
Ibrutinib holds promise for patients with 17p deletion CLL.
Topics: Adenine; Chromosome Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice, SCID; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
Topics: Adenine; Animals; Antibodies; Antigens, CD19; Cytokines; Heterografts; Humans; Lymphoma, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; Syndrome | 2017 |
Ibrutinib-induced pyoderma gangrenosum.
Topics: Adenine; Cyclosporine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prednisone; Pyoderma Gangrenosum; Pyrazoles; Pyrimidines | 2016 |
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Mutation; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein Stability; Protein Transport; Proteolysis; Pyrazoles; Pyrimidines; Ubiquitination | 2016 |
Ibrutinib for relapsed refractory hairy cell leukemia variant.
Topics: Adenine; Aged; Biopsy; Comorbidity; Drug Resistance, Neoplasm; Humans; Leukemia, Hairy Cell; Male; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retreatment; Treatment Outcome | 2017 |
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Mantle-Cell; Mice; Mutation, Missense; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Resorcinols; Xenograft Model Antitumor Assays | 2016 |
Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Chromosome Aberrations; Drug Resistance, Neoplasm; Fatal Outcome; Gene Rearrangement, B-Lymphocyte; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Time Factors | 2017 |
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Biomarkers; Biopsy; Blood Cell Count; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Red-Cell Aplasia, Pure; Treatment Outcome | 2017 |
Targeting BTK through microRNA in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzofurans; Cell Survival; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Profiling; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; Mice, Inbred C57BL; MicroRNAs; Molecular Targeted Therapy; Mutant Proteins; Neoplasm Proteins; Piperidines; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Up-Regulation | 2016 |
T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy.
Topics: Adenine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; GATA3 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; NF-kappa B; Piperidines; Primary Cell Culture; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocytes | 2017 |
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Topics: Adenine; Apoptosis; Azepines; Benzylidene Compounds; Bortezomib; Cell Line, Tumor; Cell Survival; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Humans; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Ubiquitin Thiolesterase; Waldenstrom Macroglobulinemia | 2016 |
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Pharmacogenomic Variants; Pharmacovigilance; Piperidines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Learning from Waldenstrom Macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase II as Topic; Humans; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Waldenstrom Macroglobulinemia | 2016 |
Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation.
Topics: Adenine; Algorithms; Antineoplastic Agents; Atrial Fibrillation; Humans; Piperidines; Pyrazoles; Pyrimidines | 2016 |
EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Bone Marrow; Burkitt Lymphoma; Diagnosis, Differential; Disease Progression; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Disease Management; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm Invasiveness; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; International Cooperation; Lymphoma; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2017 |
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Comorbidity; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Prevalence; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Young Adult | 2017 |
Ibrutinib in the real world patient: many lights and some shades.
Topics: Adenine; Age Factors; Clinical Studies as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sweden; United Kingdom | 2016 |
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Animals; Antibodies, Monoclonal; Apoptosis; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Piperidines; Pyrazoles; Pyrimidines; rac1 GTP-Binding Protein; Receptor Tyrosine Kinase-like Orphan Receptors; Tumor Cells, Cultured; Wnt-5a Protein; Xenograft Model Antitumor Assays | 2017 |
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Monitoring; Female; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Aggregation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ristocetin | 2017 |
Ibrutinib in Waldenström's macroglobulinemia: revamping the landscape.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2017 |
Ibrutinib-Induced Lymphocytosis: Cytological Features.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytosis; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2017 |
Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors.
Topics: Adenine; Cells, Cultured; Fumarates; HEK293 Cells; Humans; Kinetics; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2016 |
Effects of ibrutinib treatment on murine platelet function during inflammation and in primary hemostasis.
Topics: Adenine; Adenosine Diphosphate; Animals; Blood Platelets; Collagen; Crotalid Venoms; Gene Expression Regulation; Hemorrhage; Hemostasis; Inflammation; Lectins, C-Type; Lipopolysaccharides; Lung; Membrane Glycoproteins; Mice; Oligopeptides; Piperidines; Platelet Aggregation; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Purinergic P2Y12; Skin | 2017 |
A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiotonic Agents; Electric Countershock; Electrocardiography; Electrophysiology; Emergency Service, Hospital; Extracorporeal Membrane Oxygenation; Humans; Intensive Care Units; Intra-Aortic Balloon Pumping; Isoproterenol; Lidocaine; Magnesium; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Respiration, Artificial; Syncope; Tachycardia, Ventricular; Torsades de Pointes; Waldenstrom Macroglobulinemia; Workforce | 2017 |
58th American Society of Hematology Annual Meeting.
Topics: ADAMTS13 Protein; Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Central Venous Catheters; fms-Like Tyrosine Kinase 3; Genetic Therapy; Graft vs Host Disease; Hematologic Diseases; Hemophilia B; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Multiple Myeloma; Mutation; Piperidines; Protein Kinase Inhibitors; Purpura, Thrombotic Thrombocytopenic; Pyrazoles; Pyrimidines; Recombinant Proteins; Societies, Medical; Thrombosis | 2017 |
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.
Topics: Adenine; Aged; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Severity of Illness Index; Virus Activation | 2017 |
The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Knockdown Techniques; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Mutation; Piperidines; Polymerase Chain Reaction; Pyrazoles; Pyrimidines | 2017 |
Mantle Cell Lymphoma with Central Nervous System Involvement Simulating Bilateral Subdural Hematomas.
Topics: Adenine; Aged; Antineoplastic Agents; Brain Neoplasms; Diagnosis, Differential; Hematoma, Subdural; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Piperidines; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed | 2017 |
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome | 2017 |
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Topics: Adenine; Advisory Committees; Antineoplastic Agents; Australia; Bendamustine Hydrochloride; Bone Marrow; Bortezomib; Humans; Immunoglobulin M; Mutation; Myeloid Differentiation Factor 88; Piperidines; Plasma Cells; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Rituximab; Societies, Medical; Waldenstrom Macroglobulinemia | 2017 |
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2017 |
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Separation; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Sulfones; Syk Kinase; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2017 |
The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.
Topics: Adenine; Animals; Biomarkers; Humans; Mice; Neutrophil Activation; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Respiratory Burst; Triggering Receptor Expressed on Myeloid Cells-1 | 2017 |
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2017 |
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Death; Cell Proliferation; Deuterium Oxide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Pneumonia; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2017 |
More About the Risk of Ibrutinib-associated Bleeding.
Topics: Adenine; Antineoplastic Agents; Hemorrhage; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Severity of Illness Index | 2017 |
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Deprescriptions; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Rate | 2017 |
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fever; Fusariosis; Fusarium; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphadenopathy; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome | 2017 |
Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes.
Topics: Adenine; Amino Acid Sequence; Cell Line, Tumor; Drug Discovery; Humans; Molecular Targeted Therapy; Peptides; Piperidines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrazoles; Pyrimidines; Quinolines; Tandem Mass Spectrometry | 2016 |
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cytidine Deaminase; Enzyme Inhibitors; Female; Genomic Instability; Humans; Immunoglobulin Class Switching; Immunoglobulin Heavy Chains; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recombination, Genetic; Somatic Hypermutation, Immunoglobulin; Translocation, Genetic | 2017 |
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; NF-kappa B; Organ Specificity; Oxadiazoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; DNA; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phospholipase C gamma; Piperidines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Sensitivity and Specificity | 2017 |
Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Topics: Adenine; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides | 2017 |
Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Delayed Diagnosis; Disease Susceptibility; Disseminated Intravascular Coagulation; Fatal Outcome; Humans; Immunocompromised Host; Lymphoma, Mantle-Cell; Male; Meningitis, Bacterial; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Risk Factors; Shock, Septic | 2017 |
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Male; Mice; Models, Molecular; Molecular Conformation; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Poland; Prognosis; Pyrazoles; Pyrimidines; Survival Rate | 2017 |
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; CD52 Antigen; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidines | 2017 |
Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2017 |
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; France; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome | 2017 |
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Death; Cell Line; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction | 2017 |
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
Topics: Adenine; Calcium-Binding Proteins; Cell Line, Tumor; Down-Regulation; EGF Family of Proteins; Endothelial Growth Factors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Phosphatidylinositol 3-Kinases; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Ibrutinib-resistant CLL: unwanted and unwonted!
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Bridged Bicyclo Compounds, Heterocyclic; Circulating Tumor DNA; Clonal Evolution; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Differentiation Factor 88; Phosphoproteins; Piperidines; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Receptor, Notch1; RNA Splicing Factors; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Targeted therapies: Ibrutinib: new option for relapsed MZL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; CD79 Antigens; Female; Humans; Immunophenotyping; Lymphoma, Large B-Cell, Diffuse; Mutation; Myeloid Differentiation Factor 88; Piperidines; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Treatment Outcome | 2017 |
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Burkitt Lymphoma; Disease Models, Animal; Drug Discovery; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Phosphatidylinositol 3-Kinases; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mutation; Myeloid Differentiation Factor 88; Panobinostat; Piperidines; Promoter Regions, Genetic; Pyrazoles; Pyrimidines; STAT3 Transcription Factor; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; C2 Domains; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phospholipase C gamma; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2017 |
Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; CD79 Antigens; Cell Proliferation; Flow Cytometry; Humans; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phospholipase C gamma; Phosphorylation; Piperidines; Precancerous Conditions; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Splenic Neoplasms; Syk Kinase | 2017 |
Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2018 |
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Allergens; Anti-Allergic Agents; Basophils; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Skin Tests | 2017 |
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
Topics: Adenine; Adult; Aged; Cell Proliferation; Cytokines; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Signal Transduction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Treatment Outcome | 2017 |
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Piperidines; Protein Kinases; Proteome; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Movement; Cortactin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Proteins; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrazoles; Pyrimidines; Receptors, CXCR4; Signal Transduction; src-Family Kinases; Tumor Cells, Cultured | 2017 |
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chemokines; Cytokines; Humans; Leukemia, Monocytic, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Macrophages; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2017 |
Efficacy in the margins of NHL with ibrutinib.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome | 2017 |
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Topics: Adenine; Aminopyridines; Apoptosis; Casein Kinase II; Cell Proliferation; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Morpholines; Naphthyridines; Oxazines; Phenazines; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Tumor Cells, Cultured | 2018 |
Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome.
Topics: Adenine; Aged; Amiodarone; Atrial Fibrillation; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heart Failure; Humans; Male; Piperidines; Pyrazoles; Pyrimidines; Syndrome | 2016 |
The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines | 2017 |
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Topics: Adenine; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Piperidines; Primary Cell Culture; Pyrazoles; Pyrimidines; Recombinational DNA Repair; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53; Ubiquitin-Specific Peptidase 7; Ubiquitin-Specific Proteases; Xenograft Model Antitumor Assays | 2017 |
A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Renal Dialysis | 2018 |
Is HBV prophylaxis required during CLL treatment with ibrutinib?
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Biomarkers; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pre-Exposure Prophylaxis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Viral Load | 2017 |
Imbruvica
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Drug Industry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Nurses; Patient Education as Topic; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; State Medicine; Telephone; United Kingdom | 2017 |
Ibrutinib therapy for lymphoplasmacytic lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunoglobulin M; Kidney Failure, Chronic; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Paraproteins; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2017 |
Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
Topics: Adenine; Aged; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Disease Progression; Hodgkin Disease; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Animals; Aspergillosis; Brain Neoplasms; CD79 Antigens; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gene Knockout Techniques; Humans; Lymphoma; Male; Mice; Mice, Knockout; Middle Aged; Myeloid Differentiation Factor 88; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2017 |
Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Cryptococcosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Meningoencephalitis; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2017 |
Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Fatal Outcome; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Second Primary; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Chemokines; Chemotaxis; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Mutation; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2017 |
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Carcinogenesis; Immunoglobulin G; Insulin-Like Growth Factor I; Liver Neoplasms, Experimental; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oncogene Proteins; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; ras Proteins | 2017 |
The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.
Topics: Adenine; Aminoimidazole Carboxamide; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrocarbons, Fluorinated; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Repressor Proteins; Ribonucleosides; Sulfonamides; Thiazolidines; Tumor Cells, Cultured; Up-Regulation | 2017 |
[SDF-1α/CXCR4 Mediated Drug Resistance Can be Reversed by Ibrutinib in Acute Lymphoblastic Leukemia].
Topics: Adenine; Chemokine CXCL12; Drug Resistance, Neoplasm; Humans; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazoles; Pyrimidines; Receptors, CXCR4 | 2017 |
Ventricular Tachycardia Caused by Ibrutinib.
Topics: Adenine; Electrocardiography; Humans; Piperidines; Pyrazoles; Pyrimidines; Tachycardia; Tachycardia, Ventricular | 2017 |
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Topics: Adenine; Animals; Antineoplastic Agents; Benzodiazepines; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Everolimus; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Mice, SCID; Piperidines; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Ibrutinib may impair serological responses to influenza vaccination.
Topics: Adenine; Humans; Influenza Vaccines; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Seroconversion; Treatment Failure | 2017 |
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Syndrome | 2018 |
Ibrutinib-induced acute liver failure.
Topics: Adenine; Biomarkers; Combined Modality Therapy; Female; Humans; Liver Failure, Acute; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
Topics: Adenine; Aged; Gene Rearrangement; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Prognosis; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines | 2018 |
Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
Topics: Adenine; Communicable Diseases; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors | 2018 |
Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery.
Topics: Adenine; Aged; Aged, 80 and over; Humans; Male; Mohs Surgery; Piperidines; Postoperative Hemorrhage; Pyrazoles; Pyrimidines; Risk Factors; Skin Neoplasms | 2017 |
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Topics: Adenine; Aged; Cell Transformation, Neoplastic; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Syndrome | 2017 |
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cell Adhesion; Cell Adhesion Molecules; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Receptors, IgG; Rituximab; Signal Transduction; ZAP-70 Protein-Tyrosine Kinase | 2017 |
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Topics: Adenine; Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Health Resources; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Econometric; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; Rituximab; Survival Analysis | 2017 |
Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
Topics: Adenine; Antiviral Agents; HIV; HIV Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines | 2018 |
Splenic rupture following temporary cessation of ibrutinib.
Topics: Adenine; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Splenic Rupture; Time Factors; Tomography, X-Ray Computed | 2017 |
Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib.
Topics: Adenine; Aged; Case-Control Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pneumococcal Vaccines; Prospective Studies; Pyrazoles; Pyrimidines; Time Factors; Treatment Outcome; Vaccination | 2018 |
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Hematologic Neoplasms; High-Throughput Screening Assays; Humans; Lymphoma, Non-Hodgkin; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction | 2018 |
Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Autoantibodies; Glutamate Decarboxylase; Humans; Insulin Antibodies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; B-Lymphocytes; Disease-Free Survival; Female; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Male; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Retrospective Studies; Treatment Outcome; Waldenstrom Macroglobulinemia | 2017 |
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.
Topics: Adenine; Adult; Antineoplastic Agents; Clinical Decision-Making; Cost-Benefit Analysis; Genomics; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; Uncertainty; United Kingdom | 2017 |
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Resistance; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Topics: Adenine; Biomarkers; Chemokine CXCL13; Cytokines; Humans; Immunoglobulin M; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2017 |
Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Ibrutinib-associated Pneumocystis jirovecii pneumonia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Piperidines; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazoles; Pyrimidines | 2017 |
Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
Topics: Adenine; Cell Transformation, Neoplastic; Central Nervous System Diseases; Female; Humans; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2018 |
Staphylococcal Scalded Skin Syndrome Caused by a Rare Variant of Exfoliative-toxin-A+ S. aureus in an Adult Immunocompromised Woman.
Topics: Adenine; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Exfoliatins; Female; Humans; Immunocompromised Host; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines; Staphylococcal Scalded Skin Syndrome; Staphylococcus aureus; Treatment Outcome | 2018 |
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synergism; Energy Metabolism; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mitochondria; Molecular Targeted Therapy; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
Topics: Adenine; Animals; Feathers; Humans; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors.
Topics: Acrylamides; Adenine; B-Lymphocytes; Benzamides; Cell Line; Humans; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines | 2017 |
Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sequence Deletion; Sulfonamides; Tumor Suppressor Protein p53 | 2017 |
Pulmonary Cryptococcus Presenting as a Solitary Pulmonary Nodule.
Topics: Adenine; Aged; Cryptococcosis; Humans; Immunocompromised Host; Lung Diseases, Fungal; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Neoplasm Staging; Piperidines; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2017 |
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell; Middle Aged; Perinephritis; Piperidines; Pyrazoles; Pyrimidines; Thrombocytopenia | 2018 |
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Topics: Adenine; Aged; Biomarkers, Tumor; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Neoplasm Staging; NFATC Transcription Factors; Piperidines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2018 |
High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Neoplasm Transplantation; NF-kappa B; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Survival Analysis; Transcriptional Activation; Up-Regulation | 2017 |
Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.
Topics: Adenine; Anilides; Aniline Compounds; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Cell Cycle; Cell Proliferation; Central Nervous System Neoplasms; Clinical Trials as Topic; Computer Simulation; Drug Discovery; Drug Therapy, Combination; Genomics; Glioblastoma; Humans; Models, Theoretical; Nitriles; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinolines; RNA, Messenger; Stochastic Processes; Transcriptome | 2018 |
Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization.
Topics: Adenine; Animals; B-Lymphocyte Subsets; B-Lymphocytes; Cells, Cultured; Disease Models, Animal; HLA-A2 Antigen; Humans; Immunization; Immunosuppressive Agents; Isoantibodies; Isoantigens; Mice; Mice, Inbred C57BL; Piperidines; Plasma Cells; Pyrazoles; Pyrimidines | 2017 |
Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neutrophils; Panniculitis; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Topics: Adenine; Aged; B-Lymphocytes, Regulatory; B7-H1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Immune Tolerance; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Tumor Microenvironment | 2018 |
Recurrent chylothorax: a clinical mystery.
Topics: Adenine; Chylothorax; Female; Humans; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pyrazoles; Pyrimidines; Recurrence; Waldenstrom Macroglobulinemia | 2017 |
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Topics: Adenine; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Neoadjuvant Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2017 |
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
Topics: Adenine; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retreatment; Salvage Therapy; Treatment Outcome | 2018 |
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Topics: Adenine; Aged; Aged, 80 and over; Female; Fungi; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Invasive Fungal Infections; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction | 2018 |
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Topics: Adenine; Bone Marrow; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; NF-kappa B; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Microenvironment | 2018 |
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Topics: Adenine; Adolescent; Adult; Electrocardiography; Female; Healthy Volunteers; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Young Adult | 2017 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Thalidomide | 2017 |
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Chemokine CCL3; Chemokine CCL4; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2018 |
Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.
Topics: Adenine; Animals; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Glioma; Humans; Mice; Neoplastic Stem Cells; Pericytes; Piperidines; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Survival Analysis; Tight Junctions; Treatment Outcome | 2017 |
Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Topics: Adenine; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Assays; Humans; Lymphoproliferative Disorders; Microsomes; Piperidines; Polymorphism, Genetic; Precision Medicine; Pyrazoles; Pyrimidines; Recombinant Proteins | 2018 |
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Topics: Adenine; Drug Substitution; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Treatment Outcome | 2018 |
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
Topics: Adenine; Animals; Antigens, CD; Cell Adhesion; Coculture Techniques; Fibroblasts; Humans; Immunophenotyping; L Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Mice; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Tumor Cells, Cultured; Tumor Microenvironment | 2018 |
NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Nuclear Receptor Subfamily 4, Group A, Member 1; Oncogenes; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Survival adjusting for crossover: phase 3 study of ibrutinib
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials, Phase III as Topic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
Topics: Adenine; Agammaglobulinemia; Aged; Bacterial Infections; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Sinusitis | 2018 |
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival.
Topics: Adenine; Amyloidosis; Drug Tolerance; Humans; Immunoglobulin M; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis; Treatment Outcome | 2018 |
Invasive Fungal Sinusitis due to Mucor Species in a Patient on Ibrutinib.
Topics: Adenine; Humans; Invasive Fungal Infections; Mucor; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Sinusitis | 2018 |
New Indication for Ibrutinib.
Topics: Adenine; Drug Approval; Graft vs Host Disease; Humans; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; CD79 Antigens; Clonal Anergy; Endocytosis; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2018 |
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Aggregation; Platelet Function Tests; Pyrazoles; Pyrimidines; Ristocetin | 2018 |
Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
Topics: Adenine; Adult; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidines; Poland; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2018 |
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Topics: Adenine; Aged; Disease Progression; Female; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, CXCR4; Retrospective Studies; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Atrial Fibrillation; Case-Control Studies; Electrocardiography; Follow-Up Studies; Heart Atria; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Risk Factors | 2018 |
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Adhesion; Humans; Immunoglobulin M; Integrin alpha4beta1; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphocytosis; Multivariate Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell | 2018 |
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Line, Tumor; Drug Delivery Systems; HEK293 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Multiple Myeloma; NF-kappa B; Piperidines; Promoter Regions, Genetic; Protein Binding; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; STAT3 Transcription Factor | 2018 |
Choosing ibrutinib wisely.
Topics: Adenine; Humans; Lymphoma, Follicular; Piperidines; Practice Patterns, Physicians'; Pyrazoles; Pyrimidines | 2018 |
Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
Topics: Adenine; Aged; Cryptococcosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy.
Topics: Adenine; Adult; Arachis; Basophils; Female; Humans; Immunoglobulin E; Male; Nut Hypersensitivity; Peanut Hypersensitivity; Piperidines; Pyrazoles; Pyrimidines; Skin Tests | 2018 |
Reply to Bazaz and Denning.
Topics: Adenine; Animals; Invasive Fungal Infections; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Ursidae | 2018 |
Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma.
Topics: Adenine; Aspergillosis; Carcinoma, Hepatocellular; Humans; Invasive Fungal Infections; Liver Neoplasms; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Sorafenib | 2018 |
Venetoclax Data Prompt Rethink of CLL Therapy.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases | 2019 |
Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2018 |
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2018 |
Can we improve on ibrutinib in mantle cell lymphoma?
Topics: Adenine; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Grading; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comorbidity; Cost-Benefit Analysis; Drug Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Neutropenia; Outcome Assessment, Health Care; Piperidines; Pyrazoles; Pyrimidines; Quality-Adjusted Life Years; United Kingdom | 2018 |
Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner.
Topics: A549 Cells; Adenine; Animals; Cell Proliferation; Cells, Cultured; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Piperidines; Pyrazoles; Pyrimidines; Receptor, ErbB-4; Signal Transduction; Tumor Burden; Wnt-5a Protein; Xenograft Model Antitumor Assays | 2018 |
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
Topics: Adenine; Aged; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neuroaspergillosis; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Rate | 2018 |
CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.
Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell; T-Lymphocytes | 2018 |
Ibrutinib presents antitumor activity in skin cancer and induces autophagy.
Topics: Adenine; Apoptosis; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Humans; Microtubule-Associated Proteins; Piperidines; Pyrazoles; Pyrimidines; Skin Neoplasms | 2018 |
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Topics: Adenine; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Culture; Central Nervous System Fungal Infections; Humans; Invasive Pulmonary Aspergillosis; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Topics: Adenine; Cell Line, Tumor; Checkpoint Kinase 1; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Fatty Acids, Nonesterified; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipid Metabolism; Male; Middle Aged; Oxygen Consumption; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2018 |
Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
Topics: Adenine; Aged; Antiviral Agents; Fatal Outcome; Feasibility Studies; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Virus Activation | 2018 |
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Substance Withdrawal Syndrome; Waldenstrom Macroglobulinemia; Withholding Treatment | 2018 |
Ibrutinib-Induced Neutrophilic Dermatosis.
Topics: Adenine; Antineoplastic Agents; Chromosomes, Human, Pair 17; Drug Eruptions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Sweet Syndrome | 2018 |
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Topics: Adenine; Animals; Atrial Fibrillation; Disease Models, Animal; Disease Susceptibility; Dose-Response Relationship, Drug; Electrocardiography; Male; Mice; Mice, Inbred C57BL; Piperidines; Pulse Therapy, Drug; Pyrazoles; Pyrimidines; Random Allocation; Reference Values; Risk Assessment; Ventricular Fibrillation | 2018 |
Ibrutinib brain distribution: a preclinical study.
Topics: Adenine; Animals; Brain; Female; Mice; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tissue Distribution; Treatment Outcome | 2018 |
Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Piperidines; Pyrazoles; Pyrimidines; Splenic Rupture | 2018 |
MYD88 Mutations and Sensitivity to Ibrutinib Therapy.
Topics: Adenine; Adult; Child; Humans; Lymphoma, Large B-Cell, Diffuse; Multiplex Polymerase Chain Reaction; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; RNA-Directed DNA Polymerase | 2018 |
Authors' Reply.
Topics: Adenine; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines | 2018 |
p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Humans; Interleukin Receptor Common gamma Subunit; Lymphoma, Mantle-Cell; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Piperidines; Pyrazoles; Pyrimidines; Stromal Cells; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; New York; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines; Risk Factors; Young Adult | 2018 |
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.
Topics: Acute Lung Injury; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cytokines; Extracellular Traps; Influenza A Virus, H1N1 Subtype; Macrophages, Alveolar; Mice; Orthomyxoviridae Infections; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2018 |
Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation.
Topics: Adenine; Animals; Apoptosis; Bleomycin; Disease Models, Animal; Epithelial Cells; Humans; Idiopathic Pulmonary Fibrosis; Inflammation; Mice; Piperidines; Pulmonary Fibrosis; Pyrazoles; Pyrimidines | 2018 |
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; United Kingdom | 2018 |
Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.
Topics: Adenine; Aged, 80 and over; Exanthema; Histocytochemistry; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Schnitzler Syndrome; Skin; Treatment Outcome | 2018 |
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Humans; Imidazoles; Male; Middle Aged; Piperidines; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Thrombosis | 2018 |
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Genes, myc; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, Knockout; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Topics: Adenine; Aged; Brain; Brain Diseases; Humans; Magnetic Resonance Imaging; Male; Piperidines; Pyrazoles; Pyrimidines; Syndrome; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Phthalazines; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Tumor Cells, Cultured | 2018 |
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Drug Substitution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medication Adherence; Middle Aged; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Treatment Outcome | 2018 |
Inhibitor of Bruton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Anti-Inflammatory Agents; Bone Marrow Cells; Cells, Cultured; Cytokines; Diabetic Nephropathies; Extracellular Signal-Regulated MAP Kinases; Glucose; Humans; Immunomodulation; Inflammation Mediators; Macrophages; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2018 |
Multiple myeloma - a cure within reach.
Topics: Adenine; Humans; Multiple Myeloma; Oligopeptides; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.
Topics: Adenine; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Skin Diseases, Bacterial; Treatment Outcome | 2018 |
Targeted combination has synergy in MCL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Improving on R-ICE in relapsed DLBCL.
Topics: Adenine; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; United Kingdom | 2018 |
Ibrutinib: coming of age?
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib and fungus: an invasive concern.
Topics: Adenine; Adult; Fungi; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Poland; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Rituximab | 2018 |
Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Arthritis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib improves the development of acute lymphoblastic leukemia by activating endoplasmic reticulum stress-induced cell death.
Topics: Activating Transcription Factor 4; Adenine; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Piperidines; Poly (ADP-Ribose) Polymerase-1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Taurochenodeoxycholic Acid; Transcription Factor CHOP | 2018 |
New pieces in the BTKi resistance puzzle.
Topics: Adenine; MAP Kinase Signaling System; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dopamine D2 Receptor Antagonists; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Male; Molecular Targeted Therapy; Neoplasm Proteins; Oligopeptides; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Rituximab; Stress, Physiological; Vincristine | 2019 |
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cytotoxins; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Rituximab | 2018 |
Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
Topics: Adenine; Aged; Electrocardiography; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tachycardia, Ventricular | 2016 |
Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies.
Topics: Adenine; Antineoplastic Agents; Binding Sites; Calorimetry; Circular Dichroism; Cysteine; Humans; Molecular Docking Simulation; Piperidines; Pyrazoles; Pyrimidines; Serum Albumin, Human; Spectroscopy, Fourier Transform Infrared | 2018 |
Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.
Topics: Adenine; Aged; Chromatography, Liquid; Drug Stability; Glutathione; Humans; Linear Models; Male; Naphthalenes; Piperidines; Pyrazoles; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Topics: Adenine; Clinical Trials, Phase III as Topic; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Meta-Analysis as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System.
Topics: Adenine; Adverse Drug Reaction Reporting Systems; Aged; Arrhythmias, Cardiac; Drug Monitoring; Female; Humans; Incidence; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome; United States; United States Food and Drug Administration | 2018 |
Five years of ibrutinib in CLL.
Topics: Adenine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Treatment Outcome | 2018 |
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myelitis; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2019 |
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokine Receptor gp130; Glioma; Janus Kinase 2; Mice; Models, Biological; Neoplastic Stem Cells; Neural Stem Cells; Piperidines; Protein Binding; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Radiation Tolerance; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Survival Analysis; Temozolomide | 2018 |
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Docking Simulation; Piperidines; Point Mutation; Protein Kinase Inhibitors; Proteolysis; Pyrazoles; Pyrimidines; Ubiquitination | 2018 |
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Low Density Lipoprotein Receptor-Related Protein-6; Organic Chemicals; Pancreas; Pancreatic Neoplasms; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Quaternary; Pyrazoles; Pyrimidines; Receptor Tyrosine Kinase-like Orphan Receptors | 2018 |
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; Lymphoma, B-Cell; Mutation; Piperidines; Protein Domains; Proteolysis; Pyrazoles; Pyrimidines; Thalidomide | 2018 |
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
Topics: Adenine; Adult; Drug Interactions; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Models, Biological; Omeprazole; Piperidines; Proton Pump Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; Echocardiography; Female; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Reproducibility of Results | 2018 |
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
Topics: Adenine; Aged, 80 and over; Antineoplastic Agents; CARD Signaling Adaptor Proteins; Disease Progression; Female; Genomic Instability; Guanylate Cyclase; Humans; I-kappa B Proteins; Interferon Regulatory Factors; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Mutation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Skin Neoplasms | 2018 |
The need to assess financial adverse events.
Topics: Adenine; Child; Costs and Cost Analysis; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Young Adult | 2018 |
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Topics: Adenine; Animals; Biopsy; Carcinogenesis; CRISPR-Cas Systems; Drug Design; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Multiprotein Complexes; Mutation; Myeloid Differentiation Factor 88; NF-kappa B; Piperidines; Proteomics; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Toll-Like Receptor 9; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Counterpoint: Does Chemoimmunotherapy Still Have a Role in CLL? Chemotherapy Can Be Eliminated in the Management of CLL.
Topics: Adenine; Antineoplastic Agents, Immunological; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Sulfonamides | 2018 |
Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
Topics: Adenine; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; United Kingdom | 2018 |
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Treatment Outcome | 2019 |
Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Humans; Leukemia, Myeloid, Acute; Leukemia, Neutrophilic, Chronic; Mice; Mutation; Phosphoproteins; Phosphorylation; Piperidines; Precursor Cells, B-Lymphoid; Protein-Tyrosine Kinases; Proteome; Pyrazoles; Pyrimidines; Receptors, Granulocyte Colony-Stimulating Factor | 2019 |
Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anticoagulants; Blood Platelets; Drug Interactions; Hemorrhage; Humans; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2018 |
Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Eosinophilia; Humans; Immunoglobulin E; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib-related atrial fibrillation: Therapeutic challenges.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Topics: Adenine; Amino Acid Motifs; Androgen Antagonists; Androgens; Animals; Antibodies; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Phosphorylation; Piperidines; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Androgen; Sequence Analysis, RNA; Signal Transduction; Tissue Array Analysis | 2018 |
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2018 |
Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Crizotinib; Humans; Mice; Mice, Nude; Neuroblastoma; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Piperazines; Piperidines; Pyrazoles; Pyridones; Pyrimidines | 2018 |
Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aspergillosis; Aspergillus fumigatus; Cells, Cultured; Humans; Macrophages; NF-kappa B; NFATC Transcription Factors; Phagocytosis; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Benzamides; Blood Platelets; Carrier Proteins; Genetic Diseases, X-Linked; Humans; Mutation; Peptides; Piperidines; Platelet Activation; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Topics: Adenine; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Lymphoma, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Unusual cause of sinusitis and cough.
Topics: Adenine; Biopsy; Cough; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Radiography, Thoracic; Salvage Therapy; Sinusitis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware.
Topics: Adenine; Arrhythmias, Cardiac; Humans; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
Topics: Adenine; Antifungal Agents; Humans; Invasive Fungal Infections; Nitriles; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Treatment Outcome; Triazoles | 2019 |
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Topics: Adenine; Aged; Antifungal Agents; Aspergillus fumigatus; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neuroaspergillosis; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2018 |
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
Topics: Abscess; Adenine; Antifungal Agents; Aspergillosis; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Organ Specificity; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cohort Studies; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ventricular Fibrillation | 2018 |
No longer too exhausted to run.
Topics: Adenine; Antibodies, Bispecific; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Risk of Major Bleeding with Ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hematologic Neoplasms; Hemorrhage; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Risk Factors; Survival Rate | 2018 |
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Topics: Adenine; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytotoxicity, Immunologic; Humans; Mice, Inbred NOD; Phagocytosis; Piperidines; Pyrazoles; Pyrimidines; Tumor Cells, Cultured; Waldenstrom Macroglobulinemia; Xenograft Model Antitumor Assays | 2018 |
Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Costs and Cost Analysis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Models, Economic; Piperidines; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome | 2018 |
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Female; Humans; Lymphoproliferative Disorders; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Animals; Benzodioxoles; Cell Line, Tumor; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Mantle-Cell; Male; Mice; Piperidines; Proto-Oncogene Proteins c-myc; Purines; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2018 |
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
Topics: Academic Medical Centers; Adenine; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Rate | 2018 |
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Topics: Adenine; Aged; Antineoplastic Agents; B-Lymphocytes; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Inflammation Mediators; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphocyte Activation; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; RNA, Neoplasm; Transcription, Genetic | 2018 |
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Topics: Adenine; Age Factors; Aged; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2018 |
Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes.
Topics: Adenine; Animals; B-Lymphocytes; CD4-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Flow Cytometry; Humans; Lymph Nodes; Mice; Mice, Inbred C57BL; Models, Theoretical; Piperidines; Pyrazoles; Pyrimidines; Tamoxifen | 2018 |
Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?
Topics: Adenine; Aged, 80 and over; Central Nervous System Neoplasms; Cryptococcosis; Humans; Male; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Gene Expression Regulation, Leukemic; HLA-DR Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Time Factors | 2018 |
Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Luciferase-induced photoreductive uncaging of small-molecule effectors.
Topics: Adenine; Bioluminescence Resonance Energy Transfer Techniques; Luciferases; Luminescent Proteins; Photochemistry; Piperidines; Pyrazoles; Pyrimidines; Rhodamines | 2018 |
Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.
Topics: Adenine; beta 2-Microglobulin; Cell Death; Disease Progression; Humans; Immunoglobulin G; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2018 |
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; Female; Histone-Lysine N-Methyltransferase; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Repressor Proteins; Survival Rate; Tumor Suppressor Protein p53 | 2018 |
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Topics: Adenine; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Survival Rate; Tumor Suppressor Protein p53; Waldenstrom Macroglobulinemia | 2019 |
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macular Edema; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tomography, Optical Coherence | 2019 |
Novel Self-Assembled Ibrutinib-Phospholipid Complex for Potently Peroral Delivery of Poorly Soluble Drugs with pH-Dependent Solubility.
Topics: Adenine; Administration, Oral; Animals; Biological Availability; Drug Delivery Systems; Hydrogen-Ion Concentration; Male; Phospholipids; Piperidines; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Solubility | 2018 |
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Cells, Cultured; Coculture Techniques; Cytokines; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2018 |
Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice.
Topics: Adenine; Animals; Animals, Newborn; Anti-Inflammatory Agents; Cell Line, Transformed; Cells, Cultured; Culture Media, Serum-Free; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Heterocyclic Compounds, 3-Ring; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rats; Signal Transduction; Wound Healing | 2018 |
Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antigens; B-Lymphocytes; Benzamides; Calcium Signaling; Cell Membrane; Cell Polarity; Cell Proliferation; Cells, Cultured; Immunological Synapses; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Microtubule-Organizing Center; Mutation; Phospholipase C gamma; Piperidines; Protein Transport; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell | 2018 |
The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.
Topics: Adenine; Administration, Oral; Animals; Cytokines; Disease Models, Animal; Female; Immunity, Cellular; Immunologic Factors; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Caco-2 Cells; Catalytic Domain; Humans; Mice; Molecular Structure; Niacinamide; Permeability; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2018 |
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
Topics: Adenine; Base Sequence; Disease Progression; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Sequence Deletion; Tumor Suppressor Protein p53 | 2019 |
First-line ibrutinib for Bing-Neel syndrome.
Topics: Adenine; Aged; Brain; Humans; Magnetic Resonance Imaging; Male; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Heterocyclic Compounds, 2-Ring; Humans; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Piperidines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Quantitative Structure-Activity Relationship; Reproducibility of Results; Static Electricity | 2018 |
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Animals; Caco-2 Cells; Humans; Mice; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Structure-Activity Relationship | 2018 |
Immune Response to Extracellular Vesicles From Human Islets of Langerhans in Patients With Type 1 Diabetes.
Topics: Adenine; Adult; Antibody Formation; Autoantibodies; B-Lymphocytes; Cell Proliferation; Cytokines; Diabetes Mellitus, Type 1; Extracellular Vesicles; Female; Glutamate Decarboxylase; Humans; Immunologic Memory; Islets of Langerhans; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Monocytes; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; T-Lymphocytes; Th1 Cells; Th17 Cells; Th2 Cells; Young Adult | 2018 |
A new triple threat to CLL.
Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cell Survival; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Sulfonamides; Tumor Suppressor Protein p53 | 2019 |
Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Topics: Adenine; Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Histones; Humans; Lymphoma, Mantle-Cell; Male; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
Topics: Adenine; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2019 |
Superior vena cava syndrome with concomitant upper extremity deep vein thrombosis.
Topics: Adenine; Aged; Female; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Stents; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Upper Extremity Deep Vein Thrombosis; Vena Cava, Superior | 2019 |
Ibrutinib and
Topics: Adenine; Aspergillus fumigatus; Humans; Macrophages; NF-kappa B; Phagocytosis; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Macrophages; Mycobacterium tuberculosis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes | 2018 |
Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
Topics: Adenine; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Stomatitis | 2019 |
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medication Adherence; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis; Treatment Outcome | 2019 |
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antigens, CD19; Apoptosis; B-Lymphocytes; Cell Proliferation; Disease Models, Animal; Gene Silencing; Histone Deacetylase 6; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Survival Rate | 2018 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Solving lymphoma's stem-cell problem.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Allografts; Autografts; Azetidines; B-Lymphocytes; Cell Separation; Drug Approval; Fetal Blood; Graft vs Host Disease; Hodgkin Disease; Humans; Nitriles; Photopheresis; Piperidines; Problem Solving; Purines; Pyrazoles; Pyrimidines; Stem Cell Transplantation; Sulfonamides; T-Lymphocytes, Regulatory; United States; United States Food and Drug Administration | 2018 |
Precision therapies take aim at non-Hodgkin's lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Disease Models, Animal; Dogs; Drug Approval; Drug Industry; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Molecular Targeted Therapy; Piperidines; Precision Medicine; Pyrazoles; Pyrimidines; United States; United States Food and Drug Administration; Waldenstrom Macroglobulinemia | 2018 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Topics: Adenine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Salvage Therapy; Survival Rate | 2019 |
[Mantle cell lymphoma of the iris treated by ibrutinib].
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Iris; Iris Neoplasms; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome; Visual Acuity | 2018 |
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
Topics: Activating Transcription Factor 3; Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromatin; Chromosomal Proteins, Non-Histone; Circulating Tumor DNA; Cohort Studies; DNA Helicases; Drug Resistance, Neoplasm; Genome, Human; Humans; Lymphoma, Mantle-Cell; Models, Biological; Mutation; Nuclear Proteins; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Sulfonamides; Transcription Factors; Treatment Outcome | 2019 |
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Invasive Fungal Infections; Male; Middle Aged; Piperidines; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazoles; Pyrimidines; Risk Factors; Waldenstrom Macroglobulinemia | 2019 |
Is less equal with ibrutinib dose?
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pilot Projects; Piperidines; Pyrazoles; Pyrimidines | 2018 |
γδ T cells for immunotherapy.
Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes | 2018 |
Novel therapeutics in the treatment of hairy cell leukemia variant.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2018 |
A rare colonic manifestation of chronic lymphocytic leukemia.
Topics: Adenine; Aged; Colon, Sigmoid; Colonic Polyps; Female; Humans; Intestinal Mucosa; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proctocolitis; Pyrazoles; Pyrimidines; Sigmoidoscopy; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Proliferation; Cell Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Oligodeoxyribonucleotides; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Cross-Talk; Receptors, Antigen, B-Cell; Signal Transduction; Toll-Like Receptors | 2019 |
Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.
Topics: Adenine; Animals; Caudate Nucleus; Central Nervous System Neoplasms; Disease Models, Animal; Heterografts; Humans; Interleukin-10; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Tumor Burden | 2019 |
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Topics: Adenine; Aged; Female; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2019 |
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines | 2019 |
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; I-kappa B Proteins; Karyopherins; Lymphoma, Mantle-Cell; NF-kappa B; Piperidines; Protein Subunits; Pyrazoles; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Triazoles | 2018 |
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Topics: Adenine; Aged; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate; Sweden | 2019 |
Cryopreservation of primary B cells minimally influences their signaling responses.
Topics: Adenine; B-Lymphocytes; CD40 Ligand; Cells, Cultured; Cryopreservation; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Single-Cell Analysis; STAT3 Transcription Factor; Tumor Cells, Cultured | 2018 |
Ibrutinib: searching for a partner drug.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Treatment Outcome | 2019 |
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
Topics: Adenine; Adult; Aged; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Syndrome; Treatment Outcome; Waldenstrom Macroglobulinemia | 2019 |
SEROUS MACULAR DETACHMENT ASSOCIATED WITH WALDENSTROM MACROGLOBULINEMIA MANAGED WITH IBRUTINIB: A CASE REPORT AND NEW INSIGHTS INTO PATHOGENESIS.
Topics: Adenine; Humans; Piperidines; Retinal Detachment; Treatment Outcome; Waldenstrom Macroglobulinemia | 2021 |
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Ikaros Transcription Factor; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Piperidines; Proteolysis; Pyrazoles; Pyrimidines; Signal Transduction; Small Molecule Libraries; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Concurrent treatment with two B-cell receptor pathway inhibitors.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell | 2019 |
Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.
Topics: Adenine; Antineoplastic Agents, Immunological; Gene Rearrangement; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Tumor Suppressor Protein p53 | 2019 |
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Bone Marrow; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Humans; Isoquinolines; Lymphoma; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2019 |
Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening.
Topics: Adenine; Cell Line, Tumor; ErbB Receptors; Humans; Microscopy, Fluorescence; Piperidines; Protein Kinase Inhibitors; Proteome; Pyrazoles; Pyrimidines | 2019 |
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; B-Cell Lymphoma 3 Protein; Cohort Studies; Female; Gene Expression; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oncogene Proteins, Fusion; Piperidines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2019 |
Alliance to iLLUMINATE the chemo-free sign.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Professional-Patient Relations; Progression-Free Survival; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2019 |
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease; Disease Progression; Hepatitis E; Hepatitis E virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Ribavirin | 2019 |
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
Topics: Adenine; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Survival Rate | 2019 |
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Topics: Adenine; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Toll-Like Receptors | 2019 |
Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Topics: Adenine; Animals; Chromatography, High Pressure Liquid; Data Accuracy; Limit of Detection; Male; Piperidines; Pyrazoles; Pyrimidines; Quinazolinones; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Ibrutinib-associated T-cell pseudolymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pseudolymphoma; Pyrazoles; Pyrimidines; T-Lymphocytes; Withholding Treatment | 2019 |
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence | 2019 |
ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Topics: Adenine; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome; Waldenstrom Macroglobulinemia | 2016 |
Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Ceftriaxone; Lipopolysaccharides; Lung; Male; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Piperidines; Pneumonia, Pneumococcal; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Teichoic Acids | 2019 |
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Genes, bcl-2; Genes, myc; Humans; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Treatment Outcome | 2019 |
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Ribonucleoproteins; Ribosomal Protein S6; Signal Transduction; SS-B Antigen; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Hydrazines; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Niacinamide; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2019 |
Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
Topics: Abdomen; Adenine; Aged; Fatal Outcome; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mucorales; Mucormycosis; Multiple Organ Failure; Neoplasm Recurrence, Local; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines; Thorax; Tomography, X-Ray Computed | 2019 |
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Cycle Proteins; Chromatin; Drug Combinations; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epigenomics; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Signal Transduction; Single-Cell Analysis; TOR Serine-Threonine Kinases | 2019 |
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Follicular; MAP Kinase Signaling System; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Topics: Adenine; Biomarkers, Tumor; Circadian Rhythm; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitriles; Phosphorylation; Piperidines; Pyrazoles; Pyrimidines; Receptors, Glucocorticoid; Toll-Like Receptors; Transcriptional Activation; Tumor Cells, Cultured; Tumor Microenvironment | 2019 |
Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia.
Topics: Adenine; Adult; Aspergillosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucormycosis; Neoplasm Recurrence, Local; Nervous System; Piperidines; Pyrazoles; Pyrimidines | 2019 |
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alternative Splicing; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; B-Lymphocytes; Cellular Senescence; DNA Damage; Gene Deletion; Genetic Predisposition to Disease; Genomic Instability; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Mutation; Neoplasms, Experimental; Phenotype; Phosphoproteins; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; RNA Splicing Factors; Signal Transduction; Tumor Cells, Cultured | 2019 |
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib.
Topics: Adenine; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell | 2019 |
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome; Virus Activation | 2019 |
Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Topics: Adenine; Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; Heart Failure; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Patient Outcome Assessment; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; Risk Factors | 2019 |
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Topics: Adenine; Animals; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis | 2019 |
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Tumor Burden; Tumor Lysis Syndrome | 2019 |
The effect of naringenin on the pharmacokinetics of ibrutinib in rat: A drug-drug interaction study.
Topics: Adenine; Animals; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stability; Flavanones; Limit of Detection; Linear Models; Male; Piperidines; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Topics: Acrylamides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Alzheimer Disease; Animals; Brain; Cell Line; Cell Movement; Cytokines; Datasets as Topic; Enzyme Induction; Gene Expression Profiling; Humans; Mice; Mice, Inbred C57BL; Microglia; Nerve Tissue Proteins; Phagocytosis; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Small Interfering | 2019 |
Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Topics: Adenine; Brain Diseases; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Syndrome; Treatment Outcome; Waldenstrom Macroglobulinemia | 2019 |
Resistance mechanism for ibrutinib in marginal zone lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Bone Marrow; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Targeting Thioredoxin Reductase by Ibrutinib Promotes Apoptosis of SMMC-7721 Cells.
Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Proliferation; Glutathione; Humans; Molecular Docking Simulation; Molecular Targeted Therapy; Piperidines; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Sulfhydryl Compounds; Thioredoxin-Disulfide Reductase | 2019 |
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Gene Expression Regulation; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Pyrazoles; Pyrimidines; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Serositis; Treatment Outcome; United States | 2019 |
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Inhibitor of Apoptosis Proteins; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Pyrazoles; Pyrimidines; Ubiquitin-Protein Ligases | 2019 |
Three targets in 1 shot against ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Neoplasms; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Blood Platelets; Humans; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis | 2019 |
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biomarkers, Tumor; CD79 Antigens; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Recurrence; Stem Cell Transplantation; Syk Kinase; Treatment Outcome | 2019 |
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyoderma Gangrenosum; Pyrazoles; Pyrimidines | 2020 |
Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningeal Carcinomatosis; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Rituximab | 2019 |
Targeting CD20 takes the backseat in CLL.
Topics: Adenine; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2019 |
Fever and Rash in an Adult: Varicella Re-infection in Conjunction with Newly Diagnosed Chronic Lymphocytic Leukemia.
Topics: Acyclovir; Adenine; Adult; Antiviral Agents; Chickenpox; Dermatitis; Fever; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mutation; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzeneacetamides; Biomarkers, Tumor; Cell Line, Tumor; Glutaminase; Humans; Lymphoma, Mantle-Cell; Metabolic Networks and Pathways; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Signal Transduction; Thiadiazoles | 2019 |
The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib.
Topics: Adenine; Aged; Antifungal Agents; Aspergillosis; Cerebrum; Humans; Male; Piperidines; Pyrazoles; Pyrimidines; Voriconazole | 2019 |
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
Topics: Adenine; Adult; Austria; Bronchiolitis Obliterans; Chronic Disease; Female; Germany; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Male; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Switzerland | 2019 |
TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Lymphoma, Large B-Cell, Diffuse; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Piperidines; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2019 |
Promising new combination therapy for non-GCB DLBCL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Multicenter Studies as Topic; Piperidines; Prednisone; Progression-Free Survival; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2019 |
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Immunological; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Mice; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Xenograft Model Antitumor Assays | 2019 |
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Interleukin-10; Lymphoma, Mantle-Cell; Macrophages; Male; Monocytes; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Cell Surface; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment | 2019 |
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome | 2019 |
The Muddied Waters of Ibrutinib Therapy.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Male; Neuroaspergillosis; Piperidines; Pyrazoles; Pyrimidines; Recurrence | 2019 |
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.
Topics: Adenine; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2019 |
Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Receptor Tyrosine Kinase-like Orphan Receptors; T-Lymphocytes; Tumor Cells, Cultured | 2019 |
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Atrial Fibrillation; Atrial Remodeling; Calcium; Calcium Signaling; Disease Models, Animal; Echocardiography; Heart Atria; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Myocytes, Cardiac; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Five Ibrutinib-Associated Side Effects That All Clinicians Should Be Aware of.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Topics: Adenine; Aged; Anticoagulants; Antineoplastic Agents; Drug Approval; Female; Hemorrhage; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; United States; United States Department of Veterans Affairs; Veterans Health | 2019 |
Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event.
Topics: Adenine; Female; Foot Dermatoses; Hand Dermatoses; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Degradation studies of Ibrutinib under stress conditions: Characterisation and structural elucidation of novel degradants.
Topics: Adenine; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Oxidation-Reduction; Piperidines; Pyrazoles; Pyrimidines; Spectrometry, Mass, Electrospray Ionization | 2019 |
Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma.
Topics: Adenine; Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Heterozygote; Humans; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Magnetic Resonance Imaging; Mice; Piperidines; Primary Cell Culture; Pyrazoles; Pyrimidines; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL. Reply.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
Topics: Adenine; Atrial Fibrillation; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Heart; Heart Atria; Heart Ventricles; Humans; Myocardium; Myocytes, Cardiac; Organ Specificity; Piperidines; Pluripotent Stem Cells; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Platelet Counts and Risk of Major Bleeding With Ibrutinib.
Topics: Adenine; Hemorrhage; Humans; Piperidines; Platelet Count; Pyrazoles; Pyrimidines | 2019 |
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Topics: Adenine; Case-Control Studies; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Drug; Flavonoids; Flavonols; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Piperidines; Prognosis; Proteomics; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Signal Transduction; Up-Regulation | 2019 |
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Plasma | 2020 |
Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cryptococcosis; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin.
Topics: Adenine; Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Crystallization; Drug Compounding; Drug Liberation; Drug Stability; Male; Pharmaceutic Aids; Piperidines; Powders; Pyrazoles; Pyrimidines; Rats; Saccharin; Solubility; X-Ray Diffraction | 2019 |
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; DNA Copy Number Variations; Drug Resistance, Neoplasm; Exome Sequencing; Lymphoma, Mantle-Cell; Mice; Molecular Targeted Therapy; Mutation; Oxidative Phosphorylation; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Transcriptome | 2019 |
Ibrutinib: the home run for cure in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib is safer than we think.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Phosphorylation; Piperidines; Pyrazoles; Pyrimidines; RNA Polymerase II; Sulfonamides; Triazoles | 2019 |
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; B-Lymphocytes; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrazoles; Pyrimidines; Young Adult | 2019 |
Managing patients with ibrutinib-resistant CLL: don't stop ibrutinib until you are ready with the next therapy.
Topics: Adenine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Topics: Adenine; Animals; Drug Delivery Systems; Immunotherapy; Macrophages; Male; Mice; N-Acetylneuraminic Acid; Nanoparticles; Neoplasms; Phosphatidylglycerols; Piperidines; Proton Magnetic Resonance Spectroscopy; Pyrazoles; Pyrimidines; Rats, Wistar; RAW 264.7 Cells; Stearic Acids | 2019 |
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Topics: Adenine; Antineoplastic Agents; beta 2-Microglobulin; Bridged Bicyclo Compounds, Heterocyclic; Databases, Factual; Female; Hemoglobins; Humans; Immunotherapy; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sulfonamides; Survival Rate | 2019 |
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Topics: Adenine; Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mice; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ubiquitin-Activating Enzymes; Unfolded Protein Response | 2019 |
Ibrutinib and Venetoclax - Doubling Down on CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cardiomyopathies; Female; Humans; Late Onset Disorders; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ventricular Dysfunction, Left | 2020 |
Ibrutinib induces multiple functional defects in the neutrophil response against
Topics: Adenine; Aspergillosis; Aspergillus fumigatus; Humans; Neutrophils; Piperidines; Spores, Fungal | 2020 |
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2020 |
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Cohort Studies; Female; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2020 |
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
Topics: Adenine; Antineoplastic Agents; Comorbidity; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Retrospective Studies; Treatment Outcome | 2019 |
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Topics: Adenine; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Enzyme Inhibitors; Humans; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2019 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Animals; B7-H1 Antigen; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Mice, SCID; Middle Aged; Piperidines; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Retrospective Studies; Signal Transduction; Syk Kinase; Young Adult | 2019 |
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Topics: Adenine; Adult; Antineoplastic Agents; Compassionate Use Trials; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Poland; Pyrazoles; Pyrimidines; Retrospective Studies | 2019 |
[Dose reassessment: An answer to the high cost of drugs used in oncology?]
Topics: Abiraterone Acetate; Adenine; Antineoplastic Agents; Clinical Protocols; Dasatinib; Drug Costs; France; gamma-Glutamyl Hydrolase; Humans; Insurance, Pharmaceutical Services; Medical Oncology; Neoplasms; Nivolumab; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; United States; Zoledronic Acid | 2019 |
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents; Aspirin; Atrial Fibrillation; Atrial Flutter; Female; Humans; Hypertension; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Multivariate Analysis; Piperidines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Waldenstrom Macroglobulinemia | 2019 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
New first-line options in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyridones; Pyrimidines; Quinazolinones; Signal Transduction; Sulfonamides; Tumor Microenvironment | 2019 |
Ibrutinib related bleeding complications in elderly patients with B cell malignancies.
Topics: Adenine; Aged; B-Lymphocytes; Hemorrhage; Humans; Neoplasms; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Rare case of Bing-Neel syndrome treated successfully with ibrutinib.
Topics: Adenine; Brain; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mutation; Myeloid Differentiation Factor 88; Neurodegenerative Diseases; Piperidines; Pyrazoles; Pyrimidines; Syndrome; Waldenstrom Macroglobulinemia | 2019 |
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Cytokines; Disease Progression; Drug Evaluation, Preclinical; Endometriosis; Female; Mice, Inbred BALB C; Piperidines; Pyrazoles; Pyrimidines; T-Lymphocytes | 2019 |
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Survival Rate; Waldenstrom Macroglobulinemia | 2019 |
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dog Diseases; Dogs; Gene Expression Regulation, Neoplastic; Histamine; Immunoglobulin E; Mastocytoma; Piperidines; Pyrazoles; Pyrimidines; STAT5 Transcription Factor | 2019 |
Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Topics: Adenine; Death, Sudden, Cardiac; Electrocardiography; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Ventricular Fibrillation; Waldenstrom Macroglobulinemia | 2019 |
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Products; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Immunotherapy, Adoptive; Isoindoles; Lymphocyte Depletion; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Multiple Primary; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Recurrence; Salvage Therapy; Vincristine | 2019 |
Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Survival; Drug Resistance, Neoplasm; Energy Metabolism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Signal Transduction | 2019 |
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retrospective Studies; Sulfonamides | 2019 |
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; HEK293 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Structure-Activity Relationship | 2019 |
In vitro metabolism of ibrutinib in rat, dog and human hepatocytes using liquid chromatography combined with diode-array detection and Q-Exactive Orbitrap tandem mass spectrometry.
Topics: Adenine; Alkylation; Animals; Biotransformation; Dogs; Hepatocytes; Humans; Hydrogenation; Hydrolysis; Hydroxylation; Metabolic Networks and Pathways; Piperidines; Pyrazoles; Pyrimidines; Rats; Tandem Mass Spectrometry | 2019 |
IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Calcium Phosphates; Extracellular Signal-Regulated MAP Kinases; Female; Ganglia, Spinal; Gene Expression Profiling; Interleukin-6; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Piperidines; Pruritus; Pyrazoles; Pyrimidines; Signal Transduction; Skin | 2019 |
Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Female; Humans; Phosphoproteins; Phosphorylation; Piperidines; Receptor, ErbB-2; STAT3 Transcription Factor | 2020 |
Repurposing dasatinib for diffuse large B cell lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Humans; Lymphoma, Large B-Cell, Diffuse; Mechanistic Target of Rapamycin Complex 2; Mice; Phosphatidylinositol 3-Kinases; Piperidines; Proof of Concept Study; PTEN Phosphohydrolase; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2019 |
Reply to M. Skelin et al.
Topics: Adenine; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Humans; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2019 |
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?
Topics: Adenine; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2019 |
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Topics: Adenine; Atrial Fibrillation; Cardiovascular Diseases; Humans; Piperidines; Pyrazoles; Pyrimidines; Risk Factors | 2020 |
Ibrutinib outperforms FCR in CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
Topics: Adenine; Glucuronosyltransferase; Humans; Imidazoles; Indoles; Microsomes, Liver; Oximes; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Pyrimidines; Pyrimidinones | 2019 |
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leg; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Skin Neoplasms; Vincristine | 2019 |
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Topics: Abnormal Karyotype; Adenine; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Amyloid Precursor Protein Secretases; Animals; Calcium; Diamines; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Receptor, Notch1; Receptors, Antigen, B-Cell; Signal Transduction; Syndrome; Thiazoles | 2020 |
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Autoimmune hemolytic anemia, adverse event to venetoclax.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Salvage Therapy; Sulfonamides; Vincristine | 2019 |
Luciferase-Induced Photouncaging: Bioluminolysis.
Topics: Adenine; Coumarins; Fluorescence Resonance Energy Transfer; HeLa Cells; Humans; Luciferases; Luminescent Measurements; Luminescent Proteins; Piperidines; Protein Binding; Pyrazoles; Pyrimidines | 2019 |
Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
Topics: Adenine; Aged; Cryoglobulinemia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Plasmapheresis; Prednisolone; Pyrazoles; Pyrimidines; Rituximab; Vasculitis; Withholding Treatment | 2019 |
Rare case of ocular adnexal relapse with mantle cell lymphoma treated with ibrutinib monotherapy.
Topics: Adenine; Aged; Antineoplastic Agents; Eye Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome; Visual Acuity | 2019 |
Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Humans; Imidazoles; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mice; NIH 3T3 Cells; Nitriles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2019 |
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Immunocompromised Host; Invasive Fungal Infections; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2019 |
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Risk Factors; Thrombosis | 2019 |
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Tyrosine Kinase-like Orphan Receptors; Receptors, Antigen, B-Cell; Receptors, Antigen, T-Cell; Signal Transduction; Structure-Activity Relationship | 2019 |
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab | 2019 |
Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cecum; Disease Models, Animal; Heart; Heart Diseases; Inflammasomes; Ligation; Male; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Punctures; Pyrazines; Pyrazoles; Pyrimidines; Sepsis | 2019 |
Cardiovascular Toxicities Associated With Ibrutinib.
Topics: Adenine; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cardiovascular Diseases; Databases, Factual; Female; Humans; Male; Mortality; Pharmacovigilance; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2019 |
Real-Life Insight Into Ibrutinib Cardiovascular Events: Defining the Loose Ends.
Topics: Adenine; Cardiovascular Diseases; Humans; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib and lenalidomide: when 1+1 = >2.
Topics: Adenine; B-Lymphocytes; Lenalidomide; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2019 |
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Salvage Therapy; Treatment Outcome | 2019 |
Topics: Adenine; Drug Resistance; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Treatment Outcome; Waldenstrom Macroglobulinemia | 2019 |
Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma.
Topics: Adenine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Female; Humans; Liver Neoplasms; Mice; Piperidines; Sorafenib | 2020 |
Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.
Topics: Adenine; Biomarkers; Biopsy; Cryoglobulinemia; Female; Fluorescent Antibody Technique; Humans; Kidney; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Health Care Costs; Health Care Rationing; Hospitalization; Humans; Incidence; Insurance, Health; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Practice Patterns, Physicians'; Prednisone; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; United States; Vincristine; Young Adult | 2019 |
Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Ibrutinib Delivery: A Potential Nanoformulation of Novel Kinase Inhibitor.
Topics: Adenine; beta-Cyclodextrins; Chitosan; Drug Carriers; Nanoparticles; Particle Size; Piperidines; Protein Kinase Inhibitors | 2020 |
Ibrutinib-Associated Reversible Cardiomyopathy.
Topics: Adenine; Aged; Cardiomyopathies; Humans; Lymphoma, Mantle-Cell; Male; Mesentery; Piperidines; Pyrazoles; Pyrimidines | 2019 |
The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cunninghamella; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mucormycosis; Piperidines; Pyrazoles; Pyrimidines; Thyroid Nodule | 2019 |
Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Weight Gain | 2020 |
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
Topics: Adenine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline.
Topics: Adenine; Animals; Biological Availability; Chromatography, High Pressure Liquid; Female; Limit of Detection; Linear Models; Male; Nanoparticles; Piperidines; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
Ibrutinib-associated oral ulcers.
Topics: Adenine; Aged; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metronidazole; Mouthwashes; Oral Ulcer; Piperidines; Prednisolone; Pyrazoles; Pyrimidines; Treatment Outcome | 2020 |
Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Degranulation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutrophils; Phagocytosis; Piperidines; Pyrazoles; Pyrimidines; Time Factors | 2019 |
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cytokines; Diabetes Mellitus; Diabetic Foot; Disease Models, Animal; Male; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Signal Transduction; Toll-Like Receptors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2019 |
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Female; Health Care Costs; Health Resources; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Acceptance of Health Care; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2019 |
[Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease].
Topics: Adenine; Aged; Antibodies, Monoclonal; Autoimmune Diseases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2019 |
[Richter syndrome successfully treated with ibrutinib monotherapy: two case reports].
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.
Topics: Adenine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Retrospective Studies; Salvage Therapy | 2020 |
Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Canada; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Elevated level of circulatory sTLT1 induces inflammation through SYK/MEK/ERK signalling in coronary artery disease.
Topics: Adenine; Adult; Animals; Case-Control Studies; Cell Line; Coronary Artery Disease; Disease Progression; Humans; Macrophages; MAP Kinase Signaling System; Mice, Knockout, ApoE; Middle Aged; Oxazines; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptors, IgG; Receptors, Immunologic; src Homology Domains; Syk Kinase; Tumor Necrosis Factor-alpha | 2019 |
[Aspergillus spondylodiscitis in a patient treated with ibrutinib].
Topics: Adenine; Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Combined Modality Therapy; Discitis; Humans; Immunosuppressive Agents; Laminectomy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Rituximab; Voriconazole | 2020 |
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Topics: Adenine; Animals; Cell Line, Tumor; Enzyme Stability; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Receptor Tyrosine Kinase-like Orphan Receptors | 2020 |
A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome.
Topics: Adenine; Animals; Diet, High-Fat; Drug Repositioning; Gene Regulatory Networks; Humans; Lipid Metabolism; Macrophages; Metabolic Syndrome; Organ Specificity; Pharmaceutical Preparations; Piperidines; Pyrazoles; Pyrimidines; Reproducibility of Results; Signal Transduction; Zebrafish | 2019 |
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Topics: Adenine; Aged, 80 and over; Cryptococcosis; Dermatomycoses; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
An Unbiased Immunoaffinity-Based Strategy for Profiling Covalent Drug Targets In Vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Sequence; Animals; Antibodies; ATP Binding Cassette Transporter, Subfamily B, Member 2; Cell Line; Humans; Liver; Membrane Proteins; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Peptides; Piperidines; Protein Binding; Proteomics; Pyrazoles; Pyrimidines; Spleen | 2019 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Clinical Trials, Phase III as Topic; Frail Elderly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Cardiovascular adverse events of ibrutinib.
Topics: Adenine; Humans; Hypertension; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Topics: Adenine; Aged; Aged, 80 and over; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate | 2020 |
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Sulfonamides | 2019 |
Two-drug combination benefits patients with chronic lymphocytic leukemia.
Topics: Adenine; B-Lymphocytes; Drug Combinations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2020 |
Microcrystalline cellulose as an effective crystal growth inhibitor for the ternary Ibrutinib formulation.
Topics: Adenine; Animals; Biological Availability; Cell Line, Tumor; Cellulose; Chemical Phenomena; Crystallization; Drug Compounding; Humans; Male; Piperidines; Pyrazoles; Pyrimidines; Rats | 2020 |
Differential use of BTK and PLC in FcεRI- and KIT-mediated mast cell activation: A marginal role of BTK upon KIT activation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Calcium; Cells, Cultured; Cytokines; Female; Male; MAP Kinase Kinase 4; Mast Cells; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Phospholipase C gamma; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrimidines; Receptors, IgE | 2020 |
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
Topics: Adenine; Animals; Biomarkers; Blood Platelets; Collagen Type I; Exocytosis; Humans; Mice; Piperidines; Platelet Activation; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; von Willebrand Factor | 2019 |
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Cell Line; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Kinetics; Models, Biological; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2020 |
Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
Topics: Acetamides; Adaptor Proteins, Signal Transducing; Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Binding Sites; Cell Line; Drug Design; Half-Life; Humans; Ligands; Molecular Docking Simulation; Mutagenesis, Site-Directed; Piperidines; Protein Structure, Tertiary; Proteolysis; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein | 2020 |
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Topics: Adenine; Animals; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mice; Neoplasms; Piperidines; Pyrazines; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T-Lymphocytes; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
[Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
Topics: Adenine; Aged; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Transplantation, Autologous | 2019 |
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Salvage Therapy; Sulfonamides | 2020 |
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Oxaliplatin; Piperidines; Prognosis; Rituximab; Vincristine | 2020 |
Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Hepatitis B virus; Humans; Liver Failure; Lymphoma, Non-Hodgkin; Male; Middle Aged; Piperidines | 2020 |
Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.
Topics: Adenine; Aged; Female; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis | 2020 |
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Mutation; Piperidines; Protein Kinase Inhibitors; Treatment Outcome; Tumor Suppressor Protein p53 | 2020 |
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 11; CRISPR-Cas Systems; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutagenesis, Site-Directed; Mutation; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2020 |
A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
Topics: Adenine; Area Under Curve; Female; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies | 2020 |
Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Immunity, Innate; Interleukin-17; Interleukin-23; Intraepithelial Lymphocytes; Male; Mice; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Signal Transduction; Skin | 2020 |
Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation.
Topics: Acetophenones; Adenine; Animals; Atrial Fibrillation; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Humans; Male; Mice; Myocytes, Cardiac; Piperidines; Protein Interaction Maps; Proteomics; Reactive Oxygen Species; Sarcoplasmic Reticulum; Signal Transduction | 2020 |
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Netherlands; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Cell line-based assessment of BTK inhibitors.
Topics: Adenine; B-Lymphocytes; Cell Line; Humans; Mutation; Neoplasms; Piperidines; Protein Kinase Inhibitors | 2020 |
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chromatin; Epigenome; Epigenomics; Gene Expression Profiling; Genetic Heterogeneity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Machine Learning; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Sequence Analysis, RNA; Transcription Factors; Transcriptome | 2020 |
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Topics: Adenine; Cell Proliferation; Disease Progression; Humans; Immunotherapy; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2020 |
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Synergism; Humans; Imidazoles; Interleukin-1 Receptor-Associated Kinases; Lymphoma, Large B-Cell, Diffuse; Molecular Docking Simulation; Molecular Structure; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Signal Transduction; Structure-Activity Relationship | 2020 |
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Cell Line, Tumor; Humans; Immunity, Cellular; Neoplasm Proteins; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; T-Lymphocytes | 2020 |
Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
Topics: Adenine; Animals; Breast Neoplasms; Dendritic Cells; Disease Progression; Female; Humans; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Piperidines | 2020 |
Ibrutinib-induced polyneuropathy: A case report.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Polyneuropathies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2020 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Sulfonamides | 2020 |
Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
Topics: Adenine; Aged; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Tumor Lysis Syndrome; Urate Oxidase | 2020 |
Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
Topics: Adenine; Adult; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Young Adult | 2020 |
Enhanced solid-state stability of amorphous ibrutinib formulations prepared by hot-melt extrusion.
Topics: Adenine; Crystallization; Drug Compounding; Drug Stability; Hot Temperature; Piperidines; Polymers; Spectrum Analysis, Raman; Transition Temperature | 2020 |
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
Topics: Adenine; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Immunotherapy; Lymphoma, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Topics: Adenine; Adult; Aged; Antigens, CD19; Combined Modality Therapy; Drug Resistance, Neoplasm; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Receptors, Antigen, T-Cell; Retrospective Studies; Salvage Therapy | 2020 |
Ibrutinib related cerebral aspergillosis successfully treated with isavuconazole: a case report.
Topics: Adenine; Antifungal Agents; Aspergillosis; Humans; Nitriles; Piperidines; Pyridines; Triazoles | 2020 |
Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
Topics: Adenine; Aged; Aspergillosis; Aspergillus; Central Nervous System Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung; Magnetic Resonance Imaging; Male; Piperidines; Pyrazoles; Pyrimidines; Voriconazole | 2020 |
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Pyrimidines; Signal Transduction; Synthetic Lethal Mutations; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2020 |
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Mice; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
Topics: Adenine; Adult; Aged; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2020 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |
Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
Topics: Adenine; Carrier Proteins; CD79 Antigens; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Genes, Tumor Suppressor; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Mutagenesis, Site-Directed; Myeloid Differentiation Factor 88; NF-kappa B; Piperidines; Proteolysis; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Ubiquitin-Protein Ligase Complexes | 2020 |
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Topics: Adenine; Adult; Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Piperidines; Platelet Aggregation Inhibitors; Pyrazoles; Pyrimidines; Tissue Donors; Young Adult | 2020 |
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Tumor Microenvironment | 2021 |
Adenosine-producing regulatory B cells in head and neck cancer.
Topics: Adenine; Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes, Regulatory; Case-Control Studies; Cell Proliferation; Head and Neck Neoplasms; Humans; Male; Mice; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants.
Topics: Adenine; Aged; Aged, 80 and over; Anticoagulants; Female; Hemorrhage; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy.
Topics: Adenine; Animals; Autophagy; Macrophages; Mice; Mycobacterium tuberculosis; Piperidines; Tuberculosis | 2020 |
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Piperidines; Rituximab | 2020 |
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Topics: Adenine; Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphokines; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Transcriptome; Young Adult | 2020 |
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Deprescriptions; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Piperidines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2020 |
An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
Topics: Adenine; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 11; Exercise; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Unexpected pathogen presenting with purulent meningitis.
Topics: Adenine; Aged; Anti-Infective Agents; Capnocytophaga; Diagnosis, Differential; Gram-Negative Bacterial Infections; Humans; Leukemia, Lymphoid; Male; Meningitis, Bacterial; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myalgia; Piperidines; Retrospective Studies; Treatment Outcome | 2020 |
Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation.
Topics: Adenine; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Piperidines; Plasma; Stroke; Treatment Outcome | 2020 |
Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.
Topics: Adenine; Fatal Outcome; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Comorbidity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Scleroderma, Localized | 2021 |
Inhibition of effector B cells by ibrutinib in systemic sclerosis.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; B-Lymphocytes; Cells, Cultured; Cytokines; Female; Humans; Male; Middle Aged; NF-kappa B; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Scleroderma, Systemic | 2020 |
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phospholipase C gamma; Piperidines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2020 |
Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
Topics: Adenine; Animals; BALB 3T3 Cells; Dendritic Cells; Down-Regulation; Imiquimod; Inflammation Mediators; Male; Mice; Neutrophils; Oxidation-Reduction; Oxidative Stress; Peroxidase; Piperidines; Psoriasis; Signal Transduction; Skin | 2020 |
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Disease Progression; Drug Evaluation; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Treatment Outcome | 2020 |
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
Topics: Adenine; Antineoplastic Agents; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Virus Activation | 2020 |
Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients.
Topics: Adenine; Hematopoietic Stem Cell Transplantation; Humans; Leukoplakia; Piperidines; Transplant Recipients; Transplantation, Homologous | 2020 |
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Autoimmune Diseases of the Nervous System; Female; Humans; Male; Myelin-Associated Glycoprotein; Piperidines; Polyneuropathies; Protein Kinase Inhibitors; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Lung Injury; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; SARS-CoV-2; Waldenstrom Macroglobulinemia | 2020 |
The effect of ibrutinib on neutrophil and γδ T cell functions.
Topics: Adenine; Humans; Lymphocyte Activation; Neutrophils; Piperidines; Reactive Oxygen Species; T-Lymphocytes | 2020 |
SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
Topics: Adenine; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Mutation; Piperidines; Proteomics; Receptors, Granulocyte Colony-Stimulating Factor; Signal Transduction | 2020 |
Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
Topics: Adenine; Adult; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; SOXC Transcription Factors | 2020 |
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piperidines | 2020 |
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Receptor, Fibroblast Growth Factor, Type 3 | 2020 |
CAR-T and ibrutinib vs CLL: sequential or simultaneous?
Topics: Adenine; Feasibility Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Receptors, Chimeric Antigen; T-Lymphocytes | 2020 |
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Piperidines; Pyrroles; Tumor Microenvironment | 2021 |
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Female; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Retrospective Studies; Rituximab; United States; Vidarabine; Young Adult | 2020 |
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.
Topics: Adenine; B-Lymphocytes; Consensus; Humans; Immunosuppressive Agents; Mycoses; Neoplasms; Piperidines | 2020 |
Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Transplantation Conditioning; Transplantation, Homologous | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine | 2020 |
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Disease Progression; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Humans; Hydroxychloroquine; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphopenia; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prevalence; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; SARS-CoV-2; Spain; Survival Analysis | 2020 |
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ireland; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Recurrence; Survival Rate; United Kingdom | 2021 |
The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway.
Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Pancreatic Neoplasms; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
[Application of ibrutinib in primary central nervous system lymphoma].
Topics: Adenine; Central Nervous System Neoplasms; Humans; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Retrospective Studies | 2020 |
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Drug Repositioning; Humans; Jurkat Cells; Piperidines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Suramin; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study.
Topics: Adenine; Aged; Aged, 80 and over; Cohort Studies; Efficiency, Organizational; Female; Humans; Male; Middle Aged; Neoplasms; Pharmaceutical Services; Pharmacists; Piperidines; Pyrazoles; Pyrimidines; Quality Improvement; Survival Analysis; Time Factors; Time-to-Treatment; Treatment Failure | 2020 |
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Disease Management; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Predictive Value of Tests; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transdifferentiation; Cellular Reprogramming; Combined Modality Therapy; Epigenesis, Genetic; Epigenome; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Humans; Immunotherapy; Lymph Nodes; Lymphoma, Mantle-Cell; Neoplasms, Second Primary; Piperidines; Receptors, Antigen, T-Cell; Rituximab; Sarcoma; Transplantation, Autologous; Tumor Cells, Cultured | 2020 |
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
Topics: Adenine; Aged; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Models, Economic; Neoadjuvant Therapy; Palliative Care; Piperidines; Quality-Adjusted Life Years; Salvage Therapy; United States | 2020 |
QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach.
Topics: Adenine; Biological Availability; Chylomicrons; Drug Carriers; Nanoparticles; Particle Size; Piperidines | 2020 |
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
Topics: Adenine; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Piperidines; Pyrazoles | 2020 |
[Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Meningitis, Cryptococcal; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
Topics: Adenine; Glucose; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipid Metabolism; Piperidines; Pyrazoles | 2020 |
Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Red-Cell Aplasia, Pure; Steroids; Virus Diseases | 2021 |
LC-FACSeq is a method for detecting rare clones in leukemia.
Topics: Adenine; Clonal Evolution; Clone Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm, Residual; Piperidines | 2020 |
Patterns of use and safety of ibrutinib in real-life practice.
Topics: Adenine; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2021 |
The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers, Tumor; Female; Hemoglobins; Humans; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Time Factors | 2020 |
Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Decision-Making; Female; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Retrospective Studies; Symptom Assessment; Time Factors; Treatment Outcome | 2020 |
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunological Synapses; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Rituximab; T-Lymphocytes; Vidarabine | 2020 |
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Poland; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Survival Analysis; Treatment Outcome | 2020 |
Extrahepatic metabolism of ibrutinib.
Topics: Acute Kidney Injury; Adenine; Aged; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Survival; Cells, Cultured; Cytochrome P-450 CYP3A; Glutathione; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Piperidines | 2021 |
Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Topics: Adenine; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Cells; China; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prednisone; Prognosis; Rituximab; Transplantation, Autologous; Vincristine | 2020 |
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Surveys and Questionnaires | 2020 |
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
Topics: Adenine; Central Nervous System; Humans; Lymphoma, B-Cell, Marginal Zone; Piperidines; Pyrazoles; Pyrimidines | 2020 |
[Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Piperidines; Positron Emission Tomography Computed Tomography; Temozolomide | 2020 |
Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Topics: Adenine; Aged; Dose-Response Relationship, Drug; Humans; Male; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pleural Effusion, Malignant; Remission Induction; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia | 2020 |
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prognosis; Proto-Oncogene Proteins c-bcr; Purines; Quinazolinones; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Suppressor Protein p53 | 2020 |
Complete Response of a Young Woman With MYD88
Topics: Adenine; Adolescent; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Myeloid Differentiation Factor 88; Piperidines; Syndrome; Waldenstrom Macroglobulinemia | 2020 |
Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
Topics: Adenine; Ambulatory Care; Antineoplastic Agents; Appointments and Schedules; Betacoronavirus; Canada; Coronavirus Infections; COVID-19; Disease Management; Hospitalization; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Pandemics; Piperidines; Pneumonia, Viral; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Skin Diseases, Vascular; Vasculitis | 2020 |
Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
Topics: Adenine; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Diagnostic Errors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines | 2020 |
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Topics: Adenine; Antigens, CD19; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Culture Techniques; Culture Media; Cytokines; HEK293 Cells; Humans; Immunotherapy, Adoptive; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T-Lymphocyte Subsets | 2021 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Macrophages; Mice; Mice, Nude; Piperidines; Receptors, Cytoplasmic and Nuclear; Survival Rate; Triazoles; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Patients; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Drug Synergism; Histamine Antagonists; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysosomes; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2020 |
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Topics: Adenine; Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Receptor, Notch1; Treatment Outcome | 2021 |
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Protein Kinase Inhibitors; Public Health Surveillance; Retrospective Studies; Treatment Outcome | 2020 |
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Topics: Adenine; Cryptococcosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Risk Factors | 2020 |
Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
Topics: Adenine; Central Nervous System; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Retrospective Studies | 2020 |
Cutaneous adverse-events in patients treated with Ibrutinib.
Topics: Adenine; Humans; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2020 |
Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia.
Topics: Adenine; B-Lymphocytes; Granuloma, Pyogenic; Humans; Neoplasms; Piperidines; Pyrazoles | 2020 |
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lipoprotein Lipase; Male; Middle Aged; Neoplasm Proteins; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Assessment; Rituximab; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; ZAP-70 Protein-Tyrosine Kinase | 2020 |
Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.
Topics: Acrylamides; Adenine; Aminoquinolines; Aniline Compounds; Animals; Binding Sites; Dogs; Haplorhini; Humans; Indoles; Lysine; Mice; Molecular Docking Simulation; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Rabbits; Rats; Serum Albumin, Human | 2020 |
Bringing hospital care closer to patients amidst COVID-19.
Topics: Adenine; Betacoronavirus; Checklist; Coronavirus Infections; COVID-19; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pandemics; Piperidines; Pneumonia, Viral; Prescriptions; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; SARS-CoV-2; Surveys and Questionnaires; Telemedicine; Time-to-Treatment | 2020 |
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Autophagy-Related Proteins; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphatidylinositol 3-Kinase; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice, Inbred NOD; Mice, SCID; Piperidines; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2021 |
Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report.
Topics: Adenine; Adult; Antigens, CD20; Enterovirus Infections; Humans; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Rituximab | 2020 |
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Hemostasis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2020 |
Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Topics: Adenine; Adult; Aged; Animals; Antigens, CD19; Biomarkers, Tumor; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Female; Humans; Immunophenotyping; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Middle Aged; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Receptors, Antigen, T-Cell; STAT3 Transcription Factor; T-Lymphocytes; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Costs; Female; Health Care Costs; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Acceptance of Health Care; Piperidines; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; United States; Veterans | 2020 |
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Symptom Flare Up | 2020 |
Covalent Inhibitor-Based One-Step Method for Endothelin Receptor A Immobilization: from Ligand Recognition to Lead Identification.
Topics: Adenine; Biosensing Techniques; Chromatography, Liquid; ErbB Receptors; Immobilized Proteins; Ligands; Piperidines; Porosity; Receptors, Endothelin; Recombinant Fusion Proteins; Silica Gel | 2020 |
[Haemorrhagic complications following ibrutinib intake after dermatological surgery].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Survival Rate; Waldenstrom Macroglobulinemia | 2021 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbidity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inducers; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Fruit and Vegetable Juices; Hematologic Neoplasms; Humans; Lymphoproliferative Disorders; Piperidines; Polypharmacy; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction | 2020 |
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Topics: Adenine; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Europe; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Rituximab; Time Factors; United States | 2020 |
Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Topics: Adenine; Animals; Benzamides; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dogs; Percutaneous Coronary Intervention; Piperidines; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; BRCA2 Protein; Calcium-Binding Proteins; Cell Cycle Proteins; DNA Damage; Humans; Molecular Structure; Nuclear Proteins; Piperidines; Protein Kinase Inhibitors; Proteomics | 2021 |
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Aspergillosis; Aspergillus fumigatus; Humans; Immunity, Innate; Immunomodulation; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Phagocytosis; Piperidines; Signal Transduction; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2020 |
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Doxorubicin; Fatal Outcome; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Plasmablastic Lymphoma; Prednisone; Syndecan-1; Vincristine | 2020 |
ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Topics: Adenine; Adult; Anaplastic Lymphoma Kinase; Biomarkers; Female; Histiocytosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
Topics: Adenine; Aged; Ecthyma; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Skin; Staphylococcal Skin Infections; Staphylococcus aureus | 2021 |
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Topics: Adenine; Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Piperidines; Pyrimidines; Sulfonamides | 2020 |
Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Immunoglobulin A; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prospective Studies | 2021 |
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Cost Savings; Female; Health Care Costs; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medicare; Patient Acceptance of Health Care; Piperidines; Retrospective Studies; United States | 2020 |
Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.
Topics: Adenine; Aged; Antineoplastic Agents; COVID-19; COVID-19 Drug Treatment; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Recurrence; Retreatment; Treatment Outcome | 2021 |
Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidines | 2021 |
Ibrutinib-Induced Skin Rash
Topics: Adenine; Aged; Biopsy; Exanthema; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Severity of Illness Index; Skin | 2021 |
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2020 |
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Bacterial Infections; Case-Control Studies; Enzyme Inhibitors; Female; Humans; Invasive Fungal Infections; Italy; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Purines; Quinazolinones; Retrospective Studies; Risk Factors; Virus Diseases | 2021 |
Enterobius vermicularis Infection of the Lung Associated With the Use of Ibrutinib in a Patient With Chronic Lymphocytic Leukemia.
Topics: Adenine; Enterobiasis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung; Piperidines | 2020 |
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance, Neoplasm; Humans; Interferon Type I; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Nitriles; Piperidines; Primary Cell Culture; Pyrazoles; Pyrimidines; Receptors, Interferon; Signal Transduction; Tumor Cells, Cultured | 2020 |
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Off-Label Use; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Time Factors | 2020 |
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Biomarkers, Tumor; Chemokine CXCL13; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate | 2021 |
Cost-effectiveness targeting CLL.
Topics: Adenine; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Topics: Action Potentials; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Atrial Fibrillation; Atrial Function, Left; CSK Tyrosine-Protein Kinase; Databases, Genetic; Heart Atria; Heart Rate; Humans; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Piperidines; Protein Kinase Inhibitors; Risk Assessment; Risk Factors | 2020 |
Targeting N-myristoylation for therapy of B-cell lymphomas.
Topics: Acyltransferases; Adenine; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Lymphoma, B-Cell; Mice; Mice, SCID; Models, Biological; Myristic Acid; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
Topics: Adenine; Aged; Aged, 80 and over; Electronic Health Records; Female; Humans; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome; United States | 2021 |
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Deglutition Disorders; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.
Topics: Adenine; Aged; Diabetic Nephropathies; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Renal Dialysis; Renal Elimination; Treatment Outcome | 2021 |
Bruton's Tyrosine Kinase Inhibitor Attenuates Warm Hepatic Ischemia/Reperfusion Injury via Modulation of the NLR Family Pyrin Domain Containing 3 Inflammasome.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Inflammasomes; Inflammation; Liver; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Piperidines; Reactive Oxygen Species; Reperfusion Injury | 2020 |
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Prognosis | 2021 |
A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Focal Adhesion Kinase 1; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
Topics: Adenine; Aged; Biomarkers; Biopsy; Cardiac Tamponade; Echocardiography; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Radiography, Thoracic; Symptom Assessment | 2021 |
[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Topics: Adenine; Aged; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Piperidines | 2020 |
X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Disease Models, Animal; Inflammasomes; Macrophages; Male; Mice; Mice, Inbred CBA; Multiple Organ Failure; Phagocytosis; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sepsis; X-Linked Combined Immunodeficiency Diseases | 2020 |
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Pyrazines; Sulfonamides; Survival Rate | 2021 |
Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
Topics: Acute Kidney Injury; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Dendritic Cells; Disease Models, Animal; Enzyme Inhibitors; Kidney; Male; Mice, Inbred BALB C; NADPH Oxidase 2; Neutrophils; Nitric Oxide Synthase Type II; Oxidative Stress; Piperidines; Sepsis; Signal Transduction | 2021 |
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Topics: Adenine; Adult; Aged; Biomarkers, Tumor; CD40 Antigens; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Piperidines; Prognosis; Proto-Oncogene Proteins c-bcr; Proto-Oncogene Proteins c-myc; Survival Rate; TNF Receptor-Associated Factor 4; Tumor Cells, Cultured | 2021 |
Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression.
Topics: Adenine; Animals; Depression; Depressive Disorder, Major; Inflammasomes; Lipopolysaccharides; Mice; Piperidines | 2021 |
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Biomarkers, Tumor; Drug Resistance, Neoplasm; Genetic Testing; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Piperidines; Prognosis; Protein Kinase Inhibitors; Recurrence; Treatment Outcome | 2021 |
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Multiplexed Functional Assessment of Genetic Variants in CARD11.
Topics: Adenine; B-Cell CLL-Lymphoma 10 Protein; B-Lymphocytes; CARD Signaling Adaptor Proteins; Cell Line; Diploidy; Exons; Genes, Dominant; Genetic Variation; Guanylate Cyclase; Humans; Immunologic Deficiency Syndromes; Jurkat Cells; Lymphoma; NF-kappa B p50 Subunit; Piperidines; Polymorphism, Single Nucleotide; Primary Immunodeficiency Diseases; Sensitivity and Specificity | 2020 |
Partial responses to ibrutinib in Waldenström macroglobulinaemia - good enough?
Topics: Adenine; Humans; Piperidines; Prognosis; Progression-Free Survival; Pyrimidines; Waldenstrom Macroglobulinemia | 2021 |
Chemotherapy and atrial fibrillation.
Topics: Adenine; Atrial Fibrillation; Australia; Humans; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2021 |
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
Topics: Adenine; Aged; Cross Infection; Humans; Incidence; Inpatients; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Opportunistic Infections; Piperidines; Prognosis; Public Health Surveillance; Registries; Risk Factors; Sweden | 2021 |
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Quinazolinones; Receptors, Antigen, B-Cell; Rituximab; Signal Transduction | 2021 |
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Catalytic Domain; COVID-19; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Molecular; Molecular Structure; Mutation; Piperidines; Protein Conformation; Protein Kinase Inhibitors; SARS-CoV-2; src Homology Domains | 2020 |
Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.
Topics: Adenine; Cardiotoxicity; Humans; Piperidines | 2021 |
Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors | 2021 |
EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
Topics: Adenine; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Drug Synergism; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Piperidines; Purines; Pyrrolidinones; Quinazolinones; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Tetrazoles; U937 Cells | 2021 |
LC and LC-MS/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway.
Topics: Adenine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Hydrolysis; Oxidation-Reduction; Photolysis; Piperidines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2021 |
Cardio-Oncology: A Win-Win Situation: How Solving the Mystery of an Ibrutinib Off-Target Effect Reveals New Insights Into Atrial Fibrillation Mechanisms.
Topics: Adenine; Atrial Fibrillation; Humans; Neoplasms; Piperidines; Pyrazoles; Pyrimidines | 2020 |
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lymphoma, B-Cell; Molecular Targeted Therapy; Nerve Tissue Proteins; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Sulfonamides; Waldenstrom Macroglobulinemia | 2021 |
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Topics: Adenine; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Treatment Outcome | 2021 |
Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Topics: Adenine; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Piperidines; Protein Kinase Inhibitors; src-Family Kinases; Structure-Activity Relationship | 2021 |
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunologic Factors; Immunotherapy; Interleukin-2; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Precision Medicine; Prognosis; Remission Induction; Sulfonamides | 2020 |
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Purines; Quinazolinones; Recurrence; Retreatment; Rituximab; Treatment Outcome | 2021 |
IBRUTINIB FOR CONTROL OF CHOROIDAL AND ORBITAL METASTASIS FROM CHRONIC LYMPHOCYTIC LEUKEMIA.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors | 2023 |
A Stability Indicating Method Development and Validation for Separation of Process Related Impurities and Characterization of Unknown Impurities of Tyrosine Kinase Inhibitor Ibrutinib Using QbD Approach by RP-HPLC, NMR Spectroscopy and ESI-MS.
Topics: Adenine; Chromatography, High Pressure Liquid; Drug Contamination; Magnetic Resonance Spectroscopy; Piperidines; Protein Kinase Inhibitors; Reproducibility of Results; Spectroscopy, Fourier Transform Infrared | 2021 |
Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
Topics: Adenine; Aged; Brain; Humans; Intracranial Hemorrhages; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors | 2022 |
The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib.
Topics: Adenine; Aged, 80 and over; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; United States | 2020 |
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Repositioning; Gene Expression Regulation; Humans; Piperidines; Pyrazines; SARS-CoV-2 | 2021 |
Photodynamic/ photothermal therapy enhances neutrophil-mediated ibrutinib tumor delivery for potent tumor immunotherapy: More than one plus one?
Topics: Adenine; Animals; Cell Line, Tumor; Humans; Immunotherapy; Mice; Neutrophils; Photochemotherapy; Photothermal Therapy; Piperidines | 2021 |
Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Comorbidity; COVID-19; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; SARS-CoV-2 | 2021 |
Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates.
Topics: Adenine; Aged; Ecthyma; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis | 2021 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Doxorubicin; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Prednisone; Renal Insufficiency; Retrospective Studies; Rituximab; Stroke; Vincristine | 2021 |
Three efficient chemometrics assisted fluorimetric detection methods for interference-free, rapid, and simultaneous determination of ibrutinib and pralatrexate in various complicated biological fluids.
Topics: Adenine; Algorithms; Aminopterin; Calibration; Fluorometry; Limit of Detection; Piperidines; Spectrometry, Fluorescence | 2021 |
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Line; Cell Line, Tumor; Chickens; Chlorocebus aethiops; COS Cells; Cysteine; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Threonine | 2021 |
Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Lymphocytosis; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
Topics: Adenine; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Uveitis | 2022 |
[Successful treatment with silver nitrate chemical cauterization for paronychia and granulation in a patient with chronic lymphocytic leukemia undergoing ibrutinib therapy].
Topics: Adenine; Aged; Cautery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Paronychia; Piperidines; Protein Kinase Inhibitors; Quality of Life; Silver Nitrate | 2021 |
Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Topics: Adenine; Bendamustine Hydrochloride; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient Acceptance of Health Care; Piperidines; Retrospective Studies; Rituximab | 2021 |
Ibrutinib-induced acute kidney injury via interstitial nephritis.
Topics: Acute Kidney Injury; Adenine; Aged; Cytokines; Glucocorticoids; Humans; Kidney; Leukemia, Prolymphocytic; Male; Nephritis, Interstitial; Piperidines; Protein Kinase Inhibitors; Proteinuria | 2021 |
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Topics: Adenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis | 2021 |
Ibrutinib-induced leg ulcer successfully treated with platelet-rich plasma.
Topics: Adenine; Humans; Leg Ulcer; Piperidines; Platelet-Rich Plasma; Pyrazoles; Pyrimidines | 2021 |
[79-year-old man with a unilateral arm lump].
Topics: Adenine; Aged; Arm; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphedema; Male; Piperidines; Skin | 2021 |
Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib.
Topics: Adenine; Atrial Fibrillation; Heart Atria; Humans; Piperidines; Retrospective Studies; Risk Assessment | 2021 |
Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinemia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2021 |
Building on BTK inhibition in MCL.
Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrimidines; Sulfonamides | 2021 |
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Protein Kinase Inhibitors; Sulfonamides; Tumor Cells, Cultured | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
Topics: Adenine; Adenocarcinoma; Albumins; B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Piperidines | 2021 |
The role of ibrutinib in COVID-19 hyperinflammation: A case report.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Humans; Immunomodulation; Male; Piperidines; Protein Kinase Inhibitors; SARS-CoV-2; Waldenstrom Macroglobulinemia | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Republic of Korea; Retrospective Studies | 2021 |
Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision.
Topics: Adenine; Aged; Blood Cell Count; Central Nervous System Neoplasms; Cerebrospinal Fluid; Diagnosis, Differential; Eye Diseases; Eye Pain; Humans; Magnetic Resonance Imaging; Male; Optic Disk; Optic Nerve; Pain; Piperidines; Tomography, X-Ray Computed; Vision Disorders; Waldenstrom Macroglobulinemia | 2021 |
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Prolymphocytic; Piperidines; Sulfonamides | 2021 |
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Topics: Adenine; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; HSP90 Heat-Shock Proteins; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors | 2021 |
Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
Topics: Adenine; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; MicroRNAs; Mutation; Piperidines; Protein Interaction Maps; Proto-Oncogene Proteins c-bcl-6; Thiazolidinediones | 2021 |
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Proteins; Proteolysis; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Splenic Rupture; Sulfonamides; Treatment Failure; Withholding Treatment | 2021 |
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cysteine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors | 2021 |
[Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Topics: Adenine; Aniline Compounds; COVID-19 Drug Treatment; Drug Repositioning; Hematologic Neoplasms; Humans; Imatinib Mesylate; Janus Kinases; Nitriles; Oligopeptides; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinolines | 2021 |
Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Topics: Adenine; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lymphoma, Mantle-Cell; Piperidines; Reproducibility of Results; RNA-Seq; Single-Cell Analysis; Time Factors | 2021 |
Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
Topics: Adenine; COVID-19; Humans; Immunity, Innate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; SARS-CoV-2 | 2021 |
How should we use ibrutinib in patients with mantle cell lymphoma?
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease.
Topics: Adenine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition; Cyclin-Dependent Kinase 5; Cytokines; Dendritic Spines; Disease Models, Animal; Down-Regulation; Gliosis; Inflammation; Inflammation Mediators; Memory, Long-Term; Mice, Transgenic; Neurogenesis; Neuroglia; Phosphorylation; Piperidines; Plaque, Amyloid; tau Proteins | 2021 |
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Drug Synergism; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Cells, Cultured | 2021 |
Ibrutinib-related uveitis: A report of two severe cases.
Topics: Adenine; Aged; Female; Humans; Hyphema; Inflammation; Male; Middle Aged; Piperidines; Uveitis; Uveitis, Anterior; Vision Disorders | 2022 |
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Topics: Adenine; Animals; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Humans; Lymphoma, Mantle-Cell; Male; Mice, Inbred NOD; Mice, SCID; Piperidines; Protein Kinases; RNA Polymerase II; Signal Transduction; Transcription Factors; Transcription, Genetic; Transcriptome; Treatment Outcome | 2021 |
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Movement; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Proteins; Phosphorylation; Piperidines; Protein Kinase Inhibitors | 2021 |
Cerebral aspergillosis in a patient on ibrutinib therapy.
Topics: Adenine; Adrenal Cortex Hormones; Aged; Aspergillosis; Aspergillus fumigatus; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Tomography, X-Ray Computed | 2021 |
Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Breast Neoplasms; Cell Movement; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 9; MCF-7 Cells; Neoplasm Invasiveness; NF-kappa B; Phospholipase C gamma; Piperidines; Tetradecanoylphorbol Acetate; Transcription Factor AP-1 | 2021 |
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Topics: Adenine; Aniline Compounds; Chromatography, Liquid; Dasatinib; Drug Monitoring; Female; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2021 |
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Cell Line, Tumor; Cell Movement; Forkhead Box Protein O1; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation | 2021 |
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p57; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mice; Piperidines; Polycomb Repressive Complex 2; Syndecan-1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Immediate reaction to ibrutinib amenable to oral desensitization.
Topics: Adenine; Aged; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrimidines | 2021 |
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosomes, Human, Pair 2; Cohort Studies; Female; Follow-Up Studies; Gene Dosage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Survival Rate | 2021 |
[Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia].
Topics: Adenine; Aged; Humans; Immunoglobulin M; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Peripheral Nervous System Diseases; Piperidines | 2021 |
NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anemia, Sickle Cell; Animals; Blood Platelets; Disease Models, Animal; Female; Furans; Heterocyclic Compounds, 4 or More Rings; Indenes; Inflammasomes; Liver; Male; Mice, Transgenic; NLR Family, Pyrin Domain-Containing 3 Protein; Piperidines; Platelet Aggregation; Protein Kinase Inhibitors; Sulfonamides; Sulfones; Thrombosis | 2021 |
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Disease-Free Survival; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Retrospective Studies; Rituximab; Survival Rate | 2020 |
An Eschar-like souvenir from a journey to Colombia: Ecthyma gangrenosum as a differential diagnosis of tropical diseases in immunocompromised patients - a case report.
Topics: Adenine; Administration, Intravenous; Aged; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Colombia; Diagnosis, Differential; Ecthyma; Humans; Immunocompromised Host; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pseudomonas aeruginosa; Skin Ulcer | 2021 |
Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
Topics: Adenine; Female; Humans; Interleukin-1; Lymphoma; Middle Aged; Piperidines; Schnitzler Syndrome | 2021 |
Select Antitumor Cytotoxic CD8
Topics: Adenine; CD8-Positive T-Lymphocytes; Cells, Cultured; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2021 |
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Topics: Adenine; Aged; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Rituximab | 2021 |
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
Topics: Adenine; Aged; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Piperidines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Treatment Outcome | 2021 |
Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Hematologic Neoplasms; Hemorrhage; Humans; Piperidines; Risk Factors; Stroke; Thromboembolism | 2021 |
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy, Adoptive; Interleukin-6; Interleukin-8; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Receptors, Chimeric Antigen; Receptors, Interleukin-2; Remission Induction; Retreatment; Salvage Therapy; Treatment Outcome | 2021 |
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells.
Topics: Adenine; Central Nervous System; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Piperidines; T-Lymphocytes | 2021 |
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Middle Aged; Phenotype; Piperidines; Sulfonamides | 2021 |
Severe Sinus Bradycardia Associated with Ibrutinib: One Rare Case from China.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Bradycardia; China; Electrocardiography; Humans; Male; Piperidines; Severity of Illness Index; Sinoatrial Node | 2021 |
Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.
Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycoses; Piperidines; Pyrazoles; Steroids | 2021 |
Prognostic value of [
Topics: Adenine; Fluorodeoxyglucose F18; Glycolysis; Humans; Lymphoma, Non-Hodgkin; Piperidines; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Retrospective Studies; Tumor Burden | 2021 |
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Piperidines; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide | 2021 |
Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Skin; Skin Diseases | 2021 |
Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Topics: Adenine; Aged; Databases, Factual; Drug Prescriptions; Female; Health Care Costs; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medication Adherence; Middle Aged; Piperidines; Protein Kinase Inhibitors | 2021 |
Panuveitis Presumed Secondary to Ibrutinib Therapy.
Topics: Adenine; Humans; Panuveitis; Piperidines; Uveitis | 2021 |
Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
Topics: Adenine; Benzamides; Drug Interactions; Glucuronosyltransferase; Humans; Isoenzymes; Molecular Structure; Piperidines; Pyrazines | 2021 |
Rapid Resolution of Presumed Vitreoretinal Lymphoma With Systemic Ibrutinib Therapy.
Topics: Adenine; Eye Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Retinal Neoplasms; Vitreous Body | 2021 |
The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51.
Topics: Adenine; Animals; Autophagy; Beclin-1; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Enzyme Activation; Mice; Neoplasms; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Piperidines; Protein Binding; Proto-Oncogene Proteins c-akt; Signal Transduction; src-Family Kinases; Tacrolimus Binding Proteins | 2021 |
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
Topics: Acute Kidney Injury; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Blood Specimen Collection; Fibrosis; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Macrophages; Male; Mice, Inbred C57BL; Mortality; Myoglobin; Pharmaceutical Preparations; Piperidines; Protein Kinase Inhibitors; Rhabdomyolysis | 2021 |
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.
Topics: Adaptive Immunity; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
Topics: Adenine; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Red-Cell Aplasia, Pure | 2021 |
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Mice, Inbred NOD; Mice, SCID; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-hck; Tumor Cells, Cultured | 2021 |
Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
Topics: Activities of Daily Living; Adenine; Aged; Cytokines; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pilot Projects; Piperidines; Prognosis; Prospective Studies; Symptom Assessment | 2021 |
Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
Topics: Adenine; Adenocarcinoma of Lung; Aged; ErbB Receptors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Male; Neoplasms, Second Primary; Piperidines; Protein Kinase Inhibitors | 2021 |
Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
Topics: Adenine; Administration, Oral; Central Nervous System Neoplasms; Female; Humans; Hypersensitivity, Immediate; Middle Aged; Piperidines | 2021 |
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2022 |
Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; B-Lymphocytes; Cell Adhesion; Cell Survival; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Function-Associated Antigen-1; Piperidines; Protein Kinase Inhibitors; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Signal Transduction | 2021 |
Ibrutinib: another string to its bow.
Topics: Adenine; Biomechanical Phenomena; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Angiotensin-Converting Enzyme 2; Binding Sites; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; SARS-CoV-2; Serine Endopeptidases; Thermodynamics; Viral Nonstructural Proteins | 2021 |
Association between ibrutinib treatment and hypertension.
Topics: Adenine; Blood Pressure; Humans; Hypertension; Piperidines; Retrospective Studies | 2022 |
MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Founder Effect; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Biological; NF-kappa B; Phospholipase C gamma; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |
Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Adult; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2022 |
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2021 |
Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
Topics: Adenine; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Retrospective Studies; Treatment Outcome | 2021 |
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Topics: Adenine; Aged; Brain Diseases; Central Nervous System Neoplasms; Female; Humans; Immunotherapy; Piperidines; Syndrome | 2021 |
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
Topics: Adenine; Aged; Biopsy; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; DNA Copy Number Variations; DNA, Neoplasm; Female; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Mutation; Piperidines | 2021 |
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Cyanosis; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Topics: Adenine; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Piperidines; Protein Kinase Inhibitors; Receptors, CCR7 | 2022 |
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
Topics: Adenine; Antineoplastic Agents, Immunological; Clonal Evolution; Clone Cells; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Prognosis; Rituximab | 2021 |
Killing Two Birds with One Stone: the Therapeutic Role of Ibrutinib in Schnitzler Syndrome.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Immunoglobulin M; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; Piperidines; Protein Kinase Inhibitors; Schnitzler Syndrome | 2021 |
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Clonal Evolution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2021 |
Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report.
Topics: Adenine; Aged; Chylothorax; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pleural Effusion | 2022 |
Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Topics: Adenine; Adult; Aged; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Patient Acceptance of Health Care; Piperidines; Pyrimidines; Retrospective Studies | 2021 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Genes, p53; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Risk Factors; Sulfonamides | 2022 |
A case of inflammatory myopathy in graft vs host disease - A potential role for ibrutinib.
Topics: Adenine; Biopsy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myositis; Piperidines; Treatment Outcome | 2021 |
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clonal Evolution; Cyclophosphamide; Disease Progression; Doxorubicin; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Lymph Nodes; Myeloid Differentiation Factor 88; Neoplasm Proteins; Piperidines; Plasmablastic Lymphoma; Prednisone; Protein Kinase Inhibitors; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Hot-melt extrusion based sustained release ibrutinib delivery system: An inhibitor of Bruton's Tyrosine Kinase (BTK).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Calorimetry, Differential Scanning; Delayed-Action Preparations; Drug Compounding; Hot Melt Extrusion Technology; Hot Temperature; Piperidines; Solubility | 2021 |
Negative innovation: when patents are bad for patients.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Patents as Topic; Patient Harm; Piperidines | 2021 |
Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib
Topics: Adenine; Humans; Lymphocytosis; Lymphoma, Large B-Cell, Diffuse; Patient Acuity; Piperidines | 2021 |
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.
Topics: Adenine; Aged; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Risk Factors | 2021 |
Effect of Ibrutinib on Hmphocytic Leukemia: a Single-Center Experience.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2022 |
Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.
Topics: Acetylation; Acrylamides; Adenine; Afatinib; Amino Acid Sequence; Aniline Compounds; Catalysis; Catalytic Domain; Class I Phosphatidylinositol 3-Kinases; Humans; Lysine; Mass Spectrometry; Molecular Docking Simulation; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Binding; Protein Conformation; Substrate Specificity | 2021 |
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Humans; Interferon-gamma Release Tests; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Viral Matrix Proteins; Viremia | 2021 |
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Piperidines; Prednisone; Rituximab; Vincristine | 2022 |
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL.
Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
Topics: Adenine; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidines | 2021 |
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Retrospective Studies; Treatment Outcome; Turkey | 2021 |
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Heart Disease Risk Factors; Hospitalization; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prognosis; Risk Factors; Survival Rate | 2021 |
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
Topics: Adenine; Animals; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; I-kappa B Kinase; Lymphoma, Mantle-Cell; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; NF-kappa B; Piperidines; Protein Kinase Inhibitors; Signal Transduction | 2021 |
Synthesis of [
Topics: Adenine; Bromobenzenes; Carbon Isotopes; Chemistry Techniques, Synthetic; Piperidines; Protein Kinase Inhibitors | 2021 |
Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Topics: Adenine; Graft vs Host Disease; Humans; Piperidines; Retrospective Studies; Steroids | 2021 |
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Topics: Adenine; Circulating Tumor DNA; Humans; Lymphoma, Large B-Cell, Diffuse; Nivolumab; Piperidines; Pyrimidines | 2021 |
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Spain | 2021 |
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pharmaceutical Preparations; Piperidines; Prospective Studies; Retrospective Studies | 2021 |
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Prognosis; Prospective Studies; Survival Rate; Waldenstrom Macroglobulinemia | 2022 |
Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines | 2021 |
Differential adsorption of an analyte and its D
Topics: Adenine; Adsorption; Chromatography, Liquid; Piperidines; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
Topics: Adenine; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunocompromised Host; Infections; Lymphopenia; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazines; Quinazolinones; Retrospective Studies; Risk Factors; Sulfonamides; Young Adult | 2021 |
Ibrutinib ameliorates cerebral ischemia/reperfusion injury through autophagy activation and PI3K/Akt/mTOR signaling pathway in diabetic mice.
Topics: Adenine; Animals; Autophagy; Brain Ischemia; Diabetes Mellitus, Experimental; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-akt; Reperfusion Injury; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease Management; Humans; Leukemia, B-Cell; Patient Care; Piperidines; Portugal; Protein Kinase Inhibitors | 2021 |
IL2-inducible T-cell kinase inhibitor ibrutinib reduces symptoms and Th2 differentiation in mouse allergic-rhinitis model.
Topics: Adenine; Animals; Cell Differentiation; Cytokines; Disease Models, Animal; Mice; Mice, Inbred BALB C; Nasal Mucosa; Piperidines; Protein-Tyrosine Kinases; Rhinitis; Rhinitis, Allergic; Th2 Cells | 2022 |
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Topics: Adenine; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Mediastinal Neoplasms; Piperidines; Salvage Therapy | 2022 |
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2022 |
Ibrutinib's off-target mechanism: cause for dose optimization.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2021 |
Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2021 |
Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Rituximab | 2022 |
Treatment with ibrutinib does not induce a
Topics: Adenine; Clonal Evolution; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Tumor Suppressor Protein p53 | 2022 |
Discovery of novel ibrutinib analogues to treat malignant melanoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Molecular Structure; Piperidines; Skin Neoplasms; Structure-Activity Relationship | 2021 |
CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury.
Topics: Acute Lung Injury; Adenine; ADP-ribosyl Cyclase 1; Agammaglobulinaemia Tyrosine Kinase; Animals; Endotoxemia; Female; Inflammasomes; Macrophages; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Piperidines; Signal Transduction | 2022 |
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Cause of Death; Comorbidity; Disease Management; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mortality; Piperidines; Population Surveillance; Prognosis; Registries; Sweden | 2022 |
Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).
Topics: Adenine; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carbocyanines; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Neoplasms, Experimental; Piperidines; Protein Engineering; Protein Kinase Inhibitors; Static Electricity | 2022 |
Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis.
Topics: Action Potentials; Adenine; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Benzamides; Cardiac Electrophysiology; Mice; Myocytes, Cardiac; Piperidines; Pyrazines; Sinoatrial Node | 2021 |
Ibrutinib skin toxicities: Report of two cases.
Topics: Adenine; Aged; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors | 2022 |
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Melanoma; Piperidines; Proto-Oncogene Proteins B-raf; Vemurafenib; YAP-Signaling Proteins | 2022 |
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Prednisone; Rituximab; Vincristine | 2021 |
Successful treatment of cutaneous Acanthamoeba castellanii infection with miltefosine in a patient with chronic lymphocytic leukaemia on ibrutinib.
Topics: Acanthamoeba castellanii; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylcholine; Piperidines | 2022 |
Plamotamab (XmAb
Topics: Adenine; Humans; Myeloid Differentiation Factor 88; Piperidines; Receptors, CXCR4; Waldenstrom Macroglobulinemia | 2022 |
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Transcriptome | 2022 |
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.
Topics: Adenine; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; T-Lymphocytes | 2021 |
Site-Specific Labeling of Endogenous Proteins Using CoLDR Chemistry.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Catalytic Domain; Coronavirus Papain-Like Proteases; Fluorescent Dyes; Half-Life; Humans; Ligands; Piperidines; Proteolysis; Proto-Oncogene Proteins p21(ras); Pyrimidines; SARS-CoV-2 | 2021 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Tumor Suppressor Protein p53 | 2022 |
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.
Topics: Adenine; Adverse Drug Reaction Reporting Systems; Humans; Pharmacovigilance; Piperidines; Skin Neoplasms; United States; United States Food and Drug Administration | 2022 |
Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Blister; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Purpura; Skin; Staphylococcal Infections; Staphylococcus aureus | 2022 |
BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Proliferation; Dogs; Drug Synergism; Drug Therapy, Combination; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Signal Transduction; Tumor Cells, Cultured | 2021 |
Is there a role for anti-CD20 antibodies in CLL?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines; Rituximab; Sulfonamides | 2021 |
Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.
Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Piperidines; United States | 2022 |
Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Anxiety; Disease Models, Animal; Female; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Odorants; Piperidines; Rats; Restraint, Physical; Stress, Psychological | 2021 |
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Platelets; Escherichia coli; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Activation; Platelet Aggregation; Protein Kinase Inhibitors; Pyrazines; Receptors, IgG; Staphylococcus aureus | 2021 |
The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Phospholipase C gamma; Piperidines; Protein Kinase Inhibitors | 2022 |
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Topics: Adenine; Aged; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2022 |
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.
Topics: Adenine; Adult; Cardiac Tamponade; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pericardial Effusion; Pericardiocentesis; Piperidines | 2022 |
Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Blood Platelet Disorders; Blood Platelets; Humans; Immunoglobulin G; Piperazines; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Factor 4; Protein Kinase Inhibitors; Pyridones; Receptors, IgG | 2021 |
Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibody Formation; Astrocytes; B-Lymphocytes; Body Weight; Calcium-Binding Proteins; Glial Fibrillary Acidic Protein; Immunoglobulin G; Macrophage Activation; Macrophages; Microfilament Proteins; Microglia; Motor Activity; Neuroimmunomodulation; Phosphorylation; Piperidines; Plasma Cells; Rats; Recovery of Function; Spinal Cord; Spinal Cord Injuries; Spleen; Syndecan-1; Treatment Outcome; Up-Regulation | 2021 |
Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma.
Topics: Adenine; Fluorodeoxyglucose F18; Humans; Lymphoma; Piperidines; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2022 |
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Single-Cell Analysis | 2022 |
Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy.
Topics: Adenine; Atrial Fibrillation; Case-Control Studies; Heart Failure; Humans; Piperidines; Risk Factors | 2022 |
[Small B-cell neoplasm responding to ibrutinib after 17 years of cold agglutinin disease symptom].
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lymphoproliferative Disorders; Neoplasms; Piperidines | 2021 |
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Lymphoma, B-Cell; Male; Piperidines | 2022 |
The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment.
Topics: Adenine; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Piperidines | 2022 |
Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
Topics: Adenine; Adult; Biomarkers, Tumor; Ferroptosis; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prognosis; Tumor Microenvironment | 2022 |
Atypical "accelerated" chronic lymphocytic leukemia with abnormal lymphocyte chromatin clumping, bone involvement, and exceptional response to Imbruvica.
Topics: Adenine; Aged; B-Lymphocytes; Chromatin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
[Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
Topics: Adenine; Aged; Cryptococcosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
Topics: Adenine; Adult; Animals; Humans; Immunotherapy, Adoptive; Lymphoma, Mantle-Cell; Mice; Piperidines; Receptors, Chimeric Antigen | 2022 |
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhibitors | 2022 |
Research progress in overcoming ibrutinib drug resistance.
Topics: Adenine; Adult; Antineoplastic Agents; Drug Resistance; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.
Topics: ABO Blood-Group System; Adenine; Blood Group Incompatibility; Hematopoietic Stem Cell Transplantation; Humans; Piperidines; Red-Cell Aplasia, Pure | 2022 |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Sulfonamides | 2022 |
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phospholipase C gamma; Piperidines; Protein Kinase Inhibitors; Receptors, Antigen, B-Cell; Sequence Analysis, RNA; Signal Transduction | 2022 |
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.
Topics: Acrylamides; Adenine; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Interleukin-6; Laminin; Lung Neoplasms; Mutation; Piperidines | 2022 |
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Retrospective Studies; Virus Activation | 2022 |
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2022 |
The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer.
Topics: Adenine; Antibody Formation; Capsid Proteins; Dependovirus; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Piperidines; Sirolimus | 2022 |
The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.
Topics: Adenine; Adult; Constriction, Pathologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2022 |
Invasive Aspergillosis of the Spleen in the setting of Ibrutinib use.
Topics: Adenine; Aspergillosis; Humans; Invasive Fungal Infections; Piperidines; Spleen | 2022 |
Campylobacter infection in 4 patients treated with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Campylobacter Infections; Diarrhea; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Ibrutinib-associated symptomatic intracerebral haemorrhage following IV thrombolysis for acute ischaemic stroke.
Topics: Adenine; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Ischemic Stroke; Piperidines; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2022 |
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
Topics: Adenine; Adult; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Tumor Microenvironment | 2022 |
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.
Topics: Adenine; Esophageal Neoplasms; Humans; Piperidines; Progression-Free Survival | 2022 |
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2022 |
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2022 |
Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nocardia Infections; Piperidines | 2022 |
Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.
Topics: Adenine; Adult; Antibodies, Monoclonal; Exanthema; Female; Humans; Piperidines; Schnitzler Syndrome; Urticaria | 2022 |
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2022 |
Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies | 2022 |
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phospholipase C gamma; Piperidines; Proto-Oncogene Proteins c-hck | 2022 |
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
Topics: Adenine; Calcium; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
A CAPTIVATE-ing new regimen for CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2022 |
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Australia; Duration of Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2022 |
SHINE a light: frontline ibrutinib for MCL.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Piperidines | 2022 |
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.
Topics: Adenine; Chromosomes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; p21-Activated Kinases; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.
Topics: Adenine; Piperidines; Protein Kinase Inhibitors | 2022 |
Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
Topics: Acrylamides; Adenine; Aniline Compounds; Arachidonic Acid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Indoles; Piperidines; Pyrimidines; Rivaroxaban | 2022 |
High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serum.
Topics: Adenine; Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Percutaneous Coronary Intervention; Piperidines; Printing, Three-Dimensional; Pyrazoles; Solvents; Tandem Mass Spectrometry | 2022 |
Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
Topics: Adenine; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Product Surveillance, Postmarketing; Pyrazoles; Pyrimidines; Recurrence | 2022 |
Ibrutinib frontline in young patients with CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2022 |
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Sulfonamides | 2022 |
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Treatment Outcome | 2022 |
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Topics: Adenine; Cohort Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2022 |
A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
Topics: Adenine; Aged, 80 and over; Endothelial Cells; ErbB Receptors; Glomerulonephritis, Membranoproliferative; Humans; Hypertension; Kidney; Kidney Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Proteinuria; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2022 |
A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib.
Topics: Adenine; Humans; Laboratories, Clinical; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2022 |
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort.
Topics: Adenine; Aged, 80 and over; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2023 |
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Creatinine; Cytoreduction Surgical Procedures; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia.
Topics: Adenine; Colorectal Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Panitumumab; Piperidines; Protein Kinase Inhibitors; Rectal Neoplasms | 2022 |
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab | 2022 |
An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
Topics: Adenine; Adult; Aged, 80 and over; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Symptom Flare Up | 2022 |
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Topics: Adenine; Animals; Antifungal Agents; Austria; Hematologic Neoplasms; Humans; Incidence; Invasive Fungal Infections; Piperidines; Retrospective Studies | 2022 |
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.
Topics: Adenine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma. Reply.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Nodules, nodes and non-functioning macrophages: A risk with ibrutinib therapy.
Topics: Adenine; Aged; Antifungal Agents; Bronchoscopy; Humans; Lung Neoplasms; Macrophages; Male; Mediastinoscopy; Mediastinum; Neoplasm Staging; Piperidines | 2022 |
Ibrutinib use and adverse cardiovascular outcomes: A United States federated electronic medical records analysis.
Topics: Adenine; Electronic Health Records; Heart; Humans; Piperidines; United States | 2023 |
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
Topics: Adenine; Cross-Sectional Studies; Fatigue; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient Satisfaction; Personal Satisfaction; Piperidines; Pyrazoles; Pyrimidines; Quality of Life | 2022 |
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Topics: Adenine; Aged; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Russia | 2021 |
Richter transformation to aggressive plasmablastic neoplasm related to selection of a
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Plasma Cells | 2023 |
Carbon-13 labeling of ibrutinib for human microdosing.
Topics: Adenine; Carbon Isotopes; Humans; Piperidines | 2023 |
Severe Postoperative Bleeding Secondary to Ibrutinib Intake.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2023 |
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2023 |
Population Pharmacokinetic and Exposure-Safety Analyses of Ibrutinib for the Treatment of Chronic Graft-Versus-Host Disease.
Topics: Adenine; Bronchiolitis Obliterans Syndrome; Cytochrome P-450 CYP3A Inhibitors; Humans; Piperidines | 2023 |
Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.
Topics: Adenine; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2023 |
Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Topics: Adenine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Tumor Suppressor Protein p53 | 2023 |
Bleeding complication following a shave biopsy in a patient taking ibrutinib.
Topics: Adenine; Biopsy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Bezafibrate in severe liver toxicity due to ibrutinib.
Topics: Adenine; Bezafibrate; Hepatitis; Humans; Liver; Piperidines | 2023 |
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
Topics: Adenine; Adult; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Tumor Microenvironment | 2023 |
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual | 2023 |
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies | 2023 |
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Piperidines; Waldenstrom Macroglobulinemia | 2023 |
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Tumor Microenvironment | 2023 |
First use of ibrutinib for the treatment of post-transplant central nervous system graft-versus-host disease.
Topics: Adenine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Piperidines | 2023 |
Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Rituximab; Secondary Prevention | 2023 |
Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
Topics: Adenine; Aspergillosis; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2023 |
Malignant syphilis in HIV negative patient treated with ibrutinib.
Topics: Adenine; HIV Infections; Humans; Piperidines; Syphilis | 2023 |
Ibrutinib in the treatment of relapsed FL and MZL?
Topics: Adenine; Piperidines | 2023 |